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Platelet Receptor Glycoprotein VI in Ischaemic Stroke 
Isuru Pasanna Induruwa 
 
Platelet activation, thrombus growth and subsequent thromboembolism underpins the 
pathophysiology of ischaemic stroke. At sites of atherothrombotic plaque rupture, it is 
established that platelet surface receptor glycoprotein (GP) VI-dimer binds to exposed 
sub-endothelial collagen, initiating the signalling required to cause platelet activation. 
Then, separate platelet-fibrin interactions cause the thrombus to grow, culminating in 
distal tissue ischaemia; crucial in thrombotic diseases such as ischaemic stroke.  
 
The work in this thesis demonstrates that GPVI-dimer binds to fibrin also, causing platelet 
activation through a mechanism independent of collagen. In ischaemic stroke this is 
important as it not only implicates GPVI-dimer in the large-artery atherosclerotic stroke 
subtype, it suggests a key role in cardioembolic stroke, where fibrin, rather than collagen, 
is the key platelet ligand.  
 
We compared the platelet surface expression of GPVI-dimer in a control, pre-stroke atrial 
fibrillation (AF), and a stroke population admitted to hospital using flow cytometry. We 
also measured platelet activation by platelet P-selectin exposure in all the cohorts. 
 
The results demonstrate that both AF and stroke patients have more ‘active’ circulating 
platelets compared to the controls. Furthermore, both AF and stroke patients – 
irrespective of AF type or stroke aetiology, express more GPVI-dimer on their platelets 
compared to controls. In the stroke cohort, GPVI-dimer expression was significantly higher 
at day-90 post-stroke than at admission.  
 
The ability of GPVI to interact with the two main ligands that drive thrombosis, collagen 
and fibrin, cements its role as a key platelet receptor in human thromboembolic disease. 
These results intimate an important role for GPVI-dimer in driving thrombotic risk pre-
stroke, as well as after having a stroke, suggesting that the direct inhibition of GPVI-dimer 
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Cardiovascular diseases are responsible for one-third of worldwide mortality, and 
haemorrhagic and ischemic strokes were the second- and third-largest cardiovascular 
causes of disability in 2015 (Roth, 2017). 
 
In both ischaemic heart disease (IHD) and large-artery ischaemic stroke, atherosclerotic 
plaque rupture is followed by thrombus formation at the site of injury. Subsequently the 
unstable thrombus can become detached, resulting in sudden distal arterial occlusion. 
Specific to ischaemic stroke, thrombi can also originate from a cardiac source, driven by a 
thrombogenic cardiac arrhythmia called atrial fibrillation (AF). 
 
The common pathway in both these types of events is the dysfunction of the vascular 
endothelial layer, causing activation of platelets as well as the coagulation system – the 
end product of which is polymerised fibrin. Many studies have shown that patients with 
thrombotic diseases and vascular risk factors have ‘primed’, hyperactive platelets that can 
readily form thrombi (Davì, 2007).  
 
The currently available anti-platelet drugs are effective in secondary prevention of acute 
coronary or cerebrovascular events (Rothlisberger, 2015), but many patients still suffer 
from thrombotic disease, despite antiplatelet therapy (Burn, 1994; Yamamoto, 1998). One 
of the problems with drugs such as aspirin and clopidogrel is that their mechanism of 
action targets the products of platelets that are already activated. Alongside this, the risks 
of haemorrhage increase with antiplatelet use, and in some cohorts like the older 
population, this may outweigh the benefit of reduction in thrombotic events. This is also 
the same for anticoagulant medication used in stroke prevention, where due to the 
perceived risk of increased haemorrhage from these drugs, many patients who are at high-
risk of thrombotic events do not receive it (Denoël, 2014). 
 
Therefore, there is a need for anti-thrombotic drugs that strongly inhibit platelet function 
but do not induce bleeding; a major challenge which lies ahead of those doing translational 
research. Ideally it would be through a mechanism that decreases platelet activity by 
 3 
targeting a pathway different from those addressed by current antiplatelets or 
anticoagulants.  
 
A promising candidate 3here is the platelet receptor glycoprotein (GP) VI which represents 
a logical and unexploited target for anti-thrombotic medications. GPVI inhibition has 
gained much traction as a possible novel antithrombotic target over the last few years due 
to its specific mechanism of action on inhibiting platelet activation and expected lack of 
bleeding complications as seen in both pre-clinical trials and animal models (Induruwa, 
2016). Its role in thrombus formation with respect to ischaemic stroke will form the basis 
of the work described in this thesis.  
 
1.02 Ischaemic stroke 
Stroke is a considerable cause of death and disability worldwide, with nearly two-thirds of 
patients left with a drastically reduced quality of life after their stroke (Langhorne, 2009; 
Katan, 2018). Stroke not only affects the patients, but also their family, carers as well as 
the wider society. Ischaemic stroke accounts for around 85% of all strokes and a wealth of 
research has explored the various genetic, molecular, clinical and epidemiological factors 
that increases an individual’s risk of stroke.  
 
Broadly, ischaemic stroke can be divided into its subtypes according to aetiology: large 
artery atherosclerotic stroke (LAS), cardioembolic stroke (CES) and small-vessel stroke 
(SVO) (Adams, 1993). Recently, large genome-wide association studies (GWAS) have 
shown that specific genetic loci are attributed to individual subtypes of stroke (Malik, 
2018), although some loci bestride two or more stroke subtypes (Lindgren, 2014; Malik, 
2016), highlighting that ischaemic stroke is a complex syndrome with a heterogenous 
aetiology. 
 
Hyperacute treatment for ischaemic stroke is based upon achieving recanalization of the 
occluded artery through recombinant tissue plasminogen activator (rtPA) and/or 
endovascular thrombectomy followed by appropriate anti-thrombotic therapy (NICE 
NG128 May 2019). However, only a small proportion of stroke patients are eligible for 
 4 
hyperacute treatment and even still, the rates of recanalization can vary between 
individuals.  
 
Frustratingly, approximately 30-40% of all ischaemic stroke cases cannot be sub-classified 
either and are labelled as embolic stroke of undetermined source (ESUS), which has 
enhanced the previous Trial of Org 10172 in Acute Stroke Treatment (TOAST) definition 
(Adams, 1993) of cryptogenic stroke (Hart, 2017). The difficulty in these cases is knowing 
which medication would be best to prevent their future risk of stroke. Even if the aetiology 
of the stroke can be determined, based on the degree of carotid stenosis (LAS), presence 
of AF (CES) or a diagnosis of lacunar stroke (SVD), individuals with risk factors common to 
cerebrovascular disease remain at risk of stroke from all subtypes.  
 
For example, a commonly encountered scenario in transient ischaemic attack (TIA) clinic 
is a patient with AF, who also has some carotid disease, presenting with symptoms of 
amaurosis fugax. In this situation, the culprit is likely to be the inflamed carotid lesion and 
thromboembolism to the retinal vasculature. In the absence of AF, this patient would 
clearly benefit from antiplatelet therapy. However, given the patient has AF, and that 
neither single or dual antiplatelet therapy would not sufficiently alleviate their risk of CES 
(ACTIVE Investigators, 2006; You, 2012), they would still continue their anticoagulation for 
this and not receive antiplatelets – leaving them at risk of further ischaemic events from a 
large artery source, especially in the immediate period following the TIA (Rothwell, 2005).  
 
Therefore, there is a need for novel anti-thrombotic targets that can be used for treating 
multiple aetiologies of stroke. Platelets are central to the thrombus that is formed in 
ischaemic stroke. The process of platelet ‘priming’ for thrombus formation, called platelet 
activation, is a key process leading to stroke, driven by vascular risk factors and is discussed 
later in this chapter.  Understanding platelet activation and platelet function with respect 
to increasing thrombotic risk and thrombus formation in ischaemic stroke, therefore, is a 





(a) Platelet Overview 
Platelets are derived from megakaryocytes (MK) that play a major haemostatic role in the 
body. They are also vital components in other processes within the body including 
inflammation, immunity and angiogenesis. The majority of platelets circulate around the 
body in a resting state until they are cleared at the end of their lifespan of 7-10 days 
(Michelson, 2019).  
 
Platelets stem from the MK cytoplasm; their much larger (30-100 µm), highly specialised, 
precursor cells present in the bone marrow (Michelson, 2019). After entering the 
circulation, around one-third of platelets migrate to the spleen for storage, awaiting 
release when required. The average adult must produce 1x1011 platelets each day to 
maintain a steady count (Kaushansky, 2005). However, at times of increased demand or 
thrombocytopaenia, negative feedback causes thrombopoietin to increase 
megakaryocytopoiesis and platelet production as needed (Sato, 1998). 
 
(b) Platelet anatomy and platelet activation 
Platelets are small (1-3 µm diameter, 0.5 µm thickness), anucleate cells, that are discoid 
in shape when inactive within the circulation. Despite their lack of a nucleus, there is 
evidence that platelets are able to translate pre-mRNA received from MKs into proteins 
(Weyrich, 2009). This means that platelets do contain post-translational mechanisms 
which allow alteration of their phenotype and function in response to cellular activation 
induced by various platelet-ligands (Zimmerman, 2008), although this maybe time-limited 
(Angénieux, 2016).  
 
Much of the platelet’s anatomy is geared towards its primary function of activation and 
subsequent thrombus formation. Multiple regions work in unison, firstly, to ensure that 
platelets remain quiescent in the circulation, but then also allow rapid activation at sites 
of vessel injury. For example, the spectrin-based membrane skeleton, microtubule system 
and rigid actin-filament network which form the platelet cytoskeleton help maintain the 
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platelet plasma membrane in a discoid shape when inactive, but also facilitate shape 
change and spreading when platelets become activated (Cerecedo, 2013). 
 
Internally, the platelets contain three major types of secretory organelles namely a-
granules, dense bodies (d granules) and lysosomes; as well as mitochondria, glycogen-
storing lysosomes, electron-dense chains and clusters and a dense tubular system, which 
is the site of prostaglandin and thromboxane A2 (TXA2) synthesis, and calcium 
sequestration (Michelson, 2019).  
 
The most important for haemostasis and thrombosis are the a-granules and dense bodies. 
There are around 40-80 a-granules per platelet, each containing adhesion proteins such 
as von Willebrand factor (vWF) and fibrinogen, as well as chemokines and growth factors 
such as platelet factor 4 (PF4), Beta thromboglobulin (BTG), coagulation factor V, P-
selectin, platelet derived growth factor (PDGF) and thrombospondin. Dense bodies are 
lower in number and size compared to a-granules and are rich in adenosine triphosphate 
(ATP), adenosine diphosphate (ADP), calcium, magnesium and serotonin. The a-granules 
and dense bodies are able to release their contents upon platelet activation, by fusing with 
the open canalicular system (OCS). The OCS is a network of invaginations of the platelet 
membrane that has two primary functions. Firstly, to transport stored products from the 
interior of the platelet plasma membrane upon activation and secondly to increase the 
platelet surface area to absorb, release and store coagulation factors from the plasma 
(White, 1991). 
 
Interiorly, the platelet plasma membrane primarily contains phospholipids which are 
distributed so that the surface of a resting platelet does not support coagulation until 
platelets undergo activation. However, once platelets become activated, the assembly of 
the membrane changes, bringing a phospholipid called phosphatidylserine and 
cholesterol-rich lipid islands, which contain tissue factor (TF) to the outer platelet 
membrane. This reorganisation generates a pro-coagulant platelet surface driven by TF 
and thrombin formation, allowing platelets to interact with the coagulation system. 
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The exterior surface of the platelet membrane, the glycocalyx, is rather different 
containing a thicker, diverse layer of glycoproteins, glycolipids and absorbed plasma 
proteins. This layer is negatively charged, which provides a repulsive force against other 
platelets, preventing spontaneous aggregation and retaining plasma proteins on the 
platelet surface (Lewandrowski, 2009; Nurden, 2014). Probably the most important 
attribute of this glycoprotein layer is that it is densely populated with platelet receptors. 
These receptors allow the platelet to recognise and respond to vascular damage and are, 
therefore, crucial in facilitating haemostasis and thrombosis.  
 
1.04 The role of platelet activation in ischaemic stroke sub-types 
Thrombosis and its resultant symptoms can present in many ways. Slow progression of 
atherosclerotic arterial disease can present as angina or peripheral arterial disease; acute 
plaque-rupture as myocardial infarction (MI), TIA or ischaemic stroke; deep vein 
thrombosis (DVT) and pulmonary embolism which constitute venous thromboembolism 
and finally, intra-cardiac thrombosis from AF, as CES.  
 
Because the pathophysiology behind developing an arterial or venous thrombus is largely 
distinct, these conditions have often been considered different. However, the similarities 
of risk factor profiles in patients who develop both arterial and venous thromboses 
suggest an inherent common link between patients. Several epidemiological studies have 
shown that those with the conventional risk factors for arterial thrombosis, namely, 
hypertension, diabetes, dyslipidaemia, obesity and smoking, are at similar risk of venous 
thrombosis, (Ageno, 2008; Previtali, 2011) as well as developing atrial fibrillation (Violi, 
2016; Lutsey, 2018) and therefore CES. Understanding how platelets are involved in the 
development of these conditions and how their activity and function subsequently change 
as they progress to the development of thrombosis and disease has to be considered a 
vital part of platelet research in the field of stroke medicine. 
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(a) Platelet activation in atherosclerosis and large artery ischaemic stroke 
Atherosclerosis is a chronic disease characterised by lipid deposition and inflammation of 
the arterial intima. The initial accumulation of lipoproteins (mainly LDL cholesterol) within 
the intima is called a “fatty streak”, but as the condition develops, this starts off a myriad 
of inflammatory reactions driven by monocytes, neutrophils, T- and B- cells, and platelets. 
As well as these inflammatory cells, lipid deposits are now joined by necrotic cell debris 
and extracellular matrix proteins leading to the development of a lipid-rich atheroma or 
“plaque”. The molecular and cellular mechanisms that drive the development of a plaque 
to its rupture are largely governed by disordered collagen metabolism, superficial erosion 
of the intimal layer, death of arterial smooth muscle cells, thrombin generation and 
inflammation (Libby, 2009). With respect to stroke, the development of an atherosclerotic 
plaque and its subsequent rupture specifically leads to LAS, causing between 20-25% of all 
ischaemic strokes (Ekker, 2018). 
 
Whilst atherosclerosis is undoubtedly a lipid-driven disease, there are other components 
of the atherosclerotic microenvironment that may perpetuate the disease further (Finney, 
2017). For example, atherosclerotic plaques begin to develop in arterial regions exposed 
to turbulent patterns of high shear blood flow. Studies have shown that arterial 
branchpoints or curvatures exhibit the highest likelihood of developing a lesion, whereas 
unidirectional, laminar flow show protection from plaque formation (Hahn, 2009).  This is 
because with laminar flow, endothelial cells which line blood vessels, are aligned in the 
direction of flow and remain quiescent. However, in turbulent areas or areas with 
disrupted shear, the endothelial cells have an activated, pro-inflammatory phenotype with 
high rates of cell turnover and high expression of leukocyte adhesion receptors such as E-
selectin, P-selectin, vascular cell adhesion-molecule-1 (VCAM-1) and intracellular 
adhesion-molecule-1 (ICAM-1) and cytokines such as monocyte chemotactic protein 1 
(MCP-1). As a result, increased numbers of leukocytes bind to the endothelium and 




Platelets in the development of an atherosclerotic lesion 
Platelets also play an important role in the development of atherosclerosis by acting as a 
bridge between both endothelial cells and circulating or activated leukocytes. It is 
established that the classical risk factors that lead to atherosclerosis can cause underlying 
activation of circulating platelets (Finney, 2017) and this can be measured experimentally 
using a variety of platelet activation markers.  
 
P-selectin (CD62P), the cell adhesion molecule found in platelets and endothelial cells, is 
only expressed on the platelet surface upon their activation (pP-selectin). Therefore, it has 
been widely used as a parameter to measure system-wide platelet activation (Bath, 2018). 
There are approximately 10,000 P-selectin molecules on the surface of an activated 
platelet and the ability to detect it easily and reproducibly using flow cytometry has put 
this molecule to the foreground of platelet research (Blann, 2003). However, what we do 
not know is the variability of P-selectin response in a population and how this is affected 
by genetic variance, pharmacology and existing vascular risk factors. Furthermore, even 
though P-selectin is the most commonly used platelet activation marker, other markers 
such as plasma/soluble P-selectin (sP-selectin; reflecting largely endothelial activation), 
fibrinogen, vWF, BTG, PF4 are also commonly used to measure systemic, underlying 
platelet activation.  
 
Specific to atherosclerotic disease, immunohistochemical analysis of atherosclerotic 
plaques has shown strong expression of P-selectin by the endothelium overlying active 
atherosclerotic plaques and fatty streaks, whereas P-selectin was not detected in normal 
arterial endothelium or in endothelium overlying inactive fibrous plaques (Johnson-Tidey, 
1994). Koyama et al showed that the percentage P-selectin-positive platelets  were higher 
in patients with carotid plaques and that pP-selectin expression was significantly and 
positively correlated with carotid wall thickness and stiffness (Koyama, 2003) suggesting 
an intricate yet important relationship between atherosclerotic lesions and platelet 
activation. Blann et al demonstrated that sP-selectin, vWF, and BTG are all raised in 
patients with atherosclerotic peripheral vascular disease compared to healthy controls 
(Blann, 1997) and it maybe that endothelial release of P-selectin accelerates 
atherosclerotic plaque progression (Woollard, 2014). 
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P-selectin expression is not, however, specific to atherosclerosis and rather represents a 
common marker of platelet and endothelial activation in response to the presence of 
vascular risk factors. For example, increased platelet activation in adolescents with 
diabetes is observed as measured by increased pP-selectin and PF4 exposure (Israels, 
2014). Similarly, raised pP-selectin is observed in patients who solely have hypertension 
as a vascular risk factor (Preston, 2007), or CCF (O’Connor, 1999) or AF (Goette, 2000). This 
highlights that vascular risk-factors resulting in ischaemic stroke likely drive platelet 
activation and in turn, activated platelets help promote atherosclerosis and increase an 
individual’s risk of ischaemic stroke. 
 
How activated platelets assist in the progression of atherosclerotic disease is largely 
established. Circulating activated platelets are able to tether to the dysfunctional 
endothelial cells, forming a monolayer around the site of atherosclerotic plaque 
development using pP-selectin. Early on, these platelets are able to activate endothelial 
cells through the release of cytokines such as interleukin (IL) -1b (Gawaz, 2000). 
Furthermore, these activated platelets are able to capture circulating and rolling 
monocytes and neutrophils on the endothelium and then help them adhere to activated 
endothelial cells (Kuijper, 1998; Ed Rainger, 2015). This is achieved through a coordinated 
response of P-selectin exposure to the platelet surface, release of pro-inflammatory 
microparticles and cytokines such as platelet activating factor (PAF) from platelet vesicles 
(Wang, 2016), and the expression of fibrinogen bound to activated integrin aIIbb3 (Weber, 
1997). The ability of platelets to capture leukocytes is further enhanced if the they are 
already activated with thrombin or ADP (Reininger, 1998; Stone, 1999).  
 
These recruited leukocytes are then extravested into the growing arterial intima where 
they mature into macrophages (from monocytes) and endocytose LDL, transforming into 
foam cells which accumulate to form atherosclerotic plaques (Lievens, 2011). As this 
process continues, small areas of endothelial desquamation occurs, characterised by the 
presence of focal microthrombi adherent to foam cells (Moore, 2013). Inflammatory 
activation then promotes the evolution of these early atherosclerotic lesions into more 
fibrous ones, containing a core of lipids, smooth muscle cells, collagen and leucocytes. 
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Activated platelets also have an important role here, through promoting the migration of 
smooth muscle cells into the intima through the release of the chemo-attractants such as 
PDGF (Weber, 1999). 
 
As this lipid-rich core expands the vessel lumen becomes stenosed and limits blood flow 
and perfusion of distal tissue. A collagenous fibrous cap also develops over the core. 
However, the recognition that this itself does not determine the development of 
ischaemic stroke and rather, the change from a stable to a vulnerable plaque (Libby, 2009) 
and how platelets may have a role to play here and in the subsequent thrombosis is 
paramount to comprehending the role of platelets in LAS. 
 
From atherosclerosis to atherothrombosis 
The concepts of arterial thrombus formation including the specific platelet receptors 
involved at each stage will be discussed in detail in chapter II. Broadly speaking, the 
heralding event in arterial thrombus formation is the rupture of the fibrous-cap of a 
vulnerable atherosclerotic plaque, causing disruption of the endothelial cell barrier. As 
each vascular layer is revealed through endothelial disruption, both sub-endothelial 
collagen and TF are exposed to the circulatory system and its contents. Platelets adhere 
and activate on collagen, driving arterial thrombosis, whilst TF causes the generation of 
thrombin which serves to both activate platelets and generate fibrin, driving thrombosis 
and triggering thrombus stability and growth through platelet–platelet and platelet–fibrin 
interactions (Furie, 2008). Distal tissue ischaemia occurs through embolism of the whole, 
or part of, the thrombus from the carotid or vertebral arteries. 
 
(b) Platelet activation in atrial fibrillation and cardioembolic stroke 
Atrial Fibrillation: a growing health and economic problem 
AF is the most common and sustained cardiac arrhythmia and is increasing in prevalence, 
making it a worldwide burden on healthcare resources (Reiffel, 2014). AF leads to a five-
fold increased  risk of CES (Kannel, 1982) ranging from 0.5% to over 15% per year 
depending on an individual’s risk-factor profile (Lip, 2010).  
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Thrombus formation and CES can be by the arrhythmia itself, causing low velocity blood 
flow within the cardiac left atrial appendage (LAA) leading to local endothelial dysfunction 
through relative hypoxia of endothelial cells and the development of a pro-thrombotic 
state. Previous studies have shown that over 90% of all thrombi in AF patients, if detected, 
are located within the LAA (Ammash, 2011; Mahajan, 2012).  
 
However, evidence of a systemic prothrombotic state can also be detected outside the 
LAA, from measurements of inflammation and thrombosis, suggesting that AF leads to a 
global prothrombotic state leading to an increased risk of CES (Lip, 1995; Llombart, 2013). 
This partly explains why strokes in patients with AF can also originate from alternate 
sources including the left ventricle, aortic arch and extracranial arteries (Miller, 1993). 
 
Outside the classic vascular risk factors for AF: hypertension, CCF, diabetes, 
hypercholesterolaemia, both common and rare genetic variants identified by GWAS, have 
shown to increase susceptibility to AF in an individual (Feghaly, 2018). 
 
The growing concern with AF is that its prevalence is higher in the already expanding 
elderly population and that cardioembolic thrombi tend to be larger compared to other 
subtypes such as LAS, causing the subsequent strokes to be more disabling, as well as 
carrying an increased likelihood of haemorrhagic transformation (Hannon, 2014; Tu, 
2015). Whether these thrombi are also more resistant to thrombolysis, is yet to be fully 
determined and is discussed later in chapter VIII.   
 
Currently, we have settled on anticoagulation with warfarin or direct oral anticoagulants 
(DOACs) because this is currently the only pharmacological treatment to prevent CES (NICE 
CG180 May 2019). However, the risk of adverse effects such as systemic bleeding with 
these agents, especially in the older population, leads to under prescription, leaving those 
with the highest risk of stroke most vulnerable (Denoël, 2014). 
 
It is well established that platelets are central to the development of both arterial and 
venous thrombosis and also link thrombosis and inflammation through their interactions 
with the vascular endothelium and circulating leukocytes. Likewise, in AF, inflammation 
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driving a prothrombotic state and subsequently unwanted platelet activation plays a 
crucial role in the development of the thrombus, embolism and eventual stroke.  
 
Platelet activation and function in atrial fibrillation 
As discussed, AF is recognised as a condition of increased thrombotic tendency. Patients 
with AF have been shown to have elevated levels of coagulation markers such as 
fibrinogen, D-dimer, factor VIIIa; indicators of endothelial dysfunction such as vWF and 
thrombomodulin; and evidence of platelet activation through higher expression of PF4,  
BTG and P-selectin compared with individuals with sinus rhythm (Gosk-Bierska, 2016). Not 
only have studies observed increased pP-selectin (Goette, 2000) and sP-selectin (Fu, 2011) 
in AF patients, raised sP-selectin levels have been found to be predictive of adverse clinical 
outcomes in AF (Heeringa, 2006).  
 
What is not clear, however, is whether these measurements that represent a pro-
thrombotic state in AF are primarily due to AF itself or the confounding effect of the other 
vascular comorbidities known to influence these biomarkers found in AF patients.  
 
This is because similar platelet activation profiles are observed in patients with 
cardiovascular disease without AF (Blann, 2003) and it has been shown that AF patients, 
compared to disease-matched patients without AF, can have similar pP-selectin and sP-
selectin levels, further suggesting that platelet activation in AF could be the combination 
of related vascular risk factors themselves rather than AF alone (Choudhury, 2007). Results 
from the SPAF-III study of 1321 AF patients revealed that diabetes, smoking and peripheral 
vascular disease were independently associated with increased sP-selectin levels (Conway, 
2002). Therefore, we can hypothesise that the presence of relevant risk factors such as 
hypertension, diabetes and CCF, all of which can in fact increase an individual’s risk of AF 
development in the first place and also contribute to low-level systemic inflammation, can 
lead to unwanted platelet activation and increased risk of CES (O’Connor, 1999; Nomura, 
2002). 
 
Nevertheless, studies have also demonstrated that BTG and PF4 levels are higher in pAF 
patients without cardiovascular risk factors, and seemed to be related to the duration of 
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pAF (Sohara, 1997). Other studies have also shown that acute AF induction caused platelet 
activation within 15 minutes, suggesting that an acute episode of AF could enhance the 
pro-coagulable state in AF through platelet activation (Akar, 2008; Hayashi, 2011). 
 
Finally, it is difficult to fully ascertain whether these peripheral measurements of platelet 
activation mimic what is occurring in the LAA. There is limited evidence here, however, Li-
Saw-Hee and colleagues found no statistical difference in D-dimer, sP-selectin, BTG and 
vWF levels when comparing blood sampled from the atria or from the femoral vessels in 
valvular AF patients, suggesting systemic platelet activation (Li-Saw-Hee, 1999). 
 
Inflammation and platelet activation in AF 
Increasing evidence supports a role for inflammation in AF.  A common link is probably the 
low-level inflammatory nature of all the vascular risk factors that contribute to AF, as well 
as AF itself. This is highlighted further as even outside of cardiovascular risk-factors,  
sepsis-related inflammation can drive the development of AF, and AF is also observed in 
the context of cardiac inflammatory conditions (Kuipers, 2014). Histological analysis of 
atrial biopsies from AF patients have shown increased recruitment of immune cells 
compared to those in sinus rhythm (Yamashita, 2010), and inflammatory changes 
comparable to myocarditis in AF but not control patients has been previously observed 
(Frustaci, 1997).  
 
Furthermore, high levels of circulating high sensitivity C-reactive protein (hsCRP), tumour 
necrosis factor-a and IL-2, -6 and -8 are also seen in AF, compared to those in sinus rhythm 
(Marcus, 2008; Patel, 2010; Yo, 2014). Platelet ‘hyper’ activation is observed by electron 
microscopy in the presence of IL-1b, -6 and -8 even in healthy control blood (Bester, 2016), 
suggestive of an active role for pro-inflammatory cytokines in the pathophysiology of 
platelet activation in AF and  also explains why we see platelet activation systemically, as 
part of a body-wide inflammatory process. 
 
The systemic inflammatory process may also be reflected in platelet size, through 
measurement of mean platelet volume (MPV). Increasing platelet volume is observed as 
a sign of underlying platelet activation and patients with chronic AF have higher MPV 
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values compared to controls (Tekin, 2013) and restoration of sinus rhythm from AF 
appears to significantly reduce mean MPV as well as pP-selectin expression (Makowski, 
2017). 
 
Further work is necessary to completely determine whether inflammation is causative or 
merely associated with atrial fibrillation and what factors within an inflamed vascular 
system leads to thrombus formation and subsequent embolism from the LAA. 
 
From arrhythmia to embolism 
Having established that platelet activation and inflammation drive a systemic pro-
thrombotic state in AF and are likely protagonists to the development of a LAA thrombus, 
it is important to understand the local factors within the LAA that precedes 
thromboembolism in some patients. 
 
In venous thrombosis, it is a combination of low blood flow and stasis which causes the 
local release of pro-coagulant materials such as TF, P-selectin and vWF from the 
endothelium, which drives thrombosis (Wakefield, 2008). Collagen plays much less of a 
role here as the endothelium remains largely intact, although dysfunctional. This is most  
prevalent in valve pockets of lower limb veins and can be a site of thrombus initiation due 
to disturbed blood flow and local endothelial hypoxia (van Hinsbergh, 2012). 
 
The thrombus development in CES is believed to be through a similar process to venous 
thrombosis, where endothelial dysfunction through low velocity blood flow within the left 
atrium of AF patients is observed, due to the fibrillating movement of the cardiac muscle 
(Li, 1994). These abnormal flow dynamics are associated with endocardial cell damage 
with the LAA (Goldsmith, 2000). Endocardial remodelling can then occur with thrombin, 
factor V, VII and X release, activating platelets through PAR and GPCRs followed by fibrin 
deposition attaching along the endocardium to platelets through integrin aIIbb3, resulting 
in a thrombogenic surface on which a thrombus can form (Masawa, 1993).  
 
The low velocity flow within the LAA can be due to the length (1.2-4.5cm) and shape of 
the LAA itself, which can vary within a population. Individuals who have an LAA with a 
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small orifice, larger neck dimension and extensive LAA trabeculation are associated with a 
higher stroke risk by potentiating low flow and blood stasis (De Backer, 2014).  Studies 
have shown that at the level of atrial tissue, AF leads to increased release of Ca2+ and 
reactive oxygen species (ROS), to cause increased release of inflammatory, prothrombotic 
material within the LAA. AF and Low flow rates within the LAA were also associated with 
higher concentrations of D-dimer, BTG and PF4 and a greater incidence of spontaneous 
echo contrast (a radiological sign of low velocity flow and a risk factor for 
thromboembolism in AF) (Shinohara, 1998).  Increased pro-inflammatory cytokines such 
as IL-6 have also been associated with increased left atrial size, further supporting a link 
between inflammation and atrial remodelling (Guo, 2012).This is likely to be driven 
by chronic endothelial scarring within the LAA and new endothelial cell migration as well 
as inflammatory cell infiltration (Goldsmith, 2000; Luo, 2014) leading to a nidus for local 
platelet activation and thrombus development within the LAA. 
 
The risk of thromboembolism in AF has been studied extensively and varies widely 
depending on the presence of several risk-factors. Clinicians now have scoring systems 
such as the CHA2DS2-VASc (see Appendix 2) to estimate the annual risk of CES  (Lip, 2010), 
with guidelines suggesting that the those with a CHA2DS2-VASc score ≥1 should be started 
on anticoagulation to reduce their risk of ischaemic stroke (NICE CG180 May 2019, no 
date). Large studies have shown that anticoagulants reduce the risk of CES by nearly two-
thirds (ACTIVE Investigators, 2006) and in groups not on anticoagulation it has been 
observed that the chances of a discovering an LAA thrombus are higher (Mahajan, 2012). 
This efficacy in reducing the risk of thromboembolism in AF patients clearly indicates that 
the mechanism of thrombosis is at least partially dependent on the coagulation cascade 
(Blustin, 2014). 
 
What is most likely to be occurring in CES is a mixture of all of the above. Systemic 
inflammation leading to platelet activation and release of procoagulant factors from 
platelets and endothelial cells, as well as LAA endothelial dysfunction, resulting in a local 
pro-thrombotic state, release of factors such as thrombin and fibrin, leading to platelet 
activation, thrombus growth and eventual embolism. 
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(c) Platelet activation in small vessel disease and lacunar stroke 
Lacunar strokes are small, deep infarcts resulting from the occlusion of deep branch 
arteries that occur as a result of progressive leukoaraiosis and accounts for around 25% of 
all ischaemic strokes (Pantoni, 2010).  Common risk factors such as age, hypertension and 
diabetes lead to the development and progression of SVD and its consequences can not 
only be seen as SVO, but also as areas of atrophy and white matter damage using 
conventional imaging such as computerised tomography (CT) or magnetic resonance 
imaging (MRI). Furthermore, SVD can manifest as cerebral microbleeds, small 
intraparenchymal bleeds in perivascular spaces and represent the leakage of blood 
constituents through the affected vessel wall, part of the constellation of pathologies that 
make up cerebral amyloid angiopathy (CAA). This in turn likely carries a greater risk for 
large cerebral intraparenchymal bleeds (Zupan, 2016).  
 
Anatomically, SVD preferentially affects the vessels of the basal ganglia, peripheral white 
matter, leptomeningeal arteries, thalamic and cerebellar white matter vessels and vessels 
of the brainstem (Wardlaw, 2013; Rincon, 2014). We now know that the progression of 
SVD not only leads to stroke but also to vascular dementia and vascular parkinsonism and 
that these different features of SVD, although appearing to be distinct, are in fact more 
related and dynamic than previously thought (Gorelick, 2011; van Norden, 2011).   
 
The difficulty with understanding the pathophysiology of SVD is the lack of in vivo models, 
meaning that most of the information we have learnt so far has stemmed from histological 
analysis of autopsies. However, we now know that SVD is a result of several contributing 
factors including cerebral hypoperfusion, arteriosclerosis – a collection of changes within 
the small vessels such as concentric wall thickening due to hyalinosis, disorganised fibrosis 
and luminal narrowing - and increased blood-brain-barrier (BBB) permeability (Pantoni, 
2010).  
 
There is certainly a role for both systemic and local endothelial dysfunction in SVD, which 
in turn affects both cerebral hypoperfusion and BBB dysfunction, which is at least partly 
governed by an individual’s genetic susceptibility to leukoaraiosis as well (Markus, 2008). 
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Endothelial dysfunction also leads to prothrombotic changes, as it does in other stroke 
aetiologies and this is likely to be driven by inflammation. This is evidenced in the blood of 
SVD patients where markers of inflammation and thrombosis such as thrombomodulin, 
TF, vWF, P-selectin, hs-CRP, and IL-6 are raised, even when adjusted for the presence of 
vascular risk factors (Hassan, 2003; Knottnerus, 2009).  Cherian and colleagues showed 
that both E-selectin and sP-selectin levels were higher in the blood of SVO patients, 
compared to controls (Cherian, 2003). 
 
BBB permeability may also be increased through the effects of these pro-inflammatory 
molecules, as well as matrix metalloproteinases (MMP). MMP 9 in particular may be 
directly involved in BBB disruption through its ability to breakdown collagen (especially 
type IV) and laminin (Lakhan, 2013). There is evidence of increased BBB failure in 
individuals with SVD, but also in normal appearing white matter, with the highest 
permeability seen in those with the most extensive white matter disease (Topakian, 2010; 
Wardlaw, 2017). 
 
The failure of antiplatelets to halt the progression of SVD suggests a more limited role for 
platelets in this stroke subtype compared to LAS and CES (Bath, 2015; Mok, 2015). 
Furthermore, many of the robust studies investigating platelet activation in SVD have 
yielded mixed results. Lavallée and colleagues calculated platelet activation by measuring 
activated aIIbb3, pP-selectin and platelet microparticles, and measured endothelial 
activation/inflammatory markers (vWF and hs-CRP) in patients with recent SVO compared 
to controls. They found that only the endothelial activation or inflammatory markers were 
increased in patients in comparison to controls and concluded that chronic platelet 
activation does not seem to play a  role in the pathogenesis of SVD (Lavallée, 2013). 
Similarly, Oberheiden et al measured pP-selectin, TF and serum IL-6 and -7 levels in 
patients with SVD. They observed that SVD patients express significantly higher pP-
selectin, significantly elevated amounts of platelet-monocyte aggregates and significantly 
enhanced TF exposition compared to controls, although this platelet and monocyte 




1.05 Stroke treatment: antiplatelets and anticoagulation 
(a) Antiplatelets 
Antiplatelets remain the cornerstone in treatment of thrombotic diseases such acute 
coronary syndrome (ACS), ischaemic stroke and peripheral vascular disease. They are most 
commonly used as secondary prophylaxis, reducing unwanted platelet activation at the 
sites of endothelial injury, and thereby the risk of further vascular events. 
 
Aspirin is the most commonly used antiplatelet agent. For the secondary prevention of  
thrombotic disease, it is effective at doses between 75-150mg daily in ischaemic stroke, 
and data on the use of higher doses fail to show added net benefit when taking into 
account adverse events (Antithrombotic Trialists’ Collaboration, 2002). At these doses 
aspirin exerts its effects through acetylating the serine529 residue of cyclo-oxygenase 
(COX) -1 (at higher doses COX-2 too) and therefore, inhibiting >95 % of TXA2 production 
(Wood, 1994). As platelets are non-nucleated cells, the inhibition of TXA2 is permanent for 
the platelet lifecycle (Meek, 2010).  Furthermore, aspirin achieves peak plasma levels 
within 30-40 minutes of oral intake and maximal platelet inhibition by one hour, making it 
a potent anti-thrombotic agent (Marder, 2012).  
 
Clopidogrel, prasugrel and ticagrelor represent other drugs that exhibit antiplatelet 
activity through inhibiting ADP-dependent platelet aggregation by irreversibly inhibiting 
the P2Y12 subtype of ADP receptor (Savi, 1998). Unlike clopidogrel and prasugrel, 
ticagrelor is not a pro-drug and does not need liver cytochrome (CYP) 450 conversion into 
their active metabolites (Johnston, 2016).  
 
Despite antiplatelet agents being the mainstay of treatment in ischaemic stroke, the 
evidence stems from a few older and heterogenous trials. A Cochrane review concluded 
that the odds-ratio (OR) for reduction of death and dependence after stroke with 
antiplatelets was 0.95 (95% CI 0.91-0.99, P=0.008) and the number needed to treat (NNT) 
was 79 and the OR for all-cause mortality at 6-months was 0.93 (95% CI 0.87-0.99, P=0.01), 
NNT = 108 (Sandercock, 2003). Antiplatelets do confer long term benefits in reduction of 
major adverse cardiovascular events (Hackam, 2019). However, it could be argued that 
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the greatest evidence for the use of antiplatelets is within the first month (Antithrombotic 
Trialists’ Collaboration, 2002); the Cochrane review concluding that the OR for recurrent 
stroke in the first 30-days as 0.77 (95% CI 0.68 – 0.86, P< 0.0001), NNT = 140. This is 
backed-up the results of the meta-analysis by Rothwell et al, who describe the greatest 
effect of aspirin within the first two weeks of either TIA or minor stroke, with a reduction 
in the six week risk of recurrent ischaemic stroke by about 60% (Rothwell, 2016).  
 
There is some evidence for the use of dual antiplatelet therapy (DAPT), aspirin and 
clopidogrel, to reduce the risk of recurrence after minor stroke or high-risk TIA in the first 
30-days (Kheiri, 2019). The evidence as to whether this lasts to 90-days is contentious, as 
a higher risk of major haemorrhage has been observed in some studies (Wang, 2013; 
Johnston, 2018). There is no evidence for triple antiplatelet therapy (DAPT + dipyridamole)  
in ischaemic stroke (Bath, 2018). However, even as a single agent their general mechanism 
of action can lead to unwanted systemic effects of haemorrhage; for example in the case 
of aspirin, COX-1 inhibition impairs prostaglandin-dependent defences in the gastric 
mucosa, leading to ulceration and bleeding (Silverstein, 1995) and withdrawal of the drug 
causes a disproportionately swift recovery in platelet function (Marder, 2012). The use of 
clopidogrel, which arguably has better evidence than aspirin in thrombotic disease 
(CAPRIE Steering Committee, 1996), is also marred as its effectiveness depends on its 
conversion to an active metabolite by CYP2C19 and individuals who carry 2 non-functional 
copies of the CYP2C19 gene have a higher risk of cardiovascular events whilst taking 
clopidogrel, compared to those who do not (Simon, 2009). 
 
(b) Anticoagulation 
In ischaemic stroke, starting anticoagulation is reserved for those with AF, ideally 
prophylactically or as secondary prevention after CES. Rarer initiation of anticoagulation 
in ischaemic stroke are for patients with a left ventricular intracardiac thrombus or pro-
thrombotic conditions such as antiphospholipid syndrome. For many years vitamin K 
antagonist therapy, through the initiation of warfarin, had been used for CES prevention. 
This was because its efficacy over aspirin for the prevention of CES in patients with AF had 
been well established in meta-analyses which demonstrated that warfarin reduced stroke 
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by 64% compared to only 22% by aspirin; although with a modest increase in intracranial 
haemorrhage (Hart, 2007). The results from the BAFTA study then went on to show that 
this benefit in stroke reduction is also evidenced in patients over 75 years of age (Mant, 
2007). 
 
The advent of the DOAC era were heralded by the three landmark trials comparing 
dabigatran (a direct thrombin inhibitor), rivaroxaban and apixaban (both factor Xa 
inhibitors) compared to warfarin (RELY, ROCKET-AF and ARISTOTLE, respectively) 
(Connolly, 2009; Granger, 2011; Patel, 2011). This was followed by the results of the 
ENGAGE-TIMI AF 48 trial comparing another factor Xa inhibitor, edoxaban, to warfarin 
(Giugliano, 2013). High-dose dabigatran and apixaban demonstrated superiority to 
warfarin in terms of ischaemic stroke and rivaroxaban and edoxaban demonstrated non-
inferiority. All 4 direct oral anticoagulants demonstrated lower rates of intracranial 
haemorrhage compared to warfarin.  
 
Some of the shortcomings of warfarin, for example, its narrow therapeutic window and 
the need for lifelong coagulation monitoring owing to a marked variation in its effect may 
have been overcome by DOACs, however, many limitations still remain with 
anticoagulation in AF. 
 
These issues revolve around the increased risk, or perceived increased risk, of adverse 
effects such as bleeding from anticoagulation (Pugh, 2011; O’Brien, 2014). This means that 
many patients who should be receiving anticoagulation, especially the elderly, who are at 
the highest-risk of ischaemic stroke, do not receive it (Denoël, 2014; Han, 2018). Results 
from the Sentinel Stroke National Audit Programme show us that in the East of England, 
only 47% of those with known AF presenting with stroke were on anticoagulation (Sentinal 
Stroke National Audit Programme (SSNAP), 2017). 
 
Another unresolved challenge is deciding when to initiate oral anticoagulation in patients 
after CES. Although the risk of early recurrent ischaemic stroke is high, early oral 
anticoagulation is also suspected to increase the risk of potentially harmful intracranial 
haemorrhage, including haemorrhagic transformation of the infarct. This means that 
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many patients are not receiving appropriate anticoagulation therapy until up to two weeks 
after their stroke (Seiffge, 2019). 
 
1.06 Limitations of current medication 
Despite the evidence that antiplatelets significantly reduces the odds of death or 
dependency, as well as recurrent stroke and chance of a complete recovery post stroke, 
the use of antiplatelet agents do increase an individual’s risk of haemorrhage. This is 
particularly important to consider, as symptomatic ischaemic haemorrhages post 
antiplatelet therapy is more likely to cause death and disability than ischaemic stroke 
recurrence (Sandercock, 2003). However, robust evidence shows that with aspirin, the 
absolute risk reductions in serious vascular events and ischemic strokes in secondary 
prevention outnumber the absolute risk increases in haemorrhage, with a favourable net 
risk-benefit ratio (Hackam, 2019). This is also true with clopidogrel, when compared with 
aspirin in the CAPRIE trial, there was a relative risk reduction in recurrent ischaemic stroke, 
myocardial infarction or death in stroke patients with similar rates of intracranial and 
gastrointestinal haemorrhage rates compared to aspirin (CAPRIE Steering Committee, 
1996). 
 
Another limitation of current medication, and one that is most pertinent to this thesis, is 
that there is not one agent that is efficacious in all ischaemic stroke subtypes. Antiplatelets 
are effective at reducing LAS and SVO risk but not CES, and conversely, anticoagulation is 
effective in CES but recommended routinely for LAS and SVO in the absence of AF. 
However, patients are heterogenous and have complex and over-lapping risk factors for 
multiple stroke aetiologies.  
 
The dilemma is further complicated by the 25% or so strokes which are ESUS, that are 
currently treated with antiplatelet therapy. The question remains as to whether some of 
these patients should receive anticoagulation. However, the results of the recent Navigate 
ESUS trial (rivaroxaban vs aspirin in ESUS) and RE-SPECT ESUS trial (dabigatran vs aspirin 
in ESUS) demonstrated no net benefit in anticoagulation compared to aspirin in recurrent 
stroke prevention, with rivaroxaban demonstrating higher risks of bleeding (Hart, 2018; 
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Diener, 2019). However, both trials were marred by heterogenous patient inclusion. We 
await the results of the ATTICUS trial (apixaban vs aspirin in ESUS).  
 
Investigators have also trialled whether anticoagulation plus antiplatelets could be safely 
used to prevent ischaemic stroke. Results from the COMPASS study demonstrated a 
significant reduction in stroke with low-dose rivaroxaban combined with aspirin, 
compared to aspirin or higher dose rivaroxaban alone in a group of patients with stable 
coronary or peripheral artery disease (Eikelboom, 2017). However, those taking 
rivaroxaban and aspirin had significantly more episodes of major bleeding compared to 
aspirin or rivaroxaban alone, suggesting that although beneficial, anticoagulation and 
antiplatelet treatment have significant risk of adverse effects. 
 
1.07 Chapter summary 
Ischaemic stroke is a worldwide cause of disability and death (Katan, 2018). The currently 
employed anti-thrombotic medication for acute stroke has its limitations in that they only 
adequately reduce stroke-risk in specific aetiologies of ischaemic stroke, and also carry a 
risk of haemorrhagic complications. 
 
Platelets are cells central to the pathology behind different stroke subtypes including LAS, 
CES and SVO. When they become activated, they are not only involved in the formation of 
the thrombus that leads to ischaemic stroke, they are also involved in the progression of 
atherosclerosis, atherothrombosis, cardioembolism, and are linked to various 
inflammatory processes that increase thrombotic-risk prior to having a stroke. Therefore, 
it is conceivable that controlling and downregulating platelet activation and its 
thrombogenic response could be a viable solution in the search for new anti-thrombotic 
targets.  
 
Chapter II will discuss the vascular endothelium, platelets and platelet activation in more 
detail. Specifically, how endothelial dysfunction or disruption can transform platelets from 
their quiescent circulating state to becoming activated in response to various platelet 
ligands, and how this results in the development of a thrombus which eventually 





















2.01 Platelets in haemostasis and thrombosis 
Platelets have a circulating concentration of 150 – 400 x109/L in humans, and normal 
laminar blood flow causes platelets to circulate nearer to the vessel wall, ideally positioned 
to detect and respond to vascular damage (Tangelder, 1985). Primarily, platelets are 
associated with haemostasis, but uncontrolled and overwhelming platelet activation in 
the circulation leads to pathological thrombosis.  Where haemostasis can limit blood loss 
from a damaged vessel in a coordinated and organised fashion, thrombosis blocks blood 
flow in an otherwise intact vessel, leading to distal tissue ischaemia and embolism of less 
organised thrombi (Colman, 2006).  Therefore, it is essential that platelet function is tightly 
governed and that platelets remain quiescent in the circulation until they become 
activated at sites of blood vessel damage and endothelial disruption. 
 
Under normal haemostatic conditions vascular endothelial cells form a monolayer lining 
the entire circulatory system and act as a protective barrier against thrombosis by 
preventing platelets from coming into contact with the highly pro-thrombotic 
subendothelial matrix. A multitude of mechanisms coordinate together to preserve the 
non-thrombogenic behaviour of the endothelial lining, including enzymatic buffering of 
ROS, release of substances such as endothelial nitric oxide, prostacyclin (PGI2), 
CD39/ENTPD1 and promotion of numerous anticoagulation pathways (Marcus, 1997; 
Rajendran, 2013; Gimbrone, 2016). Furthermore, endothelial cells are able to help limit 
clot formation to the areas where haemostasis is needed to restore or maintain vascular 
integrity (Rajendran, 2013). 
 
However, damage or dysfunction of the endothelium bypasses these protective steps and 
exposes circulating platelets to the sub-endothelial matrix. The sub-endothelial matrix is 
composed of layers of collagen beneath the endothelium, and TF, exposed from medial 
and adventitial layers of the vessel wall (Furie, 2008). Platelets are able to rapidly recognise 
and respond to vessel damage and the sub-endothelial matrix provides a surface to which 
platelets can adhere to.  Platelets subsequently spread on the damaged surface and 
become activated, causing shape change as well as release stored pro-thrombotic 
contents from their a-granules and dense bodies. The contents of these granules support 
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the activation of nearby platelets catalysing the formation of a thrombus. This initiates the 
thrombosis cascade which culminates with platelets adhering to fibrin, the end-product of 
the coagulation cascade and forming a haemostatic plug or pathological thrombus (Furie, 
2008). The role of platelets in thrombus formation can therefore be split into several 
stages, from initial adhesion within the prothrombotic collagenous layer to aggregation 
and finally, stable clot formation. 
 
(a) Platelet tethering, rolling and adhesion 
The ability of platelets to adhere to exposed subendothelial collagen is highly influenced 
by the rate at which blood flows within a vessel and disturbances to this blood flow cause 
important changes that lead to the development of cardiovascular diseases. The velocity 
of blood layers is highest at the middle of the vessel, usually where erythrocytes flow, and 
gradually decreases when approaching the vessel wall. However, vessel shear is defined 
by both shear rate (s-1); the velocity at which fluid layers pass each other and shear stress 
(dyn/cm2); the force per unit area exerted in the direction of flow (can be thought of as 
the frictional force of the blood on the endothelial layer). Opposite to flow velocity, both 
shear rate and shear stress are maximal at the vessel wall, where the flow velocity is close 
to zero (Michelson, 2019). Under normal flow conditions, the shear rate increases as the 
vessel diameter narrows e.g. from veins to arteries and also from non-stenosed to 
stenosed vessels. Low (venous) shear rates are estimated at between 10-500 s-1 and high 
(arterial) shear at 250-5000 s-1 (Jackson, 2007). The corresponding shear stress therefore 
also increases as vessels become narrowed (Sakariassen, 2015).  
 
For the purposes of this chapter, I will discuss organised, haemostatic thrombus formation 
at high shear rates. In vessels with high shear, such as arteries, platelets cannot directly 
bind to exposed sub-endothelial collagen at sites of atherosclerotic plaque rupture or 
vessel damage. Instead, the first-step is dependent on the large multimeric glycoprotein 
vWF, released from endothelial cells into the plasma, that binds to subendothelial collagen 
through its A3 domain (Ruggeri, 2007). The higher the shear, the greater the reliance on 
vWF. Now, platelet GPIba, as part of the GP-Ib-V-IX complex, can bind to the A1 domain 
of collagen-bound vWF and later thrombin as platelets become more active. This 
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interaction initially has a fast off-rate of disassociation, meaning that platelets are unable 
to stably adhere to collagen and instead translocate or “roll” on the sub-endothelial 
surface in the direction of blood flow. 
 
The slowly rolling platelets are able to interact with collagen through their two main 
platelet surface receptors, GPVI and integrin a2b1 (Varga-Szabo, 2008). These receptors 
bind to different peptide motifs on the collagen fibril; GPVI to glycine-proline-
hydroxyproline (GPO) repeats, and the A-domain of a2b1 to glycine-phenylalanine-
hydroxyproline-glycine-glutamate-arginine (GFOGER) (Knight, 1999, 2000).  
The functional form of GPVI is a dimer, constitutively present in resting platelets as a 
proportion of total GPVI (monomers and dimers) (Jung, 2012). First, GPVI-dimers bind to 
collagen in a relatively weak interaction, but one that is sufficient to initiate signalling 
pathways leading to platelet activation. This includes the shift of platelet integrins, 
especially a2b1 [but also aIIbb3 (discussed later)] from a low-affinity to a high-affinity 
state via inside-out signalling, which binds strongly to collagen, allowing firm adhesion of 
platelets.  Other integrin receptors such as a5b1 and a6b1 also bind to fibronectin and 
laminin, respectively, in the extracellular matrix (ECM), contributing to platelet adhesion 
and activation (Moroi, 2004; Varga-Szabo, 2008).   
 
GPVI and more specifically GPVI-dimer is the receptor of interest in this piece of work. The 
binding of GPVI-dimer to collagen and subsequent signal induction and thrombosis is 
further discussed in section 3.02. 
 
(b) Platelet spreading and activation 
Platelets are now firmly adhered to collagen using GPVI-dimer, supported by integrin 
a2b1, as well as vWF on collagen, supported by GPIb-V-IX. The process of platelet 
activation now starts, initially through platelet shape change and spreading. 
Morphological changes to the platelet occur through calcium mediated cytoskeletal 
remodelling. Platelets lose their discoid shape and flatten onto the sub-endothelial matrix 
forming a monolayer. Long finger-like projections called filopodia extend from the platelet 
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cytoplasm ensuring sustained attachment to the sub-endothelial matrix and to other 
platelets. 
 
Coinciding with their shape change, activating platelets release the contents of their a-
granules and dense bodies, mainly TxA2 and ADP. TxA2 (though the thromboxane receptor) 
and ADP (which signals through P2Y1 and P2Y12 receptors) in turn attract and activate 
nearby platelets to the establishing monolayer. Importantly, inside-out signalling converts 
integrin aIIbb3 to its active fibrinogen-binding form. Because fibrinogen is bivalent, it acts 
as a bridge between platelets and platelet aggregates are formed, eventually forming a 
thrombus. 
 
(c) Platelet aggregation, stable clot formation and clot retraction 
Parallel to platelet activation, the coagulation system generates thrombin (Factor IIa). 
Activated platelets also facilitate the generation of thrombin on their surface, accelerated 
by exposure of phosphatidylserine (PS) on the platelet surface and its interaction with 
coagulation factors from the coagulation system (Furie, 2008). Thrombin can subsequently 
activate nearby platelets through the protease activated receptors (PAR) 1 and 4 on the 
platelet surface (Brass, 2003).  
 
Local circulating soluble fibrinogen and platelet released fibrinogen are converted to fibrin 
through the action of thrombin. This results in the development of a polymerised, 
insoluble fibrin mesh, which together with platelets, through integrin aIIbb3, strengthens 
the thrombus.  
 
In the final stages, platelets are able to generate contractile forces through interlocking 
platelet cytoskeletons to cause clot retraction, and the thrombus becomes stabilised 
through fibrin-bound aIIbb3. The final result is a haemostatic plug comprised of activated 
platelets, embedded within a mesh of polymerised fibrin. When properly organised, it is a 
structure that is able to withstand the forces generated by the high shear flow within the 
arterial circulation (Michelson, 2019). The stages of the platelet cascade are summarised 








Figure 2.1 Stages of haemostatic plug formation and thrombosis. (a) At sites of vessel 
injury, the endothelium is disrupted, and sub-endothelial collagen is exposed, allowing 
plasma vWF to bind to it. Through GPIb-V-IX, platelets bind to vWF in a low affinity 
interaction, in which they bind and detach from the collagen surface (tethering), causing 
them to roll across the collagen surface; (b) Platelet  GPVI-dimer, constitutively present on 
platelets, interact with collagen, initiating a signalling cascade to activate platelets, 
including inside-out signalling to convert integrins a2b1 and aIIbb3 to their high affinity 
forms. Activated α2β1 binds with high affinity to collagen, arresting the platelets on the 
collagen surface. Activated platelets release fibrinogen, ADP, and TxA2 and other 
thrombogenic substances. (c) Activated αIIbβ3 on binds to bivalent fibrinogen, bridging 
platelets to form aggregates. Locally released ADP and TXA2, induces shape change and 
platelet spreading on the collagen surface. As a further level of regulation, GPVI-dimers 
can cluster, amplifying their intracellular signalling. 
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Receptor Ligand Function 
Receptor 
Inhibition  







Platelet adhesion to 
vWF adhered to 
collagen 
Antibodies do 
exist, but none 
have reached 








Initial adhesion to 
collagen and activation 
of b1 and b3 receptors 
during thrombosis 
Revacept – 





Phase I (both agents) - no 
changes in coagulation 
parameters or platelet count 
in healthy volunteers. Phase II 
data awaited. 
a2b1 Collagen Firm adhesion to 
collagen during 
thrombosis 







Platelet aggregation  






AbESTT-II trial stopped early 
due to haemorrhage 
See section 2.02 (f) 
CLEC-2 Podoplanin Platelet signalling 
Thrombus stabilisation 
No specific data 
available 
Not known 
P2Y1 and P2Y12 ADP 
Ca2+ mobilisation 
Platelet shape change 
and activation 
See section 1.05 See section 1.06 




Increase in minor bleeds 
compared to aspirin 
PAR 1 and 4 Thrombin Vorapaxar and 
Atopaxar (PAR1) 
and several early 
clinical molecules 
for PAR4 awaiting 
data. 
TRA2P-TIMI50 trial (Vorapaxar). 
Significantly higher moderate-
severe and intracranial 
haemorrhage. Metanalysis; 
Atopaxar > Vorapaxar in 
recurrent MACE but increased 
bleeding compared to placebo 
 
Table 2.1 Major human platelet receptors involved in thrombosis, their important 
ligands, function, effect of inhibition in stroke and risks of haemorrhage. CLEC-2= C-type 
lectin-like receptor 2. TP = thromboxane receptor.  
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2.02 Platelets and the coagulation system 
Haemostasis or thrombosis requires concurrent activation of the coagulation system, as 
well as platelets, to form a stable blood clot. Platelets mainly interact with what was 
previously known as the extrinsic coagulation pathway, which starts with the release of TF 
from the smooth muscle and adventitial layers of the vessel wall upon endothelial 
disruption or dysfunction (Furie, 2008). From this initial step, coagulation proceeds 
through a series of proteolytic steps that act as a biochemical amplifier, culminating in the 
generation of thrombin, which then cleaves fibrinogen to fibrin (Gailani, 2007). Activated 
platelets also expose PS which promotes thrombin accumulation, fibrin generation and 
crosslinking at the platelet surface, further capturing circulating platelets to the growing 
thrombus. This facilitates thrombus stability through integrin aIIbb3-fibrin binding; linking 
the platelet and coagulation pathways together (Swieringa, 2018). The exact contribution 
of each pathway to thrombosis is heterogenous, largely depending on whether the 
endothelium is disrupted and collagen is exposed at high shear, often in the case in arterial 
thrombosis, or merely dysfunctional at low shear, in the case of venous or LAA thrombosis 
(Colace, 2012; Casa, 2015). 
 
(a) The coagulation cascade 
There are two main pathways within the coagulation cascade (Figure 2.2). The most 
relevant in thrombosis and haemostasis is the ‘extrinsic’ cascade. In this pathway flowing 
FVII is exposed to TF following vascular injury. TF forms a complex with factor VII, which 
activates it. The TF-FVIIa complex then activates both FIX and FX, causing the generation 
of a small amount of trace thrombin. This trace amount of thrombin then activates FVIII 
and FV, which act as co-factors for together with FIXa and FXa, respectively, to convert 
prothrombin to thrombin (Schenone, 2004). The accumulated enzyme complexes on the 
platelet surface support further thrombin generation and platelet activation in the 
propagation phase, as well as the conversion of fibrinogen to fibrin, supported by FXIIIa 
(Palta, 2014).  
 
An alternative method of supporting the clotting cascade is though the contact or 
‘intrinsic’ pathway. This pathway is important in working to amplify the signals of the 
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extrinsic pathway, as well as in inflammation. To start, FXII becomes activated when in 
contact with negatively charged substances. FXIIa then converts the serine protease 
plasma prekallikrein to kallikrein which then converts FXII to more FXIIa. Eventually, this 




Figure 2.2 The coagulation cascade is a series of proteolytic steps that lead to the 
formation of an insoluble fibrin mesh that helps to stabilise the growing thrombus. The 
red lines denote the action of DOACs and the orange star (*) denotes the mechanism of 




Thrombin (factor IIa) is the most potent platelet activator in the human circulation system 
and can activate platelets at concentrations as low as 0.1 nM (Davey, 1967; Andersen, 
1999). It is a serine protease formed from pro-thrombin (factor II) in the last stages of 
blood coagulation. Prothrombin cleaves two internal peptide bonds, catalysed by FXa and 
assisted by FVa and FVIIIa (Crawley, 2007). 
 
The primary function of thrombin is to convert fibrinogen to fibrin, through cleaving 
fibrinopeptides from the central fibrinogen N-terminal domain, exposing a binding site 
that then allows fibrin polymerisation in the presence of FXIIIa and Ca2+.  
 
The majority of thrombin generation occurs on the surface of activated platelets, and 
thrombin can directly interact with platelets through cleaving their GPCR PAR1 and PAR4 
receptors, (Kahn, 1998).  It is likely that PAR1 is the predominant signalling receptor when 
local thrombin concentrations are low, and PAR4 requires between 10- to 100- fold higher 
concentrations of thrombin (Andersen, 1999). However, PAR4 signals for longer than PAR1 
(Coughlin, 1999; Holinstat, 2006). A secondary mechanism of platelet activation by 
thrombin involves proteolysis of glycoprotein GPV, as part of the GPIb-V-IX complex, in an 
ADP dependent manner (Ramakrishnan, 2001). GPVI also has a role with platelet 
interactions with thrombin, probably supporting maintenance of platelet activation 
(Hughan, 2007). 
 
(c) Factor XIII 
Factor XIII was originally identified as a serum protein that made fibrin clots insoluble, 
hence its initial recognition and naming as fibrin-stabilizing factor (Lorand, 1981), until 
later rebranding  as a clotting factor. FXIII circulates in the plasma as a 325 kDa hetero-
tetramer (FXIII-A2B2), where the two A subunits have the catalytic active site and the two 
B units have an inhibitory function. FXIII-A2 in dimeric form, is found in the cytoplasm of 
macrophages and platelets as well. Essentially all FXIII-A2B2 circulates in a complex with 
fibrinogen (Greenberg, 1982), likely associated with regions in the fibrinogen aC and g 
chains. Platelets contain a 150-fold higher concentration of FXIII-A compared to the 
 35 
plasma (Katona E, 2001; Muszbek, 2011) and can also uptake a fraction of fibrinogen-
bound FXIII-A2B2 to be stored in their a-granules (Byrnes, 2016).  
 
Factor XIII is activated by thrombin into FXIIIa through a series of proteolytic reactions. 
Thrombin first catalyses the cleavage of activation peptide(s) from the N-termini of the 
FXIII-A subunits to produce FXIII-A2ʹB2 and then Ca2+ causes release of the two FXIII-B 
subunits, creating activated FXIII-A2* (FXIIIa) (Muszbek, 2011). FXIIIa catalyses formation 
of covalent bonds between adjacent fibrin molecules to polymerise and stabilise the fibrin 
mesh within a growing thrombus and also crosslinks α2-antiplasmin inhibitor to fibrin, 
making the fibres more resistant to fibrinolysis through plasmin (Sakata, 1980; 
Hethershaw, 2014). Therefore, studies reveal that factor FXIII plays a central role in both 
arterial and venous thrombus generation (Byrnes, 2016), reduces risk of embolization 
through increasing thrombus stability (Gosk-Bierska, 2011) and could make clots more 
resistant to rtPA (Leidy, 1990). 
 
(d) Fibrinogen and fibrin 
Fibrin formation from fibrinogen, is a central process of both arterial and venous 
thrombosis, and inhibiting its formation or causing its breakdown is the target of 
thrombolytic medications used to treat both of these clinical presentations (Byrnes, 2016).  
 
Fibrinogen (Factor I) is the most abundant circulating clotting factor in the blood and is 
also released from platelet a-granules upon activation (Lopaciuk, 1976). It circulates as a 
340 kDa dimer consisting of three pairs of heterogenous, disulphide linked, polypeptide 
chains (Aa,Bb,g)2 arranged in a central E-domain containing their N-termini, and an outer 
‘globular’ D-domain containing their C-termini (Mosesson, 2005) (Figure 1.5). The two D-
domains, or when broken down by plasmin, called D-fragments (80 kDa each), account for 
about 55% of the molecular weight of fibrinogen compared to only 15% from the E-
fragment and are oriented approximately 130 degrees to each other (Spraggon, 1997). 
The fibrinogen a-chains are important in binding to platelet integrins using their Arg-Gly-
Asp (RGD) peptide motif as well as fibrin crosslinking. The main integrin aIIbb3 binding 





Figure 2.3 The structure of human fibrinogen. Fibrinogen molecules are made of six 
polypeptide chains (Aa,Bb,g)2 comprising two outer D-domains, connected to a central E-
domain. Thrombin cleaves fibrinopeptides (FP) A and B, exposing N-terminal binding sites 
between fibrinogen chains (horizontal black line). The g-chains within the D-domain 
undergo reciprocal crosslinking mediated by FXIIIa and Ca2+, leading to a strengthened 
fibrin mesh. Plasmin can then act on fibrinogen to release D- or E- domains (vertical black 
line), or on fibrin to release D-dimer, which typically consists of two crosslinked D-domains 
from two original fibrinogen molecules. Adapted from (Medved, 2009). 
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The first stage of converting soluble fibrinogen into an insoluble fibrin (factor Ia) clot 
occurs through the removal of fibrinopeptides A and B from the centrally located a-chain 
N termini via thrombin, resulting in the formation of a fibrin monomer. At this stage, new 
N-terminal E-domain sequences known as ‘knobs’ are exposed which rapidly and 
spontaneously interact with ‘holes’ on the distal D-domains of other fibrinogen molecules. 
Specifically, it is the newly exposed Gly-Pro-Arg (GPR) sequence within the E-domain a-
chain (Pratt, 1997) which binds to the D-domain g-chain (Shimizu, 1992). This results in the 
transient creation of a two-molecule thick protofibril with a half-molecule staggered 
overlap at a D- and E- domains.  
 
A peptide analogue to the E- to D-domain binding site GPR, called Gly-Pro-Arg-Pro (GPRP), 
inhibits the continuation of polymerisation, arresting the fibrinogen to fibrin conversion 
at a the stage of fibrin monomers (Pratt, 1997). 
 
Otherwise, the fibrin oligomers are then reinforced by FXIIIa, which introduces g-glutamyl-
e-amino-lysine isopeptide crosslinks between the carboxyl-segments of abutting g-
chains. The g-g dimers join two D-domains in an end-to-end conformation (Chen, 1971; 
Spraggon, 1997) although different investigators have reported different g-g dimer 
configurations (Everse, 1998). The proto-fibrils subsequently associate laterally to form 
additional crosslinks between the carboxyl regions of a small fraction of a-chains, 
strengthening the fibrin structure further into a polymerised mesh. Even though the D-
domain in fibrinogen and fibrin differ from each other due to the presence of the g-g 
crosslinks, it has been shown that the E-domain in fibrinogen and fibrin are identical, 
except for the loss of the fibrinopeptides (Pizzo, 1973).  
 
The proteolysis of polymerised fibrin through plasmin is called fibrinolysis and is tightly 
controlled, just like the coagulation cascade. Plasminogen activator inhibitor-1, 
plasminogen activator inhibitor-2, α2-macroglobulin and α2-antiplasmin usually protect 
fibrin from plasmin degradation. However, conversion of plasminogen to plasmin and local 
increases in plasmin concentrations allows cleavage of fibrin. Plasmin initially cleaves the 
C-terminal region of the a- and b-chains within the D-domain of fibrin (Cesarman-Maus, 
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2005). Then plasmin cleaves the three polypeptide chains that connect the D- and E-
domains, releasing fibrin degradation products; an E-fragment, an unstable complex called 
D2E and the widely measured biomarker in thrombotic disease, D-dimer (Cesarman-Maus 






Figure 2.4 Soluble fibrinogen is converted to insoluble crosslinked fibrin and the action 
of plasmin creates fibrin degradation products (D-fragment, E-fragment and D-dimer).  
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(e) Fibrin(ogen) receptor integrin aIIbb3 
Integrin aIIbb3 is the most abundant platelet receptor, with approximately 80,000 copies 
per platelet membrane (Andrews, 2014), which can increase by up to a further 50% 
through the transport of aIIbb3 stored in platelet a-granules to the platelet surface upon 
platelet activation (Niiya, 1987; Joo, 2012). The main ligands for aIIbb3 are fibrinogen, 
vWF, fibronectin and vitronectin, which cause signalling through this receptor.  Although 
platelets can bind fibrin using aIIbb3, it is not felt that this causes any platelet signalling 
(Bennett, 2001). 
 
The aIIb subunit consists of 1008 amino acids, which is composed of a heavy chain and a 
light chain, whereby the light chain consists of a 20 amino acid cytoplasmic tail and a 
transmembrane helix. The entire heavy chain of aIIb is extracellular and is linked to the 
light chain by disulphide bonds. The β3 subunit is a single polypeptide chain of 762 amino 
acids and the aIIb and b3 subunits assemble into a heterodimer during its synthesis (Joo, 
2012). Both subunits have their N-terminus residing extracellularly, with the C-terminus in 
the platelet cytoplasm. The extracellular portion of aIIb can be divided in to a b-propeller 
domain and the thigh, calf-1 and calf-2 domains arranged as a b-sheet extending down 
towards the platelet membrane. The extracellular portion of β3 is notable for containing 
the metal ion-dependent adhesion site (MIDAS) within its N-terminal, the β3 A domain, 
important as integrin activity is based on cation (Mn2+, Mg2+) availability and binding at 
MIDAS and Ca2+ binding at a site known as ADMIDAS (adjacent to MIDAS site).  
 
In resting platelets aIIbb3 remains in a low affinity, quiescent state. This is a protective 
mechanism to inhibit unwanted platelet activation in the circulation which contains a high 
concentration of fibrinogen. Platelets are therefore capable of ignoring soluble circulating 
fibrinogen whilst avidly binding to immobilised fibrinogen at sites of vessel injury (Zhang, 
2018). Activation of aIIbb3 requires the generation of inside-out signals throughout the 
process of platelet adhesion and activation. Synergistic signalling from receptors such as 
GPIb-V-IX, GPVI, CLEC-2 and GPCRs (PAR and ADP) ultimately result in phospholipase C 
(PLC) activation, elevation of cytosolic Ca2+, protein kinase C (PKC) activation and 
subsequent protein phosphorylation to activate aIIbb3 (Michelson, 2019). The activation 
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process involves an unclasping of the cytoplasmic tail between the a and b subunits and 
a disruption of the aIIb and b3 transmembrane helix associations, causing a 
conformational change of aIIbb3 from a bent/coiled to an extended configuration (Du, 
1993; Ma, 2007). This creates a new ligand binding site between the N-termini of the aIIb 
and b3 subunits, which has high affinity for its ligands. 
 
Once activated, integrin aIIbb3 is able to recognise its main ligands vWF and fibrinogen 
through their Arg-Gly-Asp (RGD) domains (Varon, 1993). Whereas these RGD motifs in the 
Aa-chains are not unique to integrin aIIbb3 binding, fibrinogen also contains a unique Lys-
Gln-Ala-Gly-Asp-Val (KQAGDV) sequence at the C-terminal of its γ-chain which binds only 
to aIIbb3 assisted by Mg2+ and Ca2+ binding (Springer, 2008). This frees up the fibrinogen 
RGD domain to bind other platelet receptors such as avb3 during haemostasis or 
thrombosis. 
 
Inside-out activation now causes aIIbb3 clustering and generation of outside-in signalling. 
The early phase of this outside-in signalling happens through the b3 cytoplasmic tail and 
activation of Src family kinases and then phosphorylation of the tyrosine kinase Syk. Syk 
can weakly associate with FC receptor g-chain (FCgR) IIa following tyrosine 
phosphorylation of its immunoreceptor tyrosine-based activation motif (ITAM) residues 
due to the low-level expression of FCgRIIa. Platelet Src family kinaes mainly function to 
activate PLCg2, focal adhesion kinase (FAK), and PKC, further propagating outside-in 
signalling required for aIIbb3 to assist in platelet spreading, thrombus stability and clot 
retraction (Durrant, 2017).  
 
(f) Inhibition of integrin aIIbb3 
The integrin aIIbb3 receptor has been a target for anti-thrombotic therapy for many years. 
Currently there are three intravenously administered aIIbb3 antagonists available to use 
clinically – Abciximab, Eptifibatide (Integrillin) and Tirofiban, which primarily work on 
nullifying platelet aggregation. 
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Abciximab is a chimeric human-murine monoclonal antibody (mAb) which predominantly 
inhibits aIIbb3, with weak effects on aMb2 and aVb3 (Coller, 1999). It inhibits aIIbb3 by 
binding to its b-chain and causing steric hindrance to ligand access. In vitro studies in 
patients with ACS demonstrated that it prevented platelet aggregation as well as fibrin 
formation (Dangas, 1998). The use of abciximab is currently limited as an adjunct to 
percutaneous coronary intervention (PCI) or during procedures such as intra-arterial 
thrombolysis due to its high risk of bleeding. Specific to patients with ischaemic stroke, the 
AbESTT-II trial had to be stopped early due to high rates of intracranial haemorrhage 
within the first 5 days after abciximab administration (Adams, 2008). 
 
Both eptifibatide and tirofiban are small molecule inhibitors of aIIbb3 activity. Eptifibatide 
competitively inhibits aIIbb3 and in comparison to abciximab, has higher binding 
specificity but lower binding affinity (Stangl, 2010). Unfortunately, the clinical use of 
eptifibatide is narrow due to its short half-life of 2 hours. It demonstrated  a reasonable 
improvement in outcomes compared to placebo in clinical trials (Tcheng, 1997; O’Shea, 
2001), as well as a similar efficacy and safety profile to abciximab (Singh, 2012). Tirofiban 
is currently used as an adjunct to PCI in patients with ACS. 
 
(g) Platelets and the coagulation system 
As discussed, platelets play a key role in the response to vessel injury, alongside the 
coagulation system; not just during thrombus formation but also during specific areas 
within a formed thrombus (Swieringa, 2018). We now know that platelets are not only 
activated by collagen, but also through thrombin formed from TF through the coagulation 
system (Dubois, 2006). These collagen and TF mediated pathways run parallel to each 
other and formulate a highly coordinated thrombotic response which can contribute to 
thrombosis in both arteries and veins (Rosenblum, 1997; Furie, 2008).  
 
Platelets interact with the coagulation system in multiple ways. In high-shear dependent 
arterial thrombus formation such as in LAS, platelets become adhered and activated on 
collagen beds and the release of TF from endothelial cells means that traces of thrombin 
are also available locally (Nieswandt, 2011). Platelets regulate these reactions leading to 
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the amplification of thrombin generation in multiple ways. Firstly by PS exposure, secondly 
by binding coagulation factors via GPIb-V-IX, GPVI or integrin αIIbβ3, and finally via 
thrombin-induced direct platelet activation through PARs (Swieringa, 2018). Thrombin can 
in fact directly activate platelets, without prior collagen exposure, as seen in low-shear 
venous thrombosis, which would be the mechanism of thrombus formation in CES (Esmon, 
2009). 
 
The exposure of PS on the platelet surface is an important and key step in haemostasis 
and thrombosis and occurs due to increased cytosolic Ca2+ generated through signalling 
throughout platelet activation (Martín-Molina, 2012). GPVI-signalling is key here, as well 
as that through CLEC-2, to formulate prolonged calcium elevation via their downstream 
signalling pathways. PS exposing platelets are now able to form complexes with 
coagulation factors V, VII, IX and X, significantly enhancing the activities of these 
coagulation factors (Heemskerk, 2002). PS exposure on platelets is also essential for FXIIIa 
mediated crosslinking of fibrin on the platelet surface. Now fibrin is also able to accelerate 
the interaction between platelets whilst also allowing aIIbb3 to facilitate platelet-fibrin 
interactions and also further enhancing procoagulant PS exposure, maintaining thrombus 
growth and stability under flow (Swieringa, 2018). 
 
Thrombin acts on platelets at both the early and late stages of thrombus development. 
During the early stages, thrombin activates platelets through their PAR receptors, 
supporting the signalling processes by potentiating Ca2+ increases, activation of integrins 
α2β1 and αIIbβ3, and exposure of PS (Heemskerk, 2002). Once the thrombus starts to 
grow, PS exposed platelets around the growing fibrin network serve as a catalyst to 
amplify this process, helped by fibrin capturing more thrombin and increasing its local 
concentration around a thrombus (Monroe, 2002).  
 
2.03 Chapter summary 
Platelets are essential for both haemostasis and thrombosis. In both LAS and CES, platelets 
become activated at the site of thrombus formation and assist in thrombus growth and 
stability. When platelets bind to collagen, initially through vWF and GP1b-V-IX and then 
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firmly through GPVI-dimer and integrin a2b1, platelets become activated. Activated 
platelets then release locally acting platelet mediators such as thrombin, P-selectin, TXA2, 
ADP and PS to recruit and activate nearby platelets, developing a thrombus (Figure 2.5). 
Platelets then interact with fibrinogen and fibrin through integrin aIIbb3, their main link 
to the coagulation system, to stabilise the growing thrombus and cause clot retraction.  In 
ischaemic stroke, platelets, therefore, play a role in arterial thrombus formation through 
platelet-collagen adhesion and activation through GPVI-dimer and in CES through platelet-
fibrin interactions via integrin receptors. However, a novel role for GPVI in linking platelets 
with the coagulation system was reported in 2015 which suggested that it is far more than 
just a receptor for collagen. GPVI, its structure and function within thrombosis related to 
ischaemic stroke is discussed in chapter III. 
 
 
Figure 2.5 The integration of the coagulation cascade and activated platelets. Activated 
platelets express phosphatidylserine which can form complexes with coagulation factors 
as well as promote the conversion of fibrinogen to fibrin on the platelet surface. Local 
thrombin generation coordinated through the coagulation system is integral to fibrin 





















3.01 Structure of Glycoprotein VI 
Sugiyama and colleagues (Sugiyama, 1987) first reported a patient with idiopathic 
thrombocytopenic purpura  whose platelets did not respond to collagen and lacked a 62 
kDa platelet protein.  Masaaki Moroi and Stephanie Jung then reported another patient 
who was genetically deficient in a 62 kDa glycoprotein that was requisite for the 
interaction of platelets with collagen; they named this protein glycoprotein VI, in accord 
with the Phillips nomenclature for platelet glycoprotein receptors (M Moroi, 1989). Over 
the last 30 years, research has highlighted the important role GPVI plays in human 
thrombosis, and has been targeted in the design of novel antiplatelet agents (Dütting, 
2012). 
 
GPVI is a transmembrane glycoprotein receptor which belongs to the immunoglobulin 
superfamily and is expressed in both platelets and megakaryocytes (Clemetson, 1999; 
Jandrot-Perrus, 2000). GPVI contains two IgG-like extracellular domains (D1 and D2). D1 
contains an N-glycosylation site. D2 is connected to the membrane by a rigid mucin-like 
stalk segment that is rich in O-glycosylation sites, followed by a 19 amino acid long 
transmembrane portion and a short cytoplasmic domain (Moroi, 2004). The 
transmembrane portion contains an Arg273 that forms a salt bridge with Asp11 of FcRg, a 
subunit that is essential GPVI expression and signal transmission through GPVI; FcRg itself 
is a disulphide bonded dimer (Tsuji, 1997; Nieswandt, 2000). The cytoplasmic domain 
contains a basic domain that serves as a calmodulin binding site and a proline-rich domain 
before the C-terminal that binds to the Src family kinases Fyn and Lyn (Moroi, 2004). 
 
There are between 6000-10000 copies of GPVI on the platelet surface (Andrews, 2014). 
GPVI exists as single-chain monomers of GPVI or GPVI-dimers, comprising two monomers. 
GPVI-dimers are constitutively present on resting platelets  (20–29 % of total GPVI) and 
have high affinity for collagen, thus being the functional form of this receptor (Jung, 2009, 
2012). Upon platelet activation, the number of dimers on the platelet surface increases 
(Jung, 2012) and as a further level of regulation, activation induces clustering of the GPVI-
dimers, which may bring GPVI-associated signalling molecules in closer proximity, 
facilitating signalling (Poulter, 2017).   
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Figure 3.1 The structure of GPVI monomer and dimer. The extracellular domains contain 
two IgG domains D1 and D2, where the collagen binding sites are found in D1. Each 
monomer is non-covalently associated through a salt bridge with FCRg. Both GPVI-
monomers and -dimers recognize the GPO triplets in the primary sequence of collagen. 
However, GPVI-dimers also recognise a structure specifically found in collagen fibres, 
which may contribute to its high affinity. Adapted from (Induruwa, 2016). 
 
3.02 Glycoprotein VI ligands: collagen and collagen related 
peptide  
Collagen is the most abundant protein in humans, comprising one-third of the total 
protein, and is the most prevalent component of the sub-endothelial ECM (Shoulders, 
2009). It is made of three parallel polypeptide chains arranged in a triple-helix. Each chain 
can be homo- or hetero trimeric and within the chains, every third amino-acid residue is 
glycine, with GPO being the most common triplet (Ramshaw, 1998) and also the most 
abundant platelet stimulus, through its interaction with GPVI (Morton, 1995). These 
collagen triple helices are arranged as highly ordered fibrils which then stack together to 
form collagen fibres. 
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Other than collagen, the ECM is comprised of elastin, laminin and fibronectin and the 
extracellular interstitial spaces are filled with a proteoglycan gel within which the fibrous 
proteins above are embedded (Järveläinen, 2009). Numerous types of collagens exist in 
the ECM, but the most abundant and important in platelet interactions and thrombosis 
are types I and III (Varga-Szabo, 2008). The way collagens are arranged in a fibrillar 
network forms a strong structure that can withstand high-tensile forces.  
 
Bovine collagen, horse collagen as well as collagen ‘toolkits’ have been successfully used 
in vitro to further elucidate receptor-ligand properties between platelets and collagen 
(Raynal, 2006; Hamaia, 2012). The toolkits (TK) are comprised of overlapping triple-helical 
peptides which encompass the entire collagen domains of human collagens II and III. 
Advances in peptide synthesis have enabled the synthesis of collagen-like peptides 
(collagen related peptide; CRP), a powerful GPVI agonist comprised of 10 GPO motifs 
which can spontaneously form stable triple-helices (crosslinked CRP; CRP-XL) under 
physiological conditions (Morton, 1995). We now know that platelet adhesion to CRP-like 
peptides varies with their GPO triplet content and that two GPO triplets is the smallest 
motif within collagen that recognises and activates platelet GPVI (Smethurst, 2007). 
 
(a) Glycoprotein VI adhesion to collagen and resultant signalling 
Fibrillar collagen type I is the major physiological collagen type that binds to GPVI-dimer, 
and together with collagen type III, predominate the collagen found in the ECM (Kehrel, 
1998). It was suspected that the collagen binding region within GPVI was located in D1D2 
and that binding required the dimeric conformation of GPVI because a dimeric 
recombinant Fc-fusion protein of the GPVI-extracellular domain (GPVI-Fc2) bound to 
collagen fibres with high affinity whereas the monomeric GPVI-extracellular domain, 
GPVIex did not (Miura, 2002).  
Horii and colleagues obtained a crystal structure of D1D2, which was consistent with a 
dimer formed by a “back-to-back” arrangement of D1D2 monomers (Horii, 2006). They 
observed a shallow groove on the surface of D1 when GPVI is in this dimeric configuration, 
which matched the orientation and dimensions of collagen triple helices. This suggests 
that the dimeric configuration is vital for GPVI adhesion to collagen, explaining the nearly 
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200-fold difference between the affinities of monomeric and dimeric GPVI to collagen 
(Jung, 2012) (Figure 1.3). Table 1.2 summarises the affinity of GPVI monomer and dimer 
with collagen type I, III and CRP and TK III-30.   
 
Furthermore, the proportion of pre-existing GPVI-dimers on the platelet surface can 
increase upon collagen or thrombin induced platelet activation, by up to 35% (Jung, 2012). 
Rapid assembly of dimers on the platelet surface causes further platelet reactivity to 
collagen (Loyau, 2012). As discussed, GPVI proteins can oligomerise upon ligand binding, 
into higher-order clusters (Horii, 2006) which in turn enhances the strengths of the signal 
induced from GPVI and thereby platelet activity (Jiang, 2015; Poulter, 2017). This 
distribution and assembly of GPVI across the platelet membrane is regulated by platelet 
cytoskeletal proteins (Haining, 2017; Poulter, 2017). Thus far only crosslinked CRP (Barnes, 
1998)  and fibrous collagen (Jung, 1998) had been established in being able to induce a 















Table 3.1 The dissociation constants (binding affinity between a molecule e.g. protein and 
a ligand; Kd) ± SD for GPVI dimer and monomer binding to various collagen substrates. 
GPVI-dimer has much higher affinity for the collagenous substrates than the monomer, 
indicating that it is the functional form of GPVI on platelets. TK III-30: peptide from 
collagen toolkit III has the highest affinity for GPVI. As reported in (Jung, 2012). Similarly, 




GPVI-dimer (Kd, nM) GPVI-monomer (Kd, µM) 
CRP-XL 22.0 ± 2.1 2.7 ± 0.3 
Collagen type I 41.7 ± 0.4 8.1 ± 1.2 
Collagen type III 58.3 ± 9.4 13.8 ± 2.5 
TK III-30 11.5 ± 0.6 10.2 ± 1.9 
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The final outcome of GPVI signalling is to activate integrins a2b1 and aIIbb3 to further 
propel platelet activation and aggregation, leading to thrombus formation. Even though 
GPVI is the major signalling receptor for collagen on peptides, once activated, integrin 
a2b1 has higher for collagen compared to GPVI and enhances the activity of GPVI by fixing 
platelets on the collagen surface under flow conditions, although a2b1 cannot activate 
platelets by itself   (Jarvis, 2002). The cytoplasmic region of FcRg contains an ITAM and 
once adhered to collagen, the GPVI/FcRg complex induces sequential activation of the Src 
kinases Lyn, and Fyn which are bound to the cytosolic tail of GPVI (Watson, 2005). In 
particular Lyn is important for catalysing phosphorylation of ITAM and activation of Syk 
(Gibbins, 1996). Downstream of this lies a series of proteins, including linker for activation 
of T-cells (LAT) and adaptor proteins SLP76 and Gad, which lead to the activation of PLCg2, 
generation of intracellular calcium signals, protein kinase C activation, finally leading to 
the activation of b1 and b3 integrins (Nieswandt, 2003). Clustering is likely to be caused 
by the dimerisation of the intra- and extracellular regions of GPVI/FcRg, bringing the  
ITAMs within the cytoplasmic tail in closer proximity to each other (Poulter, 2017) with 
the cell membrane lipid rafts also aiding in GPVI signalling and cluster formation after FcRg-
chain phosphorylation (Locke, 2002). 
 
The components of the major GPVI signalling pathways are also shared with other platelet 
receptors that bind ligands other than collagen. For example, the signalling induced 
through GPIb-V-IX binding to vWF is similar to that of GPVI, in that both involve activation 
of PLCg2 via FcRg-chain, Src kinases and Syk (Liu, 2005). Another example is CLEC-2, which 
is activated through podoplanin but produces powerful platelet activation signals in 
conjunction with Src, Syk and PLCg2, similar to the GPVI/FcRg-chain complex (SuzukiI-
Inoue, 2011), as well as other integrin receptors such as aIIbb3 (Watson, 2005). 
 
3.03 Genetic variability of GPVI expression and function 
The gene coding for GPVI is located on chromosome 19q13.4 and contains different single 
nucleotide polymorphisms (SNPs). Variation at the GP6 locus accounts for a large part of 
the population vitiation of GPVI platelet surface expression, as well as the response to 
collagen or CRP-XL. Early reported variations in platelet GPVI content amongst healthy 
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individuals were identified by their responses to the snake venom protein convulxin which 
activates platelets like collagen (Furihata, 2001) and since mapping the GP6 DNA 
sequence, numerous heterozygous mutations in the GP6 gene have been reported, which 
can cause a lack of collagen-induced platelet activation (Dumont, 2009; Hermans, 2009). 
Alternative spliced variants have also been observed to lack responses to collagen (Arthur, 
2007b) suggesting that GPVI is responsible for collagen based platelet activity and 
function. 
 
The alleles of the common haplotype of 5 coding GP6 non-synonymous single nucleotide 
variations accounts for over 15% of the population variation of GPVI surface expression 
and studies have concluded that the GP6 locus accounted for 35% of the variation in 
responsiveness to CRP-XL (Joutsi-Korhonen, 2003; Jones, 2007). This highlights the direct 
effect that the variants have on the ability of a platelet to signal through GPVI. 
 
The minor GP6 haplotype occurs in homozygosity in 24 of 6000 (0.4%) individuals 
genotyped so far through recent work within the Ouwehand group, who were our 
collaborators for parts of this work. Previous studies have shown that this haplotype could 
protect against recurrent MI in patients treated  with antiplatelets, indicating an 
underlying role of GPVI in thrombosis (Snoep, 2010) and intracellular signalling (Trifiro, 
2009). 
 
Even at the time of writing this thesis, less than 20 patients with GPVI-deficiency have 
been widely reported, with the cause of GPVI deficiency ranging from an auto-antibody 
effect, congenital defect or an acquired deficiency. The common themes of presentation 
in GPVI deficient patients are purpura, petechiae and ecchymosis, resembling an ITP which 
responds to steroids, with a careful history revealing other signs of bleeding time 
prolongation such as menorrhagia and epistaxis (Arthur, 2007). Thrombocytopaenia is 
common also, and platelets demonstrate severe impairment of aggregation on collagen.  
 
Matus et al. recently reported a novel homozygous GP6 mutation in five subjects from 
four unrelated Chilean families who presented with ecchymoses and minor bleeding 
(Matus, 2013). Interestingly, all the patients demonstrated normal PT, APTT, platelet and 
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vWF counts, similar to their heterozygous relatives. By contrast, their platelets completely 
failed to aggregate in response to collagen and convulxin. This data is pertinent as they 
indicate the benefits and risks of possible future antibody-mediated GPVI-inhibition, if we 
were to consider it as a pharmacological target in human thrombosis. Furthermore, the 
work suggests a rather benign nature of symptoms associated with GPVI deficiency, but 
the cases themselves are heterogenous. We require additional data to understand how 
GPVI deficiency relates to an individual’s arterial or venous thrombotic risk in the setting 
of vascular risk factors. 
 
3.04 Glycoprotein VI in thrombotic disease 
This section will focus on GPVI-mediated thrombosis through its main ligand, collagen. 
How GPVI contributes to platelet activation in the setting of haemostasis and thrombosis 
has been discussed in section 2.01 and 3.02. 
 
Much of the work investigating the role of GPVI in thrombosis has been in knockout mice 
models, particularly as GPVI deficiency in humans appears to be a very rare platelet 
disorder (Arthur, 2007b). Therefore it is difficult to elucidate the functional role of GPVI 
from these patients alone, apart from that these individuals only exhibit a mild bleeding 
tendency, which in turn has driven the research on GPVI as an potential anti-thrombotic 
target (Sugiyama, 1987; M. Moroi, 1989; Arthur, 2007; Matus, 2013).  
 
Much of the work from mouse models has helped to shift the focus of GPVI’s activity from 
an platelet adhesion receptor, to an activatory one (Misra, 2014). In both arterial and 
venous thrombosis development, the lack of GPVI appears to be protective (Nieswandt, 
2001; Lockyer, 2006), suggesting that the major function of GPVI may not be limited to the 
denuded endothelium at sites of plaque rupture; an important fact to be discussed in 
further detail in this thesis.  
 
The majority of the GPVI studies in humans have focussed around the quantification of 
platelet surface GPVI via flow cytometry and the plasma detection of soluble GPVI (sGPVI), 
a shed ectodomain of GPVI via enzyme-linked immunosorbent assay (ELISA) (Al-Tamimi, 
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2009). Many of the studies looking into platelet detection of GPVI have quantified the 
presence of total (monomeric and dimeric) GPVI, compared to controls. Interestingly, 
patients with thrombotic diseases such as acute coronary syndromes (ACS) (Bigalke, 2010, 
2011), TIA and ischaemic stroke (Bigalke, 2010) demonstrate higher platelet total GPVI 
expression and poorer clinical outcomes. Similarly, sGPVI has been shown to be increased 
in ACS (Bigalke, 2009) and ischaemic stroke (Al-Tamimi, 2011; Wurster, 2013) suggesting 
that it could be used as a potential biomarker in human thrombotic disease. 
 
3.05 Glycoprotein VI in roles outside thrombosis 
Outside of the classical role of haemostasis, platelets contribute to many other 
physiological conditions, for instance, inflammation, immunity, vascular integrity and 
repair (Moroi, 2004). A contribution to these roles from GPVI is increasingly recognised, 
although its mechanism is not as well established as it is in thrombosis and appears to be 
pathology and organ dependent (Rayes, 2018).  
 
In inflammatory conditions such as glomerulonephritis, GPVI has been shown to 
potentiate neutrophil recruitment to inflamed glomeruli (Devi, 2010). GPVI has also shown 
to promote cutaneous macrophage expression of inflammatory mediators such as 
prostaglandin E2 and IL-6 (Pierre, 2017). As observed in thrombotic disease, plasma sGPVI 
levels are shown to be higher in patients with inflammatory conditions such as rheumatoid 
arthritis (Stack, 2017), liver cirrhosis (Egan, 2017) and thermal injury patients with sepsis 
(Montague, 2018) but lower in patients with Alzheimer’s disease (Laske, 2008).  
 
Conversely, GPVI has also been shown to protect vascular integrity during local 
inflammation by sealing the sites of damage at the inflamed vessel wall and preventing 
neutrophil-induced bleeding (Gros, 2015), possibly in conjunction with CLEC-2 (Boulaftali, 
2018). However, unlike in haemostasis, single platelets tend to adhere to sites of vascular 
inflammation, preventing blood leakage into the oedematous tissue rather than forming 
a haemostatic plug (Gros, 2015). 
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Within the immune system, GPVI also appears to have multiple roles. GPVI has been 
shown to facilitate platelet-leucocyte interactions, helping recovery in mice with 
pneumonia (Claushuis, 2017). However, GPVI has also shown to bind and assist Hepatitis 
C in spreading (Zahn, 2006). The role of GPVI in cancer is less well understood also with 
conflicting research based mainly on mouse models suggesting a role in facilitating lung 
metastasis (Jain, 2009) and conversely increasing efficacy of chemotherapy (Volz, 2019). 
 
3.06 Glycoprotein VI shedding and downregulation 
After ligand binding and platelet activation, the GPVI extracellular domain is rapidly and 
irreversibly shed from the platelet surface at the juxtamembrane cleavage site (Bergmeier, 
2004; Gardiner, 2004). This GPVI shedding is mediated by the A disintegrin and 
metalloproteinase (ADAM) family of MMPs, and in humans, it is largely attributed to 
ADAM10 where as both ADAM 10 and 17 have a role on GPVI shedding in murine platelets 
(Gardiner, 2007). They are located on the membrane of resting platelets and results in a 
roughly 55 kDa GPVI-fragment being released from platelets the platelet surface (sGPVI) 
(Bigalke, 2009).  
 
Other regulators of GPVI shedding also exist. Platelet granules also contain MMPs which 
are released from storage into extracellular and interstitial spaces (Gardiner, 2018). 
Specifically, for GPVI, MMP-9 and 13 may have a role in downregulating GPVI function in 
thrombosis, although it is not clear whether this is through receptor cleavage (Claushuis, 
2017; Howes, 2018). Other studies have shown that GPVI can be shed in the absence of 
collagen in a factor Xa-dependent manner, where drugs such as factor Xa-inhibitor 
rivaroxaban inhibited the coagulation induced GPVI shedding in vitro which is of extreme 
importance since the availability and use of DOACs (Al-Tamimi, 2011). Finally, GPVI 
deficiencies have been described in patients with immune thrombocytopenic purpura, 
where auto-antibodies are felt to induce GPVI shedding (Boylan, 2004; Rabie, 2007). 
 
Although downregulating the platelet response through receptor shedding after 
thrombosis is likely to be a protective mechanism to reduce platelet responsiveness and 
govern cellular functions, the exact role of platelet shedding is yet to be fully elucidated. 
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Elevated plasma sGPVI levels have been detected after myocardial infarction and stroke, 
suggesting a potential role in diagnostic, prognostic and therapeutic strategies in 
thrombotic diseases (Bigalke, 2010; Wurster, 2013). Therefore, the clinical significance of 
GPVI downregulation on platelets is the subject of much interest and research within the 
field (Chatterjee, 2017). 
 
3.07 Glycoprotein VI inhibition 
Much of the early work on GPVI-inhibition were focussed on mouse models or in vitro 
studies, progressing through work performed by Nieswandt and colleagues using the rat 
anti-GPVI mAb,  JAQ1, on mouse platelets (Nieswandt, 2001). They showed that JAQ1 
caused a sustained loss of GPVI from the mouse platelet surface, with a corresponding 
downregulation of platelet responsiveness and a near-complete loss of aggregation to 
collagen (Massberg, 2003). Interestingly, JAQ1 did cause a transient thrombocytopaenia 
which lasted less than 2 weeks on average, with normalisation of the murine platelet 
count. Kleinschnitz and colleagues showed that GPVI inhibition leads to  significantly 
reduced infarct size after transient middle cerebral artery occlusion (tMCAO) in mice, 
without a change in platelet count and increase in bleeding complications, although a non-
significant increase in tail bleeding times were observed (Kleinschnitz, 2007) and Pachel et 
al have recently shown that anti-GPVI protects against myocardial reperfusion injury in 
mice (Pachel, 2016). GPVI-inhibition also appears to translate well when used in elderly 
and comorbid mice with induced tMCAO ischaemic stroke, demonstrating reduced infarct 
size and improved functional outcome (Kraft, 2015).  
 
Since JAQ1, numerous other antibodies have been raised against human GPVI. The 
fragment antigen-binding (Fab) fragments of such antibodies – notably 5C4 (Massberg, 
2004), OM2 (Matsumoto, 2007), OM4 (Li, 2007), 9012 (Lecut, 2003), and mFAB-F (GPVI-
dimer specific) (Jung, 2009) are potent inhibitors of GPVI-mediated platelet activation. 
Single domain antibody clones (Walker, 2009) as well as single-chain variable fragments 
(scFv) have been developed against GPVI (Smethurst, 2004; Muzard, 2009). Researchers 
are also investigating the feasibility of blocking kinases involved in GPVI-signalling 
pathways as a method of inhibiting GPVI-mediated platelet activation (Spalton, 2009), 
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although their success maybe limited due to the shared signalling pathways used in 
platelets. 
 
Human studies investigating GPVI-inhibition have pushed the field forward in terms of 
developing GPVI as a thrombotic target. The most successful so far has been Revacept, a 
recombinant fusion protein formed between the collagen binding extracellular domain of 
GPVI and the Fc part of human IgG, creating a soluble GPVI-dimer analogue (GPVI-Fc) 
(Massberg, 2004). It specifically binds to collagen with high affinity and competes with 
native platelet GPVI to the exposed GPVI-binding site on collagen at sites of 
atherothrombosis in vivo (Bültmann, 2006).   
 
Revacept was used in an open-label Phase 1 dose-escalation study in 30 healthy men to 
better understand safety and tolerability of the drug after a single intravenous dose (5 
doses with n=6 in each group). Revacept was shown not to affect international normalised 
ratio (INR), activated partial thromboplastin time (aPTT) or platelet count, whilst dose-
dependently inhibiting collagen induced platelet aggregation for up to a week in higher 
doses with almost full inhibition seen at 24 hours (Ungerer, 2011). Specifically for 
ischaemic stroke, Revacept has shown to significantly reduce infarct size and improve 
functional recovery after tMCAO occlusion in mice (Goebel, 2013), showing potential as a 
single agent, or an adjunct to low dose rtPA administration (Reimann, 2016).  
 
In vitro models have shown that crosslinking GPVI-Fc onto collagen fibres can be a site-
selective method of inhibiting plaque induced platelet activation (Jamasbi, 2016). 
Furthermore, the addition of GPVI-Fc to in vitro atherosclerotic plaques appears to be able 
to compound the reduction in platelet activation by aspirin and ticagrelor individually or 
both together (Mojica Muñoz, 2017). The advantage of GPVI-Fc based pharmacological 
therapy is it is highly selective to collagen exposed sites of plaque-rupture only. This may 
convey additional benefits in those prone to bleeding by not effecting the haematological 
system, as it only competes with the binding site of GPVI-dimer on collagen, not on the 
platelets themselves. However, where in stroke treatment Revacept could be utilised and 
its efficacy and side-effects at higher doses in larger numbers of patients with 
cardiovascular disease is yet to be determined. We await the results of the Phase 2 study 
 57 
investigating its use in symptomatic carotid artery stenosis, TIA, amaurosis fugax or stroke 
where patients receive either Revacept (single dose) plus antiplatelet monotherapy or 
monotherapy alone, which has just completed recruitment in October 2018. 
 
The other anti-GPVI therapeutic agent of note is ACT017, a humanised Fab fragment has 
also concluded a randomised, placebo-controlled, double blind, phase 1 trial in 6 cohorts 
of 48 healthy volunteers. ACOT017 demonstrated a modest reduction in collagen induced 
platelet aggregation lasting up to 2 days alongside a non-significant increase in bleeding 
times and no significant variation in platelet count (Voors-Pette, 2019). Similar to the 
Revacept data, we will await further results on the efficacy of ACT017 in phase II trials to 
come. The main antibodies or fusion proteins developed against GPVI are listed in Table 
3.2. 
 
Although not through an antibody mediated effect, Losartan has recently been proposed 
as a novel GPVI-receptor antagonist, unique within the sartan family (Taylor, 2014). Active 
metabolites of Losartan have been identified as a specific GPVI inhibitor by reducing GPVI-
dependent human platelet adhesion to collagen under shear in vitro and aggregation of 
platelets in vivo (Grothusen, 2007), possibly through inhibition of collagen induced Ca2+ 
release (Taylor, 2014) or inhibition of collagen-induced clustering (Jiang, 2015). Although 
it must be highlighted that administration of a therapeutic dose of losartan to 
normotensive patients revealed no measurable effect on platelet reactivity, suggesting 




 Type Effects 
 
JAQ1 Rat anti-mouse mAb Reduction of platelet adhesion to SEM 
 
Inhibition of collagen-induced platelet 
aggregation in mice 
 
9012 Mouse anti-human GPVI Fab Inhibition of platelet adhesion to collagen 
and CRP 
 
Inhibition of thrombus formation under in 
vitro flow studies 
 
5C4 Rat anti-human GPVI Fab Inhibition of platelet adhesion to 
fibronectin 
 
OM2 Mouse anti-human GPVI Fab Inhibition of collagen-induced platelet 
aggregation ex vivo in monkeys 
 
OM4 Mouse anti-human GPVI Fab Inhibition of collagen induced platelet 
aggregation in vitro and ex vivo 
 
Reduction of rat carotid artery thrombus 
formation in vivo under flow 
 
10B12 Human scFv against human GPVI Inhibition of collagen- and CRP-XL-induced 
platelet aggregation 
 
mFAB-F Human anti-GPVI-dimer Fab Inhibition of recombinant GPVI binding to 
collagen and CRP 
 
Inhibition of thrombus formation under in 
vitro flow studies 
 
ACT017 Human anti-GPVI Fab Reduction in collagen-induced platelet 
aggregation in healthy human volunteers 
 
Revacept Dimeric recombinant GPVI-Fc 
fusion protein 
Inhibiting collagen-induced platelet 
aggregation in healthy men 
 
Reduce cerebral infarct size and improve 
functional recovery in mice 
 
Table 3.2 Antibodies and their inhibitory effect on GPVI-mediated platelet activity. SEM 
= subendothelial matrix. 
 
 59 
3.08 Glycoprotein VI ligands: GPVI binding to fibrinogen and fibrin 
It has long been felt that GPVI has a role in thrombosis outside of exposure to collagen. 
For example, it has been demonstrated that GPVI can support thrombin induced platelet 
activation, outside of its normal collagen-induced signalling pathway (Hughan, 2007) 
Furthermore, laminin was shown to stimulate platelet spreading through GPVI activation 
(Inoue, 2006) and GPVI inhibition was observed to significantly reduce platelet adhesion 
to fibronectin (Bültmann, 2010) and vitronectin (Schönberger, 2012), suggesting multiple 
GPVI-ligands outside the classic GPVI-collagen binding pathway. 
 
At the time of starting this PhD, two groups had also shown that GPVI could be a receptor 
for fibrin, but not much was known about this interaction at the time (Alshehri, 2015; 
Mammadova-Bach, 2015). Mammadova-Bach and colleagues demonstrated that 
thrombin generation in fibrinogen-deficient patients was reliant on functional GPVI, that 
9012 Fab (anti-GPVI) causes a reduction in both static adhesion of recombinant GPVI to 
fibrin, and human platelet adhesion to fibrin at different shear rates, and that recruitment 
of circulating platelets to fibrin-rich clots was GPVI-dependent. Alshehri et al. showed that 
the pattern of tyrosine phosphorylation through thrombin in human and mouse platelets, 
in the absence of integrin aIIbb3 and PAR4, was similar to what is seen when induced by 
GPVI, and that the GPVI ectodomain (sGPVI) bound to immobilised fibrin. Both groups 
concluded that fibrin is a novel ligand for the platelet collagen receptor GPVI; however, 
from these studies it was difficult conclusively decide whether it was the monomeric, 
dimeric or both forms of GPVI that was stipulated to bind to fibrin. 
 
What made the GPVI-fibrin interaction tantalising in terms of ischaemic stroke was that it 
suggested that the main collagen binding, platelet activating receptor, GPVI-dimer, could 
have an important role in the thrombus formation in both large artery and cardio embolic 
stroke. If indeed GPVI did bind fibrin, this suggested a key role in stabilising thrombus 
growth through GPVI-fibrin interactions during atherosclerotic plaque rupture in large 
artery stroke, after platelets had been activated through GPVI-collagen binding. This was 
previously suggested from observations that GPVI plays a role in the latter stages of 
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thrombus formation where platelet-fibrin interactions predominate, although at the time 
it was not known whether this was due to an relation with fibrin or not (Bender, 2011). 
 
What is also interesting is that Mammadova-Bach et al report a marked impairment in 
thrombin generation at both low and high sear rates, along with reduced platelet adhesion 
to fibrin in GPVI- deficient patients (Mammadova-Bach, 2015). This suggested that GPVI 
may also play a role in propagation of thrombus formation at low shear, and also during 
the early stages of thrombus formation too. Therefore, GPVI-dimer could also have an 
instrumental part to play in the development of non-arterial thrombi, independent of 
plaque rupture, ECM exposure and GPVI-collagen binding, and instead through GPVI-fibrin 
interactions alone. This is especially important in thrombotic diseases such as venous 
thromboembolism or cardioembolic stroke, where low shear, hypoxia-driven endothelial 
dysfunction causes activation of the coagulation system, fibrin deposition and platelet 
activation. 
 
3.09 Objectives of the thesis 
This thesis aims to address the following research questions 
1) Does GPVI-dimer bind to fibrin(ogen) and activate platelets?  (Chapter IV and 
V) 
2) Does it play a primary, or supportive role in these interactions? (Chapter IV and 
V) 
3) Does inhibition of GPVI-dimer lead to reduced thrombus formation on both 
collagen and fibrin? (Chapter V) 
4) Do patients with atrial fibrillation, at risk of cardioembolic stroke, have more 
active platelets compared to healthy controls, and is part of this activity related 
to GPVI expression on platelets? (Chapter VI) 
5) Similarly, do patients who present with stroke have more active platelets 
compared to controls, and is part of this activity related to GPVI expression on 
platelets? (Chapter VII) 
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6) What does this tell us about the role of GPVI-dimer in thrombotic disease with 
respect to thrombus formation and structure in ischaemic stroke and could it 
represent a viable anti-thrombotic target? (Chapter VIII) 
 




It is the dimeric, collagen binding form of GPVI that also binds to fibrin and therefore 
plays a key role in thrombus formation in ischaemic stroke patients. 
 
Secondary hypotheses 
1. Inhibition of GPVI-dimer will reduce thrombus formation on collagen and fibrin 
surfaces in vitro 
2. GPVI-dimer is over-expressed on the platelet surface of patients at risk of 
cardioembolic stroke from atrial fibrillation 
3. GPVI-dimer is over-expressed on the platelet surface of patients with ischaemic 
stroke 












CHAPTER IV. METHODS: 
INVESTIGATING THE BINDING OF 
GLYCOPROTEIN VI-DIMER TO 








Phosphate buffered saline 
Phosphate buffered saline (PBS) was made from dissolving a phosphate-saline tablet with 
200 mL of distilled water to obtain a 137 mM NaCl, 2.7 mM KCl and 10 mM phosphate 
buffer solution (pH 7.4 at room temperature; Sigma- Aldrich, USA), stored at 4 °C. 
 
Hepes-Tyrodes buffer  
Hepes-Tyrodes (HT) buffer contains the following; 134 mM NaCl, 2.9 mM KCl, 0.34 mM 
NaH2PO4, 5.5 mM glucose, and 5mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic 
acid (HEPES) and was filtered prior to storage at 4 °C. The buffer is used at room 




Flow (Fc) buffer (136mM NaCl, 2.7mM KCl, 5mM HEPES, 10 mM Glucose, 2mM MgCl2, 
2mM CaCl2 , 0.5% bovine serum albumin (BSA)) was used in flow adhesion experiments. 
The buffer was filtered prior to storage at 4 °C and a pH of 7.4 was verified prior to 
experimental use.  
 
(b) Collagen, Collagen-Related Peptide and fibrinogen 
Collagen 
Pepsin-treated bovine collagen type-III (col-III; (non-fibrous; Koken, Japan and horse 
collagen (HORM; fibrous; Takeda, Austria) were mainly used instead of synthetic peptides 
where described.  
 
The synthetic crosslinked collagen related peptide CRP-XL; [GCO–(GPO)10–GCOG-NH2] was 
used as a GPVI-specific agonist (Morton, 1995). GPP10-XL [GCP-(GPP)10G–NH2] is an 
inactive analogue where the third hydroxyproline is substituted for a proline; therefore it 
does not bind GPVI, justifying its use as a negative control (Smethurst, 2007). Both 
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peptides were synthesised and crosslinked in-house, by Drs A Bonna and J-D Malcor at the 
Farndale laboratory. 
 
Fibrinogens and their substrates 
Different human fibrinogen preparations were used in the initial experiments, prior to 
settling on Fibrinogen 3 (Fib-3; Enzyme Research Laboratories, UK) because it was 
plasminogen-, vWF- and fibronectin-depleted, but not factor XIII-depleted.   
 
Human fibrinogen D-fragment and E-fragment was commercially obtained (Thermo Fisher 
Scientific, USA) as well as fibrin D-dimer (Abcam, UK). Table 4.1 summarises the 
commercial preparations of human fibrinogen and derivatives used. The manufacturer’s 
stated purity was confirmed by sodium dodecyl sulphate polyacrylamide gel 




Name Abbreviation Characteristics Commercial Source 
Fibrinogen Fib-Sigma 340 kDa. Other characteristics 
not stated by manufacturer 
Sigma Aldrich, UK 





















Fibrin D-dimer D-dimer 200 kDa, plasmin-cleaved Abcam, UK 
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Table 4.1 The commercial preparations of human fibrinogen, D-, E- fragments and D-dimer 
used as well as the manufacturer stated structure and composition. 
 
(c) Recombinant glycoprotein VI monomer and dimer 
GPVIex is a 41 kDa recombinant protein comprising the extracellular domain of GPVI, 
including the collagen binding portions D1 and D2 (amino acids 1-214), alongside most of 
the highly glycosylated extracellular stem portion.  
 
GPVI-Fc2 is a 150 kDa fusion protein of the GPVI extracellular domain (same amino acid 
sequence as GPVIex) and the Fc domain of IgG, which spontaneously dimerizes [(GPVI-Fc)2, 
abbreviated as GPVI-Fc2].  Both proteins were expressed, designed and characterized by 
Dr M Moroi and colleagues (Miura, 2002). 
 
 
Figure 4.1 Recombinant proteins of GPVI-extracellular domain containing the collagen 
binding D1 and D2 domains and the heavily glycosylated stem portions. S-S denotes 
disulphide bonds. Figure courtesy of Dr Stephanie Jung. 
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(d) Antibodies used in GPVI detection 
mFAB-F is a GPVI-dimer–specific, inhibitory, human Fab that recognises the dimers on 
resting and activated platelets as well as inhibiting collagen induced platelet aggregation. 
204-11 mAb was first developed as a mouse antibody against GPVI and was found to 
detect both forms of GPVI on resting or activated platelets, without exerting any inhibitory 
of activatory properties. The Fab portion from this mAb, 204-11 Fab, was developed later 
as a GPVI-dimer–specific, non-inhibitory Fab. All antibodies were developed by Drs M 
Moroi and S Jung. 
 
1G5 (BioCytex, France) is an mouse mAb raised against recombinant GPVIex (Inoue, 2006; 
Al-Tamimi, 2009), but binds to both monomers and dimers with similar affinity and 
therefore used to detect total GPVI. GPVI-specific antibodies their affinities for GPVI 
monomer and dimer are summarised in Table 4.2 (Jung, 2009, 2012).  
 
 
Table 4.2 The dissociation constants (Kd) for binding of recombinant GPVI-dimer and 
monomer to antibodies against the extracellular domain of GPVI. Both mFAB-F and 204-
11 Fab are specific to GPVI-dimer, therefore their binding to GPVI-monomer is too low to 
calculate Kd values. 1G5 and 204-11 can be used to detect both forms of GPVI. Data 
reported by (Jung, 2012). 
 
Antibody Kd (dimer), nM Kd (monomer), nM Form Specificity 
mFAB-F 10.83 ± 0.60 Undetectable Fab Dimer 
204-11 Fab 1.05 ± 0.10 Undetectable Fab Dimer 
204-11 mAb 0.16 ± 0.01 4.09 ± 0.44 IgG Both 
1G5 0.37 ± 0.03 0.20 ± 0.02 IgG Both 
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4.02 Methods 
(a) Preparation of fibrin from fibrinogen 
To prepare polymerised fibrin (pFibrin) for static adhesion, aggregometry and flow 
adhesion studies, thrombin (2 U/mL; Sigma-Aldrich, UK) was added to fibrinogen (10 
μg/mL, unless otherwise stated), incubated for 30 min at room temperature before 
coating onto the required surface and left overnight at 4°C. The coated surface was 
blocked with 0.5% BSA, treated with hirudin or protease inhibitor cocktail for 10 min to 
inhibit active thrombin, and then washed with PBS. Presence of fibrin strands was 
confirmed by Dr S Jung (Supplementary Figure 4.2) by staining with anti-fibrin 
(UC45)/Alexa-Fluor-Plus 555 anti-mouse IgG (ThermoFisher Scientific).  
 
Immobilized monomeric fibrin (mFibrin) was prepared by adding GPRP (2 mM) to 
fibrinogen (10 μg/mL, unless otherwise stated), and incubated for 30 min at room 
temperature before adding thrombin as above; other procedures are the same as for 
pFibrin.  
 
(b) Glycoprotein VI-fibrin binding ELISA assay 
96-well black optical polymer-bottom ELISA plates (Thermo Fisher Scientific, USA) or 
Maxisorp ELISA plates (Thermo Fisher Scientific, USA) were incubated with fibrinogen or 
collagenous substrates in PBS as required. The coated plates were left overnight at 4°C 
and washed with PBS (250 µL x 3) the following morning, blocked with 0.5% BSA and left 
for 1-hour. The required concentrations of GPVIex or GPVI-Fc2 (usually 0–50 µg/mL unless 
otherwise stated) diluted in 0.5% BSA was then added before a further 1-hour incubation.  
 
Bound GPVI was detected using the pan-GPVI antibody 1G5 as the primary antibody (4 
µg/mL in 0.5% BSA), followed by (1:10000 in 0.5% BSA) IRDye®800CW goat anti-mouse 
IgG (Li-cor Biosciences, USA) or 1:4000 Alexa-fluor 647–conjugated anti–human Fc 




GPVI binding was quantified using fluorescence (AU) through the immunofluorescence or 
near infra-red detection capabilities of the Li-cor Odyssey CLx system.  
 
(c) Human washed platelet preparation 
Blood was taken by venepuncture from healthy volunteers with informed consent under 
the ethics obtained (Human Biology Research Ethics Committee, HB REC.215.18). The 
universal 9 mL Sarstedt blood tubes were pre-prepared with the addition of 900 µL of 
citrate prior to venepuncture (1.62 g of trisodium citrate/50 mL of distilled water) to make 
a final ratio of 1:9. 
 
To prepare washed platelets, whole blood was centrifuged at 1200 RPM for 12 minutes to 
retain platelet rich plasma (PRP). 4.5 µL of 1 mg/mL prostaglandin E2 (PGE2) was added per 
9 mL of PRP to inhibit unwanted platelet activation. The PRP was removed and then 
centrifuged at 2200 RPM for 10 minutes, creating platelet poor plasma (PPP) and a platelet 
pellet at the bottom of the tube. The PPP is removed and can be used in aggregometry if 
needed. 1 mL of HT per 9 mL of original blood volume is then added to the platelet pellet 
and mixed to re-suspend. 
 
A Beckman Coulter Counter was used to establish the platelet count by using 5 µL of re-
suspended platelets in 10 mL of isotonic counter solution. The platelets were allowed to 
rest for 20 minutes prior to experimentation. 
 
(d) Platelet aggregometry 
A PAP-8E light transmission aggregometer (Bio/Data corporation, USA) was used for all 
aggregation experiments. 300 µL of washed platelets at a concentration of 2.5 x 108 were 
added to siliconized glass tubes, either untreated or pre-incubated with 100 µg/mL of 
mFAB-F to inhibit GPVI-dimer, or 45 µM of Eptifibatide to inhibit integrin aIIbb3. The 
platelets ± inhibitors were left for 10 minutes prior to starting aggregometry. Platelets are 
then warmed to 37°C for 1 minute and the stimulations are allowed to proceed under 
stirring. At 3 minutes, D-fragment, D-dimer, fibrinogen or pFibrin (5- 20 μg/mL) was added 
to the platelet mixture. If no aggregation occurred by 8 min, HORM collagen was added to 
induce platelet aggregation, verifying that the platelets were active.  
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(e) Whole blood flow adhesion 
  
Figure 4.2 Flow adhesion set up. Whole blood is perfused through a Perspex flow chamber 
placed within a metal gasket. This is then mounted onto the confocal microscope dock for 
image acquisition. 
 
The flow adhesion set-up within the Farndale lab is illustrated in Figure 4.2. Glass 
coverslips were coated with fibrinogen, fibrin, their relevant substrates and collagen III at 
10 µg/mL in PBS and left overnight at 4°C in a black humid chamber. The following day, 36 
µL of the anticoagulant D-phenylalanyl-prolyl-arginyl chloromethyl ketone (PPACK) was 
added to a 9 mL universal blood and healthy volunteer blood or blood from patients with 
Glanzmann’s thrombasthenia (GT) which was collected via venepuncture, with informed 
consent under the ethics obtained as above. Glass coverslips with the immobilised 
substrate are then attached to a 125 µm deep flow chamber within a metal gasket and 
then mounted to an Olympus FV300 laser-scanning confocal microscope.  
 
Platelets in whole blood were fluorescently labelled with 1:4500 DiOC6 (3,3’-
dihexyloxacarbocyanine iodide) and left for 5 minutes. After this stage, any required 
platelet receptor inhibitors are added (human Fab 100 µg/mL as a control Fab; mFAB-F 
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100 µg/mL for GPVI-dimer; Eptifibatide 45 µM for aIIbb3 and Gi9 10 µg/mL for a2b1) and 
left for a further 15 minutes. After perfusion of Fc buffer (treated with protease inhibitor 
cocktail for preparations that required thrombin) for 1-minute, whole blood was perfused 
over the coverslips at a either 350 s-1 or 1000 s-1. Whole blood preparations are topped up 
with 1:1000 PPACK every hour. 
 
Shear rate g(cs), s-1 100 300 1000 3000 
Flow rate ml/sec 0.000391 0.001174 0.003915 0.011744 
Flow rate (Q) ml/min 0.023 0.070 0.235 0.705 
 
Table 4.3 Pump settings for flow adhesion experiments. The flow rate (Q) in mL/min that 




After 5 min, Z-stacks (DZ = 0.69 µm increments from the coverslip plane) were collected 
and analysed by ImageJ 1.35 (National Institutes of Health). The coverslip plane was 
defined as the Z-plane with the largest fluorescent platelet area and used to calculate 
platelet surface area coverage (SA; µm2). Thrombus volume (µm3) was calculated as the 
sum of the detected surface areas of all images in the Z-stack, multiplied by DZ. Mean 
thrombus height (MTH) was calculated as thrombus volume/field area (Figure 4.3). 
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Figure 4.3 Calculation of platelet surface area coverage (SA) and mean thrombus height 
(MTH). 
 
4.03 Statistical analysis 
Kd were recalculated using non-linear regression (one-site model). For means testing for 
parametric and non-parametric data, student’s t-test and Mann-Whitney U test were 
performed after normality testing.  Prism version 7.2 (GraphPad, CA) was used for 
statistical analysis and Image J version 1.22 (NIH) was used for analysis and quantification 
of flow adhesion images and data. 
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Supplementary Figure 4.1 SDS-PAGE confirming the manufacturer’s stated purity of 
fibrinogen and its derivatives. Fib-3, Fib-S, D-fragment, and D-dimer were applied at 
protein concentrations of 1- and 5-μg/protein per lane, Western-blotted, stained by 
Coomassie blue, and then scanned by the Licor Odyssey.  Fib-3 (lanes 1, 2) and Fib-S (lanes 
3, 4) show similar banding patterns, with the expected α, β, and γ subunits (as indicated 
in lane 1 only for simplicity). With D-dimer, lanes 5 and 6) the approximately 70 kDa band 
visible corresponds to the covalently crosslinked gamma chain, indicated in lane 6 as γ–γ. 
D-fragment only shows the γ and β chains, and no γ–γ as expected. The D-fragment a-
chain is in a degraded form with a lower molecular weight. This experiment was done by 









Supplementary Figure 4.2 pFibrin was created as per the methods. pFibrin was 
immobilised on MatTek glass dishes and stained with anti-fibrin/Alexa-fluor 547–anti-
mouse IgG (blue) after the surface was blocked with 1% BSA. The dishes were then 
thoroughly washed. pFibrin (blue) is clearly evident. P-selectin (red) expression (platelet 
activation marker) and aggregate formation is evident on the surface of the adhered 
platelets. Images were obtained with a 60x oil immersion objective on an Olympus FV500 











CHAPTER V. RESULTS: GLYCOPROTEIN 
VI-DIMER CONTRIBUTES TO 
THROMBUS FORMATION THROUGH 





Platelet collagen receptor Glycoprotein VI-dimer recognizes fibrinogen and fibrin through 
their D-domains, contributing to platelet adhesion and activation during thrombus 
formation. Induruwa I, Moroi M, Bonna A, Malcor JD, Howes JM, Warburton EA, Farndale 




(a) GPVI-Fc2 binds to immobilised fibrinogen D-domain and fibrin D-dimer 
Integrin aIIbb3 has been established as the main receptor for fibrinogen on platelets, 
where it exists in its inactive, low-affinity form until inside out signalling which opens up a 
fibrinogen binding site. This conformational change is pivotal for platelet aggregation and 
thrombus build up, which occurs through the initiation of outside-in signalling causing 
thrombin generation and platelet PS exposure (Ma, 2007). Integrin aIIbb3 can now also 
capture locally available fibrin to engage it in the growing thrombus, vital for thrombus 
growth and clot retraction.  
 
GPVI was identified as a receptor for fibrin potentially through fibrin-mediated GPVI-
signalling which supported continued thrombus growth through thrombin generation and 
increased PS exposure (Alshehri, 2015; Mammadova-Bach, 2015). Both studies also 
concluded that the polymerised structure of fibrin was essential for GPVI binding and that 
there was no interaction between fibrinogen and mFibrin with GPVI. 
 
As GPVI-dimer is the functional, collagen binding, form of GPVI, we wanted to investigate 
whether it was the GPVI-dimer that also bound to fibrin and whether it could also bind to 
fibrinogen. 
 
First an ELISA-based adhesion assay was used to investigate whether either of the 
recombinant GPVI constructs (GPVIex monomer and GPVI-Fc2 dimer) bound to immobilised 
fibrinogen or fibrin. The initial experiments were done using GPVI-Fc2 due to the limited 
supply of GPVIex. Fibrinogen (Fib-3) as well as the pFibrin and mFibrin created from each 
of the original concentrations of Fib-3 (10 – 200 µg/mL) were coated on plates as described 
in the methods section. The following day, GPVI-Fc2 was added at increasing 
concentrations between 0-50 µg/mL. At all coating concentrations of fibrinogen, mFibrin, 
or pFibrin, binding was too low and scattered to determine and accurate Kd. Therefore, it 
was determined that GPVI-Fc2 did not bind fibrinogen or fibrin under these conditions 







Figure 5.1 GPVI-Fc2 does not bind fibrinogen, pFibrin or mFibrin up to 200 µg/mL. The 
numbers in parentheses indicate the concentrations of fibrinogen used to coat the ELISA 
plate wells (μg/mL in PBS). GPVI-Fc2 (50 µg/mL shown) does not bind immobilised 
fibrinogen or their constituent pFibrin or mFibrin in this assay, up to 200 µg/mL. GPVI-Fc2 
binds well to collagen (10 µg/mL). Fluorescence values shown are the mean ± SEM, from 
3 different experiments, with duplicate repeats. 
 
Since the full-length fibrinogen or fibrin did not bind GPVI-Fc2 in this assay, we decided to 
use plasmin cleaved fibrinogen (D-, E-) and fibrin subdomains (D-dimer) alongside 
different commercially available fibrinogens as described in Table 2.1 and fibronectin and 
vitronectin. Collagen III was used as a positive control and 0.5% BSA as a negative control. 
GPVI-Fc2 (0-50 µg/mL tested) demonstrated specific and saturable binding to D-fragment 























































































Figure 5.2 (previous page) GPVI-Fc2 binds to D-fragment, D-dimer and collagen III. (A) 
GPVI-Fc2 (50 µg/mL shown) binds to D-fragment and D-dimer as well as collagen. In 
contrast, there is only very low binding to Fib-Sigma, Fib-1, Fib-3, and the corresponding 
pFibrin and mFibrin produced from thrombin +/- GPRP addition respectively. GPVI-Fc2 
demonstrates no binding to E-fragment, Fib Peak 1, fibronectin or vitronectin. 
Fluorescence values shown are the mean ± SEM, from 5 different experiments, with 
duplicate repeats. (B) Kinetic analyses of the binding of GPVI-Fc2 to D-fragment and D-
dimer to determine Kd values. GPVI-Fc2 (0-100µg/mL) exhibits saturable binding to both D-
fragment and D-dimer (coated at 5- and 10µg/mL). The Kd values for D-fragment and D-
dimer are comparable to the Kd value for collagen III (B-inset). 
 
The recombinant GPVI monomer, GPVIex (0–50 µg/mL), did not bind D-fragment, D-dimer 
or fibrinogen and exhibited poor collagen binding compared to GPVI-Fc2, as previously 
reported (Jung, 2012) (Figure 5.3). We were not able to test pFibrin binding due to the 
limited availability of GPVIex but since it did not bind to D-dimer, it was felt binding to 
pFibrin was unlikely. These results suggest that it is the dimeric form of GPVI, rather than 
GPVI-monomer is involved in binding to fibrinogen and fibrin, through their D-domains 









Figure 5.3 GPVIex does not bind D-domain or D-dimer. GPVIex (50 μg/mL shown) 
demonstrates no binding to immobilized Fib-Sigma, Fib-1, Fib-3, D-fragment or D-dimer 
with some binding to collagen III (all coated at 10µg/mL). Fluorescence values shown are 
the mean ± SEM, from 3 different experiments, with duplicate repeats. 
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To ensure that it was the extracellular D1D2 portion of GPVI-Fc2 and not the IgG or Fc 
portions of GPVI-Fc2 that bound to D-fragment and D-dimer, human Fc and DDR2-Fc2 
(recombinant Fc-fusion protein of discoidin domain–containing receptor 2, another 
collagen-binding protein, provided by Dr B Leitinger (Xu, 2011)) (0-20 µg/mL) and human 
IgG (0-25 µg/mL) were used in a similar binding assay with the fibrinogen substrates and 
collagen III as a positive control. As expected, DDR2-Fc2 bound to collagen, but, neither 
DDR2-Fc2, Human Fc or Human IgG were able to bind to fibrinogen derivatives. GPVI-Fc2 
bound well to fibrinogen derivatives and collagen (Figure 5.4). 
 
Furthermore, human integrin a2- and a1-domains (kindly provided by Dr S Hamaia) were 
tested to see if they bound to D-fragment or D-dimer (all coated at 10 µg/mL). These a-
domains bind their respective peptide sequences GFOGER and GLOGEN in the presence of 
Mg2+, whereas EDTA abolishes a-domain binding (Hamaia, 2012). As expected, a2 bound 
to GFOGER in the presence of Mg2+ and not EDTA and a1 bound to GLOGEN in the 
presence of Mg2+ and not EDTA. Neither of the a-domains were able to bind D-fragment 
or D-dimer irrespective of the availability of Mg2+ further suggesting that the GPVI-dimer 




Figure 5.4 GPVI-Fc2 binds D-domain and D-dimer through its D1D2 collagen binding 
extracellular domain. (A) Fib-3, D-fragment, D-dimer and collagen III were coated at 10 
µg/mL and reacted with 20 µg/mL of GPVI-Fc2 (black), DDR2-Fc2 (dark grey) and Human -
Fc (light grey). Only GPVI-Fc2 is able to bind D-domain, D-dimer and collagen. DDR2-Fc2 
bound to collagen as expected. (B) Fib-3, D-fragment, D-dimer and collagen III were coated 
at 10 µg/mL and reacted with 25 µg/mL of GPVI-Fc2 (black), Human IgG (grey). Human IgG 
did not bind fibrinogen, its derivatives or collagen III. Fluorescence values shown are the 








Figure 5.5 Integrin a2- and a1-domains do not bind D-domain or D-dimer. GFOGER, 
GLOGEN, D-fragment and D-dimer were coated at 10 µg/mL and left for 2 hours on 
Maxisorp 96-well clear plates. At each incubation step, 250 µL of PBS was used to wash 
x3. The GST-conjugated a2- and a1-domains (10 µg/mL) were then added to the coated 
wells. After 1 hour, a buffer containing 1:10000 HRP-conjugated anti-GST antibody was 
added. Colour was developed using a TMB substrate kit (Pierce) as per manufacturer’s 
instructions. Absorbance was measured using a 96-well plate reader at A450. Absorbance 
values shown are the mean ± SEM, from 1 experiment, with triplicate repeats. The a-
domains bind their respective peptide sequences in the presence of Mg2+, but not D-
fragment or D-dimer. 
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(b) mFAB-F inhibits GPVI-Fc2 binding to immobilised D-fragment, D-dimer 
and collagen 
 
The theory that GPVI-dimer binds to D-fragment and D-dimer in a specific manner is 
further supported by the ability of GPVI-dimer specific inhibitory antibody mFAB-F to 
reduce its binding to D-fragment and D-dimer (and collagen). Compared to the non-
specific human Fab, mFAB-F significantly reduced GPVI-Fc2 binding to collagen (P=0.01), D-
fragment (P=0.001) and D-dimer (P=0.004). 
 
 
Figure 5.6 mFAB-F significantly inhibits GPVI-Fc2 binding D-domain, D-dimer and 
collagen. Collagen III, D-fragment and D-dimer were coated at 25 µg/mL and left 
overnight. GPVI-Fc2 (50 µg/mL) was incubated for 15 minutes in the presence of either 
human Fab (hFab; 100 µg/mL), mFAB-F (100 µg/mL) or no inhibitor (control). mFAB-F is 
able to significantly reduce the binding of GPVI-Fc2 to D-fragment, D-dimer and collagen 




































































(c) The GPVI-dimer binding site on fibrin(ogen) is proximate to the 
collagen binding site 
 
The evidence so far suggested that the GPVI-dimer binds the D-domain of immobilised 
fibrinogen and the D-dimer region of fibrin. However, it had not yet been determined 
where the D-domain or D-dimer would interact with GPVI-dimer. Therefore, another ELISA 
assay was setup to investigate whether the binding site on GPVI-dimer to fibrin(ogen) was 
proximate to that of collagen, based on the current understanding that the collagen 
binding site on platelet GPVI-dimer was in its extracellular D1 domain (Horii, 2006).  
 
The results demonstrate that if GPVI-Fc2 is incubated in solution with collagenous 
substrates (collagen III, HORM, CRP-XL), its ability to bind to both immobilised D-fragment 
and D-dimer is reduced in a concentration-dependent manner. CRP-XL showed the most 
effective inhibition of GPVI-Fc2 binding to D-fragment and D-dimer at concentrations ³0.05 
µg/mL. Collagen III and HORM were able to inhibit GPVI-Fc2 binding at concentrations of 
³0.5 µg/mL. GPP10-XL was used as a negative control and did not inhibit the binding of 
GPVI-Fc2 to D-fragment or D-dimer (Figure 5.7). 
 
The converse experiment, where immobilised collagen substrates were reacted with GPVI-
Fc2 incubated with fibrinogen, fibrin and their respective subdomain fragments was also 
performed. None of these substrates were able to inhibit GPVI-Fc2 binding to collagen. This 
may because their affinity to GPVI-dimer is too low, compared with that between GPVI-
Fc2 and collagen when they are in suspension, or possibly that D-fragment and D-dimer 
may adopt a different conformation in solution so that they may not be able to interact 





Figure 5.7 Collagenous substrates compete with GPVI-dimer in binding to immobilised 
D-fragment and D-dimer. ELISA plates were coated with D-fragment and D-dimer (10 
µg/mL) and left overnight.  GPVI-Fc2 (20 µg/mL) was incubated with increasing 
concentrations of 0–20 µg/mL of collagen III, HORM, CRP-XL (0-1.5 µg/mL shown), or the 
negative control GPP10-XL in solution. (A) Collagen III and HORM showed similar 
concentration-dependent abilities to inhibit binding of GPVI-Fc2 to D-fragment, with 
complete inhibition at ³0.5 μg/mL. CRP-XL was effective at lower concentrations, 
producing complete inhibition at ³0.05 μg/mL. (B) The inhibition of GPVI-Fc2 to D-dimer 
showed a similar inhibition profile to D-fragment. As expected, GPP10-XL had little effect 
against GPVI-Fc2 binding. Data is presented as mean ± SEM obtained from 3 separate 
experiments with each data point determined in duplicate. 
  
(A) D-fragment


























Figure 5.8 GPVI-Fc2 is not able to interact with fibrinogen, fibrin or their subdomains in 
solution. ELISA plates were coated with collagen III, HORM and CRP-XL (10 µg/mL) and left 
overnight. GPVI-Fc2 (20 µg/mL) was incubated with 0–20 µg/mL of D-fragment, D-dimer, 
Fib-3 or pFibrin-3. E-fragment was used as a negative control. D-fragment, D-dimer, Fib-3 
pFibrin-3 or E-fragment could not inhibit binding of GPVI-Fc2 to immobilized collagenous 
substrates, suggesting that GPVI-Fc2 cannot bind to them in solution. Data is presented as 
mean ± SEM obtained from 3 separate experiments with each data point determined in 
duplicate.  
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The work so far helped to establish that recombinant GPVI-dimer and not the monomer 
bound to fibrinogen and fibrin, through their D-domain and D-dimer, and that GPVI-dimer 
specific inhibition by mFAB-F was able to significantly reduce binding. Furthermore, a 
competition assay using collagenous substrates in solution with recombinant GPVI-dimer 
inhibited its binding to D-fragment and D-dimer. However, it was curious as to why 
fibrinogen substrates incubated with recombinant GPVI-dimer were not able to inhibit 
GPVI-dimer binding to collagen.  
 
The ELISA assays described above are purified systems and serve to give us an indication 
of receptor-ligand interactions. However, these reactions in platelets are far more 
complex and can also be heterogenous. Various factors, including the activity of other 
receptors such as integrin αIIbβ3, availability of GPVI-dimer on the platelet surface, and 
signalling mechanisms via GPVI-dimer that may affect the affinity of GPVI-dimers to 
fibrinogen and fibrin. The next logical step, therefore, was to investigate how platelet GPVI 
interacted with fibrinogen and fibrin. 
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(d) D-dimer inhibits collagen induced platelet aggregation in solution 
 
Aggregometry was used to investigate if fibrinogen or fibrin interacted with platelet GPVI 
in the same way as collagen. Washed platelets were stimulated by fibrinogen and its 
derivatives or by HORM and light transmission was recorded at 37°C under stirring, as 
described in the methods. The addition of fibrinogen (Fib-3; 5-20 µg/mL), D-fragment (5-
10 µg/mL) or D-dimer (5-20 µg/mL), did not cause platelets to aggregate, but upon the 
addition of HORN collagen, platelet aggregation occurred (Figure 5.9A), consistent with 
the findings earlier that fibrinogen and its subdomains did not inhibit GPVI-Fc2 binding to 
collagen. pFibrin was able to cause spontaneous platelet aggregation (Figure 5.9B). The 
pFibrin induced aggregation was not inhibited by mFAB-F (100 µg/mL), however, 
Eptifibatide (45 µM) completely abrogated it. This suggests that the platelets are likely to 
become slightly activated during the washing process, especially integrin aIIbb3, but more 
importantly that platelet aggregation through pFibrin in suspension doesn’t require GPVI-
dimer. 
 
An interesting finding was that the addition of D-dimer to the platelet suspension inhibited 
HORM–induced aggregation of washed platelets in a concentration dependent manner 
(Figure 5.9C; raw values displayed in Supplementary Table 5.1). In platelets pre-incubated 
with 100 μg/mL of mFAB-F, thereby inhibiting GPVI-dimer activity, the addition of 5- or 10 
µg/mL of D-dimer concentrations to the platelet + mFAB-F suspension did not affect 
mFAB-F inhibition of HORM-induced platelet aggregation. Higher D-dimer concentration 
(20 µg/mL) however, relieves the inhibition (Figure 5.9D). This suggests that D-dimer may 
bind at a separate, but nearby site, perhaps producing a conformational change that may 
reduce the affinity of mFAB-F.  
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Figure 5.9 D-dimer is able to inhibit collagen induced platelet aggregation in a 
concentration dependent manner. Aggregometry of washed platelets (2.5x108 
platelets/mL) either untreated (A-C) or incubated with mFAB-F (D; 100 µg/mL) was 
performed. At 3 minutes, D-fragment, D-dimer, Fib-3 or pFibrin was added to the platelets 
as indicated. If no aggregation occurred by 8 minutes, HORM (3 µg/mL) was added to 
induce aggregation and confirm platelet activity. (A) Fib-3, D-fragment and D-dimer (10–
20 µg/mL) did not cause platelet aggregation. (B) pFibrin (20 µg/mL) was able to cause 
spontaneous platelet aggregation, prior to the addition of HORM. This was unaffected by 
mFAB-F (100 µg/mL) and abolished by Eptifibatide (45 µM). (C) D-dimer concentration-
dependently inhibited HORM–induced aggregation of platelets. (D) Pre-incubation of 
platelets in mFAB-F prior to addition of D-dimer caused an inhibition of platelet 
aggregation at 20µg/mL of D-dimer only. The above are representative figures as each 
experiment (A-D) was repeated 3 times, using different donor blood each time. 
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(e) Platelet glycoprotein VI-dimer inhibition reduces thrombus formation 
on fibrin(ogen) under flow 
 
To mimic the formation of a thrombus under venous or arterial shear, a flow chamber set-
up was used as described in the methods. Glass coverslips were coated with the substrates 
(below) and left overnight. 
§ D-fragment 10 µg/mL 
§ D-dimer 10 µg/mL  
§ Fib-3   10 µg/mL 
§ pFibrin  10 µg/mL 
§ mFibrin 10 µg/mL 
§ Collagen III 10 µg/mL 
 
For the initial experiments, DiOC6 fluorescently labelled, PPACK anticoagulated healthy 
volunteer blood was used, with either: 
• Control No antibodies added 
• Human Fab 100 µg/mL (control Fab) 
• mFAB-F  100 µg/mL (GPVI-dimer inhibition) 
• Eptifibatide  45µM  (integrin aIIbb3 inhibition; Tocris Biosciences, UK) 
• Gi9  10 µg/mL (integrin a2b1 inhibition; GeneTex, UK) 
 
Shear rates of 350s-1 to mimic venous shear or 1000 s-1 to mimic arterial shear were 
employed. Higher shear rates were not used due to the increased volume of blood, and 
also antibodies required to perform these experiments. Further information specific to the 
experiment can be found in the corresponding figure legends. Statistical significance 
between control/human-Fab vs. antibody inhibition was calculated using paired t-tests. 
 
In general, platelets adhered to and formed thrombi on collagen, fibrinogen and mFibrin 
the best at 350 s-1, with poorer platelet adhesion to both D-fragment and D-domain being 
observed. This may suggest that under shear, the full-length fibrinogen maybe required to 
capture platelets efficiently. Platelets also did not adhere to pFibrin very well; however, 
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when they did adhere, they tended to make thrombi better than on D-fragment and D-
dimer alone. As expected, the platelets formed the largest thrombi on collagen, their MTH 
were often twice as large any of the other fibrinogen substrates (Figure 5.10) 
 
GPVI-dimer inhibition through mFAB-F significantly reduces SA of all fibrinogen substrates 
(D-fragment (P=0.0045), D-dimer (P=0.046), Fib-3 (P = 0.025), pFibrin (P=0.027), mFibrin 
(P=0.046)) and collagen III (P = 0.01) compared to the control. Although only significantly 
reduced on D-fragment (P=0.0018) and mFibrin (P=0.0029), MTH was non-significantly 
reduced on all coated substrates with GPVI-dimer inhibition (Figure 5.10: B&C). 
 
The poor reduction in MTH maybe explained due to the fact that platelets poorly adhered 
to fibrinogen substrates with GPVI-dimer inhibition in the first place, and that this may 
precludes them from forming thrombi. This suggests that the primary role of GPVI-dimer 
with respect to a GPVI-fibrin interaction is to assist platelets in adhering to fibrin(ogen) 
surfaces. As expected, the greatest inhibition of MTH with mFAB-F was seen on collagen 
III (P= 0.0091) (Figure 5.10 B&C). 
 
Inhibition of aIIbb3 using Eptifibatide nullified platelet adhesion and thrombus formation 
on all fibrinogen surfaces (Figure 5.10). On collagen, platelets adhered well, using their 
functional GPVI-dimer and a2b1, but were unable to form more than a platelet monolayer 
under shear (A, bottom right). 
 
The inhibition of a2b1 using Gi9 made no significant difference to SA or MTH on fibrinogen 
substrates or collagen (Figure 5.10: D&E). To ensure specificity, mFAB-F was tested against 
a concentration-matched human FAB preparation in healthy volunteer blood. mFAB-F 
demonstrated a reduction in SA and MTH on all tested substrates, with significant SA 
inhibition on fibrinogen (P=0.0061), pFibrin (P=0.0069), mFibrin (P=0.015), and collagen III 
(P=0.035). MTH was reduced on D-fragment (P=0.048), D-dimer (P=0.042), Fib-3 









Figure 5.10 Quantification of platelet SA and MTH at 350 s-1. mFAB-F significantly reduces 
thrombus formation on fibrinogen substrates. (A) The images in are representative of 6 
flow experiments performed with blood from different healthy donors. (B +C) Inhibition 
of αIIbβ3 abrogated SA and MTH to all fibrinogen derivatives. mFAB-F reduced platelet 
adhesion (SA) to all 5 fibrinogen derivatives and significantly suppressed MTH on D-
fragment, mFibrin and collagen compared to the control. (D+E) The inhibition of GPVI-
dimer with mFAB-F compared to the effect of human Fab and Gi9 (anti-α2β1) under the 
same conditions. Compared to human Fab, mFAB-F significantly reduced SA and MTH on 
all tested substrates, except SA on D-fragment and D-dimer, which nevertheless tended 
towards significance. *P<0.05, **P<0.01 ***P<0.001). 
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In contrast to collagen-bound vWF binding to GPIba at high-shear, the fibrinogen binding 
through platelet integrin aIIbb3 occurs at low shear rates (Savage, 1996). This is crucial 
when considering what role GPVI-dimer may play in its interaction with fibrin. Having 
established that at shear rates of 350 s-1 GPVI-dimer played an important role in platelet 
attachment to fibrinogen substrates, it was important to establish whether this would 
translate to shear rates of 1000 s-1. 
 
The same coating conditions, as well as antibody concentrations were used. Fluorescently 
labelled, PPACK anticoagulated whole blood was perfused over fibrinogen substrates and 
collagen. Platelets tended to adhere less to all substrates, including collagen at this shear 
rate and even though thrombus formation is seen on fibrinogen, pFibrin, mFibrin and col 
III, platelets are less able to form large thrombi. The inhibition of αIIbβ3 again abrogates 
SA and MTH at this shear rate, with platelets not adhering to the coverslip plane at all. 
mFAB-F has a significant effect in reducing SA to D-dimer (P = 0.053), fibrinogen (P=0.021), 
pFibrin (P=0.040), and collagen (P=0.020), as well as reducing MTH on fibrinogen (P=0.026) 
and collagen (P=0.0028) (Figure 5.11 B&C). This suggests that GPVI-dimer forms less stable 
interactions with fibrinogen derivatives at higher shear rates and that αIIbβ3 plays the 
predominant role here. 
 
When comparing the inhibitory effects of mFAB-F on SA and MTH between the two shear 
rates used (Table 5.1), it seems clear that GPVI-dimer plays its predominant role in platelet 
adhesion to fibrinogen and fibrin at low shear. At the higher shear rate, the effect of GPVI-
dimer inhibition was most effective in reducing MTH, but this was more variable and 









Figure 5.11 Quantification of platelet SA and MTH at 1000 s-1. (A) The images are 
representative of 5 flow experiments performed with blood from different healthy donors. 
(B + C) At high shear, platelets struggle to attach to, and form thrombi on D-fragment and 
D-dimer (SA and MTH around 3-fold less compared to at 350 s-1). Thrombus formation is 
seen on fibrinogen, pFibrin, mFibrin and col III. Eptifibatide abrogates SA and MTH, except 
on mFibrin and collagen even at 1000 s-1. The effect of mFAB-F is more variable, with the 















Table 5.12 Comparing surface area coverage (%) and mean thrombus height (µm) at low 
(350 s-1) and high shear (1000 s-1). The table shows the % reduction in surface area 
coverage (SA) or mean thrombus height (MTH) on all tested substrates with mFAB-F 
compared to the control. The higher reduction in SA or MTH achieved when comparing 
350 s-1 and 1000 s-1 is highlighted in light grey. Statistical significance was calculated using 
paired t-tests and significance of inhibition compared to the control is denoted where 
applicable *P<0.05, **P<0.01 ***P<0.001.  
  
% reduction in SA or MTH with GPVI-dimer inhibition (mFAB-F; 100 µg/mL) compared to control (no inhibition) 
 SA 350 s-1 SA 1000 s-1 MTH 350 s-1 MTH 1000 s-1 
D-fragment 76.2** 13.2 26.3** 60.9 
D-dimer 86.5* 36.5** 15.6 56.6 
Fib-3 59.8* 47.7* 68.8 80.7* 
pFibrin 35.7* 26.0* 17.4 24.2 
mFibrin 43.4* 33.2 50.8** Increased 
Collagen III 39.8** 55.5* 32.2** 59.5** 
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Glanzmann’s thrombasthenia (GT) is a bleeding disorder where patients have either no 
αIIbβ3 or non-functional αIIbβ3 on their platelet surface. GT platelets can adhere to 
exposed SEM and undergo shape change but the subsequent platelet spreading and 
thrombus formation is defective (Nurden, 2006). 
 
Blood was obtained from 2 individuals with GT (patients A +B). The absence of integrin 
aIIbb3 but not GPVI on the platelet surface was confirmed by flow cytometry using blood 
from patient A (Supplementary Figure 5.1) 
 
Labelled whole blood was then perfused over surfaces of D-fragment, D-dimer, fibrinogen, 
pFibrin and mFibrin (100 μg/mL) and collagen (10 µg/mL). Whole blood was obtained from 
a healthy volunteer for control measurements. Thrombasthenic blood was either perfused 
with or without the addition of mFAB-F (100 μg/mL) at 350 s-1. 
 
GT platelets retain some ability to adhere on all fibrinogen substrates, albeit at 
dramatically reduced levels compared to normal platelets. Despite this, no thrombus 
formation is seen on any of the fibrinogen substrates. Adhesion to collagen, through 
functioning GPVI and a2b1, is within normal values, although only a platelet monolayer is 
seen, rather than large thrombi. This is once again due to lack of aIIbb3 and the inability 
of platelets to properly aggregate. Therefore, the effect of adding mFAB-F to GT blood in 
terms of MTH cannot be assessed. However, SA appears to be further reduced when 
mFAB-F is added to GT blood. It is difficult to say with these results whether GPVI-dimer 
has an independent role in platelet adherence to fibrinogen and fibrin, but these results 
suggest that in the presence of functioning aIIbb3, GPVI-dimer has a supportive and 










Figure 5.12 Analysis of Glanzmann’s thrombasthenia platelets (n=2) under flow 
conditions. (A) GT platelets retain some ability to adhere on all fibrinogen substrates but 
only adhesion to collagen is within normal values. (B) There is no aggregate formation 
except a monolayer of platelets on collagen. mFAB-F appears to cause a reduction in 
platelet adherence to fibrinogen and collagen the most, with also a reduction of thrombus 





The two seminal papers by Mammadova-Bach et al. and Alshehri et al. in 2015 opened up 
a new field of research on GPVI as a possible receptor for fibrin (Alshehri, 2015; 
Mammadova-Bach, 2015). At the time of carrying out the experiments detailed in chapters 
IV and V, very little was known about the GPVI-fibrin interaction. In fact, many in the field 
of platelet research did not believe the initial discoveries to be correct. This newly 
identified role for GPVI still remains a little contentious, but there is now a growing 
evidence base that recognises GPVI as a receptor for fibrin. 
 
Mammadova-Bach’s paper from the Jandrot-Perrus group in France was the first to 
describe that GPVI is a functional receptor for fibrin. They used thrombin assays on PRP 
from control and GPVI-deficient patients to demonstrate that tissue-factor-triggered 
thrombin generation was defective in the GPVI-deficient patients. Similarly, this effect was 
reduced by the anti-GPVI Fab 9012. In a static binding assay using recombinant GPVI-Fc, 
9012 inhibited the interaction between GPVI-Fc and fibrin. Under flow, 9012 reduced 
platelet ability to adhere to fibrin at 300 s-1 and 1500 s-1 and finally, 9012 was able to 
decrease the recruitment of platelets to fibrin-rich clots by up to 85%. 
 
Three months later in August 2015, Alshehri and colleagues at the Watson group in 
Birmingham published their work, recognising that fibrin can activate GPVI-signalling in 
human and mouse platelets. They first showed that human and mouse platelets could 
undergo tyrosine phosphorylation induced by fibrin in the absence of aIIbb3 (in mice) or 
presence of Eptifibatide (in mice and humans). The authors reported that the pattern of 
tyrosine phosphorylation was similar to that induced by the activation of GPVI, including 
the FcRg-chain. Furthermore, they reported that the GPVI shed from the surface of 
platelets, which is presumed to be monomeric GPVI, binds to immobilised fibrin but not 
to fibrinogen. The spreading of platelets on fibrin was abolished in the absence of GPVI in 
humans and mice. Fibrin was also able to induce a threefold increase in the number of PS-
exposing platelets which as inhibited in GPVI-deficient patients. Possibly of most interest 
was the theory that GPVI plays an important role in thrombus stability. Using an FeCl3 
injury model they showed a 6.6-fold increase in the rate of embolisation from formed 
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thrombi in GPVI-deficient mice compared to wild type mice. Taking the papers together, 
the authors had described that GPVI was able to bind to fibrin, induce signalling causing 
tyrosine phosphorylation, thrombin generation together with platelet PS exposure and 
support thrombus formation under flow. 
 
The main results from this chapter are as follows: 
1) Recombinant GPVI-dimer (GPVI-Fc2), but not the monomer (GPVIex) binds to 
immobilised D-domain of fibrinogen and the D-dimer of fibrin.  
2) Collagen substrates competitively inhibit the binding of GPVI-Fc2 to immobilised D-
fragment and D-dimer in ELISA, suggesting proximity of the binding sites. 
3) GPVI-Fc2 does not bind to, and platelets are not activated by, fibrinogen substrates 
in solution. However, D-dimer in a platelet suspension can inhibit HORM induced 
platelet aggregation in a concentration dependent manner. 
4) GPVI-dimer specific inhibitory antibody mFAB-F is able to significantly reduce GPVI-
Fc2 binding to D-domain and D-dimer under static conditions, as well as platelet 
adhesion and thrombus formation on fibrinogen substrates under shear (350s-1 and 
1000s-1). 
 
This work was the first to conclusively report that the active, collagen binding form of 
GPVI, the GPVI-dimer, also binds to fibrinogen and fibrin through the D-domain region. 
However, in our static adhesion assays, GPVI-dimer was not able to bind to coated 
fibrinogen and fibrin directly. To investigate this further we looked into whether this was 
due to poor binding of the larger proteins (fibrinogen and fibrin) when coated in wells 
(Supplementary Figure 5.2) As suspected, fibrinogen and fibrin adhered poorly to the 
wells. However, since they each have two D-domains per molecule, the availability of 
fmoles D-domains/mm2 of well surface was similar. Therefore, we hypothesise that the 
reason we observed no binding of GPVI-dimer to fibrinogen and fibrin under our ELISA 
conditions could be due to the conformation the large fibrinogen and fibrin chains take up 
when immobilised in a well, where the possible D-domain binding sites are not available 
for recognition for GPVI-dimer (Zhang, 2017).  
 
 103 
Mammadova-Bach and colleagues also did not note any binding to fibrinogen in a similar 
assay, although they noted binding to fibrin. To overcome this, when the plasmin cleaved 
fibrinogen and fibrin subdomains were coated, we observed specific and saturable binding 
of GPVI-dimer to D-fragment and D-dimer. GPVI-dimer did not bind to the central 
fibrinogen E-domain. 
 
At the time of carrying out this work, one of the main questions we had was whether it 
was the dimeric, monomeric or both versions of GPVI that bound to fibrin – the answer to 
which would have had huge implications on future translational work. Our results show a 
clear preference of GPVI-dimer in binding to fibrinogen and fibrin, where the monomer 
showed no binding to fibrinogen substrates at all (we were not able to test GPVIex against 
polymerised fibrin, however, it did not bind to D-dimer). Furthermore, mFAB-F, which is 
able to recognise constitutive dimers on the platelet surface inhibited binding of GPVI-Fc2 
and platelets to fibrinogen and fibrin, suggesting a key role for GPVI-dimer here. 
 
As mentioned earlier, it remains controversial as to which form of GPVI, the monomer or 
the dimer binds to fibrin. Certainly, the GPVI-Fc construct used by Mammadova-Bach 
closely resembles our dimeric GPVI-Fc2, with the exception of an amino acid linker 
sequence (Slater, 2019). The antibody they used, 9012 Fab, can however inhibit both 
monomeric and dimeric GPVI on platelets. Comparisons between the GPVI-ectodomain 
used by the Watson group and our GPVIex are harder to make, especially as they have not 
characterised its binding to collagen. The physiological consequence of GPVI-monomer 
binding to fibrin is also unclear. It is likely that if the GPVI monomer is able to bind to fibrin 
as suggested by the Watson group, it would have to quickly dimerise/oligomerise in order 
to initiate the signalling required for platelet activation (Alshehri, 2015). 
 
The ability of collagens in solution with GPVI-Fc2 to inhibit its binding to coated D-fragment 
and D-dimer suggests that the collagen and D-domain binding sites on GPVI-dimer are 
proximate. This is further confirmed by the observation that soluble D-dimer is able to 
inhibit collagen-induced platelet aggregation in suspension. 
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A key finding from our work is that the immobilised nature of the fibrinogen substrates is 
important for platelet interactions through GPVI-dimer. Firstly, fibrinogen sub-domains in 
solution with GPVI-dimer cannot inhibit its binding to collagen. Secondly, aggregometry 
confirms that D-fragment, D-dimer and fibrinogen in solution do not cause platelet 
aggregation either and together these results suggest that GPVI-dimer cannot bind to 
fibrinogen, fibrin or their subdomains unless they are immobilised. Fibrin is able to induce 
platelet aggregation in suspension, but through a pathway that is independent of GPVI-
dimer, presumably through aIIbb3. This is crucial as platelet aggregation through binding 
to soluble fibrinogen does not occur in the circulation under normal conditions either, 
unless initial platelet activation has occurred, converting aIIbb3 to its high-affinity state 
(Li, 2010).  
 
Measuring the effect of GPVI on platelet adhesion and thrombus formation on fibrinogen 
substrates under flow is more complex than measuring direct binding using ELISA alone, 
especially as it involves a role for aIIbb3 at shear. GPVI-dimer inhibition using mFAB-F 
demonstrated that at low shear, GPVI-dimer inhibition significantly reduced platelet 
adhesion to all immobilised fibrinogen substrates. At higher shear, this effect was more 
varied, suggesting that GPVI-dimer exerts most of its effects on binding to fibrinogen and 
fibrin at low shear. It is clear that integrin aIIbb3 remains the most important receptor in 
platelet interactions with fibrinogen and fibrin. Its inhibition lead to completer abrogation 
of platelet adhesion and thrombus formation at both shear rates, particularly at high 
shear. Integrin a2b1 does not play an important role in platelet-fibrin adhesion, as it does 
with collagen. 
 
Integrin aIIbb3 has always been recognised as the main receptor involved in platelet 
aggregation and thrombus growth. However, an interesting observation was that even 
with GPVI-dimer inhibition alone, the ability of platelets to form large thrombi was 
compromised, despite the presence of  aIIbb3. A question that is then raised is whether 
GPVI-dimer inhibition leads to the reduction of signalling that could lead to platelet 




To explore this further, firstly we quantified thrombus formation under flow using GT 
platelets, with or without GPVI-dimer inhibition. Under flow, GT platelets were able to 
support binding to fibrinogen and fibrin, but these adhered platelets did not appear spread 
nor activated, suggesting that signalling may not occur in the absence of aIIbb3. GT 
platelets with additional GPVI-dimer inhibition adhered to fibrinogen substrates less than 
the GT platelets alone, suggesting that GPVI-dimer has a weak but independent role in 
platelet adhesion to fibrinogen substrates but cannot activate them without the presence 
of functioning aIIbb3. 
 
Previous studies have indicated that there are convergent tyrosine kinase signalling 
pathways downstream from GPVI and aIIbb3. For example, the cross-linking of GPVI 
induces Src-dependent tyrosine phosphorylation of FcRg (Gibbins, 1997). Similarly, 
signalling mediated by aIIbb3 also includes tyrosine kinases such as Syk and Src (Clark, 
1994; Gao, 1997), with specific blockade reducing the tyrosine phosphorylation of 
signalling proteins downstream from Syk in both the GPVI- and aIIbb3-dependent 
signalling pathways (Spalton, 2009). Our results demonstrate that the Src kinase inhibitor, 
Dasatinib, and mFAB-F each exert a similar inhibitory effect on platelet adhesion and 
spreading on fibrinogen substrates, indicating platelet-adhesion-induced signalling 
through GPVI-dimer is an important step in platelet spreading and activation on fibrinogen 
and fibrin (Supplementary Figure 5.3) 
 
To summarise, these results suggest that it is the GPVI-dimer that recognises immobilised 
fibrinogen and fibrin through their D-domain and D-dimer, respectively. Integrin aIIbb3 
remains the most important platelet receptor with respect to fibrin(ogen) interactions. 
GPVI-dimer exerts its main effects on platelet adhesion to fibrinogen and fibrin and may 
have a weak but independent role here. It is also likely that aIIbb3 and GPVI-dimer have 
collaborative roles in platelet activation when binding to fibrinogen and fibrin, 
demonstrated by platelets treated with both mFAB-F and Hip8 showing a further decrease 
in adhesion to fibrinogen substrates compared with Hip8 (integrin aIIbb3 inhibitor) alone 
(Supplementary Figure 5.3). The exact nature of this collaboration is yet to be determined, 
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but GPVI-dimer is likely to assist aIIbb3 in platelets binding to immobilised fibrinogen on 
the surface of other platelets, as well as increasing the stability of platelets already 
adhered to fibrin within a clot. Whether GPVI therefore has an effect in making clots less 
permeable and more resistant to lysis, which would have an impact on the effectiveness 
of acute stroke treatments such as rtPA needs to be established. 
 
GPVI-dimer clearly plays a key part in both initiation of thrombosis at sites of 
atherosclerotic plaque rupture through collagen and then the propagation and stability of 
these thrombi through binding to fibrin. However, what is tantalising is that our findings 
also intimate a role for GPVI-dimer in conditions where blood clots form without prior 
collagen exposure, including cardioembolic thrombi in AF, and other thromboembolic 
conditions such as DVT. Since this work was completed, the active research and evidence 
base on the GPVI-fibrin interaction has increased. A further discussion on this topic as well 
as how it relates to thrombus formation in ischaemic stroke can be found in chapter VIII. 
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Supplementary Figure 5.1 Flow cytometry analysis verified that the GT platelets from 
patient A contain no integrin aIIbb3 but had normal levels of GPVI.  Samples were 
measured in an Accuri C6 flow cytometer. The normal platelets had appropriate levels of 
aIIbb3 and GPVI. The GT platelets show have no aIIbb3 but normal levels of GPVI. This 








Supplementary Figure 5.2 Analysis of fibrinogen, D-fragment, D-dimer and fibrin 
adherence to plates. Nunc fluorescence black 96-well glass-bottomed plates were coated 
with a fibrinogen substrate (5, 50 μL/well of 10, 50, 100 μg/mL), 3 wells each, and left 
overnight at 4ºC. The substrate was discarded, and the wells washed 4 times (200 μL PBS, 
5 min, each wash). A 25 μL aliquot of 1%/8M urea was added to each well, and after 30 
min, protein was assayed by using the Pierce™ BCA Protein Assay Kit. Experiment 




Supplementary Figure 5.3 Confocal images of washed platelets adhered to fibrinogen 
derivatives and HORM collagen and the effect of inhibitors. Washed platelets suspended 
in HT buffer were pre-treated with human Fab (control, 200 mg/mL), inhibitory anti-GPVI-
dimer mFAB-F (200 mg/mL) or the Src inhibitor Dasatinib (50 nM) for 10 min and then 
were allowed to adhere to fibrinogen, fibrinogen derivative or HORM collagen 
immobilized on MatTek glass dishes, followed by fixation and staining with fluorescently 
labelled antibody. Images show platelets stained with Alexa-fluor 488–1G5 (green; pan 
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GPVI) and Alexa-fluor 647–anti-P-selectin (red) to measure platelet activation. Images 
were obtained with a 60x oil immersion objective on an Olympus confocal microscope. As 
shown in the left-most column of images, platelets spread well on fibrinogen, D-fragment, 
mFibrin and HORM collagen, with evident surface expression of P-selectin. Platelet 
aggregate formation was seen on pFibrin, whereas platelets spread but did not appear 
aggregated on mFibrin. HORM collagen supported aggregate formation, with the 
characteristic binding of GPVI along the HORM fibres. In contrast, platelets did not spread 
well on D-dimer, with only some platelets showing P-selectin expression. Treatment with 
mFAB-F (middle column of images) prevented platelet spreading on fibrinogen, D-
fragment and HORM collagen, and decreased the extent of spreading, with evident 
filopodia observed, on mFibrin and pFibrin, whereas there was little change in the less-
spread platelets on D-dimer. mFAB-F prevented aggregate formation on both pFibrin and 
HORM collagen, consistent with inhibition of activation through GPVI. Dasatinib (A, right-
most column of images) shows effects similar to those of mFAB-F. Experiments carried out 
by Dr S Jung. 
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Seconds None D-dimer (5) D-dimer (10) D-dimer (20) 
500 1 1.3 1.5 1.3 
515 14.8 1 1.5 1.4 
530 44.3 0.9 1.2 1.5 
545 59.8 0.9 1.5 1.5 
560 67.8 0.9 1.6 1 
575 70.2 3.8 7.4 2 
590 70.8 22.8 28 9.9 
605 69.9 42.8 43.3 24.7 
620 74.3 52.6 51.2 35 
635 74.2 57.8 52.4 39.3 
650 73.5 61.5 55.2 41 
665 74.7 62.7 52.2 39.7 
680 74.8 60.3 49.9 38.5 
695 76 60.2 47.6 36 
710 75.2 60.4 45.4 34.5 
725 75.1 56.7 43 33.2 
740 76.3 54.2 40.7 31.9 
755 75.4 53.9 38.8 30.4 
770 74.9 50.6 37.5 30.1 
 
 
Supplementary Table 5.1 Platelets were either pre-incubated with D-dimer (dose 
indicated in parentheses) or not (none). HORM collagen was added at 8 minutes (480 
seconds) to each of the wells. This table displays the raw values of % aggregation for each 
of the parameters. The values are shown from 500 seconds onwards, at 15 second 










CHAPTER VI. FIBRIN BINDING PLATELET 
RECEPTOR GLYCOPROTEIN VI-DIMER IS 
SIGNIFICANTLY OVEREXPRESSED IN 
PATIENTS WITH ATRIAL FIBRILLATION  
The Glycoprotein VI Receptor in Atrial 




 Chapter Summary 
Patients with AF express significantly lower total GPVI but significantly higher levels of 
GPVI-dimer on their platelet surface compared to controls without AF. They also have 
more active circulating platelets as measured by P-selectin exposure compared to 
controls. pAF patients express significantly lower total GPVI expression, but similar GPVI-
dimer expression compared to those in permanent AF. Those taking anticoagulation 
express more total GPVI and GPVI-dimer, which could be due to factor Xa inhibitors 
downregulating GPVI shedding from the platelet surface. Serum fibrinogen, BNP and hs-
CRP are all correlated with higher GPVI expression, and the presence of congestive cardiac 
failure was associated with total GPVI expression. In the whole population, higher GPVI-
dimer expression was independently associated with the presence of AF.   
 114 
6.01 Introduction 
From in vitro models and animal studies, it can be established that GPVI-dimer is likely to 
play a key role in the pathogenesis of ischaemic stroke, through its interactions with 
collagen and fibrin. However, there are only a small number of clinical studies investigating 
GPVI expression in thrombotic disease, and even fewer looking specifically at ischaemic 
stroke. These studies are further limited as they have either quantified platelet surface 
expression of total GPVI (monomer and dimer) or soluble GPVI (sGPVI; the extracellular 
portion of GPVI that is shed after platelet activation). 
 
Since GPVI-dimer, the active form of GPVI, is constitutively present on circulating platelets 
and its expression increases with platelet activation and platelet-ligand interactions, it is 
imperative to establish how GPVI-dimer levels vary in response to stroke risk factors or 
thrombotic disease.  
 
Individuals with AF represent a cohort that are at high-risk of stroke and previous studies 
have shown that the whole coagulation system demonstrates a hypercoagulable state, 
with platelet priming, ready to be involved in thrombosis (Hayashi, 2011; Danese, 2014). 
What is not established is whether this priming also means that they express more GPVI, 
especially more GPVI-dimer, and how this in turn may relate to their platelet function with 
respect to thrombus formation and CES.  
 
The aim of the Glycoprotein VI Receptor in Atrial FIbrillation and ThromboEmbolism 
(GRAFITE) study was to investigate platelet GPVI-dimer expression and platelet activity in 
patients with AF who have not had a stroke using flow cytometry analysis of venous whole 
blood and compare it to healthy controls who do not have AF, who had their platelets 
analysed for the same parameters. 
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(a) Rationale for flow cytometry assessment of AF patients’ platelets 
Whole blood flow cytometry is now a commonly used method to measure different 
modalities of platelet activation and receptor expression. It has several advantages:  
1. Physiological platelet activation can be studied in presence of the necessary 
clotting factors present in whole blood 
2. There is minimal manipulation of the samples, preventing in vitro platelet 
activation 
3. Only small volumes of blood are required for analysis, but the method has a high 
sensitivity for the detection of platelet sub-populations 
 
Dr Jung and Dr Moroi have developed a flow cytometry method with appropriate 
antibodies to separately assess the levels of GPVI-dimer and total GPVI in platelet 
populations. Indeed, their 204-11 Fab is the only currently available antibody that binds 
to GPVI-dimers in resting and activated platelets; it’s characteristics have been thoroughly 
tested in previous in vitro work (Jung, 2012). We compared dimer levels with those of total 
GPVI measured by the antibody HY101, which recognises both GPVI monomers and dimers 
(Chen, 2002).  
 
P-selectin exposure on the platelet surface and fibrinogen binding represent two 
commonly used methods of quantifying platelet activation. Fibrinogen binding to platelets 
necessitates the conversion of integrin aIIbb3 to its high-affinity state and requires lower 
concentrations of activating stimuli compared to platelet P-selectin secretion, 
representing an early phase of platelet activation. P-selectin exposure requires repeated 
stimuli and platelet degranulation (a-granules), reflecting a later-phase of platelet 
activation (Ruf, 1995). 
 
In this study, to determine if patients with AF have more active platelets, both fibrinogen 
binding and P-selectin exposure in non-activated “resting platelets” or after exogenous 
stimulation by ADP or the CRP-XL was quantified. These agonists activate platelets through 
distinct and separate activation pathways. CRP-XL binds specifically to GPVI to initiate an 
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activation cascade (Smethurst, 2007) and ADP activates platelets through purinergic 
receptors P2g1 and P2g12 (Li, 2010).   
 
Flow cytometry compatible antibodies to detect platelet P-selectin exposure and 
fibrinogen binding are commercially available. Although there are a lack of studies 
measuring platelet-fibrinogen binding in AF patients, elevated serum fibrinogen levels 
have been observed in patients with both paroxysmal (pAF) and persistent AF (Lip, 1996; 
Mukamal, 2006; Fu, 2011). Increased platelet exposure of P-selectin has been previously 
observed in both AF and ischaemic stroke (Goette, 2000; Marquardt, 2002), representing 
a validated marker to ensure the robustness of our results. 
 
 
Figure 6.1 Schematic demonstrating the binding of HY101, 204-11 Fab and anti-P-selectin 
(CD62P) on platelets. HY101 as a whole antibody would bind to GPVI monomer and dimer 
through its two Fab binding regions. Each dimer would bind two molecules of 204-11 Fab. 
The exact binding sites of HY101 and 204-11 Fab are not known. 
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(b) Rationale for serum analysis of AF and stroke biomarkers 
BNP, D-dimer and hs-CRP represent commonly measured AF and stroke biomarkers. BNP 
is a validated biomarker in cardiac failure and myocardial infarction. Because it is released 
from a pressure loaded left atrium, it is a measure of atrial stretch and atrial dysfunction 
during AF as well (Wożakowska-Kapłon, 2004). Studies have shown an association 
between AF and BNP with persistently higher plasma levels than in healthy matched 
controls and a reduction to that of control subjects following successful restoration of 
sinus rhythm (Wozakowska-Kapłon, 2010). 
 
Similarly, published data on D-dimer levels in AF demonstrate that elevated D-dimer 
values may be associated with the presence of atrial thrombosis, correlated with infarct 
volume and may also represent a useful parameter for assessing the degree of 
hypercoagulability of AF patients (Danese, 2014). 
 
Elevated serum levels of C-RP and hs-CRP has been shown to predict the presence of a 
prothrombotic state in AF (Lip, 2007), the recurrence of AF after cardioversion (Yo, 2014) 
and risk of CES (Dawood, 2016) and represents a close link between AF and a pro-
inflammatory state. 
 
Whether there is a link between GPVI levels, either total or specifically GPVI-dimer, and 
these serum biomarkers in AF has never been established.   
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6.02 GRAFITE study aims 
1) Identify whether patients with AF who have not had a stroke express higher levels of 
GPVI (total or dimer) on their platelet surface compared to healthy controls without 
AF 
2) Investigate whether these patients have more active platelets as demonstrated by 
increased fibrinogen binding and P-selectin exposure compared to healthy controls  
3) Identify if there are any differences in platelet GPVI expression and platelet activity 
considering: 
a) Type of AF: Paroxysmal vs Persistent AF 
b) Whether on anticoagulation treatment or not 
c) Duration of AF 
4) Identify correlations between GPVI expression and levels of serum AF biomarkers 
 
6.03 GRAFITE study approvals and support 
The study was conducted at Cambridge University Hospitals NHS Foundation Trust (CUH) 
between December 2016 and March 2019. The study protocol was approved by the 
Cambridge East Research Ethics Committee (16/EE/0436) and was registered in the 
ISRCTN registry (ISRCTN33370579). 
 
6.04 Participant eligibility to recruitment 
(a) Inclusion and exclusion criteria 
CUH admits around 1300 patients a month under general medicine via the emergency 
department. Patients with atrial fibrillation who are admitted under a medical team with 
AF as a main diagnosis or a comorbidity were eligible to participate in the study.  
 
Patients with a new onset of AF would be diagnosed by 12-lead ECG which is routinely 
carried out for every patient whilst they are in the emergency department. Paroxysmal AF 
(pAF) carries the same risk of stroke as persistent AF and therefore, those patients were 
eligible for participation in the study if the patient was documented to be in AF at the time 
of recruitment. Patients with a confirmed TIA or stroke in the last 10 years were excluded 
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from the study. The recruitment to the study included a number of other strict inclusion 
and exclusion criteria indicated in Table 6.1. 
 
Inclusion Exclusion 
Able to give informed consent 
 
Presence of AF on ECG either as a new or 
existing diagnosis  
 
Paroxysmal or persistent AF (as 
ascertained by medical history) 
 
On anticoagulation (warfarin or DOACs) or 
not on anticoagulation 
 
No clear confirmation of the presence of 
atrial fibrillation in medical notes or ECG 
Not admitted under a medical team to 
CUH  
 
Age less than 18 years  
 
Pregnancy
Active or previous history of malignancy  
 
Known platelet disorder  
 
Haemoglobin <90g/L at the time of blood 
sampling 
 
Known HIV/AIDS  
 
Known hepatitis B or hepatitis C infection  
 
TIA or stroke – ischaemic or haemorrhagic, 
within the last 10 years and no active 
myocardial infarction. 
 
Table 6.1 Inclusion and exclusion criteria for the GRAFITE study population 
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(b) Sample size 
From the existing data we had at the time of GRAFITE study design, the median 
fluorescence intensity (MFI) of the GPVI dimer in patients presenting with stroke was 
(MFI= 0.6±0.15) compared to healthy control (MFI =0.5±0.14). Power calculations using 
the following study parameters: a 0.05, 1-b 0.8, suggested that we can resolve differences 
in GPVI dimer MFI between two donor populations (P<0.05) using a sample size of less 
than 20. 
 
(c) Patient recruitment 
The details of patients admitted from the previous day’s medical take are discussed at 
morning report, a meeting that is routinely attended by members of the research team, 
as well as all medical teams within CUH. Patient comorbidities including the presence of 
AF, are discussed at this meeting and was the main source of identification of patients 
during the study. The list of medical patients admitted was also available on the CUH 
electronic patient medical record database. 
 
The direct care team approached the patient on behalf of the research team and ask their 
consent for the research team to see if they fit the inclusion criteria, and if the individual 
would be willing to consider participation. The research team then approached the 
individual in order to provide more information about the study and allow time to consider 
participation. Patients were typically recruited from medical inpatient wards, which 
included a mixture of acute medical, cardiology and geriatric inpatients. Participants were 





Figure 6.2 Flow diagram of patient approach to recruitment. Assessment by the research 



















carried out after the study information was provided to the patient, – typically 24h later, 
when they had had a chance to consider participation. 
(d) Healthy control recruitment 
Healthy donors from the National Institute for Health Research Cambridge BioResource 
were invited to participate in the study alongside study participants. The NIHR Cambridge 
BioResource is a pool of over 15000 volunteers, both with and without health conditions 
who are willing to be approached for research. For the purposes of these studies, only 
those without previous thrombotic disease (IHD or stroke) and those not on antiplatelets 
were approached. No age limits were set. Potential donors attended an appointment 
where written consent was obtained for participation. The study protocol was given ethics 
approval by the Cambridge East Ethics Committee (ref 10/H0304/65).  
 
Blood samples were drawn from the antecubital fossa vein using a 21-gauge butterfly 
needle. The first tube drawn was a K2 EDTA Vacutainerâ (BD, NJ) with tourniquet applied 
that was solely used for a full blood count measurement. Blood was then drawn into a 
0.109mol/L sodium citrate Vacuetteâ (Greiner, Kremsmünster, Austria) with the 
tourniquet removed to prevent artefactual platelet activation for functional assays. 
Samples were transferred to the laboratory on-site for immediate analysis. 
 
Controls with a history of pAF, permanent AF or stroke were excluded from the analysis 
for the purposes of this study. 
The following data were collected from the control cohort. 
1. Basic demographic variables 
2. Medication history: anti-hypertensive, statin, antiplatelet and anticoagulation 
3. Clinical details: relevant vascular risk factors: hypertension, CCF, diabetes, 
hypercholesterolaemia, IHD, any previous stroke history. 
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6.05 Study investigations 
(a) Platelet GPVI expression, function & haematological investigations 
Blood was obtained via venepuncture from patients who were willing to participate in the 
study as well as from the healthy control population. 
 
Typically, between 25-30 mL of blood was collected into S-monovetteâ tubes (Sarstedt, 
Germany) for the investigations outlined below. All blood samples were taken on a general 
medical ward at CUH and taken to either the Cell Function Laboratory, Ouwehand group 
at the Department of Haematology, University of Cambridge for GPVI quantification and 
platelet function testing, or the Department of Clinical Biochemistry, CUH for serum 
biomarker analysis within 20 minutes of venepuncture. 
 
S-monovetteâ 3 mL, 0.106 mol/L citrate tube 
1. Platelet total GPVI (monomer and dimer) expression and GPVI-dimer expression 
2. Platelet function: 
a) P-selectin exposurewithout agonist or with of ADP or CRP-XL agonism 
b) Fibrinogen binding in platelets without added agonist or in platelets induced 
with ADP or CRP-XL. 
 
S-monovetteâ 1.6 mL, 1.6 mg/mL potassium-EDTA tube 
1. Full blood count  
 
S-monovetteâ 3 mL, 0.106 mol/L citrate tube 
2 x S-monovetteâ 4 mL, 1.6 mg/mL Serum Gel with Clotting Activator  
1. International Normalised Ratio (INR) 
2. D-dimer 
3. Fibrinogen 
4. Brain Natriuretic Peptide (BNP) 
5. Hs-CRP 
Serum biomarker analysis carried out by Department of Clinical Biochemistry, CUH. 
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S-monovetteâ 3.4 mL, 1.6 mg/mL potassium-EDTA tube 
S-monovetteâ 4.9 mL, 1.6 mg/mL potassium-EDTA tube 
S-monovetteâ 4 mL, 1.6 mg/mL Serum Gel with Clotting Activator 
1. Genotyping, gene expression 
2. Metabolomic analysis 
 
Done in collaboration with the Ouwehand Laboratory, Department of Haematology, 
University of Cambridge. Results not yet available, therefore, will not form part of this 
thesis. 
 
(b) Clinical data collection 
After consent was obtained from the patient, further details were gained from the 
patient’s electronic medical notes including: 
1. Basic demographic variables 
2. Medication history: anti-hypertensive, statin, antiplatelet and anticoagulation 
3. Clinical details: admission diagnosis, relevant vascular risk factors: hypertension, 
CCF, diabetes, hypercholesterolaemia, ischemic heart disease, any previous stroke 
history and AF type and duration if known. 
4. CHA2DS2-VASc score 
5. Modified Rankin Scale (mRS) at admission 
 
6.06 Methods 
(a) Total GPVI and GPVI-dimer quantification using flow cytometry 
Citrated whole blood was diluted at a 1:5 ratio with HEPES-Buffered Saline (HBS: 0.15 M 
NaCl, 5 mM KCl, 1 mM MgSO4, 10 mM HEPES, pH 7.4) (Sigma-Aldrich Ltd, UK).  
 
The relevant primary antibody was added:  
1. Either anti-total GPVI HY101, 12.5 µg/mL (IBGRL, UK) 
2. Anti-GPVI-dimer 204-11 Fab, 5 µg/mL (developed by Dr M Moroi and Dr S Jung, in 
collaboration with Kaketsu-ken, Japan);  
3. IgG2a negative control, 12.5 µg/mL (BioLegend, UK) or  
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4. Mouse Fab negative dimer control, 5 µg/mL (BioLegend)  
 
and incubated at room temperature for 10 min.  
 
The fluorescent secondary antibody FITC-F(ab’)2 (Jackson Laboratory, USA) was added at 
40 µg/mL and incubated in the dark for 10 min. The sample was subsequently diluted in 
0.5 mL HBS prior to flow cytometric analysis using a FC500 flow cytometer (Beckman-
Coulter Ltd., High Wycombe, UK). Platelets were identified using light scatter and results 
recorded as Median Fluorescent Intensity (MFI).  
 
(b) Platelet function analysis using flow cytometry 
To assess platelet activation, 5 µl of aspirinated (100 µM) and hirudinized (4 U/ml) citrated 
whole blood was added to 45 µl of HBS (after 5 minutes incubation) to make up final 
volume of 50 µL containing PE-conjugated anti-CD62P (Clone Thromb6, Bristol Institute 
for Transfusion Science, UK) at a final dilution of 1:50 and with FITC-conjugated anti-
fibrinogen (F0111; Dako Ltd, UK) and either  
no agonist 
1. HBS  
or addition of exogenous agonists 
1. ADP (final concentration of 0.5 µM, Sigma-Aldrich) or  
2. CRP-XL (final concentration of 4 µg/ml; Farndale Laboratory, University of 
Cambridge).  
 
For the CRP-XL–induced platelets, apyrase (4 U/mL, final concentration) was added to 
inhibit activation through the ADP-induced pathway (Sigma-Aldrich) before addition of 
CRP-XL.  
 
All activation reactions were stopped after 20 minutes by adding 100-fold volume of saline 
containing 0.2% formyl (37% formaldehyde, 0.85% NaCl; Sigma-Aldrich) (further 10-
minute incubation) prior to flow cytometry analysis. Negative controls for the anti-P-
selectin were set using a 9E10 isotype control (Bristol Institute for Transfusion Science) 
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and for anti-fibrinogen, the antibody was incubated in the presence of 10 mM EDTA 
(Sigma-Aldrich Ltd, Gillingham, UK). 
 
Platelets were identified by light scatter and results were recorded as the percentage of 
platelets positive (%PP) for the relevant activation marker, calculated as the percentage 
of platelets expressing the relevant activation marker with MFI greater than 98% of the 
isotype control. 
 
(c) Serum AF and stroke biomarker analysis 
Serum samples from AF patients was sent to the on-site Department of Clinical 
Biochemistry for immediate analysis. Results were anonymised and electronically 
delivered after analysis. Control patients did not undergo biomarker analysis. 
 
6.07 Statistical analysis 
A P-value of <0.05 was taken as statistically significant. Linear regression revealed that 
age and mean platelet volume (MPV) were associated with GPVI expression in the 
patients. Therefore, GPVI expression and P-selectin exposure results from all cohorts were 
adjusted for age and MPV and predicted values calculated from adjusted unstandardized 
residuals were subsequently used when comparing mean values between cohorts. Specific 
statistical tests employed are included in the figure legends. 
 
Age- and MPV-adjusted values were also entered into a simple linear regression analysis 
to determine association between total GPVI or GPVI-dimer expression with other single 
predictor variables. Significantly associated predictor variables (P<0.05) were then 
entered into a multiple regression model to determine independent predictors for GPVI-
dimer expression. Unstandardized coefficient (B), standard error (SE) and significance (P) 
are reported for each of the significantly associated variables. Multivariable logistic 
regression analysis included the following predictors: total GPVI, GPVI-dimer, age and MPV 
to determine which variables were independently associated with AF. Data was analysed 




(a) Recruitment and population details 
Over the duration of the study, a total of 79 patients with AF were recruited. However, 4 
patients were excluded from analysis as detailed in Table 6.2. 
 
 
Table 6.2 Patients with AF excluded from the study analysis. MVR = mitral valve 
replacement 
 
The presence of any platelet disorders, active or previous history of malignancy or any 
other reason that met exclusion criteria were thoroughly checked at admission and then 
at 4 months after inclusion into the study.  
 
The remaining 75 patients were included in subsequent analysis. Their demographic 
details, blood parameters, comorbidities, admission medication of the control and AF 
populations are supplied in Table 6.3.  
 
Compared to the control population, the AF population were significantly older (median 
age (Q1-Q3): controls, 60 years (47–68); AF, 74 years (66–79), P<0.0001) and included a 
smaller proportion of female (control, 65.8%; AF, 38.7%, P<0.0001). Full blood count 
analysis revealed that haemoglobin (Hb) and platelet counts were not different between 
the control and AF groups, however, the AF population had significantly larger platelets as 
measured by mean platelet volume (MPV (fL)±SD: control 10.4±0.9; AF 10.6±1.0, P=0.04). 
 
Date Study ID Age (Yrs) Anticoagulated Reason for exclusion 
10/01/2017 GRA0001 59.1 YES On heparin infusion, recent MVR 
30/03/2017 GRA0030 58.0 NO Error in GPVI quantification 
14/12/2018 GRA0071 79.9 YES Error in GPVI quantification 
05/03/2019 GRA0099 66.3 NO Incomplete platelet function data 
 127 
As expected, the AF population had a greater burden of vascular risk factors compared to 
healthy controls (P<0.0001), none of the patients had had a stroke in the control group. 
Two patients with AF had had small ischaemic infarcts around 20 years ago, with no 
residual neurological deficit and this was felt to be of unlikely significance now and 
therefore included in the analysis. 2 patients in the AF group had chronic kidney disease 
(CKD) stage 2-3, whereas none of the patients in the control group had CKD. 
 
A significantly higher proportion of AF patients were taking an antiplatelet, 
anticoagulation, anti-hypertensives and a statin at admission compared to the control 
group. The median (Q1-Q3) CHA2DS2-VASc score of the AF group was 3. There was no 
association between BMI or NEWS scores and GPVI expression or platelet function. None 




Table 6.3 The demographic details, blood parameters, comorbidities, admission 
medication of the control and AF populations. Controls were younger, had fewer risk 
factors and were on fewer anti-thrombotic medication. Individuals were classified as 
having a risk factor if there was a documented history of it, were on treatment for it, or 
were diagnosed with it during the admission.  
*2 patients within the AF group had had strokes previously in 1997 and 1998 but were 
included in the analysis. 
 Control AF Significance 
n 299 75 - 
Median age (Q1-Q3) 60 (47-68) 74 (66-79) <0.0001 
Female (%) 65.8 38.7 <0.0001 
Mean Haemoglobin (g\L) ± SD 136.5±11.4 134.0±20.2 0.15 
Mean Plt Count (10x9/L) ± SD 259.6±57.3 247.0±80.1 0.11 
Mean Plt Volume (fL) ± SD 10.4±0.9 10.6±1.0 0.04 
Risk factors for thrombotic disease, n (%) 
Congestive Cardiac Failure 0 (0) 22 (29.3) <0.0001 
Hypertension  26 (8.7) 51 (68.0) <0.0001 
Diabetes 1 (0.33) 19 (25.3) <0.0001 
Ischaemic Heart Disease 0 (0) 14 (18.6) <0.0001 
Cholesterol 23 (7.7) 31 (41.3) <0.0001 
Stroke in last 5 years* 0 (0) 0 (0) - 
Admission medication n (%) 
ACE inhibitor or ARB 20 (6.7) 28 (37.3) <0.0001 
Aspirin 0 (0) 14 (18.6) <0.0001 
Clopidogrel 0 (0) 3 (4.0) 0.02 
Apixaban 0 (0) 9 (12.0) <0.0001 
Dabigatran 0 (0) 1 (1.3) 0.20 
Rivaroxaban 0 (0) 25 (33.3) <0.0001 
Warfarin 0 (0) 12 (16.0) <0.0001 
Statin 22 (7.4) 34 (45.3) <0.0001 
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(b) General platelet characteristics of AF patients 
 
Patients with AF had larger platelets as measured by MPV, compared to the controls 
(P=0.04), although neither their platelet count nor their haemoglobin level was 
significantly different. 
 
As expected, the total GPVI and GPVI-dimer levels are strongly associated with each other 
(B 0.32, SE 0.01, P<0.0001). However, GPVI expression appears to be negatively associated 
with P-selectin exposure post ADP and CRP-XL as well as fibrinogen binding post CRP-XL 
addition (Table 6.4). 
 
 
Table 6.4 Bivariate comparisons between either total GPVI or GPVI dimer and measured 
platelet function.  
  
 Total GPVI GPVI-dimer 
 Coefficient B Significance (P) Coefficient B Significance (P) 
P-Selectin Resting 0.03 <0.0001 0.001 0.26 
P-Selectin exposure (+ ADP) -0.03 0.02 -0.004 <0.0001 
P-Selectin exposure (+ CRP-XL)  -0.08 <0.0001 -0.007 <0.0001 
Fibrinogen Binding Resting 0.23 0.16 -0.19 0.15 
Fibrinogen Binding (+ ADP) 0.12 <0.0001 0.01 <0.0001 
Fibrinogen Binding (+ CRP-XL)  -0.04 <0.0001 -0.005 <0.0001 
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(c) Platelet GPVI expression in individuals with AF compared to controls 
 
Compared to controls, AF patients’ platelets expressed significantly lower total GPVI (MFI 
± SD; control 4.03±0.08, AF 3.82±0.20, P<0.0001). Conversely, GPVI-dimer levels were 
significantly higher in the AF cohort compared to controls (MFI ± SD; control 0.57± 0.01, 




Table 6.5 Total GPVI and GPVI-dimer expression as measured by median fluorescence 
intensity (MFI) in the control cohort compared to individuals with AF. The higher value is 
indicated in bold. Significance (P) was calculated using unpaired t-test. 
  
 Control (n=299) AF (n=75) P 
Platelet GPVI expression (MFI) ± SD 
Total   4.03±0.08 3.82±0.20 <0.0001 





Figure 6.3 Expression of (A) total GPVI and (B) GPVI-dimer between control and AF 
patients. Significant differences between means of each cohort were calculated using an 



















Control (299) AF (75)
****
(A) Total GPVI (B) GPVI-dimer
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(d) Platelet P-selectin exposure and fibrinogen binding in AF cohort 
 
Compared to controls, AF patient’s resting platelets expose more P-selectin on their 
surface (P<0.0001). However, after the addition of ADP or CRP-XL, they expose 
significantly less P-selectin compared to controls (P<0.0001).  
 
Conversely, AF platelets have significantly less bound fibrinogen on their surface 
compared to controls prior to addition of exogenous agonists (P<0.0001). After ADP or 
CRP-XL are added, they are able to bind more fibrinogen, but this remains significantly less 
compared to the control cohort (P<0.0001) (Table 6.6, Fig 6.4). 
 
 
Table 6.6 % Platelet positive (%PP) for P-selectin exposure and fibrinogen binding in 
control vs AF patients. Resting refers to circulating platelets where in vitro ADP or CRP-XL 
had not been added to activate the platelets.  
  
 Control (n=299) AF (n=75) P 
Median (Q1-Q3) P-Selectin Exposure (%PP) 
Resting 19.8 (19.7-20.0) 25.7 (22.3-27.0) <0.0001 
+ADP  75.4 (73.7-76.4) 62.6 (61.1-64.4) <0.0001 
+CRP-XL 83.5 (82.5-84.6) 76.7 (75.7-78.3) <0.0001 
Median (Q1-Q3) Fibrinogen Binding (%PP) 
Resting 1.02 (0.94-1.08) 0.68 (0.57-0.7) <0.0001 
+ADP  49.2 (47.1-50.7) 30.2 (29.3-30.8) <0.0001 
+CRP-XL 33.4 (32.4-34.5) 21.7 (20.5-23.8) <0.0001 
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Figure 6.4 (A) P-selectin exposure and (B) fibrinogen binding in resting platelets or after 
addition of ADP or CRP-XL in the control and AF groups. Significant differences between 
means of each cohort were calculated using a Mann Whitney-U test and the error bars 


































(e) GPVI expression between individuals with paroxysmal or permanent 
AF 
There are mixed reports estimating the risk of stroke with pAF, but current evidence 
suggests that permanent AF and pAF carry the same risk of CES; therefore, guidelines tell 
us that pAF patients should be treated with anticoagulation too (Hohnloser et al. 2007; 
NICE NG128 May 2019). Whether GPVI expression varies within permanent AF and pAF 
and how this could relate to stroke risk is not established. Out of the 75 AF patients, there 
were 33 patients with pAF, meaning that the groups were reasonably evenly matched in 
terms of numbers. It was no surprise that the pAF patients were significantly younger 
(P=0.0004). They also had a significantly lower INR, but this is because many patients take 
a mixture of warfarin and DOACs, making the INR value difficult to interpret. A similar 
proportion of patients with pAF were on anticoagulation compared to those in permanent 
AF and their median CHA2DS2-VASc scores were not significantly different (P=0.26). 
 
What was striking was that pAF patients had significantly lower serum fibrinogen 
(P=0.004), hs-CRP (P=0.004) and BNP (P=0.002) levels despite being in AF at the time of 
blood collection. The MPV of permanent AF patients was also significantly higher 
(mean±SD, permanent AF 10.85±0.94, pAF 10.33±1.04, P=0.03) but there were no 
differences in haemoglobin level or platelet count between the two groups (Table 6.7).  
 
There was also no difference in the admission NEWS score or BMI between the two 




Table 6.7 The demographic details, comorbidities, blood parameters and biomarkers of 
the permanent AF (n=42) and pAF (n=33) populations. Median values are presented with 
IQR (Q1-Q3). 
  
 Permanent AF  Paroxysmal AF  P 
Mean age (years) ± SD 75.3±8.2 67.5±10.1 0.0004 
Female (%) 21 (50.0) 8 (25.8) 0.03 
On anticoagulation (%) 31 (73.8) 19 (57.6) 0.14 
Mean Haemoglobin (g\L) ± SD 130.4.4±19.7 138.5±20.2 0.09 
Mean Plt Count (10x9/L) ± SD 243.4±82.0 251.7±78.6 0.66 
Mean Plt Volume (fL) ± SD 10.85±0.94 10.33±1.04 0.03 
Risk factors for thrombotic disease, n (%) 
Congestive Cardiac Failure 15 (35.7) 7 (21.2) 0.21 
Hypertension  29 (69.0) 22 (66.7) 1.0 
Diabetes 7 (16.7) 12 (36.4) 0.06 
Ischaemic Heart Disease 10 (23.8) 4 (12.2) 0.24 
Cholesterol 14 (33.3) 17 (51.5) 0.16 
Biomarkers and risk-scores 
Admission CHA2DS2-VASc 3 (2-5) 3 (2-4) 0.26 
INR  1.63 (1.2-2.1) 1.21 (1.04-1.71) 0.008 
Serum Fibrinogen  4.2 (3.1-6.6) 3.04 (2.8-4.3) 0.004 
D-dimer 223 (96-405) 141 (75-367) 0.37 
Serum hs-CRP  8.05 (3.9-39.3) 3.39 (1.26-12.7) 0.004 
BNP  1645 (861-3231) 580 (124-1704) 0.002 
Serum Creatinine  79 (64-93) 83 (71-89) 0.84 
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Patients with pAF demonstrated significantly lower total GPVI expression (MFI±SD; 
permanent AF 3.87±0.18; pAF 3.75±0.20, P =0.006) but their dimer levels were not 
different (MFI ± SD; permanent AF 0.60±0.01; pAF 0.60±0.01, P =0.11) (Table 5.7, Figure 
5.4). The lower total GPVI in the pAF cohort is maybe an explanation as to why the whole 
AF cohort (which included permanent and pAF) patients exhibited lower total GPVI 
expression compared to the controls (Table 6.8, Figure 6.5). 
 
pAF patients also demonstrated significantly less P-selectin exposure (P<0.0001) and 
fibrinogen binding compared to those in permanent AF (P=0.002), as well as more P-
selectin exposure after ADP addition (P=0.03). However, there were no significant 
differences in P-selectin exposure or fibrinogen binding between the two groups after the 






Table 6.8 Differences in platelet GPVI expression, P-selectin exposure and fibrinogen 
binding between those in permanent AF and paroxysmal AF. Significant differences (P1) 
between means of the permanent and paroxysmal cohorts only were calculated using an 
unpaired t-test for parametric or Mann Whitney-U test for non-parametric data.  
  
 Control (n=299) Permanent AF (n=42) Paroxysmal AF (n=33) P1 
Platelet GPVI expression (MFI)±SD 
Total   4.03±0.08 3.87±0.18 3.75±0.20 0.007 
Dimer 0.57± 0.01  0.60±0.01 0.60±0.01 0.11 
Median (Q1-Q3) P-Selectin Exposure (%PP) 
Resting 19.8 (19.7-20.0) 26.7 (25.1-28.0) 24.1 (20.6-26.0) <0.0001 
+ADP  75.4 (73.7-76.4) 63.2 (62.0-64.5) 61.8 (60.0-64.2) 0.03 
+CRP-XL 83.5 (82.5-84.6) 76.9 (75.9-78.1) 76.4 (75.3-78.4) 0.83 
Median (Q1-Q3) Fibrinogen Binding (%PP) 
Resting 1.02 (0.94-1.08) 0.71 (0.64-0.79) 0.59 (0.46-0.72) 0.002 
+ADP  49.2 (47.1-50.7) 30.1 (29.4-30.8) 30.5(29.3-31.1) 0.58 
+CRP-XL 33.4 (32.4-34.5) 21.0 (22.4-23.9) 21.1 (19.2-23.8) 0.10 
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Figure 6.5 Expression of (A) total GPVI and (B) GPVI-dimer between permanent AF (AF) 
and paroxysmal AF (pAF) patients. Significant differences between means of each cohort 
were calculated using an unpaired t-test and the error bars represent the mean MFI ± SD. 
 
(f) Differences in GPVI expression according to anticoagulation status 
 
There were 50 patients (75%) with AF taking a variety of anticoagulation (+OAC) as 
summarised in Table 6.9. Rivaroxaban was the most popular choice of the DOACs, and 12 










Table 6.9 Different anticoagulation medications taken by the AF patients.  
*The patients on therapeutic dalteparin had been taking it for over 72 hours and therefore 
were included in the analysis as (+OAC).  
Anticoagulation n (%) 
Apixaban 10 (20.0) 
Dabigatran 1 (2.0) 
Edoxaban 0 
Rivaroxaban 25 (50.0) 
Warfarin 12 (24.0) 


























(A) Total GPVI (B) GPVI-dimer
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As expected, a higher proportion of patients not on anticoagulation (-OAC) took 
antiplatelets. There were no statistical differences in antihypertensive or statin 
prescription. Patients on anticoagulation had a significantly higher MPV (P=0.02) and 
median creatinine (P=0.03) but age, haematological parameters and serum biomarkers 
were not significantly different as shown in Table 6.10. Also, a similar proportion of 
patients had permanent AF between the two groups. There was also no difference in the 
admission NEWS score or BMI between the two cohorts (not shown). 
 
Table 6.10 The demographic details, blood parameters, biomarkers and other admission 
medication of AF patients taking anticoagulation (+OAC; n=50) and not (-OAC; n=33). The 
two cohorts were evenly matched in terms of measured parameters, except mean platelet 
volume and creatinine. Median values are presented with interquartile range (Q1-Q3).  
 AF (+OAC) (n=50) AF (-OAC) (n=25) P 
Median age  74.7 (67–80) 73.1 (63-78) 0.37 
Female n, (%) 20 (40.0) 9 (36.0) 1.0 
Permanent AF (%) 31 (62.0) 11 (44.0) 0.15 
Mean Haemoglobin (g\L) ± SD 133.4±20.4 135.0±20.1 0.75 
Mean Plt Count (10x9/L)± SD 249.1±89.6 242.8±58.0 0.75 
Mean Plt Volume (fL) ± SD 10.80±1.1 10.23±0.82 0.02 
Median CHA2DS2-VASc Score  3 (2-4) 2 (1-4) 0.12 
Median INR  1.75 (1.3-2.2) 1.07 (1.01-1.20) <0.0001 
Median Fibrinogen 4.2 (3.0-5.3) 3.16 (2.8-4.2) 0.11 
Median D-dimer 161 (75-385) 153 (89-451) 0.61 
Median Hs-CRP  7.6 (3.2-26.3) 3.58 (1.32-15.5) 0.13 
Median BNP  2364 (514-2857) 863 (258-3147) 0.31 
Median Creatinine  88 (66-95) 78 (67-82) 0.03 
Admission medication n (%) 
ACE inhibitor or ARB 21 (42.0) 7 (28.0) 0.31 
Aspirin 6 (12.0) 8 (32.0) 0.06 
Clopidogrel 2 (4.0) 1 (4.0) 1.0 
Statin 23 (46.0) 11 (44.0) 1.0 
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There were no significant differences between P-selectin exposure or fibrinogen binding 
between the two cohorts overall. AF patients taking anticoagulation expressed 
significantly more total GPVI and GPVI-dimer compared to those not taking 




Table 6.11 Differences in platelet GPVI expression, P-selectin exposure and fibrinogen 
binding between AF patients taking anticoagulation (+OAC) and those who were not (-
OAC).  Significant differences (P1) between means of the AF anticoagulated and not 
anticoagulated groups only were calculated using an unpaired t-test for parametric or 
Mann Whitney-U test for non-parametric data. 
  
 Control (n=299) AF + OAC (n=50) AF - OAC (n=25) P1 
Platelet GPVI expression (MFI)±SD 
Total   4.03±0.08 3.86±0.20 3.74±0.16 0.01 
Dimer 0.57± 0.01  0.60±0.02 0.60±0.01 0.03 
Median (Q1-Q3) P-Selectin Expression (%PP) 
Resting 19.8 (19.7-20.0) 26.1 (23.9-27.6) 24.7 (22.0-26.6) 0.13 
+ADP  75.4 (73.7-76.4) 62.8 (60.9-64.5) 62.5 (61.2-64.3) 0.92 
+CRP-XL 83.5 (82.5-84.6) 76.7 (75.2-78.0) 77.1 (76.1-78.6) 0.14 
Median (Q1-Q3) Fibrinogen Binding (%PP) 
Resting 1.02 (0.94-1.08) 0.69 (0.59-0.77) 0.67 (0.53-0.74) 0.44 
+ADP  49.2 (47.1-50.7) 30.3 (29.5-31.1) 30.1 (29.1-30.6) 0.21 
+CRP-XL 33.4 (32.4-34.5) 21.9 (19.6-23.7) 21.5 (20.7-23.9) 0.62 
 141 
(g) Differences in GPVI expression according to anticoagulation type 
 
35 patients out of 50 were on factor Xa (+FXa) inhibitors (Table 6.9; rivaroxaban 25, 
apixaban 10). There were only low numbers; 15 patients who were on non-FXa inhibitors 
(other OAC, warfarin 12, dabigatran 1, dalteparin 2), therefore, the results are difficult to 
interpret with certainty.  
 
However, those taking FXa inhibitors appeared to have higher total GPVI expression those 
who were not on anticoagulation all together (-OAC, n=25) (MFI ±SD; +FXa 3.86±0.21, -
OAC 3.74±0.16, P=0.02) but not compared to those taking other anticoagulation (other 
OAC, n=15) (MFI ±SD 3.84±0.21, P=0.74). Similarly, GPVI-dimer expression was also 
significantly raised in those on FXa inhibitors compared to those not on anticoagulation 
(MFI ± SD; +FXa 0.60±0.01, -OAC 0.59±0.01, P=0.04) but not compared to those taking 
other anticoagulation (MFI ± SD; 0.60±0.02, P=0.92) (Figure 6.6). There were no 
differences in resting P-selectin exposure or fibrinogen binding between any of the above 
tested groups (not shown).  
 
Similar results are also demonstrated when comparing total GPVI (P=0.002) and GPVI-
dimer expression (P=0.006) between those just on rivaroxaban (n=25) compared to those 
on no anticoagulation (n=25) (Figure 6.7). 
 
The fact that patients on FXa inhibitors may express more GPVI-dimer on their platelet 
surface is an interesting finding, supported by existing literature which will be discussed in 
section 6.09. It may explain some of the differences observed between the anticoagulated 





Figure 6.6 Expression of (A) Total GPVI and (B) GPVI-dimer between patients on all factor 
Xa inhibitors (+FXa), non-factor Xa inhibitors (other OAC) and AF patients not on 
anticoagulation (-OAC). Significant differences between means of each cohort were 
calculated using an unpaired t-test and the error bars represent the mean MFI ± SD 
 
Figure 6.7 Total GPVI and GPVI-dimer expression in patients taking Rivaroxaban 
compared to those not on anticoagulation. Significant differences between means of 
each cohort were calculated using an unpaired t-test and the error bars represent the 























































Simple linear regression analysis with total GPVI or GPVI-dimer expression as dependent 
variables demonstrates that being on rivaroxaban is a predictor of significantly higher total 
GPVI expression (P=0.047) and GPVI-dimer expression (P=0.03) (Table 6.12).  
 
 
Table 6.12 Predictors of total GPVI and GPVI-dimer according to anticoagulation type 
 
(h) GPVI expression and AF duration 
 
The subclinical nature of AF means it is difficult to truly assess duration of the disease. 
However, for the 75 AF patients there were 61 with a documented year of AF diagnosis in 
the medical notes. The data therefore firstly divided into whether this diagnosis was made 
in the last 2 years, or longer. 30 patients had an AF diagnosis made within the last 2 years 
and 31 over 2 years ago. 7 patients in fact had their AF diagnosed within the month prior 
to recruitment.  
 
There were also no differences between P-selectin exposure or fibrinogen binding 
between the two cohorts but both total GPVI and GPVI-dimer expression were higher in 
patients diagnosed with AF over 2 years ago (Table 6.13, Figure 6.8). 
  
 Total GPVI GPVI-dimer 
 Coefficient B Significance (P) Coefficient B Significance (P) 
All anticoagulants 0.12 0.01 0.008 0.03 
Factor Xa inhibitors 0.09 0.06 0.005 0.14 
Rivaroxaban  0.12 0.047 0.008 0.03 
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Table 6.13 Differences in platelet GPVI expression, P-selectin exposure and fibrinogen 
binding between patients diagnosed with AF in the last 2 years or earlier. Significant 
differences (P1) between means of the AF <2 and >2 years groups only were calculated 
using an unpaired t-test for parametric or Mann Whitney-U test for non-parametric data. 
  
 Control (n=299) AF < 2 years (n=30) AF > 2years (n-31) P1 
Platelet GPVI expression (MFI)±SD 
Total   4.03±0.08 3.76±0.19 3.89±0.17 0.01 
Dimer 0.57± 0.01  0.60±0.02 0.60±0.01 0.01 
Median (Q1-Q3) P-Selectin Expression (%PP) 
Resting 19.8 (19.7-20.0) 25.3 (22.5-26.8) 26.0 (23.6-27.4) 0.82 
+ADP  75.4 (73.7-76.4) 63.0 (61.2-64.8) 62.4 (60.9-63.8) 0.19 
+CRP-XL 83.5 (82.5-84.6) 77.3 (76.0-78.7) 76.4 (75.0-77.9) 0.06 
Median (Q1-Q3) Fibrinogen Binding (%PP) 
Resting 1.02 (0.94-1.08) 0.68 (0.52-0.76) 0.68 (0.56-0.74) 0.92 
+ADP  49.2 (47.1-50.7) 30.2 (29.2-30.8) 30.5 (29.6-31.1) 0.82 




Figure 6.8 Total GPVI and GPVI-dimer expression in AF with a diagnosis made within 2 
years compared to over 2 years ago. Significant differences between means of each 
cohort were calculated using an unpaired t-test and the error bars represent the mean 
MFI ± SD. 
 
(i) Correlation between GPVI expression with AF and stroke biomarkers 
The serum biomarkers included in analysis were D-dimer, fibrinogen, BNP and hs-CRP, 
collected at the same time as the blood sample for GPVI quantification. After adjusting for 
age and MPV, Spearman’s rho correlation coefficient testing was used to assess for any 
correlation between these biomarkers and total GPVI or GPVI-dimer expression. 
 
Fibrinogen was only positively correlated with total GPVI expression whereas, BNP and hs-
CRP demonstrated significant positive correlation with total and GPVI-dimer expression 

























Table 6.14 Correlation between total GPVI or GPVI-dimer expression and serum 
biomarkers in stroke patients (n=127) . 
 
 
Figure 6.9 Correlation between GPVI-dimer expression and serum d-dimer levels. 
Calculated using Spearman’s rho correlation coefficient. Regression line from simple 
linear regression is presented in black. 
  
 D-dimer (ng/mL) Fibrinogen (g/L) BNP (pg/mL) hs-CRP (mg/L) 
Spearman’s r, Significance (P) 
Total GPVI  0.02, 0.89 0.38, 0.001 0.78, <0.0001 0.93, <0.0001 
GPVI-dimer -0.34, 0.003 0.02, 0.88 0.52, <0.0001 0.72, <0.0001 




















(j) Variables associated with GPVI expression in a population with AF 
 
Associations between single predictor variables and total GPVI or GPVI-dimer which were 
adjusted for age and MPV, were carried out using simple linear regression (Table 6.15). 
Supplementary table 6.01 shows the associations between age and MPV with GPVI 
expression. 
 
As expected from the results demonstrated in section 6.1.5, pAF was associated with 
significantly lower total GPVI expression (B -0.124, SE 0.04, P=0.006), whereas the 
presence of CCF and being on anticoagulation at admission (as suggested in section 6.1.6) 
were associated with higher total GPVI expression (CCF; B 0.11, SE 0.05, P=0.02, +OAC; B 
0.12 SE 0.05, P=0.01). Fibrinogen, BNP and hs-CRP were associated with higher total GPVI 
expression and D-dimer, BNP and hs-CRP with higher GPVI-dimer expression. 
 
Neither gender or any of the illness acuity measurements taken on admission within the 





Table 6.15 Simple linear regression to determine associations between single predictor 




 Total GPVI GPVI-dimer 
 Coefficient B Significance (P) Coefficient B Significance (P) 
Female Sex 0.002 0.97 -0.001 0.78 
Paroxysmal AF -0.12 0.006 -0.006 0.11 
Comorbidities 
CCF  0.11 0.02 0.008 0.054 
Hypertension  0.06 0.22 0.004 0.33 
Diabetes 0.04 0.40 0.005 0.22 
Ischaemic Heart Disease 0.02 0.70 -0.001 0.88 
Cholesterol 0.01 0.72 0.001 0.78 
BMI -0.001 0.77 0.00 0.21 
Serum Biomarkers 
D-dimer (ng/mL) 0.00 0.77 0.01 0.01 
Fibrinogen (g/L) 0.31 0.001 0.00 0.62 
BNP (pg/mL) 0.02 <0.0001 0.01 <0.0001 
hs-CRP (mg/L) 0.02 <0.0001 0.01 <0.0001 
Creatinine (µmol/L) 0.001 0.20 0.00 0.55 
Admission Parameters 
Anticoagulation at admission 0.12 0.01 0.02 0.15 
CHA2DS2-VASc score 0.02 0.11 0.00 0.92 
NEWS score 0.00 0.00 0.00 0.78 
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(k) Associations between the presence of AF in all participants (n=374) 
with GPVI-dimer expression 
Associations between single predictor variables and GPVI-dimer expression for the whole 
population (control n=299 and AF n=75), were carried out using simple linear regression 









Table 6.16 Simple linear regression to determine associations between single predictor 
variables; the presence of AF, permanent AF or paroxysmal AF (pAF) and GPVI-dimer 





Coefficient B Significance (P) 
AF 0.69 <0.0001 
Permanent AF 0.16 0.15 
pAF -0.018 0.11 
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(l) Presence of AF and relationship to GPVI-dimer 
 
The whole population of study participants (control, and AF; n=374) were dichotomised 
into whether they had AF or not, which was then used as the dependent variable in a 
multivariable binary logistic regression analysis. Unadjusted values of total GPVI, GPVI-
dimer, age and MPV were tested as independent variables. 
 
 
Table 6.17 Binary logistic regression analysis of parameters: total GPVI, GPVI-dimer, age 
and MPV, to assess for predictors of stroke. 
 
The results suggest GPVI-dimer expression is an independent predictor of AF (Odds Ratio 
16.4 (1.5-75.5), P=0.02), when modelled together with total GPVI, age and MPV. Lower 
total GPVI expression is independently predictive of the presence of AF in this model (Odds 
Ratio 0.5 (0.32-0.78), P=0.002). 
 
  
Parameters Coefficient B Odds Ratio 95% CI Significance (P) 
Age (years) 0.126 1.13 1.10 – 1.18 <0.0001 
GPVI dimer 2.798 16.4 1.5– 75.5 0.02 
MPV (fL) 0.263 1.3 0.95 – 1.71 0.09 




The aim of the GRAFITE study was to further the knowledge on a key platelet receptor, 
GPVI by studying its expression on the platelet surface in a cohort of individuals with AF 
who are at high risk of having an ischaemic stroke. 
 
Previous work investigating GPVI expression in AF is limited to just one study. As part of a 
sub-group analysis of GPVI expression in patients with ACS or stable angina, Bigalke and 
colleagues measured platelet surface expression of total GPVI and P-selectin exposure 
using flow cytometry in patients who were either in sinus rhythm or AF at the time of 
recruitment (Bigalke, 2009). They also determined the plasma concentration of sGPVI in 
these patients. They demonstrated that total GPVI expression was significantly decreased 
in patients with ACS who were in AF, compared to those in sinus rhythm (P=0.023). 
Furthermore, the corresponding sGPVI levels were significantly higher in the AF group 
(P=0.038). What was interesting was that these differences in GPVI expression between 
AF and sinus rhythm was not seen in patients with stable angina and that P-selectin 
measurements were also not significantly different between any of the groups. It is 
difficult to interpret these results as the AF cohort had concurrent ACS, because ACS has 
been previously shown to increase total GPVI expression (Bigalke, 2010, 2011). The fact 
that AF patients had lower GPVI expression and higher sGPVI only with ACS and not stable 
angina suggests that there could be increased GPVI shedding in AF patients in the ACS 
setting. The authors imply that this is due to a significantly higher platelet activation in the 
ACS and AF cohort in the first place leading to more shedding compared to the others. 
 
Recently Barrachina and colleagues used 1G5 and 204-11 Fab (supplied by Dr S Jung) to 
quantify total GPVI and GPVI-dimer expression respectively, as well as pP-selectin in 12 
severely obese individuals (BMI >40) and 11 grade 1 obese individuals (BMI 26-35), 
compared to 12 lean controls (Barrachina, 2019). What they observed was higher 
expression of total GPVI and GPVI-dimer in both the obese cohorts compared to lean 
individuals (severe obese vs control total GPVI; P=0.0029 and GPVI-dimer; P=0.016), with 
increased platelet aggregation in response to CRP-XL or collagen in the obese cohorts. 
They observed no significant differences in P-selectin expression between the groups. 
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GPVI expression was also significantly correlated with BMI in the severely obese patients 
(total GPVI r=0.70, P=0.0001, GPVI-dimer r=0.49, P=0.01). 
 
These studies illustrate that there is higher GPVI expression in individuals at-risk of 
thrombotic disease. The fact that P-selectin exposure was not different between obese 
compared to lean individuals, whereas both total GPVI and GPVI-dimer were serves to 
highlight this point further. Similarly in the work by Bigalke, both stable angina and ACS 
patients with AF showed no significant differences in P-selectin, whereas total GPVI 
expression was higher in the ACS group (Bigalke, 2010). 
 
The main results from this chapter are as follows 
1) Patients with AF express less total GPVI (P<0.0001) compared to controls but have 
more GPVI-dimer on their platelet surface (P<0.0001). 
2) Patients with paroxysmal AF express significantly less total GPVI compared to those 
in permanent AF (P=0.007), although their GPVI-dimer levels were not different 
(P=0.11). The presence of paroxysmal AF is an independent predictor of lower total 
GPVI expression (P=0.006). 
3) AF patients taking anticoagulation expressed more total GPVI (P=0.01) and GPVI-
dimer (P=0.03) compared to those not on anticoagulation. This was specifically 
seen in those taking Factor Xa inhibitors (total GPVI, P=0.02; GPVI-dimer, P=0.04). 
4) Higher GPVI-dimer expression was an independent predictor of the presence of AF 
within our population (P=0.02). 
 
This is the first study to look at GPVI expression and platelet function in a cohort of AF 
patients, who are at high risk of ischaemic stroke. Apart from AF, they also had other 
vascular risk factors described in Table 6.3 which in turn would contribute to their stroke 
risk; as demonstrated by a median CHA2DS2-VASc score of 3. The presence of AF as well as 
these other risk factors create a systemic pro-thrombotic state, driven by inflammation 
endothelial dysfunction and platelet activation as discussed in Chapter I (Lip, 1995; 
Llombart, 2013) and how platelet levels of GPVI vary in response to these stimuli forms 
the basis of what we are trying to understand with this research. 
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One of the limitations of the work by Bigalke and colleagues was that GPVI-dimer 
expression was not measured in their AF cohort. Our results demonstrate that patients 
with AF express significantly higher GPVI-dimer compared to the control group, despite 
expressing lower total GPVI (Figure 6.3). These results are similar to that seen in obese 
patients who also demonstrated higher GPVI-dimer expression (as well as total GPVI) 
compared to controls (Barrachina, 2019).  Furthermore, in our AF cohort, the presence of 
CCF, and pro-thrombotic and inflammatory biomarkers such as serum fibrinogen, BNP and 
hs-CRP were associated with GPVI expression. As previously described in the literature, AF 
as well as other cardiovascular diseases involve systemic inflammation and the 
upregulation of pro-inflammatory biomarkers such as hs-CRP (Galea, 2014; Dawood, 
2016). We could hypothesise that the systemic inflammatory state in the setting of AF in 
these patients, could be driving platelet expression of GPVI-dimer on the platelet surface. 
In turn, the presence of more GPVI-dimer on the platelet surface may then be key to 
platelet interactions with collagen and fibrin and drive thrombus formation in AF.  
 
What was an unexpected result was the observation that AF patients express significantly 
lower total GPVI levels on their platelets compared to controls yet exhibit significantly 
higher GPVI-dimer expression (Figure 6.3). Whether this represents more GPVI monomer 
being dimerised in the setting of AF is unknown. Lower total GPVI expression in AF patients 
has been observed previously by Bigalke et al, with a corresponding higher sGPVI seen in 
the plasma (Bigalke, 2009). Although this was in the setting of ACS, the conclusion from 
the authors was that this observation represents increased platelet activation followed by 
MMP induced preferential shedding of monomeric GPVI from the platelet surface. 
Certainly, increased MMP levels have been observed in AF patients (Xu, 2012; Li, 2014). 
Therefore, it may well be that MMPs are causing GPVI to be shed from the platelet surface 
in AF patients more so than in controls. Our study would have been strengthened by 
quantifying serum sGPVI in control and AF patients, which would have indicated whether 
AF patients had higher sGPVI, therefore, higher monomeric GPVI shedding compared to 
controls. 
 
When the AF cohort is further divided into either permanent or pAF, we see that the pAF 
patients express even lower total GPVI, but similar GPVI-dimer compared to the 
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permanent AF group (Figure 6.5). We wondered whether this was because of less 
circulating thrombotic markers such as fibrinogen and hs-CRP (as well as BNP) within the 
pAF group, indicating a lower overall systemic inflammatory burden (Table 6.7).  However, 
this may not be the case as both permanent AF and pAF patients still expressed 
significantly lower total GPVI compared to the control group (both P<0.0001), highlighting 
that lower total GPVI is common to both forms of AF. One of the limitations of this study 
is that we also did not measure these biomarkers in the control cohort, therefore, have no 
means of accurate comparison. 
 
Resting P-selectin exposure was significantly higher in the AF cohort compared to controls 
consistent with circulating platelets in AF patients being more primed for thrombotic 
activity, this is in keeping with platelets expressing more GPVI-dimer. However, resting 
fibrinogen binding, as well as P-selectin exposure and fibrinogen binding after ADP or CRP-
XL stimulation were significantly lower, despite all AF patients expressing more GPVI-
dimer compared to controls (Table 6.6). We hypothesised whether this could be due to 
the effects of anticoagulants. Certainly, the mechanism by which most anticoagulants act 
in the body is to reduce the systemic effect of the coagulation system. However, the whole 
AF cohort were split into patients taking anticoagulation or not, we were unable to see 
any significant differences in fibrinogen binding or P-selectin exposure in response to ADP 
or CRP-XL stimulation (Table 6.11). It may indicate that there are variables outside the 
remits of what was measured in our work, causing an overall reduction platelet function 
in AF patients compared to controls. 
 
We also observed that patients on FXa inhibitors such as rivaroxaban an apixaban may 
express more GPVI on their platelets compared to those not taking anticoagulants (Figure 
6.6 and 6.7). Previous work has demonstrated that FXa causes GPVI downregulation in 
vitro, possibly through FXa induced ADAM10 activation and subsequent GPVI shedding, 
and that rivaroxaban (a factor X inhibitor) but not dabigatran (a direct thrombin inhibitor) 
blocks this process (Al-Tamimi, 2011). The numbers in each of the cohorts tested are small, 
so the results must be interpreted with caution. However, being on FXa inhibitors were 
predictive of both higher GPVI-dimer levels and total GPVI (Table 6.12).  
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These findings have potential impact on choosing the correct anticoagulant in patients. If 
FXa inhibitors do indeed inhibit GPVI downregulation, it may lead to increased thrombotic 
events in patients prescribed FXa inhibitors, as they will express more GPVI on their 
platelet surface. However, this needs to be evaluated in the context of larger trials 
investigating GPVI expression and sGPVI with different anticoagulant treatment and again 
highlights not measuring sGPVI as a potential limitation of this study.  
 
GPVI-dimer expression was also significantly associated with BNP and hs-CRP levels (Table 
6.15) and negatively correlated with serum D-dimer levels (Figure 6.9). Our previous work 
and results from another group demonstrated that D-dimer in solution can inhibit collagen 
induced platelet aggregation in vitro through GPVI (Onselaer, 2017; Induruwa, 2018). 
Although we can only speculate, this could either be that D-dimer binds to GPVI-dimer at 
a location close to where 204-11 Fab binds (used to detect GPVI-dimer) or it be a 
protective mechanism against thrombosis in AF patients, despite the observation of higher 
GPVI-dimer levels. In keeping with this previous work has described that soluble fibrin 
causes a GPVI signalling defect (Lee, 2017). 
 
Finally, our results demonstrate that GPVI-dimer expression an independent predictor of 
the presence of AF, independent of age, MPV and total GPVI (Table 6.17) suggesting that 
higher GPVI-dimer expression must have an inherent role in the presence of AF and may 
explain why patients with AF for over 2 years expressed more total GPVI and GPVI-dimer 
compared to those with a diagnosis of AF made less than 2 years ago (Table 6.13). To 
summarise, patients with AF have a pro-thrombotic platelet profile, with higher GPVI-
dimer expression and resting P-selectin exposure compared to controls, whether patients 
have permanent or pAF. Despite this, may questions remain unanswered within the 
limitations of this study further discussed in section 8.05. Further information on how GPVI 
expression and platelet function changes from a pre-stroke AF population to those who 
have just had a stroke will be explored in Chapter VII, which discusses the Glycoprotein VI 
in Stroke (GYPSIE) study and may give us further insights into how GPVI is involved in 
ischaemic stroke.  
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6.10 Supplementary Files 
Modelling associations between age and MPV inserted as single predictor variables with 
unadjusted total GPVI and GPVI-dimer expression for the AF population (n=75), was 
carried out using simple linear regression. Both total GPVI and GPVI-dimer expression and 
platelet function values were adjusted for age and MPV prior to analysis in this chapter. 
 
 
Supplementary Table 6.1 Simple linear regression to determine associations between 
single predictor variables; age and MPV with unadjusted total GPVI and GPVI-dimer 






   
 Total GPVI GPVI-dimer 
 Coefficient B Significance (P) Coefficient B Significance (P) 
Age (years)  0.04 0.725 0.04 0.91 












CHAPTER VII. PLATELET RECEPTOR 
GLYCOPROTEIN VI-DIMER IS 
SIGNIFICANTLY OVER-EXPRESSED IN 
ISCHAEMIC STROKE PATIENTS  





Stroke patients express significantly more GPVI, both total GPVI and GPVI-dimer, on their 
platelet surface compared to healthy controls and non-stroke patients. Stroke patients 
also demonstrate significantly more resting P-selectin exposure as well as P-selectin 
exposure after exogenous addition of ADP or CRP-XL compared to healthy controls and 
non-stroke patients. At ‘day 90’ post-stroke, the GPVI-dimer levels are significantly higher 
than at admission, but this effect is not observed with total GPVI expression or P-selectin 
exposure. All ischaemic stroke aetiologies (LAS, CES, SVO) and haemorrhagic strokes 
demonstrate more total GPVI and GPVI-dimer expression compared to the controls. 
Current antithrombotic medication does not appear to effect GPVI expression in stroke 




Platelet activation and subsequent thromboembolism underpins the pathophysiology of 
ischemic stroke. Currently used antiplatelet and anticoagulation agents are effective at 
reducing ischemic events (Rajkumar, 2015) but at the expense of systemic side effects such 
as bleeding (Lee, 2013). Therefore, there is a need for more specific anti-thrombotic 
targets which also provide a safer pharmacological profile. 
 
The focus of the GRAFITE study, discussed in the previous chapter was to investigate GPVI 
expression and platelet activity in patients with AF who had not yet had a stroke. 
Quantitating platelet GPVI expression in a cohort of patients who have had a stroke, 
therefore, was the next step in delineating the role of GPVI, and especially GPVI-dimer, in 
stroke.  
 
What makes investigating GPVI most tantalising is its ability to bind to both fibrillar 
collagen and fibrin (Onselaer, 2017; Induruwa, 2018; Mangin, 2018). It is well established 
that GPVI-collagen interactions activate platelets but the extent of platelet activation 
through GPVI-fibrin interactions remains to be fully established. Nevertheless, this 
suggests an important role for GPVI in the pathophysiology of large artery ischaemic stroke 
(LAS), where GPVI-dimer activates platelets when it binds to exposed collagen at sites of 
atherothrombotic plaque rupture and endothelial disruption. The GPVI–fibrin interaction 
then highlights a role for GPVI in cardioembolic stroke (CES), where endothelial 
dysfunction within the cardiac LAA causes activation of the coagulation system, leading to 
platelet activation and thrombus formation through the generation of thrombin and fibrin 
as discussed earlier. 
 
What is also crucial is that as well as GPVI-dimers being constitutively present on the 
surface of resting platelets (about 20-29% of total GPVI), dimer expression can further 
increase on the platelet surface upon platelet activation (Chen, 2002; Jung, 2012) and 
propel thrombus formation. 
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The aim of the GlYcoProtein Six In StrokE (GYPSIE) study was to investigate whether 
patients presenting with stroke have inherently more active platelets and whether this 
was due to a constitutively higher number of GPVI-dimers and/or increased GPVI-
dimerization, representing a potentially controllable point of thrombosis in ischemic 
stroke 
 
7.02 GYPSIE study aims 
1) Identify whether patients who present with stroke express higher GPVI (total or dimer) 
on their platelet surface compared to healthy controls 
2) Investigate whether these patients have more active platelets as demonstrated by 
increased P-selectin exposure compared to healthy controls  
3) Investigate whether the observed GPVI expression and platelet activity is different at 
90 days post stroke 
4) Identify if there are any differences in platelet GPVI expression and platelet activity 
considering: 
d) Any effects exerted by antiplatelet, anticoagulation or hyperacute 
treatment 
e) Aetiology of stroke; ischaemic vs haemorrhagic and ischaemic sub-
categories 
 
7.03 GYPSIE study approvals and support 
The GYPSIE study was conducted at Cambridge University Hospitals NHS Foundation Trust 
(CUH) between January 2015 and September 2018. The study protocol was given ethics 
approval by the East of England – Essex Ethics Committee (ref 14/EE/1062). 
 
7.04 Participant eligibility to recruitment 
(a) Inclusion and exclusion criteria 
The stroke service at CUH admits around 800 patients with a confirmed stroke, per year. 
The vast majority of these are seen in the CUH emergency department (ED) and as a result 
of a coordinated improvement in services over the last ten-years, most patients are 
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bought over as ‘blue light’ emergencies by the ambulance service – allowing efficient 
triage, clerking, imaging and treatment within 4 hours of symptom onset. 
 
Patients with suspected ischaemic or haemorrhagic stroke presenting to ED within 8 hours 
of symptom onset were invited to participate in the study. Those already on antiplatelets 
or anticoagulation were included, along with those given rtPA by the time of blood 
collection. For those unable to provide written informed consent at the time, their 
designated next of kin were approached, and the patient re-consented if capacity was 
regained. The recruitment to the study included a number of other strict inclusion and 
exclusion criteria illustrated in Table 7.1. 
 
Inclusion Exclusion 
Presents to CUH ED with a suspected 
stroke (ischaemic or haemorrhagic) 
 
Time of onset of confirmed stroke 
symptoms within 8 hours of arrival in ED 
 
Patient is able to provide informed 
consent, or personal/nominated consultee 
advice is obtained indicating that patient 
can be enrolled  
Stroke symptoms fully resolved in < 8 
hours e.g. TIA 




5) Active or previous history of malignancy  
6)  
7) Known platelet disorder  
 
Haemoglobin <9.5 g\L or platelet count 
<150 x 109/L at the time of blood 
sampling 
 
Known HIV/AIDS  
 
Known hepatitis B or hepatitis C infection 
 
No active myocardial infarction 
 
Table 7.1 Inclusion and exclusion criteria for the GYPSIE study population 
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(b) Sample size 
At the time of commencing the GYPSIE study, the power calculations were based on 
published work on healthy donor blood carried out by Dr S Jung (Jung, 2012). This work 
established a mean copy number for GPVI-dimer of 860±215/platelet which then rises to 
1175 and 1325 upon activation with CRP-XL or thrombin. Power calculations using the 
following study parameters: a 0.05, 1-b 0.8, suggested that we can resolve differences in 
GPVI-dimer expression between two donor populations (P <0.05) using a sample size of 
less than 20.  
After the collection of pilot data, revised power calculations were carried out, as discussed 
in section 6.04b. 
 
(c) Patient recruitment 
As a Hyperacute stroke unit, patients with suspected stroke from within the region are 
admitted directly into the CUH ED where they are seen directly by a stroke nurse 24h a 
day. As this study required immediate access to the labs for same day analysis, the stroke 
nurses would inform the research team of any eligible patients between 0900-1630 on 
weekdays. Details of medical patients admitted to ED are also available on the CUH 
electronic patient medical record database. 
 
Any individual who met the criteria for recruitment was therefore approached by the 
research team. As discussed, consent was obtained from the next of kin where informed 
consent was not possible and re-consented at a later date if applicable. Participants were 
consented to provide a venous blood sample to carry out study investigations within 








Figure 7.1 Flow diagram of patient approach to recruitment. Assessment, consenting, 
blood sampling and analysis was all carried out on the same day. 
 
(d) Healthy control recruitment 
Healthy donors who were deemed to be at low risk of stroke from the National Institute 
for Health Research Cambridge BioResource were invited to participate in the study 
alongside study participants as detailed previously in section 4.4.4. Therefore, the controls 
used were the same as those in the GRAFITE study, except 2 patients with AF were not 
excluded (n=301). As previously, all control participants were of the common GPVI 
haplotypes. 
 
The following data were collected from the control cohort. 
1. Basic demographic variables 
2. Medication history: anti-hypertensive, statin, antiplatelet and anticoagulation 
3. Clinical details: relevant vascular risk factors: hypertension, CCF, diabetes, 
hypercholesterolaemia, IHD and any previous stroke history. 
 
7.05 Study Investigations 
(a) Platelet GPVI, function and haematological investigations 
Blood was obtained via venepuncture from patients who were willing to participate in the 
study as well as from the healthy control population as described previously in section 
4.5.1. No serum biomarkers were analysed as part of this study. The blood tubes and 
amounts taken from patients and controls are outlined below. 
 
Identification of 
patients as they 














S-monovetteâ 3 mL, 0.106 mol/L citrate tube 
3. Platelet total GPVI (monomer and dimer) expression and GPVI-dimer expression 
4. Platelet function: 
c) P-selectin expression without agonist or with of ADP or CRP-XL agonism 
d) Fibrinogen binding without agonist or with of ADP or CRP-XL agonism 
 
S-monovetteâ 1.6 mL, 1.6 mg/mL potassium-EDTA tube 
1. Full blood count  
 
S-monovetteâ 3.4 mL, 1.6 mg/mL potassium-EDTA tube 
S-monovetteâ 4.9 mL, 1.6 mg/mL potassium-EDTA tube 
S-monovetteâ 4 mL, 1.6 mg/mL Serum Gel with Clotting Activator 
3. Genotyping, gene expression 
4. Metabolomic analysis 
Done in collaboration with the Ouwehand Laboratory, Department of Haematology, 
University of Cambridge. Results not yet available, therefore, will not form part of this 
thesis. 
 
(b) Clinical data collection 
After consent was obtained from the patient, further details were gained from the 
patient’s electronic medical notes including: 
1. Basic demographic variables 
2. Medication history: anti-hypertensive, statin, antiplatelet and anticoagulation 
3. Clinical details: admission diagnosis, relevant vascular risk factors: hypertension, 
CCF, diabetes, AF, hypercholesterolaemia, IHD and any previous stroke history 
4. Whether participants were thrombolysed and whether the blood sampling 
occurred before or after thrombolysis 
5. Whether participants underwent thrombectomy 
6. NIHSS on admission 
7. Pre-admission CHA2DS2-VASc score 
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8. Modified Rankin Scale (mRS) at discharge (collected later) 
9. Death within six months of stroke 
 
7.06 Methods 
The rationale for flow cytometry analysis of receptor expression and platelet function 
(section 6.01a) and methods on quantification of GPVI expression (section 6.06a) are 
preciously described. Fibrinogen binding was not measured in the whole cohort of patients 
during this study therefore only P-selectin exposure is reported for platelet function.  
 
(a) Platelet function analysis using flow cytometry 
To assess platelet activation, 5 µl of aspirinated (100 µM) and hirudinized (4 U/ml) citrated 
whole blood was added to 45 µl of HBS (after 5 minutes incubation) to make up final 
volume of 50 µL containing PE-conjugated anti-CD62P (Clone Thromb6, Bristol Institute 
for Transfusion Science, UK) at a final dilution of 1:50 and either  
no agonist 
3. HBS  
or addition of exogenous agonists 
2. ADP (final concentration of 0.5 µM, Sigma-Aldrich) or  
4. CRP-XL (final concentration of 4 µg/ml; Farndale Laboratory, University of 
Cambridge).  
 
For the CRP-XL–induced platelets, apyrase (4 U/mL, final concentration) was added to 
inhibit activation through the ADP-induced pathway (Sigma-Aldrich) before addition of 
CRP-XL.  
 
All activation reactions were stopped after 20 minutes by adding 100-fold volume of saline 
containing 0.2% formyl (37% formaldehyde, 0.85% NaCl; Sigma-Aldrich) (further 10-
minute incubation) prior to flow cytometry analysis. Negative controls for the anti-P-
selectin were set using a 9E10 isotype control (Bristol Institute for Transfusion Science). 
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Platelets were identified by light scatter and results were recorded as the percentage of 
platelets positive (%PP) for the relevant activation marker, calculated as the percentage 
of platelets expressing the relevant activation marker with MFI greater than 98% of the 
isotype control. 
 
(b) Stroke sub-classification 
Electronic discharge letters from the direct care teams and inpatient medical records, 
which contain admission information and stroke aetiology, were used to subclassify 
ischaemic strokes as per the TOAST classification.(Adams, 1993) Ischaemic strokes were 
therefore classified into 
1: large artery atherosclerosis (LAS)  
2: cardioembolic stroke (CES) 
3: small vessel occlusion (SVO) 
4: stroke of other aetiology (Other) 
5: stroke of undetermined aetiology (UD).  
 
Haemorrhagic strokes (bleed) were not sub-classified. Electronic records were re-checked 
six months from discharge to see if stroke aetiology was deemed to have changed from 
the original classification and our data updated accordingly. 
 
(c) Statistical analysis 
A P value <0.05 was taken as statistically significant. Initially, simple linear regression 
analysis was used to determine association between total GPVI or GPVI-dimer expression 
with predictor variables. Age and MPV were significantly associated with GPVI expression 
in the stroke patients. Therefore, GPVI expression and P-selectin exposure results from all 
cohorts were adjusted for age and MPV and predicted values calculated from adjusted 
unstandardized residuals were subsequently used when comparing mean values between 
cohorts. 
 
Data was tested for normality using the Kolmogorov-Smirnov test. Mean comparisons of 
continuous variables were carried out using either the paired or unpaired t-test for 
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parametric data or the Wilcoxon signed-rank (paired) or Mann-Whitney U (unpaired) test 
for non-parametric data. Non-categorical data was analysed using the Chi-squared test. 
Similarly, analysis of correlation was carried out using Pearson’s test for parametric and 
Spearman testing for non-parametric data, respectively.  
 
Age and MPV adjusted values were also entered into a simple linear regression analysis to 
determine association between total GPVI or GPVI-dimer expression with other single 
predictor variables. Significantly associated predictor variables (P <0.05) on linear 
regression were then tested to ensure they fulfil the criteria for regression diagnostics and 
entered into a multiple regression model to determine independent predictors for GPVI-
dimer expression only, as this is the functional form of GPVI, and the molecule of interest 
for this study. Unstandardized coefficient (B), standard error (SE) and significance (P) are 
reported for each of the significantly associated variables. Furthermore, logistic regression 
analysis with stroke as the dependent variable and total GPVI, GPVI-dimer, age and MPV 
was used to see which variables were independently associated with stroke. 
 
Main statistical analysis was carried out using PRISM v8.2 (Graph Pad, USA) and SPSS 




(a) Recruitment and population details 
Results from 301 healthy individuals were included in the study. A total of 247 participants 
presenting with stroke symptoms were recruited over the study period. This included 186 
stroke patients and 61 non-stroke patients, of which 8 had had TIAs and were therefore 
excluded from the final analysis. Non-stroke patients were defined as patients who 
presented with a suspected stroke to ED who were initially recruited but then 
subsequently were given an alternative diagnosis. 83 patients from the stroke and non-
stroke cohorts were excluded due to; presence/history of malignancy, blood/platelet 
disorder or incomplete blood collection, errors in sample analysis or donor request (Figure 
7.2). No patients were excluded from the study on the basis of stroke severity or acuity of 
illness. 
 
Figure 7.2 Flow diagram of all patients recruited prior to exclusion from study. The boxes 
shaded in grey depict the final numbers included in the analysis of stroke and non-stroke  
cohorts. The non-stroke cohort comprised of patients with a range of diagnoses as 












Table 7.2 The variety in final diagnoses of the included non-stroke patients (n=27) 
 
Demographic details, blood parameters, comorbidities, admission scores and medication 
of the control, stroke and non-stroke population discussed below, are included in Table 
7.3.  
 
The control population were significantly younger compared to the stroke group and non-
stroke groups (median age (IQR): controls, 60 years (47–68); stroke, 79 years (67–85), P 
<0.0001; non-stroke, 70 years (58–84), P <0.0001) and included a larger proportion of 
female participants compared to the stroke cohort (control, 65.8%; stroke, 38.0%, P 
<0.0001). Subsequent analysis however revealed no significant differences between total 
GPVI (P=0.30), GPVI-dimer (P=0.91) or resting P-selectin exposure (P=0.96) between males 
or females in the stroke cohort. Full blood count analysis revealed that although there 
were differences between the control and stroke cohorts in mean haemoglobin and 
platelet counts, they were well within normal parameters. The stroke population had 
significantly larger platelets as measured by MPV compared to controls, but not the non-
stroke cohort (MPV (fL) ± SD: stroke 10.80±0.99, control 10.4±0.9; P=0.007, non-stroke, 
10.61±0.87, P=0.35).  
 
The control population also had fewer vascular risk factors compared to both the stroke 
and non-stroke groups (P<0.0001), whereas the risk-factors between the stroke and non-





Carpal tunnel syndrome 1 
Bell’s palsy 1 
Non-specific symptoms 1 
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stroke cohorts were not significantly different apart from a higher proportion of AF 
(P=0.005) and hypertension (P=0.03) in the stroke group.  As expected, a higher proportion 
of stroke and non-stroke patients were taking aspirin, clopidogrel and a statin at admission 
compared to the control group (P <0.0001).  
 
At admission, the stroke group had a median NIHSS of 8 (IQR 4–15). 50 patients received 
thrombolysis with alteplase. 4 of those patients also underwent thrombectomy and a 
further 2 patients had thrombectomy without prior thrombolysis. 33/50 patients who 
were thrombolysed had their blood taken after receiving thrombolysis and this is 
discussed later in this chapter.  
 
The stroke and non-stroke cohorts were evenly matched in terms of quantified markers 
of illness severity such as C-RP (P=0.92) and NEWS score (P=0.21). The CHA2DS2-VASc 
scores were not significantly different between the stroke and non-stroke groups (P=0.97) 
but both were significantly higher than the control group (P<0.0001) reflecting the higher 
risk factor burden within the stroke and non-stroke cohorts. 24/129 (18.6%) patients 
admitted with stroke and 5/27 (18.5%) non-stroke patients died within six months of 




 Control Stroke 0-day Non-Stroke  P1 P2 P3 
n 301 129 27    
Age  60 (47-68) 79 (67-85) 70 (58-84) <0.0001 0.0001 0.18 
Female (%) 65.8 38.0 59.3 <0.0001 0.53 0.06 
Hemoglobin (g\L) ± SD 136.4±11.4 139.8±17.9 137.3±16.05 0.02 0.70 0.51 
Platelet Count (10x9/L)± SD 260.2±57.3 239.6±88.1 269.3±59.8 0.004 0.45 0.50 
Mean platelet volume (fL)±SD 10.4±0.9 10.80±0.99 10.61±0.87 0.007 0.18 0.35 
CHA2DS2-VASc Score 1 (1-2) 3 (2-4) 3 (1-5) <0.0001 <0.0001 0.97 
Admission NIHSS  - 8 (4-15) - - - - 
Admission C-RP NA 3.38 (1-7) 1.76 (1-5) - - 0.92 
Admission NEWS  NA 1 (0-2) 1 (0-1) - - 0.93 
Thrombolysed, n (%) NA 50 (38.8) NA - - - 
Thrombectomy, n (%) NA 6 (4.7) NA - - - 
Risk factors for thrombotic disease, n (%) 
Atrial Fibrillation  2 (0.66) 61 (47.3) 5 (18.5) <0.0001 <0.0001 0.005 
Congestive Cardiac Failure 0 (0) 9 (7.0) 4 (14.8) <0.0001 <0.0001 0.24 
Hypertension  27 (9.0) 94 (72.9) 14 (51.9) <0.0001 <0.0001 0.03 
Diabetes 1 (0.33) 24 (18.6) 4 (14.8) <0.0001 0.0002 0.79 
Ischemic Heart Disease 0 (0) 24 (18.6) 5 (18.5) <0.0001 <0.0001 0.99 
Cholesterol 24 (8.0) 50 (38.8) 7 (25.9) <0.0001 0.005 0.27 
Previous stroke 0 (0) 26 (20.2) 7 (25.9) <0.0001 <0.0001 0.6 
Admission medication, n (%) 
ACE inhibitor or ARB 21 (7.0) 24 (18.6) 3 (11.1) 0.0006 0.65 0.51 
Aspirin 1 (0.33) 33 (25.6) 5 (18.5) <0.0001 <0.0001 0.60 
Clopidogrel 0 (0) 7 (5.4) 4 (14.8) 0.0003 <0.0001 0.18 
Apixaban 0 (0) 1 (0.8) 1 (3.7) 0.66 0.13 0.77 
Dabigatran 0 (0) 1 (0.8) 0 (0) 0.66 - 0.63 
Rivaroxaban 1 (0.33) 3 (2.3) 1 (3.7) 0.44 0.39 0.73 
Warfarin 0 (0) 9 (7.0) 0 (0) <0.0001 - 0.34 
Statin 22 (7.3) 36 (27.9) 10 (37.3) <0.0001 <0.0001 0.48 
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Table 7.3 (previous page). Baseline characteristics of control, stroke and non-stroke 
groups at admission, including haematological parameters, vascular risk factors and 
admission details. Means are reported with standard deviation and medians with 
interquartile range in the parenthesis. Differences between cohorts were calculated using 
Student’s t-test for parametric and Chi-squared test for non-parametric data and are 
reported as a P value.  
 
P1 = control vs. stroke 0 day, P2 = control vs. non-stroke, P3 = stroke 0 day vs. non-stroke 
SD = standard deviation, IQR = interquartile range, NIHSS = National Institutes of Health 
Stroke Scale, C-RP = C-reactive protein, NEWS =National Early warning Score 2, ACE = 
angiotensin-converting-enzyme, ARB = angiotensin-receptor blocker 
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(b) General platelet characteristics of control and stroke cohorts 
 
As discussed earlier, the platelet counts between groups were well within normal 
parameters, and the differences in the counts themselves are not likely to affect the flow 
cytometric quantification of GPVI expression or P-selectin exposure. 
 
The stroke and non-stroke patients had significantly larger platelets, as measured by MPV 
(Table 7.3). Age and MPV were not correlated in the control or stroke cohorts 
(Supplementary Figure 7.3). 
 
As GPVI-dimer constitutes part of the total GPVI measurements, therefore, as expected, 
the MFI of GPVI-dimer expression was significantly correlated with total GPVI expression 
in the control (r2=0.14, P<0.0001) and stroke (r2=0.49, P<0.0001) cohorts (Figure 7.3).  
 
Figure 7.3 Correlation between total GPVI and GPVI-dimer in A) controls B) stroke 
population at day 0, calculated using Pearson correlation coefficient. Black line represents 
regression line calculated using simple linear regression and Pearson R value and 95% 
confidence interval is presented within each image.  
 
P-selectin exposure after exogenous addition of ADP was correlated to P-selectin exposure 
after CRP-XL addition in controls (control, r=0.21, P<0.0001) and stroke patients (r=0.41, 
P<0.0001) (Figure 7.4) 
 
A) Control B) Stroke






































Figure 7.4 Correlation between P-selectin exposure after ADP addition to P-selectin 
exposure after CRP-XL in A) controls B) stroke population at day 0. Correlations calculated 
using Spearman’s rank correlation coefficient and regression line is presented in black. 
 
Interestingly, P-selectin exposure after CRP-XL addition in the stroke population was also 
not correlated with total GPVI-expression (r=0.07, P=0.40) or resting P-selectin exposure 
(r=0.1, P=0.26). GPVI-dimer expression was however correlated with P-selectin exposure 
after CRP-XL addition (r=0.33, P=0.0002). 
  





















































Figure 7.5 Correlation between GPVI-dimer and P-selectin exposure after CRP-XL in the 
stroke population at day 0. Correlations calculated using Spearman’s rank correlation 
coefficient.  Black line represents simple linear regression line.  
  
























(c) GPVI expression in control compared with stroke and non-stroke 
groups 
 
Compared to controls, stroke patients expressed significantly higher GPVI-dimer (MFI±SD; 
control 0.566± 0.01, stroke 0.633±0.105, P<0.0001) and total GPVI (MFI±SD; control 
4.027±0.08, stroke 4.294±0.32, P<0.0001) at admission.  
 
Compared to the non-stroke group, who had a similar risk factor profile to the stroke 
cohort, stroke patients again demonstrated higher GPVI-dimer (MFI ± SD; non-stroke 
0.543±0.03, P<0.0001), and total GPVI expression (MFI ± SD; non-stroke 3.954±0.91, 
P<0.0001). 
 
Neither the total GPVI or GPVI-dimer expression was significantly different between 




Table 7.4. Total GPVI and GPVI-dimer expression as measured by median fluorescence 
intensity (MFI) in the control cohort compared to the stroke and non-stroke cohorts. P1 = 








P1 P2 P3 
Platelet GPVI expression (MFI)±SD  
Total   4.027±0.08 4.294±0.32 3.952±0.30 <0.0001 0.42 <0.0001 





Figure 7.6. GPVI expression between control, stroke and non-stroke cohorts. A) Total 
GPVI and B) GPVI-dimer are both significantly higher in the stroke population at admission 
compared to the control and non-stroke cohorts (P<0.0001). The error bars represent the 
mean MFI of each of the cohorts ± SD 
 
(d) Platelet P-selectin exposure in control, stroke and non-stroke groups 
 
Even though GPVI expression was not different between control and non-stroke cohorts, 
resting platelets from both stroke and non-stroke patients already showed some 
activation compared to the controls as indicated by higher P-selectin exposure (P<0.0001). 
Furthermore, stroke patients demonstrated significantly more P-selectin exposure after 
ADP stimulation compared to non-stroke patients and more P-selectin exposure after CRP-
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Table 7.5. P-selectin exposure (%PP) in control, stroke and non-stroke populations. P1 = 





Figure 7.7. P-selectin exposure between control, stroke and non-stroke cohorts. A) P-
Selectin exposure in resting platelets in control, stroke and non-stroke cohorts and after 








P1 P2 P3 
Median (Q1-Q3) P-Selectin exposure (%PP)  
Resting 19.8 (19.7-19.9) 33.2 (28.6-33.2) 29.6 (28.5-30.3) <0.0001 <0.0001 <0.0001 
+ADP  75.4 (73.7-76.4) 75.2 (73.9-77.1) 71.4 (68.7-73.6) 0.18 <0.0001 <0.0001 



























(e) GPVI expression and P-selectin exposure and day 0 + 90 in stroke 
patients 
 
Out of the 129 patients, 114 had had ischaemic strokes of different aetiologies. From 
those, excluding those who had died, discharged to nursing care, were too frail to attend 
follow up or those originally from another geographical area, 51 ischaemic stroke patients 
who attended their 3-month follow up (median days to follow up (IQR): 110 (92-128)) were 
consented to give a repeat blood sample which was analysed for GPVI expression and 
platelet function as before. This will be referred to as the ‘day-90’sample and was included 
in the analysis to facilitate comparison of GPVI expression and platelet function at day-0 
and day-90 post stroke. 
 
Comparing the 51 patients who were followed up with the 78 who were not (table 7.5) 
reveals that those who were followed up were significantly younger (P=0.002) and had a 
greater proportion of male subjects (P=0.003). As expected, those who were not followed 
up were more disabled on discharge, as measured by mRS (P<0.0001) and a significantly 
higher proportion had died by six months (P=0.0004). Interestingly, there were no 
significant differences in admission parameters and comorbidities (except for CCF) 





Table 7.6. Characteristics of the stroke cohort who were followed up at day-90, compared 
to those who were not; including haematological parameters, vascular risk factors and 
admission details. Means are reported with standard deviation and medians with 
interquartile range in the parenthesis. Differences between cohorts were calculated using 
Student’s t-test for parametric and Chi-squared test for non-parametric data and are 
reported as a P value (significance).  
 
  
 Day 90 Follow up No Day 90 follow up  Significance 
n 51 78  
Age  71.5 (61-81) 80 (72-80) 0.002 
Female (%) 11 (21.6) 38 (48.7) 0.003 
Hemoglobin (g\L) ± SD 143.3±16.8 137.5±18.3 0.07 
Platelet Count (10x9/L)± SD 231.1±74 244.9±96 0.39 
Mean platelet volume (fL) ± SD 10.87±1.1 10.82±0.9 0.80 
CHA2DS2-VASc Score 3 (1-4) 3 (3-5) 0.10 
Admission NIHSS  7.5 (4-14) 9 (5-16) 0.22 
Admission C-RP 3.2 (1-6) 3.4 (2-8) 0.67 
Admission NEWS  1 (0-2) 1 (0-2) 0.19 
Discharge mRS 1 (1-2) 3 (1-5) <0.0001 
Death within 6 months n, (%) 2 (3.9) 22 (28.2) 0.0004 
Risk factors for thrombotic disease, n (%) 
Atrial Fibrillation  23 (45.1) 48 (48.7) 0.07 
Congestive Cardiac Failure 0 (0.0) 9 (11.5) 0.01 
Hypertension  38 (74.5) 56 (71.8) 0.84 
Diabetes 7 (13.7) 17 (21.8) 0.36 
Ischemic Heart Disease 8 (15.7) 16 (20.5) 0.64 
Cholesterol 23 (45.1) 27 (34.6) 0.27 
Previous stroke 12 (23.5) 14 (18.0) 0.50 
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Total GPVI expression not different at day 90 compared to day-0 (day-0, 4.262±0.36; day-
90, 4.220±0.36, P=0.52) however, GPVI-dimer levels were significantly higher (day-0, 
0.626±0.056 day-90, 0.686±0.09, P<0.0001).  
 
 Interestingly, despite an observation of significantly increased GPVI-dimer expression, 
resting P-selectin is in fact significantly lower at day-90 compared to admission (day-0, 
33.5 (32.8-34.2); day-90 30.44 (29.7-31.1), P<0.0001). Similarly, P-selectin exposure after 
ADP (day-0, 75.60 (74.8-76.4; day-90 69.26 (67.5-71.1), P<0.0001) and CRP-XL (day 0, 
84.65 (84.3-86.0); day-90, 83.37 (83.0-84.0), P=0.0001) stimulation at day-90 is also lower 
compared to day-0 (Figure 7.8). 
 
 
Figure 7.8. Matched GPVI expression and P-selectin exposure between ischaemic stroke 
patients at day 0 and at day 90 (n=51). A) Total GPVI expression B) GPVI-dimer expression 
at day 0 and day 90 post stroke. The error bars represent the mean MFI of each of the 
cohorts ± SD. C) P-selectin exposure in resting, +ADP or +CRP-XL at day 0 or day 90 post 
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At their follow up appointment, more patients had been started on a DOAC or clopidogrel, 
compared to when they were admitted (Table 7.6). The fact that the GPVI-dimer levels are 
higher despite more patients being started on antiplatelets and anticoagulation suggests 
that conventional antithrombotic medication probably does not impact GPVI-dimer 
expression. The effect of antiplatelet therapy we do observe is as a significantly impaired 
P-selectin response after ADP addition in patients on clopidogrel, as expected, at the time 
of venepuncture at day 90 which is discussed in more detail in section 7.1.7. 
 
 
Table 7.7 Number of patients on antithrombotic medication at day 0 compared to day 90 
 
(f) GPVI expression according to stroke aetiology 
 
All ischaemic stroke patients were sub-classified by stroke aetiology as described in the 
methods. Haemorrhagic strokes (bleed) were not further sub-classified and sub-arachnoid 
haemorrhages were not recruited.  
 
129 patients were categorized into LAS (n=17), CES (n=56), SVO (n=18), Other (n=2), UD 
(n=21) and bleed (n=15). Data from stroke patients classified into strokes of Other 
aetiology were excluded due to low numbers and UD were excluded due to ambiguity in 
interpreting their aetiological significance. 
 
All remaining stroke subtypes (LAS, CES, SVO, bleed) demonstrated significantly higher P-
selectin exposure compared to controls (P<0.0001, all categories) suggesting that patients 
who have had a stroke have more activated circulating platelets compared to controls. 
Furthermore, all strokes, whether ischaemic or haemorrhagic, demonstrated significantly 
Medication Day 0 Day 90 
Aspirin 11 13 
Clopidogrel 2 18 
Warfarin 3 1 
DOAC 2 17 
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higher total GPVI (P<0.0001, all categories) and GPVI-dimer expression (P<0.0001, all 
categories) compared controls (Figure 7.9) 
 
There were no significant differences when comparing total GPVI (P=0.33) GPVI-dimer 
(P=0.29) or resting P-selectin exposure (P=0.57) between all ischaemic (n=91) and 




Figure 7.9 A) Total GPVI expression B) GPVI-dimer expression C) Resting P-selectin 
exposure between control, subclassified ischaemic strokes and haemorrhagic strokes. 
Error bars median (Q1-Q3) %PP. Numbers in parentheses represent the number of 
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(g) GPVI expression with antiplatelet, anticoagulation and thrombolysis 
 
One important question is whether antithrombotic medication or receiving thrombolysis 
effects GPVI expression or platelet function. At admission 33 (25.6%) patients in the stroke 
cohort were on aspirin, 7 (5.4%) on clopidogrel and 14 (10.8%) on anticoagulation (1 
apixaban, 1 dabigatran, 3 rivaroxaban, 9 warfarin). 50 (38.8%) patients received 
thrombolysis. 
 
Total GPVI (P=0.37), GPVI-dimer (P=0.14) expression and resting P-selectin exposure 
(P=0.58) were not significantly different in those taking antiplatelets at admission, 
compared to those not taking antiplatelets or anticoagulation at admission. Similarly, 
there were no differences in any of the measured parameters between those taking 
antiplatelets or anticoagulation. 11 patients who were newly started on clopidogrel by 
their day-90 sample (i.e. were not on clopidogrel on admission) demonstrated significantly 
lower P-selectin exposure after ADP stimulation at day-90 (P=0.002) (Figure 7.10), 
although their total GPVI (P=0.46), GPVI-dimer (P=0.11) or resting P-selectin exposure 







Figure 7.10 P-selectin exposure after exogenous addition of ADP in patients who were 
on clopidogrel by day 90 but not on antiplatelets at admission. Error bars represent 



























There were also no differences in patients who were thrombolysed compared to those 
who were not in terms of total GPVI (P=0.94) or GPVI-dimer expression (P=0.74) (Figure 
7.11)A. 
 
Similarly, resting P-selectin (P=0.82) or P-selectin exposure after addition of ADP (P=0.97) 
or CRP-XL (P=0.90) were also not different between these cohorts. 
 
We then analysed whether blood sampling after thrombolysis made any difference to 
GPVI expression or platelet function. There were no differences observed in total GPVI 
(P=0.62) or GPVI-dimer (P=0.51) expression (Figure 7.11B) and as above no differences in 




Figure 7.11 Total GPVI and GPVI-dimer expression between A) thrombolysed (n=50) 
compared to not thrombolysed (n=79) and B) blood taken pre-thrombolysis (n=16) 
compared to post-thrombolysis (n=32). The error bars represent the mean MFI of each of 






































(h) Variables associated with GPVI expression in stroke patients 
 
Simple linear regression was used in order to determine the relationship between total 
GPVI or GPVI-dimer expression and a single predictor variable.  
 
In stroke patients, the presence of AF and diabetes were both significantly associated with 
total GPVI (AF B 0.13, SE 0.06, P=0.02; diabetes B 0.2, SE 0.07, P=0.008) B and GPVI-dimer 
(AF B 0.02, SE 0.009, P=0.01; diabetes B 0.03, SE 0.01, P=0.01) expression. Hypertension 
was also a significantly associated with GPVI-dimer expression only (B 0.02, SE 0.01, 
P=0.02).  
 
Furthermore, parameters such as the CHA2DS2-VASc score of all stroke patients and 
admission NIHSS and discharge mRS were both associated with total GPVI (CHA2DS2-VASc 
B 0.05, SE 0.02, P=0.001; NIHSS B 0.01, SE 0.005, P=0.02). and GPVI-dimer expression. 
(CHA2DS2-VASc B 0.01, SE 0.002, P<0.0001; NIHSS B 0.002, SE 0.001, P=0.009). Discharge 
mRS was also associated with GPVI-dimer expression (B 0.005, SE 0.002, P=0.03), but not 
total GPVI (Table 7.8).  Neither gender, or any of the markers of illness acuity measured 








Table 7.8 Simple linear regression to determine associations between single predictor 
variables and total GPVI or GPVI-dimer expression.  
  
 Total GPVI GPVI-dimer 
Coefficient B Significance (P) Coefficient B Significance (P) 
Female 0.08 0.07 0.02 0.08 
Comorbidities 
Atrial Fibrillation  0.13 0.02 0.02 0.01 
CCF  0.06 0.58 0.01 0.47 
Hypertension  0.12 0.07 0.02 0.02 
Diabetes 0.20 0.008 0.03 0.01 
Ischaemic Heart Disease 0.1 0.18 0.01 0.10 
Cholesterol 0.01 0.82 0.002 0.87 
Previous Stroke -0.01 0.91 -0.003 0.81 
Admission and discharge parameters 
Antiplatelets at admission 0.00 0.89 0.00 0.78 
CHA2DS2-VASc score 0.05 0.001 0.01 <0.0001 
Admission NIHSS score 0.01 0.02 0.002 0.009 
Admission C-RP 0.00 0.83 0.00 0.65 
Admission NEWS score 0.005 0.78 0.01 0.60 
Discharge mRS 0.02 0.16 0.005 0.03 
Death within six months 0.08 0.23 0.02 0.12 
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The variables that were significantly associated with GPVI-dimer expression were then 
modelled using multiple linear regression (Table 7.8). This analysis revealed that only the 
CHA2DS2-VASc score, a composite score of vascular risk factors (usually reserved for AF 
patients but in this case calculated for all stroke patients) was independently associated 
with GPVI-dimer expression. 
 
Model summary: Adjusted R2 = 0.14, P=0.001 
 
Table 7.9 Multiple regression analysis of factors associated with GPVI-dimer expression. 
There was no multicollinearity between any of the tested variables in this model. 
  
GPVI dimer Coefficient B Standard Error Significance (P) 
CHA2DS2-VASc score 0.008 0.004 0.03 
Atrial Fibrillation 0.018 0.01 0.06 
Admission NIHSS score 0.001 0.001 0.11 
Diabetes 0.006 0.014 0.67 
Hypertension 0.005 0.013 0.72 




(i) Predictors of stroke in the whole population 
 
The whole population of study participants (control, stroke and non-stroke; n=457) were 
dichotomised into whether they had had a stroke or not, which was then used as the 
dependent variable in a multivariable binary logistic regression analysis. Unadjusted 
values of total GPVI, GPVI-dimer, age and MPV were tested as independent variables. 
 
Table 7.10 Binary logistic regression analysis of parameters: total GPVI, GPVI-dimer, age 
and MPV, to assess for predictors of stroke. 
 
The results suggest GPVI-dimer expression is an independent predictor of stroke (Odds 
Ratio 10.4 (1.4-76.5), P=0.02), when modelled together with total GPVI, age and MPV.  
  
Parameters Odds Ratio 95% CI Significance (P) 
Age (years) 1.08 1.06 – 1.10 <0.0001 
MPV (fL) 1.42 1.08 – 1.83 0.01 
GPVI dimer 10.4 1.4 – 76.5 0.02 
Total GPVI 1.07 0.74 – 1.55 0.73 
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7.08 Discussion 
Through its unique ability to bind collagen and fibrin, platelet receptor GPVI has been the 
subject of extensive research in the last decade, especially the consideration of its 
inhibition as a novel antithrombotic target in clinical studies. Despite this, many questions 
remain, especially focused around the relationship between GPVI expression and 
thrombotic disease in vivo, as well as the relationship between the GPVI-monomer and 
dimer in the setting of thrombotic disease.  
 
Previous clinical studies investigating GPVI in thrombotic disease have either focussed on 
quantifying soluble GPVI (sGPVI); the metalloproteinase-cleaved ectodomain of GPVI shed 
from the platelet upon activation (Gardiner, 2004; Rabie, 2007) or the surface expression 
of platelet total GPVI (Bigalke, 2010; Wurster, 2013). Plasma sGPVI measurements in 
stroke patients have demonstrated increased levels in LAS, but not SVO and CES subtypes 
(Al-Tamimi, 2011) and others have reported that sGPVI levels were lower in stroke 
patients than in TIA (Wurster, 2013). These mixed results in stroke are difficult to translate 
into clinical use. Conversely, platelet expression of total GPVI has consistently been shown 
to be increased in ischaemic stroke and TIA patients compared to non-stroke patients 
(Bigalke, 2010; Wurster, 2013) and this result also extends to patients with acute coronary 
syndrome (Bigalke, 2010). This is important because the adhesive and signalling abilities 
of platelets have been shown to be proportional to the GPVI density on the platelet, 
implying a potential role for it in thrombus formation and stroke (Chen, 2002). However, 
despite their practicality, none of the previous work has quantified platelet expression of 
the dimeric active form of GPVI, which would be the target for any pharmacological 
intervention in thrombotic disease. 
 
 
The main results from this chapter are as follows 
1) Patients with stroke express more total GPVI (P<0.0001) and GPVI-dimer 
(P<0.0001) on their platelet surface compared to healthy controls and non-stroke 
patients. 
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2) GPVI-dimer expression at ‘day-90’ post stroke is significantly higher than at 
admission (P=0.0007), whereas total GPVI is not different (P=0.07) and P-selectin 
exposure is significantly less (P<0.0001). 
3) All stroke patients, whether subclassified by ischaemic stroke categories or into 
haemorrhagic stroke, express higher GPVI-dimer compared to the control 
population (P<0.0001). 
4) The presence of AF (P=0.01), hypertension (P=0.02) and diabetes (P=0.01) are 
associated with higher GPVI-dimer expression. Higher GPVI-dimer expression was 
an independent predictor of stroke within our population (P=0.02). 
5) The elevation of GPVI-dimer observed in stroke patients is not reversed by existing 
anti-thrombotic medication. 
 
This study represents the first piece of work to investigate both total GPVI and GPVI-dimer 
in a cohort of patients presenting to hospital with stroke. Our results agree with previous 
work by Bigalke and colleagues who observed higher total GPVI expression in stroke and 
TIA patients compared to a control population (Bigalke, 2010). Our novel finding however, 
is that stroke patients also have more GPVI-dimers on their platelet surface at the time of 
their stroke compared to both a control and non-stroke population (Figure 7.6).  
 
What is yet to be conclusively established is whether the over-expression of GPVI-dimer 
specifically to stroke patients is due to presence of vascular risk-factors, whether the 
increased dimer expression is due to the acute stroke itself, or both. There certainly maybe 
a risk-factor driven element to GPVI-dimerisation. This is evidenced from our results since 
AF, an inflammatory condition known to modulate platelet activity (Guo, 2012; Harada, 
2015), hypertension and diabetes as well as a higher CHA2DS2-VASc score, a composite 
score made up of individual stroke risk-factors, were all significant predictors of higher 
GPVI-dimer expression (Table 7.8). Therefore, it may be likely that the stroke patients had 
more GPVI-dimer on the platelets prior to their stroke, inherently increasing their stroke-
risk. This is further evidenced as even in the control group, the presence of hypertension 




It is likely that vascular risk factors also play a role in driving P-selectin exposure, as both 
the stroke and non-stroke cohorts, who had similar proportion of risk factors 
demonstrated more resting P-selectin exposure on their circulating platelets (Table 7.5). 
However, we did not observe higher GPVI-dimer expression in the non-stroke patients 
compared to the stroke patients (Table 7.4), suggesting that resting platelet P-selectin 
exposure may not necessarily relate to thrombotic risk through a GPVI pathway. This is 
further highlighted by the fact that resting P-selectin was not correlated to GPVI 
expression (Supplementary Figure 7.4) in stroke patients. What we do observe is that GPVI 
levels could govern platelet response to exogenous agonists. P-selectin exposure after 
CRP-XL addition strongly correlated to GPVI-dimer but not total GPVI expression in the 
stroke cohort (Figure 7.5) and even though P-selectin exposure post ADP was not related 
to GPVI expression, overall P-selectin exposure after CRP-XL and ADP addition were highly 
correlated (Figure 7.4). This means that whereas GPVI expression and resting platelet 
activation appear unrelated, a significant proportion of the variability of platelet activation 
in response to collagen is due to GPVI-dimer levels and the remainder is due to other 
shared, or non-GPVI related pathways. 
 
Analysis of platelets from patients at day-90 post-stroke reveals that GPVI-dimer 
expression, but not total GPVI or P-selectin exposure, was significantly higher compared 
to day-0 (Figure 7.8). This could be because acute stroke conditions on day-0 could actually 
favour GPVI-dimer shedding, whereas by day-90 this is no longer the case.  This could 
result in an apparently higher GPVI-dimer level at day-90, which in fact may more 
accurately reflect the constitutive number of dimers present in the patients’ platelets prior 
to stroke.  Conversely, P-selectin exposure appears to decline from day-0 to 90 in stroke 
patients, returning to levels similar to that of the non-stroke group. This suggests an acute 
rise approximate to time of stroke, before returning to previous levels as described in the 
literature previously (Marquardt, 2002). Our results do not point to an antiplatelet effect 
apart from P-selectin exposure after ADP addition in patients taking clopidogrel, however 
antiplatelet effects on suppressing P-selectin exposure has also been described in the 
literature (Bath, 2017; Fox, 2019) and may play a role in the significantly lower P-selectin 
exposure seen at day-90.  
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At admission, GPVI-dimer expression was higher in all ischemic stroke subtypes and all 
haemorrhagic stroke patients (Figure 7.9). This is not surprising, as ischaemic and 
haemorrhagic stroke patients share similar risk-factor profiles, and therefore would be 
expected to demonstrate higher GPVI expression.  Although there were only 15 
haemorrhagic strokes, compared to 91 ischaemic ones (excluding UD and Other), there 
were no observed differences between GPVI expression between the two stroke types. It 
is likely that those patients who had a haemorrhagic stroke would also have been at risk 
of ischaemic stroke, and that GPVI expression is unlikely to play a differentiating role here.  
 
Our results finally demonstrate that GPVI-dimer expression was predictive of stroke 
independent of age, MPV and crucially, total GPVI (Table 7.10) and secondly that a higher 
admission NIHSS score, which represents a higher stroke severity was associated with 
higher GPVI expression (Table 7.8). 
 
To further the quest for new anti-thrombotic targets in ischemic cardio- or 
cerebrovascular disease, we demonstrate that GPVI-dimer, the functional form of the 
platelet-collagen receptor, is over-expressed in stroke patients and could emerge as a 
viable and safe option to inhibit platelet activity. GPVI-dimer inhibition, in contrast to 
drugs targeting other platelet receptors such as integrin αIIbβ3 (Ciccone, 2014), may not 
cause the unwanted side-effect of bleeding, since GPVI-deficient patients exhibit little 
bleeding tendency (Sugiyama, 1987; M Moroi, 1989). This is consistent with observations 
that GPVI inhibition in aged and comorbid mice has proved protective against ischemic 
stroke without increasing bleeding complications (Kraft, 2015), and with translational 
studies in healthy volunteers showing early promise (Ungerer, 2011; Voors-Pette, 2019). 
Further work will need to be carried out in the context of clinical trials to fully assess the 
risks and benefits of GPVI inhibition in patients with, or at risk of, thrombotic disease. 
 
The purpose of this study was to explore the presence and significance of GPVI-dimer on 
the platelet surface, and especially its relationship with platelet activation in the presence 
of cardio- and cerebrovascular risk factors and thrombotic disease. Crucially, we 
demonstrate that stroke patients overexpress GPVI-dimer at least until day 90 post-stroke, 
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and that anti-thrombotic therapy; including antiplatelet drugs, anticoagulation or 
thrombolysis do not affect GPVI expression (Figure 7.11).  
 
The ability of GPVI to interact with the two main ligands that drive thrombosis, collagen 
and fibrin (Alshehri, 2015; Mammadova-Bach, 2015; Induruwa, 2018) cements its role as 
a central platelet receptor in human thromboembolic disease. Furthermore, our results 
intimate an important role for GPVI-dimer in thrombosis in both large-artery and 
cardioembolic stroke and the over-expression of GPVI-dimer in all ischemic stroke patients 
suggests that direct inhibition of GPVI-dimer would be a promising therapy against 




7.09 Supplementary files 
 
Initial statistical analysis revealed that age and MPV were both correlated with GPVI-dimer 
expression. Linear regression revealed that age (P=0.049) MPV (P <0.0001) were 
significant associates of GPVI-dimer expression (Supplementary Figure 7.1). MPV was also 
correlated with total GPVI expression (r2=0.18, P<0.0001) whereas age was not (r =0.08, 
P=0.34).  
 
In the control population, neither age or MPV were related to GPVI-dimer expression 
(Supplementary Figure 7.2). Resting P-selectin exposure was also associated with MPV (r 




Supplementary Figure 7.1 Correlation between GPVI-dimer (MFI), and A) age and B) MPV 
(fL) in the stroke population. A) Calculated using Spearman’s rank correlation coefficient 
and B) using Pearson correlation coefficient. 
 
  


























Supplementary Figure 7.2 Correlation between GPVI-dimer (MFI), and A) age and B) MPV 
(fL) in the control population. A) Calculated using Spearman’s rank correlation coefficient 
and B) using Pearson correlation coefficient. 
 




Supplementary Figure 7.3 Correlation between age and MPV (fL) in A) control and B) 
stroke 0-day populations. Calculated using Spearman’s rank correlation coefficient.  
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Resting P-selectin exposure in control platelets were correlated to GPVI-dimer expression 
(r=0.16, P=0.006), However, we do not see this in the stroke population where GPVI-dimer 
and resting P-selectin exposure are not correlated (stroke, r=-0.04, P=0.65) 




Supplementary Figure 7.4 Correlation between resting P-selectin exposure and GPVI-
dimer expression in A) controls B) stroke population at day 0. Correlations calculated 
using Spearman’s rank correlation coefficient.  Black line represents regression line 
calculated using simple linear regression and Spearman r value and 95% confidence 
interval is presented within each image. 
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) r= 0.16 (0.04-0.27)
P=0.006



















) r= -0.04 (-0.22-0.14)
P=0.65
 198 
Modelling associations between age and MPV inserted as single predictor variables with 
unadjusted total GPVI and GPVI-dimer expression for the stroke population, was carried 
out using simple linear regression. Both total GPVI and GPVI-dimer expression and platelet 
function values were then adjusted for age and MPV prior to analysis. 
 
 
Supplementary Table 7.1 Simple linear regression to determine associations between 
single predictor variables; age and MPV with unadjusted total GPVI and GPVI-dimer 








 Total GPVI GPVI-dimer 
 Coefficient B Significance (P) Coefficient B Significance (P) 
Age (years)  0.12 0.19 0.17 0.049 










CHAPTER VIII. PLATELET RECEPTOR 









8.01 GPVI binding to fibrin; what we know now 
As discussed in chapter III the two seminal papers from Mammadova-Bach et al. and 
Alshehri et al. in 2015 opened up a new avenue of research in to the possibility of GPVI as 
a receptor for fibrin. 
 
They established that the activation of platelets through GPVI is stimulated with 
polymerised fibrin, which suggested the now recognised contribution of GPVI as a 
receptor for polymerised fibrin. Briefly, the authors described that the presence of fibrin-
stimulated signalling caused tyrosine phosphorylation, thrombin generation and platelet 
PS exposure in order to support thrombus formation under flow. Initially however, 
whether GPVI was a receptor for fibrin at all was contentious. Much of the platelet 
research community were dubious from the limited evidence available with regards to this 
interaction, and some of this debate still remains. 
 
At the time of writing this thesis, a lot more research has been completed on GPVI-
fibrin(ogen), which has eased some of the initial concerns from other groups. The main 
point of contention that remains is about which form of GPVI, the monomer or the dimer, 
binds to fibrin. Similarly, whether GPVI binds to both fibrinogen and fibrin and whether 
this is a primary interaction or a collaborative one together with other platelet receptors 
such as integrin aIIbb3 are also still debated. 
 
After the initial two papers by Mammadova-Bach and Alshehri, other researchers also 
became interested in the subject. Our group noticed the potential dual role for GPVI in 
thrombus formation in LAS and CES, through its interaction with both collagen and fibrin, 
hence sought to investigate this further in both AF patients at risk of stroke and stroke 
patients. Despite this only one or two relevant papers were published in the following two 
years. This was until Onselaer and colleagues in 2017, from the Birmingham platelet group 
reported in 2017 that recombinant monomeric GPVI, made up of the collagen binding D1 
and D2 domains bound to fibrin and not fibrinogen (Onselaer, 2017). They also 
demonstrated that fibrin was not able to activate GPVI-deficient human (and mouse) 
platelets and reported that recombinant GPVI-dimer (Revacept) did not bind to fibrin.  
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The work by Onselear and colleagues, which preceded the publication of our work 
discussed in chapters IV and V (Induruwa, 2018), further solidified the idea that GPVI could 
indeed have roles in thrombosis outside of the established GPVI-collagen interaction. 
However, numerous key differences were present between these results of our work and 
theirs. Firstly, our GPVI-monomer (GPVIex) did not bind fibrin or D-fragment (probably the 
GPVI-binding site in fibrinogen). We found that our GPVI-dimer (GPVI-Fc2) bound 
saturably, with one-site kinetics to D-fragment of fibrinogen and D-dimer of fibrin. 
Onselaer did not report whether Revacept bound to fibrinogen or D-fragment but showed 
that their monomer did not bind to fibrinogen. Both the study by Onselaer et al. and our 
study demonstrated that neither form of GPVI bound to E-fragment. 
 
Furthermore, in 2018 Ebrahim and colleagues from the Siess group in Munich reported 
that two forms of their GPVI-dimer (GPVI-Fc1 (Revacept) and GPVI-Fc2) did not bind to 
physiologically prepared fibrin from purified fibrinogen.  Nor did they bind to fibrin 
produced through exposing TF coated surfaces of atherosclerotic plaque slices to arterially 
flowing blood (Ebrahim, 2018). They also reported no binding of their recombinant dimer 
to fibrinogen. However, Ebrahim and colleagues did not test a monomeric form of GPVI to 
demonstrate whether either form of GPVI could bind to their fibrin, which is one of the 
main limitations of this work. 
 
Therefore, thus far the published research was uncertain about which form of GPVI bound 
to fibrin, if at all, with only our group establishing that it could also interact with 
immobilised fibrinogen through the D-domain. The fact that mFAB-F could inhibit platelets 
binding to and being activated on fibrin coated surfaces under flow, however, suggested 
a specific role for GPVI-dimer in these interactions.  
 
Initially, why GPVI could bind to fibrin but not fibrinogen as reported by other groups was 
curious to us. Some of the early work indicated that GPVI did not bind to monomeric fibrin 
either, which is similar in structure to fibrinogen. Subsequently, Mangin and colleagues 
reported that human GPVI monomer binds to immobilised fibrinogen which leads to 
intracellular signalling and platelet activation as well as platelet aggregation under flow 
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(Mangin, 2018). This is similar to our work, although we reported that it is the GPVI-dimer 
that bound to the immobilised fibrinogen D-domain. The need for fibrinogen to be 
immobilised appears to be important certainly through the in vitro results obtained as 
both groups reported that GPVI was not able to interact with fibrinogen in suspension. 
This is in keeping with physiological observations that platelets do not form thrombi 
merely through binding to soluble fibrinogen in the circulation. This also highlights that 
integrin aIIbb3 must play a role in platelet-fibrin(ogen) adhesion. What remains unclear is 
the exact nature of the collaborative relationship between GPVI and integrin aIIbb3. Our 
work in patients with GT suggested that GPVI-dimer may have a limited but independent 
role in the absence of aIIbb3. However, in normal platelets, whether GPVI propagates 
aIIbb3 induced signalling when adhering to fibrin(ogen), much like a2b1 with collagen, or 
whether GPVI binds to fibrinogen first, leading to signalling that promotes the high-affinity 
conformation of aIIbb3 or a mixture of both is not established. It is likely that GPVI has 
different roles in different sites and stages of thrombus formation. 
 
To explain the discrepant observations by the different laboratories we must consider the 
methods employed, e.g., ELISA assays with immobilised substrates, a system far from a 
physiological interaction between platelets and fibrin. Static binding assays cannot mimic 
how GPVI would bind to fibrin fibres within a clot, particularly as platelets would interact 
with clots formed from a three-dimensional network of fibrin fibres that have been also 
been crosslinked via the transglutaminase activity of FXIIIa and Ca2+. A review by Alexandre 
Slater from the Birmingham platelet group, published in 2019, dissected why the four 
different groups have obtained discrepant results (Slater, 2019). Their conclusion is that it 
could be due to 1) the recombinant GPVI constructs, both monomeric and dimeric; 2) 
different preparations of fibrinogen and fibrin; used and 3) as discussed above, binding 
assay conditions. I have summarised the results reported by each group in Table 8.1. 
































































Table 8.1 Published results from different groups investigation the GPVI-fibrin(ogen) 
interaction.  
 
8.02 GPVI binding to fibrin and relationship with stroke thrombus 
architecture 
GPVI adhering to fibrin as well as immobilised fibrinogen to cause platelet activation opens 
up a wealth of possibilities when considering the role of GPVI in thrombotic disease, 
particularly ischaemic stroke. Within a thrombus, many blood cells including platelets, 
erythrocytes, leukocytes are trapped, associated with fibrin, exposed collagen and other 
coagulation-related proteins. Therefore, consideration of how platelets and platelet GPVI 
is organised within the constituents and histology of a thrombus, will help us elucidate the 
potential roles that GPVI will have in thrombosis through its roles as a collagen and 
fibrin(ogen) receptor. This in turn will facilitate in understanding of how potential anti-
GPVI medication could fit into the current line-up of anti-thrombotics used in stroke. 
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The advent of thrombectomy for ischaemic stroke enables analysis of excised thrombi 
from LAS and CES and histological analysis to date has revealed different cellular 
composition between clots from these two ischaemic stroke subtypes. These studies 
reveal that non-cardioembolic stroke thrombi are generally erythrocyte rich, and that 
fibrin-rich thrombi are significantly associated with a cardioembolic source (Boeckh-
Behrens, 2016; Sporns, 2017). Furthermore, thrombus histology of ESUS was significantly 
associated with that of cardioembolic strokes rather than non-cardioembolic ones 
(Boeckh-Behrens, 2016; Santos, 2016; Sporns, 2017) in keeping with evidence that a 
proportion of thrombi in ESUS strokes maybe from a cardiac source (Wachter, 2017). This 
is of particular relevance considering how GPVI is involved in predominantly collagen-
driven large artery carotid thromboembolism as well as thrombin and fibrin driven 
cardioembolism. 
 
The physiological significance of GPVI activity therefore could have multiple roles in the 
growing thrombus, regardless of stroke aetiology. For example, in LAS, GPVI-dimer would 
bind to collagen and activate platelets, thereby propagating the release of various platelet 
agonists to cause nearby platelet activation and thrombus growth. In venous thrombi or 
CES, it would be endothelial dysfunction, TF release and fibrin deposition on the 
endothelial layer that would attract platelets. A platelet monolayer would grow on the 
thrombus through GPVI-collagen adhesion in LAS or GPVI-fibrin adhesion in CES (as well 
as other platelet receptors including GP1b, a2b1 and aIIbb3). As this platelet layer 
develops into a thrombus, fibrin is actively formed on the surface of activated platelets, 
triggering divergent coagulation pathways in order to reinforce thrombus growth in both 
LAS and CES.  
 
We can therefore hypothesise that GPVI must have a role in these platelet-fibrin 
interactions to help develop, but also stabilise the thrombus. Studies have shown that 
platelet dependent fibrin formation commences at the base of the thrombus, growing 
upwards and outwards (Swieringa, 2018). This means that densely packed fibrin fibres are 
generally found within the core of a thrombus, alongside collagen and activated platelets 
(Stalker, 2014), whereas loosely packed fibrinogen and fibrin is likely to be present in the 
outer shell of the thrombus (Macrae, 2018). This suggests a model in which thrombus 
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stability could be sustained by GPVI with collagen and fibrin in the centre of the thrombotic 
core but thrombus growth through platelet activation also in association with fibrin(ogen) 
on the outside of the thrombus; potentially together with integrin aIIbb3; relevant in 
arterial, venous and cardiac-thrombosis. An in vitro thrombus model reported by Lehmann 
and colleagues demonstrated that TF induced fibrin deposition and then GPVI driven 
platelet adherence and activity (quantitated through PS expression) drove thrombus 
growth in venous thrombosis, a mechanism of thrombosis similar to that in CES (Lehmann, 
2018). 
 
To further understand the role that GPVI could play in the clot structure, we also sought 
to determine GPVI binding to fibrin clots formed from thrombin catalysis of near serum 
concentrations of fibrinogen, which mimics the clots formed from a three-dimensional 
network of fibrin fibres as seen in vivo. These fibrin clots were either non-crosslinked or 
crosslinked using FXIII and Ca2+, closely approximating physiological conditions. This set of 
experiments, designed by Dr M Moroi, are detailed in supplementary section 8.09. The 
recombinant GPVI constructs we used were 1) our dimer used in previous work (GPVI-Fc2) 
2) Revacept (another GPVI-dimer) or 3) GPVI-His (monomer of Revacept) followed by clot-
bound protein analysis.  
 
Both GPVI-Fc2 (Supplementary Figure 8.1) and Revacept (data not shown) bound to non-
crosslinked and crosslinked fibrin clots with dose-dependent, saturable one-site binding 
kinetics; crosslinking of the clots increased the affinity two-fold. The sequence of the dimer 
constructs were the same as those previously used in ELISA (chapter IV and V) with 
immobilised substrates and the Kd values determined in this clot assay were consistent 
with those obtained for D-fragment and D-dimer by ELISA. By contrast, monomeric GPVI 
binding to either type of clot was non-saturable and nearly linear, indicating very low 
affinity or non-specific binding (data not shown). 
 
Anti-GPVI-dimer antibody mFAB-F partially but significantly inhibited the GPVI-Fc2 binding 
to the clot (100 μg/mL, P=0.02; 150 µg/ml, P=0.001; 200 µg/ml, P=0.002, n=6), indicating 
a GPVI-dimer–specific interaction.  D-fragment and D-dimer weakly inhibited (P=0.0129 
and P=0.0235, respectively), supporting the conclusion that GPVI-Fc2 binds to these 
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fragments and bind to fibrin clots in close proximity to where D-dimer binds to GPVI 
(Supplementary Figure 8.2).  
 
We then formed clots from a mixture of platelets and fibrinogen, to examine how platelet-
surface GPVI and other receptors [GPIb and CD61 (integrin β3)] contribute to the 
interaction between platelets and fibrin in the clot. Interestingly, the addition of Integrillin 
(anti-aIIbb3) to fibrin clots increased the amount of clot-bound GPVI-dimer (data not 
shown). This is consistent with our previous work in GT patients and indicates that GPVI-
dimer may have an independent role to play in thrombus formation in the absence of the 
main fibrin receptor, integrin aIIbb3 on platelets. 
 
Overall these results suggest that GPVI, but more specifically GPVI-dimer and not the 
monomer, would significantly contribute to the binding of resting platelets to fibrin within 
a clot. Whether this GPVI-fibrin interaction then induces signalling to assist activation of 







Figure 8.1 Hypothetical model of GPVI-dimer involvement in a stroke thrombus. GPVI-
dimer binds to exposed collagen or deposited fibrin, causing platelet activation and 
spreading. As the thrombus grows, a fibrin core develops, and platelets are packed here 
using GPVI-dimer and aIIbb3-based adhesion. Loosely bound fibrin(ogen) on the 
periphery of the thrombus facilitates growth through GPVI-dimer and aIIbb3.  
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8.03 GPVI expression in pre-stroke AF and stroke cohorts 
In recent years, platelets have become increasingly recognised as important markers as 
well as potential clinical targets for several diseases and disease processes. Many are 
outside the conventionally associated haemostasis and thrombosis; such as inflammation, 
metastases and neurodegenerative conditions (Yun, 2016). We now have a reasonable 
understanding of how increased platelet activation has a role in facilitating disease 
progression, and markers such as pP-selectin or sP-selectin allow us to quantitate and 
compare this between different disease pathologies. However, little work has been carried 
on investigating how expression of the key platelet receptors, GP1b-V-IX, GPVI and aIIbb3 
varies in thrombosis and how indeed this relates to the platelet phenotype if we consider 
a population’s thrombotic risk. 
 
The results from the GRAFITE study, which measured platelet surface expression of GPVI 
in an AF population at high stroke-risk as well as the GYPSIE study, which measured 
platelet surface expression of GPVI in a stroke population, suggest that both pre-stroke 
and post-stroke patients significantly overexpress the functional form of GPVI, the GPVI-
dimer, when compared to a healthy control cohort. Since both studies were carried out 
using the same personnel, in the same lab, with the same materials we are in a strong 
position to compare the GPVI expression and platelet function results from both studies.  
 
In both studies, age and MPV in the patient cohorts were significantly higher than the 
control group. MPV is associated with both platelet activation (Park, 2002), AF 
(Choudhury, 2007; Makowski, 2017) and stroke (Greisenegger, 2004; Ghahremanfard, 
2013) and age is a well-established risk-factor for both AF and stroke (Kernan, 2014). 
Therefore, statistically adjusting all GPVI expression and platelet function measurements 
by age and MPV allowed us to reduce some of the variability and associations caused by 
these two factors. 
 
What we observe is a significant rise in GPVI-dimer expression when moving from a 
healthy, to a pre-stroke diseased (non-stroke form GYPSIE and AF from GRAFITE) and then 
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a post-stroke population (Figure 8.2). Total GPVI expression was more variable, where AF 
patients expressed less total GPVI than both the control and stroke cohorts  
 
 
Figure 8.2 Expression of total GPVI and GPVI-dimer in all the cohorts tested. The 
expression of GPVI-dimer (mean MFI) increases when moving from a healthy control to a 
pre-stroke, then post-stroke sample, whereas total GPVI expression is more variable. The 
grey-box indicates the GPVI-dimer level above which stroke-risk increases. ns = not 
significant, *P<0.05, **P<0.01, ***P<0.001 calculated using an unpaired t-test. 
 
If we compare CES patients in the GYPSIE study to the AF patients in the GRAFITE study, 
again, we see that patients who have had an AF-related CES, express significantly higher 
GPVI (both total and dimer, P<0.0001) compared to the pre-stroke AF cohort (Figure 8.3). 
There are limitations when analysing this data, as they are not the same patients with AF 
who have then had a CES. Furthermore, whether some of the AF patients had an in-situ 
LAA thrombus at the time of sampling, however, was never ascertained and would have 

































Figure 8.3. Total GPVI and GPVI-dimer expression between AF and CES patients. Total 
GPVI and GPVI-dimer are both significantly higher in CES compared to AF patients 
(P<0.0001). The error bars represent the mean MFI of each of the cohorts ± SD and 
significance was calculated using unpaired t-tests. 
 
The GPVI-dimer MFI from all non-stroke patients over both studies were combined 
(n=402; healthy controls, non-stroke, AF) and plotted against all the stroke patients 
(n=129) in a receiver operating characteristic (ROC) curve where the binary classifier was 
defined as stroke yes or no (0 or 1) (Figure 8.4). The area under ROC curve = 0.87 (95% CI 
0.82-0.91), P<0.0001, suggests that GPVI-dimer MFI is a good test to distinguish between 
non-stroke and stroke. The cut-off value for GPVI-dimer MFI indicative of stroke was 0.611. 
This is the value which represents the highest sensitivity (65.12%) and specificity (95.02%) 





















Figure 8.4 GPVI-dimer expression represented as a receiver operative characteristic 
(ROC) curve. The GPVI-dimer expression (MFI) cut-off value for stroke is observed at 0.611 
and the area under the curve = 0.87 (95% CI 0.82-0.91), P<0.0001. 
Consistent with our findings, previous studies have suggested that a GPVI MFI value (total 
GPVI) above a certain threshold was sensitive and specific for stroke (area under curve 
0.683)  (Bigalke, 2010). Bigalke et al demonstrated that these patients with a higher total 
GPVI MFI had a poorer clinical outcome and increased likelihood of death at three months 
(P=0.045). None of our stroke patients went on to have another cardiovascular event 
during the six-month period, allowing for the limitations of our data collection. However, 
24 of them had died within six-months.  
Table 8.2 compares those within the stroke cohort who had a GPVI-dimer MFI of <0.611 
to >0.611. The results show that the admission CHA2DS2-VASc score is significantly higher 
in those with an MFI of >0.611 (P=0.0003), again suggesting that vascular risk-factors may 
be related to GPVI-dimer expression and maybe driving dimerization itself, which could 
result in a stroke. However, no significant differences were seen between the two cohorts 
when analysing admission NIHSS score or C-RP, discharge mRS or the proportion who had 
died by six months. 
  































Table 8.2 Comparison between stroke patients with a GPVI-dimer MFI <0.611 and >0.611. 
Statistical analysis between non-parametric continuous data was carried out using a 
Mann-Whitney U test. Statistical differences between the two cohorts analysing death at 
6 months was carried out using a Chi Squared test. 
 
Studies have demonstrated that premature activation of platelets, in the setting of 
vascular risk-factors, rather than coagulation system activation can cause pathological clot 
formation (van Rooy, 2015). The results from GRAFITE and GYPSIE studies suggest that 
vascular risk factors are related to GPVI-dimer expression and could indeed be a driver for 
GPVI-dimerization; precipitating a stroke in a pre-stroke AF and stroke population. 
 
Total GPVI expression appears to be more variable and less clear-cut. Whether the reason 
we see similar dimer levels but lower total GPVI levels when looking at the AF and stroke 
cohorts is due to rapid exposure of monomeric GPVI from the internal platelet granules at 
the time of the stroke, or due to factors outside what is measured in these studies is not 
clear. sGPVI measurements would have enabled us to better ascertain if the reason total 
GPVI is lower in the AF patients compared to controls and stroke patients is due to 
increased monomeric GPVI shedding. We are currently re-grouping the collected and 
stored serum samples from all the patients to see if sGPVI quantitation can be carried out. 
 
 MFI <0.611 MFI >0.611  Significance (P) 
n 45 84  
Admission NIHSS  7 (4-15) 8 (4-15) 0.58 
Admission CHA2DS2-VASc Score 3 (1-4) 4 (3-5) 0.0003 
Admission C-RP 3.3 (1.6-7.0) 3.4 (1.4-8.2) 0.92 
Discharge mRS 2 (1-4) 2 (1-4) 0.27 
Death at 6 months (%) 5 (11.1) 21 (25.0) 0.07 
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What we also cannot fully elucidate from our results, however, is whether the reason 
GPVI-dimer is higher in the stroke population is due to the stroke itself or whether it was 
already raised pre-stroke. The fact that GPVI-dimer expression is even higher at day 90 
post-stroke suggests that it is unlikely to be an acute effect.  
 
What do the results from the GRAFITE and GYPSIE studies tell us about how GPVI 
expression relates to platelet function in response to exogenous agonists? Herein lies 
another limitation of this work; we do not have results for platelet fibrinogen binding for 
the stroke cohort, which would have represented an interesting marker to compare 
between the pre-stroke and stroke cohorts.  
 
We observe a significant rise in resting P-selectin exposure when moving from healthy 
control to AF to stroke cohorts, indicating that as vascular risk increases, there is also a 
similar and measurable increase in ‘activation’ of circulating platelets. This however, 
appears to be a distinct mechanism to GPVI-dimer expression as we did not see a 
correlation between GPVI-dimer and P-selectin exposure in either the AF or stroke 
population.  
 
In the AF patients we see that both P-selectin exposure and fibrinogen binding after CRP-
XL are significantly negatively associated with GPVI-dimer expression. We observe the 
opposite in stroke patients where P-selectin exposure after CRP-XL is significantly 
positively correlated with GPVI-dimer expression. We initially hypothesised that this could 
be due to the effect of anticoagulation, at least in the AF cohort. However, if we divide the 
AF patients into anticoagulation (n=50) or not (n=25), we do not see any difference in 
either fibrinogen binding or P-selectin exposure with regards to GPVI-dimer expression.  
We observe a very strong negative correlation between GPVI-dimer and P-Selectin 
exposure after CRP-XL in both anticoagulated and not anticoagulated groups (P<0.0001 
for both). A similar result is seen with fibrinogen binding where there was a strong 
negative correlation between GPVI-dimer and fibrinogen binding, regardless of 
anticoagulation (P=0.0003 and P<0.0001, respectively). Therefore, there must be other 
parameters, such as genetic variation, affecting how platelets in the AF cohort function 
compared to stroke patients outside of anticoagulation. 
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Another difference between the AF and stroke cohorts with regards to GPVI-dimer and P-
selectin exposure after CRP-XL could be due to GPVI clustering. Poulter et al. 
demonstrated that GPVI oligomerised, or clustered, after binding to collagenous 
substrates which in turn could facilitate both platelet activation and function (Poulter, 
2017). The clustering observed was platelet-wide, not just in the area that was in contact 
with collagen fibres. This supports the theory that proximity of GPVI-dimer binding sites 
increases GPVI avidity by bringing together the necessary signalling components to initiate 
efficient platelet activation and thrombus formation (Poulter, 2017). GPVI clustering  after 
thrombosis could be a requisite for platelet function in response to agonists such as ADP 
and collagen (Berlanga, 2007). In AF patients, where no thrombotic event had taken place, 
this would not have occurred, hence why we do not see an impressive P-selectin response 
in response to collagen.  
 
However, why overall these parameters were less in the AF patients compared to controls 
is not clear. None of our AF patients went on to have a stroke during the study period, 
therefore, we cannot determine how their platelet function and also GPVI expression 
would change after a thrombotic event. 
 
8.04 Limitations of experimental work 
We must take into consideration some of the limitations of the experimental work 
performed in Chapter IV. All experiments described in this thesis were carried out by me, 
after appropriate laboratory training. That being said, it does not detract from 
introduction of a high level of subjectivity and human error.  
 
Generally, working with platelets can be difficult. Once out of blood, the platelet function 
tends to decrease with time and how quickly this occurs varies between individual to 
individual. This is not a problem in most static assays but can be cumbrous during time 
consuming platelet function experiments such as aggregometry and flow adhesion. 
Accounting for this is difficult and we may have been subject to errors in data produced in 
experiments carried out towards the end of the day. 
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We were also encumbered by the amount of healthy volunteer blood used in the 
laboratory work as our ethics was limited to members of the biochemistry group leading 
to selection bias. This meant that there was only a small and limited pool of young, healthy 
blood donors available, who do not represent the wider population. Volunteer-related 
factors which also have to be taken into account prior to investigating platelet function 
including, exercise, circadian variations, food and coffee consumption, NSAID use and 
smoking. To limit these effects, we did exclude anyone who had taken medication which 
could affect platelet function in the last 7 days and took blood at the same time every day. 
 
Pre-registration of the research question and subsequent research plan would avoid some 
of the bias associated with the experiments performed and data analysed only by myself. 
Specific improvements within the experimental methodology could also have accounted 
for a reduction in experimental errors. For example, the preparation of polymerised fibrin 
from fibrinogen requires the addition of specific amounts of thrombin as well as the 
addition of GPRP to then produce monomeric fibrin. Due to time and product constraints 
we could not check each time using an anti-fibrin/anti D-dimer antibody whether we had 
successfully created fibrin each time, but this would be a useful addition to the protocol 
which may have helped to explain some of the negative results seen in the ELISA studies 
(Figure 5.1 + 5.2).   
 
To enable analysis of thrombus formation under flow adhesion, the operator must define 
the coverslip plane (see Figure 4.3) in order to quantify both platelet SA and MTH. This can 
be subject to observer bias, and in these set of experiments the coverslip plane was 
defined only by me. A way of reducing this would have been to have another member of 
the group to also come and define the coverslip plane ‘blind’ each time we were 








8.05 Limitations of translational work 
Further work needs to be carried out to evaluate how GPVI-expression leads to platelet 
function in the setting of thrombotic disease as well as in pre-stroke populations.  
Although the findings discussed here suggest interesting and plausible pathophysiological 
processes, we must exercise a degree of caution when attempting to interpret their clinical 
relevance.  
 
One of the major limitations of the observational case-control studies (Chapters VI and 
VII) presented in this thesis are the differences between the control and patient 
populations. Certainly, the overall AF and stroke patient cohorts appear suitably reflective 
of the broader stroke population, however, they are distinct to the control population 
recruited with significant differences in age and sex. With little crossover in the ages of 
our two populations, for example, it was difficult to form matched groups which were 
comparable as only a small proportion of the two groups overlapped. The GPVI expression 
and platelet function results were instead adjusted to age, as a major confounding factor. 
However, adjusting data for GPVI expression and platelet function by age and MPV, as well 
as the subgroup analyses from there onwards raises the risk of obtaining a type one 
statistical error. The groups within the study are limited in size, and therefore, it is difficult 
to know how the results we obtain relates to that from the wider population. Future 
studies would be designed to recruit healthy controls that are healthy but otherwise 
represent a sample that is comparative of the patient cohort.  
 
Further patient recruitment would have helped overcome potential issues with 
insufficient sample size within the subgroup analysis, for example, when attempting to 
assess if haemorrhagic strokes also significantly express higher GPVI-dimer compared to 
the controls, similar to what we see with the ischaemic strokes (Figure 7.9) and whether 
patients taking FXa inhibitors express more GPVI-dimer than those not on anticoagulation 
(Figures 6.6 and 6.7) 
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As mentioned in the previous section, platelet function can be affected by numerous 
factors. Platelets can be activated during venepuncture and we used methods such as 
taking blood without a tourniquet/releasing the tourniquet prior to collecting the citrate 
sample to minimise this. Although it was possible to govern this during the sample 
collection of the GRAFITE study (as all venepuncture was only carried out by me), many of 
the samples for the GYPSIE study were taken by different stroke research nurses with 
varying venepuncture ability. It is entirely possible that during venepuncture, where blood 
is also being taken for clinical results, the tourniquet was not released every time – leading 
to unwanted platelet activation. This is also true of platelet activation during specimen 
transport and processing. To minimise this, during the GYPSIE study, a member of the lab 
team met the team in ED to collect the sample. By the time the GRAFITE study was 
underway, we had altered the study design so that the samples were being delivered 
straight after venepuncture with minimal delay. Whether the differences in venepuncture 
technique explained the difference in the platelet function results. In the AF population 
ADP and CRP agonism demonstrated lower P-selectin exposure (all samples taken by me) 
and in the stroke population, ADP and CRP agonism demonstrated significantly higher P-
selectin exposure (samples taken by various research nurses) compared to controls in not 
known. 
 
Flow cytometry analysis of the samples for platelet function and GPVI expression were 
carried out by one staff member on a particular day. Experimenter bias therefore could 
have been reduced if one member ran the sample on the flow cytometer and another lab 
member did the analysis of data. However, due to staff time constraints, this was not 
possible. Similarly, in the GYPSIE study, strokes were subclassified as per the TOAST 
classification only by me. Involving another stroke physician ‘blinded’ to do this would 
have further reduced bias during data analysis. 
 
With regards to the day-90 follow up sample, there were some patients who did not 
attend follow-up, or who were too frail to attend follow-up. It would have been interesting 
to quantify GPVI expression in these patients, who we ascertained were older and frailer 
than the patients followed up. We also do not have the genetic data from the AF or stroke 
participants to see whether they have a rare GPVI haplotype. This would certainly affect 
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the population GPVI levels as well as the interpretation of our work and is currently under 
analysis. 
 
However, we did observe a generally consistent pattern that patients with vascular risk 
factors had higher resting platelet activity and GPVI-dimer expression. Although this study 
was not designed as a longitudinal cohort study, the availability of two further 
measurements would have certainly strengthened our data set. Firstly, a follow up blood 
sample from all AF patients at three months would have allowed us to compare 
fluctuations in GPVI-dimer expression in a group who have not had a stroke, to the stroke 
day-90 measurements. Secondly, a longer follow up period for both AF and stroke patients 
to see if they have any thrombotic events, with the plans in place to repeat their blood 
sample would have added to our current knowledge. 
 
Therefore, these limitations need to be considered when planning future work and the 
findings of these studies need to be verified in larger more focussed studies with a pre-
specified primary outcome, sub-group analyses and stringent follow-up procedures in 
place. 
 
However, there are repeated observations from our translational work that suggests that 
GPVI-dimer should be the focus of any future work looking at GPVI as an anti-thrombotic 
target. This is because: 
 
1) Patients with AF, regardless of anticoagulation, express significantly more GPVI-
dimer on their platelet surface whereas total GPVI is significantly lower.  
2) Stroke patients express significantly more GPVI-dimer on their platelet surface at 
admission and at 90-days post stroke.  
3) After adjusting for age and MPV, both the AF and stroke populations showed 
independent associations with GPVI-dimer expression and the presence of 
vascular risk factors and serum biomarkers. 
4) Higher GPVI-dimer is a specific and sensitive measure of the presence of stroke 
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8.06 GPVI-dimer as a potential antithrombotic target 
Considering the roles that GPVI-dimer appears to play in binding to fibrin both in static 
and flow systems using immobilised fibrin and in fibrin clots consisting of larger crosslinked 
fibrin fibres, as well as the over-expression of GPVI-dimer in both pre-stroke and stroke 
populations, there are specific areas within stroke treatment where inhibiting the activity 
of GPVI-dimer could be utilised. 
1) GPVI-dimer inhibition as an adjunct to intravenous thrombolysis 
2) GPVI-dimer inhibition during intra-arterial thrombolysis or thrombectomy 
3) GPVI-dimer inhibition as an anti-thrombotic in primary or secondary prevention of 
ischaemic stroke 
(a) GPVI-dimer inhibition as an adjunct to intravenous thrombolysis 
The acute phase of ischaemic stroke is associated with abnormal fibrin properties leading 
to reduced clot permeability and a lower likelihood of successful lysis (Undas, 2009). 
Whether all types of ischaemic stroke share these abnormal fibrin properties is unknown, 
but fibrin constitutes a large part of CES and ESUS thrombi and also to some extent LAS. 
 
Previous studies have shown that more permeable clots (i.e., greater ease of which soluble 
molecules move through the platelet, fibrin and erythrocyte architecture within the clot) 
are more amenable to fibrinolysis (Diamond, 1993; Siudut, 2016). Since GPVI-dimer could 
play a role in clot stability through supporting close platelet interactions with fibrin, GPVI-
dimer inhibition could have a part in increasing thrombus permeability and facilitating 
either recanalization at the time of administering intravenous rtpA. 
 
This has been demonstrated previously in an MCAO mouse model. Reimann and 
colleagues used 0.1 or 0.35 mg/kg of rtPA either with or without 1mg/kg of Revacept and 
demonstrated that the addition of the soluble dimeric GPVI-Fc (Revacept) to rtPA 
significantly increased cerebral reperfusion as well as intracerebral oedema (Reimann, 
2016). They also showed that the addition of Revacept to rtPA did not result in any excess 
bleeding, suggesting that low doses of an anti-GPVI-dimer could safely provide better 
recanalization rates with the added benefit of requiring a lower dose of rtPA. 
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(b) GPVI-dimer inhibition during intra-arterial thrombolysis or 
thrombectomy 
Studies analysing thrombus histology have noted that further manoeuvres were needed 
at thrombectomy to retrieve cardioembolic clots and the authors concluded that this 
could be due to the higher organisational degree of such thrombi (Boeckh-Behrens, 2016). 
In keeping with this, clots with a higher erythrocyte and less fibrin content have been 
shown to be associated with a significantly higher likelihood of successful thrombectomy 
(Hashimoto, 2016; Shin, 2018). aIIbb3 inhibitors such as abciximab are used during intra-
arterial thrombolysis or to alleviate in-stent thrombosis in both the cardiology- and neuro- 
interventional settings (Tong, 2000). As an intra-arterial agent aimed directly at the 
thrombus, a GPVI-dimer inhibiting drug could break up some of the platelet-fibrin and 
platelet-collagen interactions within a thrombus to assist in recanalization. 
 
Work by Ahmed and colleagues, presented at the International Society on Thrombosis and 
Haemostasis World Congress 2019, revealed that GPVI blockade with anti-GPVI Fab 
ACT017 promotes efficient disaggregation of human thrombi pre-formed on collagen or 
on human atherosclerotic plaque material in an in vitro model (Unpublished Ahmed 2019). 
This implies that impairing GPVI-mediated platelet activation could facilitate thrombus 
disaggregation in the setting of intra-arterial procedures to facilitate recanalization. 
 
(c) GPVI-dimer inhibition in stroke prevention 
The results of the translational work discussed in this thesis supports the idea that GPVI-
dimer expression is associated with AF and stroke. Although many questions, including 
causality, remain unanswered, being a receptor for collagen and fibrin we are able to 
hypothesise that GPVI plays a key role in thrombus formation. Previous work has shown 
that GPVI is crucial to the recruitment of platelets to areas of disrupted and dysfunctional 
endothelium (Massberg, 2003). Furthermore, GPVI-clustering leads to sustained GPVI 
induced signalling which can increase platelet activity in in vitro thrombotic settings 
(Poulter, 2017). Therefore, the higher GPVI-dimer expression in the pre-stroke population 
could relate to a higher likelihood of a thrombotic event.  
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A recent study revealed that AF was underestimated in ischaemic stroke (Wachter, 2017). 
The fact that histology from clots from a CES and ESUS stroke were similar raises an 
important hypothesis that many of those patients with ESUS are likely to have 
undiagnosed AF. Currently, until AF is proven, these patients remain on antiplatelet 
therapy - which do not adequately reduce their risk of stroke. 
 
GPVI-dimer inhibition, therefore, could have a role in reducing thrombotic risk in patients 
with AF pre-stroke as well as those who have had ischaemic stroke due to LAS, CES and 
SVO and finally in those who have had an ESUS also. In this setting, another advantage 
could be that those already on GPVI inhibitors could undergo safe thrombolysis 
(Schuhmann, 2019), as currently patients on warfarin with an INR (usually >1.4) and DOACs 
are excluded from receiving rtPA. 
 
8.07 Published and planned papers from this thesis 
Publications 
• Induruwa I, Jung S, Warburton EA. Int J Stroke 11(6), 618-625. 
Beyond antiplatelets: The role of glycoprotein VI in ischaemic stroke.  
 
• Induruwa I, Moroi M, Bonna A, Malcor JD, Howes JM, Warburton EA, Farndale RW, 
Jung SM. J Thromb Haemost. 2018; 16(2): 389-404. 
Platelet collagen receptor Glycoprotein VI-dimer recognizes fibrinogen and fibrin 




• Induruwa I et al. Platelet Receptor Glycoprotein VI-dimer is significantly over-
expressed in ischaemic stroke patients: The results of the GYPSIE study (Under 
review). 
 
• Induruwa et al. Fibrin binding platelet receptor Glycoprotein VI-dimer is 
significantly over expressed in patients with atrial fibrillation. 
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• Moroi M, Induruwa I, Farndale R, Jung S. Dimers of the platelet collagen receptor 
Glycoprotein VI (GPVI) bind specifically to in-situ fibrin fibres in clots, but not to 
intact fibrinogen (Under review). 
 
8.08 Future work 
To fully assess the GPVI-dimer expression, especially in the context of its inhibition, it must 
be assessed in a variety of different thrombotic pathologies. These would include arterial 
diseases such as ACS, MI and peripheral vascular disease as well as venous thrombosis in 
DVT and pulmonary embolism. Further studies, if designed similarly to the translational 
work here, must be pragmatically planned, for example with a more suitable age and sex 
matched control population, to avoid the limitations discussed above and include analysis 
of sGPVI to better understand the relationship between GPVI expression and shedding in 
thrombotic disease. 
 
Basic sciences work would include investigating GPVI-dimer in fibrin clots in more detail. 
Some of our results included in section 8.09 suggest that the thrombus architecture and 
structure, particularly whether they are crosslinked or non-crosslinked (using FXIIIa) 
effects GPVI-dimer adhesion to fibrin. 
 
Alongside this, histological analysis of thrombi retrieved from thrombectomy will then 
form the next stage of our work. We are currently starting the EGRESS – Emboli and Gene 
RESearch in Stroke Study within the CUH stroke department in collaboration with the 
Department of Radiology, Biochemistry and the Addenbrooke’s centre for Clinical 
Investigation, for which I am a named Principal Investigator.  
 
EGRESS will recruit patients eligible for thrombectomy presenting with LAS, CES or ESUS. 
Histology and immunohistochemistry from collected thrombi will then be analysed to: 
a. identify cellular aggregates. 
b. identify glycoprotein VI (GPVI) within the thrombus with relationship to 
distinct fibrin, leukocyte and erythrocyte regions. 
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c. analyse gene expression, including DNA and non-coding RNA in order to 
determine different patterns present in CES and LAS. 
d. investigate any association between different nucleic acid expression 
patterns and stroke aetiology. 
e. Investigate any association between different nucleic acid expression 
patterns or SNPs in thrombi and collected peripheral blood samples. 
 
Finally, we have identified that mFAB-F, an inhibitory human antibody specific for GPVI-
dimer developed by Drs M Moroi and Dr S Jung, inhibits thrombus formation on 
fibrinogen, fibrin and collagen under both arterial and venous shear (chapter V). Ideally, 
we must investigate its use as a future anti-thrombotic target to inhibit GPVI-dimer activity 
in patients, but its low affinity excludes it from pharmacological use at present. Future 
work would involve affinity maturation, stable expression, as well as structural, analytical 
and immunogenic property characterisation of mFAB-F.  
 
Translational work would involve investigating its pharmacodynamics, pharmacokinetics, 
and overall safety and tolerability in the context of a clinical study involving high-risk TIA 
or ischaemic stroke patients. The development of mFAB-F therefore represents possibly 
the most relevant consideration of future work to arise from this piece of work. 
 
8.09 Conclusion 
Stroke is one of the leading causes of disability and death in the world. Thrombus 
formation is a process combining both platelet and blood coagulation system activation. 
Platelet GPVI-dimer is central to both these processes, by functioning as a collagen and 
fibrin receptor for platelets. This suggests a central role in thrombus formation in 
ischaemic stroke, especially in LAS and CES, which currently dichotomises acute stroke 
treatment into either antiplatelet or anticoagulation.  
 
The work within this thesis demonstrates that firstly, it is the same dimeric, collagen 
binding form that binds to both fibrinogen (at the D-domain) and fibrin (at the D-dimer 
region). We observe that patients from both a pre-stroke as well as ischaemic and 
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haemorrhagic stroke population, overexpress GPVI-dimer on the platelet surface 
compared to healthy and diseased counterparts. The over expression of GPVI-dimer is 
likely linked to platelet response to collagen rather than its circulating activity – in keeping 
with the fact that GPVI-dimer must encounter its ligands to cause the necessary signalling 
to cause platelet activation. Nevertheless, the overexpression of GPVI-dimer in the AF (as 
well as obese (Barrachina, 2019)) and a stroke population suggests that their platelets are 
more ‘primed’ to response to vascular injury at sites of thrombus formation. 
 
In a stroke cohort, inhibiting GPVI-dimer to control thrombosis would have little impact 
on bleeding as it primarily controls thrombus formation at the site of vascular injury, with 
limited systemic effects on haemostasis. Therefore, GPVI-dimer inhibition represents a 
valuable and valid pharmacological target to control this platelet response and possibly 
reduce thrombus formation in different categories of pre- and post-stroke patients. 
 
Especially as the role of GPVI in binding to fibrin becomes clearer and results of the anti-
GPVI-dimer agents in healthy and diseased subjects (Revacept and ACT017) are on the 
horizon, no doubt the next few years will herald an exciting time in GPVI research. Our 
own Fab, mFAB-F also showed promise in in vitro work and witnessing its development, 
as well as Revacept and ACT017 into anti-thrombotic agents, and considering how they 
may shape the way ischaemic stroke patients are managed in the future will prove to be 




8.10 Supplementary files 
These experiments were done in conjunction with Dr M Moroi and Dr S Jung who designed 




Supplementary Figure 8.1 GPVI-Fc2 binding to A) non-crosslinked and B) crosslinked 
fibrin clots. A) the quantitative relationship between the amount of GPVI-Fc2 and band 
strength; total clot-bound GPVI-Fc2 and albumin (non-specific binding) are expressed as a 
percent of the normalization standard (clotting mixture containing 25 μg/mL each of GPVI-
Fc2 and albumin, but no added thrombin). Specific binding of GPVI-Fc2 (%, red circles) is 
calculated by subtracting non-specific binding (albumin, %, black squares) from the total 
binding of GPVI-Fc2 (%, black circles) and fit to a one-site binding model (red curve). The 
GPVI-Fc2 binding to the clot is dose-dependent and saturable, exhibiting classical receptor 
binding kinetics.  
B) GPVI-Fc2 was reduced, and thus detected as GPVI-Fc with anti-human IgG antibody 
which detected the Fc portion of GPVI-Fc and the control protein was human Fc. After 
normalization with the standard, total binding of GPVI-Fc2 (black circles, %) was subtracted 
by the value for human Fc (black squares, %) to obtain specific binding of GPVI-Fc2 (%, red 
circles); specific binding was fitted to a one-site model. GPVI-Fc2 binding to the crosslinked 
















































(A) Albumin (B) human Fc
specific binding
KD = 248.4 µg/mL (1.19 ± 0.26 µM) KD = 81.66 µg/mL (0.496 ± 0.166 µM)
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clot is dose-dependent and saturable and had 2.4x higher affinity than its binding to the 




Supplementary Figure 8.2 Effects of inhibitors on GPVI-Fc2 binding to fibrin clots. The 
effects of the anti-GPVI-dimer–specific antibody mFAB-F; collagen mimetic CRP-XL; 
fibrinogen fragment D (D), and D-dimer (DD) on GPVI-Fc2 binding to non-crosslinked fibrin 
were analysed. The concentrations of each antagonist in μg/mL is given in parentheses. 
mFAB-F significantly inhibits GPVI-Fc2 binding to fibrin clots at concentrations greater than 
100 μg/mL and fragment D  and D-dimer weakly inhibited the binding at the highest 
concentration of 100 μg/mL. CRP-XL had no effect. *P<0.05, **P<0.01, compared to the 
Control (no added inhibitor) were calculated using a paired t-test. This experiment was 








ACTIVE Investigators et al. (2006) ‘Clopidogrel plus aspirin versus oral anticoagulation for 
atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of 
Vascular Events (ACTIVE W): a randomised controlled trial’, Lancet, 367(9526), pp. 1903–
1912. 
Adams, H. . et al. (1993) ‘Classification of Subtype of Acute Ischemic Stroke’, Stroke, 23(1), 
pp. 35–41. 
Adams, H. P. et al. (2008) ‘Emergency administration of abciximab for treatment of 
patients with acute ischemic stroke: results of an international phase III trial: Abciximab in 
Emergency Treatment of Stroke Trial (AbESTT-II).’, Stroke, 39(1), pp. 87–99. 
Ageno, W. et al. (2008) ‘Cardiovascular Risk Factors and Venous Thromboembolism: A 
Meta-Analysis’, Circulation, 117(1), pp. 93–102. 
Ahmed, M. (2019) ‘GPVI Sustains Platelet Activation to Maintain the Integrity and Stability 
of a Growing Thrombus’, in International Society on Thrombosis and Haemostasis World 
Congress. Melbourne. 
Akar, J. G., Jeske, W. and Wilber, D. J. (2008) ‘Acute Onset Human Atrial Fibrillation Is 
Associated With Local Cardiac Platelet Activation and Endothelial Dysfunction’, Journal of 
the American College of Cardiology, 51(18), pp. 1790–1793. 
Al-Tamimi, M., Mu, F.-T., Arthur, J. F., et al. (2009) ‘Anti-glycoprotein VI monoclonal 
antibodies directly aggregate platelets independently of FcgammaRIIa and induce GPVI 
ectodomain shedding.’, Platelets, 20(2), pp. 75–82. 
Al-Tamimi, M., Mu, F.-T., Moroi, M., et al. (2009) ‘Measuring soluble platelet glycoprotein 
VI in human plasma by ELISA’, Platelets, 20(3), pp. 143–149. 
Al-Tamimi, M., Grigoriadis, G., et al. (2011) ‘Coagulation-induced shedding of platelet 
glycoprotein VI mediated by factor Xa’, Blood, 117(14), pp. 3912–3920. 
Al-Tamimi, M., Gardiner, E. E., et al. (2011) ‘Soluble glycoprotein VI is raised in the plasma 
of patients with acute ischemic stroke’, Stroke, 42(2), pp. 498–500. 
Alshehri, O. M. et al. (2015) ‘Fibrin activates GPVI in human and mouse platelets.’, Blood. 
American Society of Hematology, 126(13), pp. 1601–1608. 
Ammash, N. et al. (2011) ‘Left Atrial Blood Stasis and Von Willebrand Factor–ADAMTS13 
Homeostasis in Atrial Fibrillation’, Arteriosclerosis, Thrombosis, and Vascular Biology, 
31(11), pp. 2760–2766. 
 230 
Andersen, H. et al. (1999) ‘Protease-activated receptor 1 is the primary mediator of 
thrombin-stimulated platelet procoagulant activity.’, Proceedings of the National 
Academy of Sciences. National Academy of Sciences, 96(20), pp. 11189–93. 
Andrews, R., Arthur, J. and Gardiner, E. (2014) ‘Targeting GPVI as a novel antithrombotic 
strategy’, Journal of Blood Medicine, p. 59. 
Angénieux, C. et al. (2016) ‘Time-Dependent Decay of mRNA and Ribosomal RNA during 
Platelet Aging and Its Correlation with Translation Activity’, PLOS ONE. Edited by C. Schulz, 
11(1), p. e0148064. 
Antithrombotic Trialists’ Collaboration, A. T. (2002) ‘Collaborative meta-analysis of 
randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, 
and stroke in high risk patients.’, BMJ. BMJ Publishing Group, 324(7329), pp. 71–86. 
Arthur, J. F., Dunkley, S. and Andrews, R. K. (2007) ‘Platelet glycoprotein VI-related clinical 
defects’, British Journal of Haematology, 139(3), pp. 363–372. 
De Backer, O. et al. (2014) ‘Percutaneous left atrial appendage occlusion for stroke 
prevention in atrial fibrillation: an update’, Open Heart, 1(1), pp. e000020–e000020. 
Barnes, M. J., Knight, C. G. and Farndale, R. W. (1998) ‘The collagen-platelet interaction.’, 
Current opinion in hematology, 5(5), pp. 314–20. 
Barrachina, M. N. et al. (2019) ‘GPVI surface expression and signalling pathway activation 
are increased in platelets from obese patients: Elucidating potential anti-
atherothrombotic targets in obesity’, Atherosclerosis. Elsevier, 281, pp. 62–70. 
Bath, P. M. et al. (2017) ‘Remote Assessment of Platelet Function in Patients with Acute 
Stroke or Transient Ischaemic Attack’, Stroke Research and Treatment, 2017, pp. 1–13. 
Bath, P. M., Woodhouse, L. J., et al. (2018) ‘Antiplatelet therapy with aspirin, clopidogrel, 
and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with 
acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.’, 
Lancet. Elsevier, 391(10123), pp. 850–859. 
Bath, P. M., May, J. and Heptinstall, S. (2018) ‘Clinical utility of remote platelet function 
measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and 
bleeding disorders’, Platelets. Taylor & Francis, 29(5), pp. 1–6. 
Bath, P. M. and Wardlaw, J. M. (2015) ‘Pharmacological treatment and prevention of 
cerebral small vessel disease: a review of potential interventions.’, International Journal 
of Stroke. Wiley-Blackwell, 10(4), pp. 469–78. 
Bender, M., Hagedorn, I. and Nieswandt, B. (2011) ‘Genetic and antibody-induced 
 231 
glycoprotein VI deficiency equally protects mice from mechanically and FeCl3-induced 
thrombosis’, Journal of Thrombosis and Haemostasis. John Wiley & Sons, Ltd (10.1111), 
9(7), pp. 1423–1426. 
Bennett, J. S. (2001) ‘Platelet-fibrinogen interactions.’, Annals of the New York Academy 
of Sciences, 936, pp. 340–54. 
Bergmeier, W. et al. (2004) ‘GPVI down-regulation in murine platelets through 
metalloproteinase-dependent shedding’, Thrombosis and Haemostasis, 91(5), pp. 951–
958. 
Berlanga, O. et al. (2007) ‘Glycoprotein VI oligomerization in cell lines and platelets.’, 
Journal of Thrombosis and Haemostasis, 5(5), pp. 1026–33. 
Bester, J. and Pretorius, E. (2016) ‘Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets 
and clot viscoelasticity’, Scientific Reports. Nature Publishing Group, 6(1), p. 32188. 
Bigalke, B. et al. (2009) ‘Regulation of platelet glycoprotein VI (GPVI) surface expression 
and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome 
(ACS).’, Basic research in cardiology, 104(3), pp. 352–7. 
Bigalke, B., Stellos, K., et al. (2010) ‘Expression of platelet glycoprotein VI is associated with 
transient ischemic attack and stroke.’, European journal of neurology, 17(1), pp. 111–7. 
Bigalke, B., Haap, M., et al. (2010) ‘Platelet glycoprotein VI (GPVI) for early identification 
of acute coronary syndrome in patients with chest pain’, Thrombosis Research. Elsevier 
Ltd, 125(5), pp. e184–e189. 
Bigalke, B. et al. (2011) ‘Glycoprotein VI for diagnosis of acute coronary syndrome when 
ECG is ambiguous’, International Journal of Cardiology. Elsevier B.V., 149(2), pp. 164–168. 
Blann, A. D. et al. (1997) ‘Soluble P-selectin in atherosclerosis: a comparison with 
endothelial cell and platelet markers.’, Thrombosis and haemostasis, 77(6), pp. 1077–80. 
Blann, A., Nadar, S. K. and Lip, G. Y. H. (2003) ‘The adhesion molecule P-selectin and 
cardiovascular disease’, European Heart Journal. Oxford University Press, 24(24), pp. 
2166–2179. 
Blustin, J. M. et al. (2014) ‘Distribution of thromboembolism in valvular versus non-
valvular atrial fibrillation’, Expert Review of Cardiovascular Therapy. Taylor & Francis, 
12(10), pp. 1129–1132. 
Boeckh-Behrens, T. et al. (2016) ‘Thrombus histology suggests cardioembolic cause in 
cryptogenic stroke’, Stroke, 47(7), pp. 1864–1871. 
 232 
Boulaftali, Y. et al. (2018) ‘Glycoprotein VI in securing vascular integrity in inflamed 
vessels.’, Research and Practice in Thrombosis and Haemostasis. Wiley-Blackwell, 2(2), pp. 
228–239. 
Boylan, B. et al. (2004) ‘Anti-GPVI-associated ITP: An acquired platelet disorder caused by 
autoantibody-mediated clearance of the GPVI/FcRy-chain complex from the human 
platelet surface’, Blood, 104(5), pp. 1350–1355. 
Brass, L. F. (2003) ‘Thrombin and Platelet Activation’, Chest, 124(3), pp. 18S-25S. 
Bültmann, A. et al. (2006) ‘Local delivery of soluble platelet collagen receptor glycoprotein 
VI inhibits thrombus formation in vivo’, Thrombosis and Haemostasis. Schattauer GmbH, 
95(05), pp. 763–766. 
Bültmann, A. et al. (2010) ‘Impact of glycoprotein VI and platelet adhesion on 
atherosclerosis—A possible role of fibronectin’, Journal of Molecular and Cellular 
Cardiology, 49(3), pp. 532–542. 
Burn, J. et al. (1994) ‘Erratum: Long-term risk of recurrent stroke after a first-ever stroke: 
The Oxfordshire Community Stroke Project (Stroke (February 1994) 25 (333-337))’, Stroke, 
25(9), p. 1887. 
Byrnes, J. R. and Wolberg, A. S. (2016) ‘Newly-Recognized Roles of Factor XIII in 
Thrombosis.’, Seminars in thrombosis and hemostasis. NIH Public Access, 42(4), pp. 445–
54. 
CAPRIE Steering Committee (1996) ‘A randomised, blinded, trial of clopidogrel versus 
aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.’, 
Lancet, 348(9038), pp. 1329–39. 
Casa, L. D. C., Deaton, D. H. and Ku, D. N. (2015) ‘Role of high shear rate in thrombosis’, 
Journal of Vascular Surgery. Mosby, 61(4), pp. 1068–1080. 
Cerecedo, D. (2013) ‘Platelet cytoskeleton and its hemostatic role’, Blood Coagulation & 
Fibrinolysis, 24(8), pp. 798–808. 
Cesarman-Maus, G. and Hajjar, K. A. (2005) ‘Molecular mechanisms of fibrinolysis’, British 
Journal of Haematology, 129(3), pp. 307–321. 
Chapin, J. C. and Hajjar, K. A. (2015) ‘Fibrinolysis and the control of blood coagulation.’, 
Blood reviews. NIH Public Access, 29(1), pp. 17–24. 
Chatterjee, M. and Gawaz, M. (2017) ‘Clinical significance of receptor shedding-platelet 
GPVI as an emerging diagnostic and therapeutic tool’, Platelets. Taylor & Francis, 28(4), 
pp. 362–371. 
 233 
Chen, H. et al. (2002) ‘The platelet receptor GPVI mediates both adhesion and signaling 
responses to collagen in a receptor density-dependent fashion.’, Journal of Biological 
Chemistry, 277(4), pp. 3011–9. 
Chen, R. and Doolittle, R. F. (1971) ‘γ-γ Cross-linking sites in human and bovine fibrin’, 
Biochemistry. American Chemical Society, 10(24), pp. 4486–4491. 
Cherian, P. et al. (2003) ‘Endothelial and platelet activation in acute ischemic stroke and 
its etiological subtypes’, Stroke, 34(9), pp. 2132–2137. 
Choudhury, A. et al. (2007) ‘Platelet Surface CD62P and CD63, Mean Platelet Volume, and 
Soluble/Platelet P-Selectin as Indexes of Platelet Function in Atrial Fibrillation’, Journal of 
the American College of Cardiology, 49(19), pp. 1957–1964. 
Ciccone, A. et al. (2014) ‘Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke’, 
Cochrane Database of Systematic Reviews, (3), p. CD005208. 
Clark, E. A. et al. (1994) ‘Regulation of the protein tyrosine kinase pp72syk by platelet 
agonists and the integrin alpha IIb beta 3.’, The Journal of biological chemistry, 269(46), 
pp. 28859–64. 
Claushuis, T. A. M. et al. (2017) ‘Platelet glycoprotein VI aids in local immunity during gram-
negative pneumonia derived sepsis.’, Blood, 131(8), pp. 864–876. 
Clemetson, J. M. et al. (1999) ‘The platelet collagen receptor glycoprotein VI is a member 
of the immunoglobulin superfamily closely related to FcalphaR and the natural killer 
receptors.’, The Journal of biological chemistry, 274(41), pp. 29019–24. 
Colace, T. V., Muthard, R. W. and Diamond, S. L. (2012) ‘Thrombus Growth and Embolism 
on Tissue Factor-Bearing Collagen Surfaces Under Flow’, Arteriosclerosis, Thrombosis, and 
Vascular Biology, 32(6), pp. 1466–1476. 
Coller, B. S. (1999) ‘Potential non-glycoprotein IIb/IIIa effects of abciximab.’, American 
Heart Journal, 138(1 Pt 2), pp. S1-5. 
Colman, R. W. (2006) ‘Are hemostasis and thrombosis two sides of the same coin?’, Journal 
of Experimental Medicine. The Rockefeller University Press, 203(3), pp. 493–5. 
Connolly, S. J. et al. (2009) ‘Dabigatran versus Warfarin in Patients with Atrial Fibrillation’, 
New England Journal of Medicine.  Massachusetts Medical Society , 361(12), pp. 1139–
1151. 
Conway, D. S. G. et al. (2002) ‘Plasma von Willebrand Factor and Soluble P-Selectin as 
Indices of Endothelial Damage and Platelet Activation in Relationship to Stroke Risk 
Factors’, Circulation, 106, pp. 1963–1967. 
 234 
Coughlin, S. R. (1999) ‘How the protease thrombin talks to cells’, Proceedings of the 
National Academy of Sciences, 96(20), pp. 11023–11027. 
Crawley, B. et al. (2007) ‘The central role of thrombin in hemostasis’, Journal of Thrombosis 
and Haemostasis, 5(s1), pp. 95–101. 
Danese, E. et al. (2014) ‘Hypercoagulability, D-dimer and atrial fibrillation: an overview of 
biological and clinical evidence’, Annals of Medicine, 46(6), pp. 364–371. 
Dangas, G. et al. (1998) ‘Administration of abciximab during percutaneous coronary 
intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: 
implications for a potential anticoagulant effect of abciximab.’, Arteriosclerosis, 
Thrombosis, and Vascular Biology, 18(8), pp. 1342–9. 
Davey, M. G. and Luscher, E. F. (1967) ‘Actions of Thrombin and Other Coagulant and 
Proteolytic Enzymes on Blood Platelets’, Nature. Nature Publishing Group, 216(5118), pp. 
857–858. 
Davì, G. and Patrono, C. (2007) ‘Platelet Activation and Atherothrombosis’, New England 
Journal of Medicine.  Massachusetts Medical Society , 357(24), pp. 2482–2494. 
Dawood, F. Z. et al. (2016) ‘High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial 
Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study)’, The 
American Journal of Cardiology, 118(12), pp. 1826–1830. 
Denoël, P. et al. (2014) ‘Could Some Geriatric Characteristics Hinder the Prescription of 
Anticoagulants in Atrial Fibrillation in the Elderly?’, Journal of Aging Research, 2014, pp. 
1–8. 
Devi, S. et al. (2010) ‘Platelet recruitment to the inflamed glomerulus occurs via an 
alphaIIbbeta3/GPVI-dependent pathway.’, The American Journal of Pathology. Elsevier, 
177(3), pp. 1131–42. 
Diamond, S. L. and Anand, S. (1993) ‘Inner clot diffusion and permeation during 
fibrinolysis’, Biophysical Journal. Cell Press, 65(6), pp. 2622–2643. 
Diener, H.-C. et al. (2019) ‘Dabigatran for Prevention of Stroke after Embolic Stroke of 
Undetermined Source’, New England Journal of Medicine. Massachusetts Medical Society, 
380(20), pp. 1906–1917. 
Du, X. et al. (1993) ‘Long range propagation of conformational changes in integrin alpha 
IIb beta 3.’, Journal of Biological Chemistry, 268(31), pp. 23087–92. 
Dubois, C. et al. (2006) ‘Glycoprotein VI–dependent and –independent pathways of 
thrombus formation in vivo’, Blood, 107(10). 
 235 
Dumont, B. et al. (2009) ‘Absence of collagen-induced platelet activation caused by 
compound heterozygous GPVI mutations’, Blood, 114(9), pp. 1900–1903. 
Durrant, T. N., van den Bosch, M. T. and Hers, I. (2017) ‘Integrin αIIbβ3 outside-in 
signaling.’, Blood. The American Society of Hematology, 130(14), pp. 1607–1619. 
Dütting, S., Bender, M. and Nieswandt, B. (2012) ‘Platelet GPVI: A target for 
antithrombotic therapy?!’, Trends in Pharmacological Sciences, 33(11), pp. 583–590. 
Ebrahim, M. et al. (2018) ‘Dimeric Glycoprotein VI Binds to Collagen but Not to Fibrin’, 
Thrombosis and Haemostasis. Schattauer GmbH, 46(02), pp. 351–361. 
Ed Rainger, G. et al. (2015) ‘The role of platelets in the recruitment of leukocytes during 
vascular disease.’, Platelets. Taylor & Francis, 26(6), pp. 507–20. 
Egan, K. et al. (2017) ‘Increased soluble GPVI levels in cirrhosis: evidence for early in vivo 
platelet activation’, Journal of Thrombosis and Thrombolysis, 43(1), pp. 54–59. 
Eikelboom, J. W. et al. (2017) ‘Rivaroxaban with or without Aspirin in Stable Cardiovascular 
Disease’, New England Journal of Medicine. Massachusetts Medical Society, 377(14), pp. 
1319–1330. 
Ekker, M. S. et al. (2018) ‘Epidemiology, aetiology, and management of ischaemic stroke 
in young adults.’, Lancet Neurology. Elsevier, 17(9), pp. 790–801. 
Esmon, C. T. (2009) ‘Basic mechanisms and pathogenesis of venous thrombosis.’, Blood 
reviews. Howard Hughes Medical Institute, 23(5), pp. 225–9. 
Everse, S. J. et al. (1998) ‘Crystal structure of fragment double-D from human fibrin with 
two different bound ligands.’, Biochemistry, 37(24), pp. 8637–42. 
Feghaly, J. et al. (2018) ‘Genetics of Atrial Fibrillation.’, Journal of the American Heart 
Association, 7(20), p. e009884. 
Finney, A. C. et al. (2017) ‘Integrin signaling in atherosclerosis.’, Cellular and molecular life 
sciences : CMLS. NIH Public Access, 74(12), pp. 2263–2282. 
Fox, S. C. et al. (2019) ‘How does measurement of platelet P-selectin compare with other 
methods of measuring platelet function as a means of determining the effectiveness of 
antiplatelet therapy?’, Platelets, 30(3), pp. 290–295. 
Frustaci, A. et al. (1997) ‘Histological substrate of atrial biopsies in patients with lone atrial 
fibrillation.’, Circulation, 96(4), pp. 1180–4. 
Fu, R. et al. (2011) ‘A Study of blood soluble P-selectin, fibrinogen, and von Willebrand 
 236 
factor levels in idiopathic and lone atrial fibrillation’, Europace, 13(1), pp. 31–36. 
Furie, B. and Furie, B. C. (2008) ‘Mechanisms of thrombus formation.’, The New England 
journal of medicine, 359(9), pp. 938–949. 
Furihata, K. et al. (2001) ‘Variation in human platelet glycoprotein VI content modulates 
glycoprotein VI-specific prothrombinase activity.’, Arteriosclerosis, thrombosis, and 
vascular biology, 21(11), pp. 1857–63. 
Gailani, D. and Renné, T. (2007) ‘Intrinsic Pathway of Coagulation and Arterial Thrombosis’, 
Arteriosclerosis, Thrombosis, and Vascular Biology. Lippincott Williams & Wilkins, 27(12), 
pp. 2507–2513. 
Galea, R. et al. (2014) ‘Inflammation and C-reactive protein in atrial fibrillation: cause or 
effect?’, Texas Heart Institute journal. Texas Heart Institute, 41(5), pp. 461–8. 
Gao, J. et al. (1997) ‘Regulation of the pp72syk protein tyrosine kinase by platelet integrin 
alpha IIbbeta 3’, The EMBO Journal, 16(21), pp. 6414–6425. 
Gardiner, E. E. et al. (2004) ‘Regulation of platelet membrane levels of glycoprotein VI by 
a platelet-derived metalloproteinase.’, Blood. American Society of Hematology, 104(12), 
pp. 3611–7. 
Gardiner, E. E. et al. (2007) ‘Controlled shedding of platelet glycoprotein (GP)VI and GPIb-
IX-V by ADAM family metalloproteinases.’, Journal of Thrombosis and Haemostasis, 5(7), 
pp. 1530–7. 
Gardiner, E. E. (2018) ‘Proteolytic processing of platelet receptors’, Research and Practice 
in Thrombosis and Haemostasis. John Wiley & Sons, Ltd, 2(2), pp. 240–250. 
Gawaz, M. et al. (2000) ‘Platelets induce alterations of chemotactic and adhesive 
properties of endothelial cells mediated through an interleukin-1-dependent mechanism. 
Implications for atherogenesis’, Atherosclerosis, 148(1), pp. 75–85. 
Ghahremanfard, F. et al. (2013) ‘The relationship between mean platelet volume and 
severity of acute ischemic brain stroke.’, Neurosciences, 18(2), pp. 147–51. 
Gibbins, J. et al. (1996) ‘Tyrosine phosphorylation of the Fc receptor gamma-chain in 
collagen-stimulated platelets.’, The Journal of biological chemistry, 271(30), pp. 18095–9. 
Gibbins, J. M. et al. (1997) ‘Glycoprotein VI is the collagen receptor in platelets which 
underlies tyrosine phosphorylation of the Fc receptor γ-chain’, FEBS Letters, 413(2), pp. 
255–259. 
Gimbrone, M. A., García-Cardeña, G. and García-Cardeña, G. (2016) ‘Endothelial Cell 
 237 
Dysfunction and the Pathobiology of Atherosclerosis.’, Circulation Research. NIH Public 
Access, 118(4), pp. 620–36. 
Giugliano, R. P. et al. (2013) ‘Edoxaban versus Warfarin in Patients with Atrial Fibrillation’, 
New England Journal of Medicine.  Massachusetts Medical Society , 369(22), pp. 2093–
2104. 
Goebel, S. et al. (2013) ‘The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct 
Volume and Functional Outcome in Stroke’, PLoS ONE, 8(7). 
Goette, A. et al. (2000) ‘Increased expression of P-selectin in patients with chronic atrial 
fibrillation.’, Pacing and clinical electrophysiology : PACE, 23(11 Pt 2), pp. 1872–5. 
Goldsmith, I. et al. (2000) ‘Atrial endocardial changes in mitral valve disease: A scanning 
electron microscopy study’, American Heart Journal, 140(5), pp. 777–784. 
Gorelick, P. B. et al. (2011) ‘Vascular contributions to cognitive impairment and dementia: 
a statement for healthcare professionals from the american heart association/american 
stroke association.’, Stroke. NIH Public Access, 42(9), pp. 2672–713. 
Gosk-Bierska, I. et al. (2011) ‘Platelet factor XIII gene expression and embolic propensity 
in atrial fibrillation’, Thrombosis and Haemostasis, 106(07), pp. 75–82. 
Gosk-Bierska, I., Wasilewska, M. and Wysokiński, W. (2016) ‘Role of Platelets in 
Thromboembolism in Patients with Atrial Fibrillation’, Advances in Clinical and 
Experimental Medicine, 25(1), pp. 163–171. 
Granger, C. B. et al. (2011) ‘Apixaban versus Warfarin in Patients with Atrial Fibrillation’, 
New England Journal of Medicine. Massachusetts Medical Society, 365(11), pp. 981–992. 
Greenberg, C. S. and Shuman, M. A. (1982) ‘The zymogen forms of blood coagulation 
factor XIII bind specifically to fibrinogen.’, Journal of Biological Chemistry, 257(11), pp. 
6096–101. 
Greisenegger, S. et al. (2004) ‘Is elevated mean platelet volume associated with a worse 
outcome in patients with acute ischemic cerebrovascular events?’, Stroke. Lippincott 
Williams & Wilkins, 35(7), pp. 1688–91. 
Gros, A. et al. (2015) ‘Single platelets seal neutrophil-induced vascular breaches via GPVI 
during immune-complex-mediated inflammation in mice.’, Blood. American Society of 
Hematology, 126(8), pp. 1017–26. 
Grothusen, C. et al. (2007) ‘EXP3179 inhibits collagen-dependent platelet activation via 
glycoprotein receptor-VI independent of AT1-receptor antagonism: Potential impact on 
atherothrombosis’, Arteriosclerosis, Thrombosis, and Vascular Biology, 27(5), pp. 1184–
 238 
1190. 
Guo, Y., Lip, G. Y. H. and Apostolakis, S. (2012) ‘Inflammation in atrial fibrillation’, Journal 
of the American College of Cardiology. Elsevier Inc., 60(22), pp. 2263–2270. 
Hackam, D. G. and Spence, J. D. (2019) ‘Antiplatelet therapy in ischemic stroke and 
transient ischemic attack: An overview of major trials and meta-analyses’, Stroke, 50(3), 
pp. 773–778. 
Hahn, C. and Schwartz, M. A. (2009) ‘Mechanotransduction in vascular physiology and 
atherogenesis.’, Nature reviews Molecular cell biology. NIH Public Access, 10(1), pp. 53–
62. 
Haining, E. J. et al. (2017) ‘Tetraspanin Tspan9 regulates platelet collagen receptor GPVI 
lateral diffusion and activation’, Platelets, 28(7), pp. 629–642. 
Hamaia, S. W. et al. (2012) ‘Mapping of potent and specific binding motifs, GLOGEN and 
GVOGEA, for integrin α1β1 using collagen toolkits II and III.’, The Journal of biological 
chemistry. American Society for Biochemistry and Molecular Biology, 287(31), pp. 26019–
28. 
Han, T. S. et al. (2018) ‘Anticoagulation therapy in patients with stroke and atrial 
fibrillation: a registry-based study of acute stroke care in Surrey, UK.’, BMJ open. British 
Medical Journal Publishing Group, 8(7), p. e022558. 
Hannon, N. et al. (2014) ‘Acute hospital, community, and indirect costs of stroke 
associated with atrial fibrillation: Population-based study’, Stroke, 45(12), pp. 3670–3674. 
Harada, M., Van Wagoner, D. R. and Nattel, S. (2015) ‘Role of inflammation in atrial 
fibrillation pathophysiology and management.’, Circulation journal : official journal of the 
Japanese Circulation Society. NIH Public Access, 79(3), pp. 495–502. 
Hart, R. G. et al. (2017) ‘Embolic Stroke of Undetermined Source: A Systematic Review and 
Clinical Update’, Stroke, 48(4), pp. 867–872. 
Hart, R. G. et al. (2018) ‘Rivaroxaban for Stroke Prevention after Embolic Stroke of 
Undetermined Source’, New England Journal of Medicine. Massachusetts Medical Society, 
378(23), pp. 2191–2201. 
Hart, R. G., Pearce, L. A. and Aguilar, M. I. (2007) ‘Meta-analysis: antithrombotic therapy 
to prevent stroke in patients who have nonvalvular atrial fibrillation.’, Annals of internal 
medicine, 146(12), pp. 857–67. 
Hashimoto, T. et al. (2016) ‘Histopathologic Analysis of Retrieved Thrombi Associated With 
Successful Reperfusion After Acute Stroke Thrombectomy’, Stroke, 47(12), pp. 3035–3037. 
 239 
Hassan, A. et al. (2003) ‘Markers of endothelial dysfunction in lacunar infarction and 
ischaemic leukoaraiosis’, Brain, 126(2), pp. 424–432. 
Hayashi, M. et al. (2011) ‘Platelet activation and induction of tissue factor in acute and 
chronic atrial fibrillation: Involvement of mononuclear cell-platelet interaction’, 
Thrombosis Research, 128(6), pp. e113–e118. 
Heemskerk, J. W. M., Bevers, E. M. and Lindhout, T. (2002) ‘Platelet activation and blood 
coagulation.’, Thrombosis and haemostasis, 88(2), pp. 186–93. 
Heeringa, J. et al. (2006) ‘A longitudinal population-based study of prothrombotic factors 
in elderly subjects with atrial fibrillation: the Rotterdam Study 1990–1999’, Journal of 
Thrombosis and Haemostasis, 4(9), pp. 1944–1949. 
Hermans, C. et al. (2009) ‘A compound heterozygous mutation in glycoprotein VI in a 
patient with a bleeding disorder.’, Journal of Thrombosis and Haemostasis, 7(8), pp. 1356–
63. 
Hethershaw, E. L. et al. (2014) ‘The effect of blood coagulation factor XIII on fibrin clot 
structure and fibrinolysis’, Journal of Thrombosis and Haemostasis. John Wiley & Sons, Ltd 
(10.1111), 12(2), pp. 197–205. 
van Hinsbergh, V. W. M. (2012) ‘Endothelium--role in regulation of coagulation and 
inflammation.’, Seminars in immunopathology. Springer, 34(1), pp. 93–106. 
Hohnloser, S. H. et al. (2007) ‘Incidence of Stroke in Paroxysmal Versus Sustained Atrial 
Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An 
ACTIVE W Substudy’, Journal of the American College of Cardiology. Elsevier, 50(22), pp. 
2156–2161. 
Holinstat, M. et al. (2006) ‘PAR4, but Not PAR1, Signals Human Platelet Aggregation via Ca 
2+ Mobilization and Synergistic P2Y 12 Receptor Activation’, Journal of Biological Chemistry, 
281(36), pp. 26665–26674. 
Horii, K., Kahn, M. L. and Herr, A. B. (2006) ‘Structural basis for platelet collagen responses 
by the immune-type receptor glycoprotein VI’, Blood, 108(3), pp. 936–942. 
Howes, J.-M. et al. (2018) ‘MMP-13 binds to platelet receptors αIIbβ3 and GPVI and 
impairs aggregation and thrombus formation.’, Research and practice in thrombosis and 
haemostasis. Wiley-Blackwell, 2(2), pp. 370–379. 
Hughan, S. C. et al. (2007) ‘GPVI potentiation of platelet activation by thrombin and 
adhesion molecules independent of Src kinases and Syk.’, Arteriosclerosis, thrombosis, and 
vascular biology, 27(2), pp. 422–9. 
 240 
Induruwa, I. et al. (2018) ‘Platelet collagen receptor Glycoprotein VI-dimer recognizes 
fibrinogen and fibrin through their D-domains, contributing to platelet adhesion and 
activation during thrombus formation’, Journal of Thrombosis and Haemostasis, 16(2), pp. 
389–404. 
Induruwa, I., Jung, S. M. and Warburton, E. A. (2016) ‘Beyond antiplatelets: The role of 
glycoprotein VI in ischemic stroke’, International Journal of Stroke, 11(6), pp. 618–625. 
Inoue, O. et al. (2006) ‘Laminin stimulates spreading of platelets through integrin 
alpha6beta1-dependent activation of GPVI.’, Blood. American Society of Hematology, 
107(4), pp. 1405–12. 
Israels, S. J. et al. (2014) ‘Markers of platelet activation are increased in adolescents with 
type 2 diabetes.’, Diabetes care. American Diabetes Association, 37(8), pp. 2400–3. 
Jackson, S. P. (2007) ‘The growing complexity of platelet aggregation.’, Blood. American 
Society of Hematology, 109(12), pp. 5087–95. 
Jain, S., Russell, S. and Ware, J. (2009) ‘Platelet glycoproteinÂ VI facilitates experimental 
lung metastasis in syngenic mouse models’, Journal of Thrombosis and Haemostasis, 7(10), 
pp. 1713–1717. 
Jamasbi, J. et al. (2016) ‘Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its 
Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation.’, JACC. 
Basic to translational science. Elsevier, 1(3), pp. 131-142. 
Jandrot-Perrus, M. et al. (2000) ‘Cloning, characterization, and functional studies of human 
and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin 
superfamily.’, Blood, 96(5), pp. 1798–807. 
Järveläinen, H. et al. (2009) ‘Extracellular matrix molecules: potential targets in 
pharmacotherapy.’, Pharmacological reviews. American Society for Pharmacology and 
Experimental Therapeutics, 61(2), pp. 198–223. 
Jarvis, G. E. et al. (2002) ‘Distinct roles of GPVI and integrin α 2 β 1 in platelet shape change 
and aggregation induced by different collagens’, British Journal of Pharmacology. 
Blackwell Publishing Ltd, 137(1), pp. 107–117. 
Jiang, P. et al. (2015) ‘Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism 
of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan.’, PLoS ONE. 
Public Library of Science, 10(6), p. e0128744. 
Johnson-Tidey, R. R. et al. (1994) ‘Increase in the adhesion molecule P-selectin in 
endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion 
molecule-1.’, The American Journal of Pathology, 144(5), pp. 952–61. 
 241 
Johnston, S. C. et al. (2016) ‘Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic 
Attack’, New England Journal of Medicine. Massachusetts Medical Society, 375(1), pp. 35–
43. 
Johnston, S. C. et al. (2018) ‘Clopidogrel and Aspirin in Acute Ischemic Stroke and High-
Risk TIA’, New England Journal of Medicine, 379(3), pp. 215–225. 
Jones, C. I. et al. (2007) ‘Mapping the platelet profile for functional genomic studies and 
demonstration of the effect size of the GP6 locus’, Journal of Thrombosis and Haemostasis. 
Wiley/Blackwell (10.1111), 5(8), pp. 1756–1765. 
Joo, S.-J. (2012) ‘Mechanisms of Platelet Activation and Integrin αIIβ3.’, Korean Circulation 
Journal. The Korean Society of Cardiology, 42(5), pp. 295–301. 
Joutsi-Korhonen, L. et al. (2003) ‘The low-frequency allele of the platelet collagen signaling 
receptor glycoprotein VI is associated with reduced functional responses and expression.’, 
Blood. American Society of Hematology, 101(11), pp. 4372–9. 
Jung, S. M. et al. (2012) ‘Constitutive dimerization of glycoprotein VI (GPVI) in resting 
platelets is essential for binding to collagen and activation in flowing blood’, Journal of 
Biological Chemistry, 287(35), pp. 30000–30013. 
Jung, S. M. and Moroi, M. (1998) ‘Platelets interact with soluble and insoluble collagens 
through characteristically different reactions.’, The Journal of biological chemistry, 
273(24), pp. 14827–37. 
Jung, S. M., Tsuji, K. and Moroi, M. (2009) ‘Glycoprotein (GP) VI dimer as a major collagen-
binding site of native platelets: Direct evidence obtained with dimeric GPVI-specific Fabs’, 
Journal of Thrombosis and Haemostasis, 7(8), pp. 1347–1355. 
Kahn, M. L. et al. (1998) ‘A dual thrombin receptor system for platelet activation.’, Nature, 
394(6694), pp. 690–4. 
Kannel, W. B. et al. (1982) ‘Epidemiologic Features of Chronic Atrial Fibrillation’, New 
England Journal of Medicine, 306(17), pp. 1018–1022. 
Katan, M. and Luft, A. (2018) ‘Global Burden of Stroke’, Seminars in Neurology, 38(02), pp. 
208–211. 
Katona E, E. et al. (2001) ‘Enzyme-linked immunosorbent assay for the determination of 
blood coagulation factor XIII A-subunit in plasma and in cell lysates.’, Journal of 
immunological methods, 258(1–2), pp. 127–35. 
Kaushansky, K. (2005) ‘The molecular mechanisms that control thrombopoiesis.’, Journal 
of Clinical Investigation. American Society for Clinical Investigation, 115(12), pp. 3339–47. 
 242 
Kehrel, B. et al. (1998) ‘Glycoprotein VI is a major collagen receptor for platelet activation: 
it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, 
glycoprotein IIb/IIIa, and von Willebrand factor do not.’, Blood, 91(2), pp. 491–9. 
Kernan, W. N. et al. (2014) ‘Guidelines for the Prevention of Stroke in Patients With Stroke 
and Transient Ischemic Attack’, Stroke, 45(7), pp. 2160–2236. 
Kheiri, B. et al. (2019) ‘Clopidogrel and aspirin after ischemic stroke or transient ischemic 
attack: an updated systematic review and meta-analysis of randomized clinical trials’, 
Journal of Thrombosis and Thrombolysis, 47(2), pp. 233–247. 
Kleinschnitz, C. et al. (2007) ‘Targeting platelets in acute experimental stroke: Impact of 
glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and 
intracranial bleeding’, Circulation, 115(17), pp. 2323–2330. 
Knight, C. G. et al. (1999) ‘Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific 
for platelet Gp VI and mediates platelet activation by collagen.’, Cardiovascular research, 
41(2), pp. 450–7. 
Knight, C. G. et al. (2000) ‘The collagen-binding A-domains of integrins alpha(1)beta(1) and 
alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native 
(triple-helical) collagens.’, Journal of Biological Chemistry. American Society for 
Biochemistry and Molecular Biology, 275(1), pp. 35–40. 
Knottnerus, I. L. H. et al. (2009) ‘Endothelial dysfunction in lacunar stroke: a systematic 
review.’, Cerebrovascular Diseases, 27(5), pp. 519–26. 
Koyama, H. et al. (2003) ‘Platelet P-Selectin Expression Is Associated With Atherosclerotic 
Wall Thickness in Carotid Artery in Humans’, Circulation. Lippincott Williams & Wilkins, 
108(5), pp. 524–529. 
Kraft, P. et al. (2015) ‘Efficacy and Safety of Platelet Glycoprotein Receptor Blockade in 
Aged and Comorbid Mice With Acute Experimental Stroke’, Stroke, 46(12), pp. 3502–3506. 
Kuijper, P. H. M. et al. (1998) ‘P-selectin and MAC-1 mediate monocyte rolling and 
adhesion to ECM-bound platelets under flow conditions’, Journal of Leukocyte Biology, 
64(4), pp. 467–473. 
Kuipers, S., Klouwenberg, P. M. K. and Cremer, O. L. (2014) ‘Incidence, risk factors and 
outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review’, 
Critical Care, 18(6), p. 688. 
Lakhan, S. E. et al. (2013) ‘Matrix metalloproteinases and blood-brain barrier disruption in 
acute ischemic stroke.’, Frontiers in neurology. Frontiers Media SA, 4, p. 32. 
 243 
Langhorne, P., Coupar, F. and Pollock, A. (2009) ‘Motor recovery after stroke: a systematic 
review’, Lancet Neurology, 8(8), pp. 741–754. 
Laske, C. et al. (2008) ‘Association of platelet-derived soluble glycoprotein VI in plasma 
with Alzheimer’s disease’, Journal of Psychiatric Research. Pergamon, 42(9), pp. 746–751. 
Lavallée, P. C. et al. (2013) ‘Circulating Markers of Endothelial Dysfunction and Platelet 
Activation in Patients with Severe Symptomatic Cerebral Small Vessel Disease’, 
Cerebrovascular Diseases. Karger Publishers, 36(2), pp. 131–138. 
Lecut, C. et al. (2003) ‘Human platelet glycoprotein VI function is antagonized by 
monoclonal antibody-derived Fab fragments’, Journal of Thrombosis and Haemostasis. 
Blackwell Science Inc, 1(12), pp. 2653–2662. 
Lee, M. et al. (2013) ‘Risk–Benefit Profile of Long-Term Dual- Versus Single-Antiplatelet 
Therapy Among Patients With Ischemic Stroke’, Annals of Internal Medicine. American 
College of Physicians, 159(7), p. 463. 
Lee, M. Y. et al. (2017) ‘Soluble fibrin causes an acquired platelet glycoprotein VI signaling 
defect: implications for coagulopathy.’, Journal of thrombosis and haemostasis : JTH. NIH 
Public Access, 15(12), pp. 2396–2407. 
Lehmann, M. et al. (2018) ‘Platelets Drive Thrombus Propagation in a Hematocrit and 
Glycoprotein VI–Dependent Manner in an In Vitro Venous Thrombosis Model’, 
Arteriosclerosis, Thrombosis, and Vascular Biology, p. ATVBAHA.118.310731. 
Leidy, E. M. et al. (1990) ‘Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit 
model of femoral artery thrombosis.’, Thrombosis Research. Elsevier, 59(1), pp. 15–26. 
Lewandrowski, U. et al. (2009) ‘Platelet membrane proteomics: a novel repository for 
functional research’, Blood, 114(1), pp. e10–e19. 
Li-Saw-Hee, F. L. et al. (1999) ‘Indexes of hypercoagulability measured in peripheral blood 
reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral 
stenosis.’, The American journal of cardiology, 83(8), pp. 1206–9. 
Li, H. et al. (2007) ‘The fab fragment of a novel anti-GPVI monoclonal antibody, OM4, 
reduces in vivo thrombosis without bleeding risk in rats’, Arteriosclerosis, Thrombosis, and 
Vascular Biology, 27(5), pp. 1199–1205. 
Li, M. et al. (2014) ‘Changes in matrix metalloproteinase-9 levels during progression of 
atrial fibrillation’, Journal of International Medical Research. SAGE PublicationsSage UK: 
London, England, 42(1), pp. 224–230. 
Li, Y.-H. et al. (1994) ‘Clinical implications of left atrial appendage function: its influence 
 244 
on thrombus formation’, International Journal of Cardiology. Elsevier, 43(1), pp. 61–66. 
Li, Z. et al. (2010) ‘Signaling during platelet adhesion and activation.’, Arteriosclerosis, 
thrombosis, and vascular biology. NIH Public Access, 30(12), pp. 2341–9. 
Libby, P. (2009) ‘Molecular and cellular mechanisms of the thrombotic complications of 
atherosclerosis.’, Journal of Lipid Research. American Society for Biochemistry and 
Molecular Biology, 50 Suppl(Suppl), pp. S352-7. 
Lievens, D. and Hundelshausen, P. von (2011) ‘Platelets in atherosclerosis’, Thrombosis 
and Haemostasis. Schattauer GmbH, 106(11), pp. 827–838. 
Lindgren, A. (2014) ‘Stroke genetics: a review and update.’, Journal of Stroke. Korean 
Stroke Society, 16(3), pp. 114–23. 
Lip, G. Y. et al. (1995) ‘Increased markers of thrombogenesis in chronic atrial fibrillation: 
effects of warfarin treatment.’, Heart, 73(6), pp. 527–533. 
Lip, G. Y. et al. (1996) ‘Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: 
evidence for intermediate elevated levels of intravascular thrombogenesis.’, American 
heart journal, 131(4), pp. 724–30. 
Lip, G. Y. H. et al. (2007) ‘High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as 
Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial 
Fibrillation: Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and 
Prognosis’, Stroke, 38(4), pp. 1229–1237. 
Lip, G. Y. H. et al. (2010) ‘Refining Clinical Risk Stratification for Predicting Stroke and 
Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach’, Chest, 
137(2), pp. 263–272. 
Liu, J. et al. (2005) ‘Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in 
an  IIb 3- and aggregation-independent manner’, Blood, 106(8), pp. 2750–2756. 
Llombart, V. et al. (2013) ‘Cardioembolic stroke diagnosis using blood biomarkers.’, 
Current cardiology reviews, 9(4), pp. 340–52. 
Locke, D. et al. (2002) ‘Lipid Rafts Orchestrate Signaling by the Platelet Receptor 
Glycoprotein VI’, Journal of Biological Chemistry, 277(21), pp. 18801–18809. 
Lockyer, S. et al. (2006) ‘GPVI-deficient mice lack collagen responses and are protected 
against experimentally induced pulmonary thromboembolism.’, Thrombosis Research. 
Elsevier, 118(3), pp. 371–80. 
Lopaciuk, S. et al. (1976) ‘Subcellular distribution of fibrinogen and factor XIII in human 
 245 
blood platelets.’, Thrombosis Research. Elsevier, 8(4), pp. 453–65. 
Lorand, L., Credo, R. B. and Janus, T. J. (1981) ‘Factor XIII (fibrin-stabilizing factor).’, 
Methods in enzymology, 80 Pt C, pp. 333–41. 
Loyau, S. et al. (2012) ‘Platelet glycoprotein VI dimerization, an active process inducing 
receptor competence, is an indicator of platelet reactivity’, Arteriosclerosis, Thrombosis, 
and Vascular Biology, 32(3), pp. 778–785. 
Luo, Z.-Q. et al. (2014) ‘Left atrial endocardial dysfunction and platelet activation in 
patients with atrial fibrillation and mitral stenosis’, The Journal of Thoracic and 
Cardiovascular Surgery. Mosby, 148(5), pp. 1970–1976. 
Lutsey, P. L. et al. (2018) ‘Atrial fibrillation and venous thromboembolism: evidence of 
bidirectionality in the Atherosclerosis Risk in Communities Study’, Journal of Thrombosis 
and Haemostasis, 16(4), pp. 670–679. 
Ma, Y., Qin, J. and F, P. (2007) ‘Platelet integrin aIIbb3: activation mechanisms’, Journal of 
Thrombosis and Haemostasis, 5(7), pp. 1345–1352. 
Macrae, F. L. et al. (2018) ‘A fibrin biofilm covers blood clots and protects from microbial 
invasion’, The Journal of Clinical Investigation. American Society for Clinical Investigation, 
128(8), pp. 3356–3368. 
Mahajan, R. et al. (2012) ‘Importance of the underlying substrate in determining thrombus 
location in atrial fibrillation: implications for left atrial appendage closure’, Heart, 98(15), 
pp. 1120–1126. 
Makowski, M. et al. (2017) ‘Platelet reactivity and mean platelet volume as risk markers 
of thrombogenesis in atrial fibrillation’, International Journal of Cardiology, 235, pp. 1–5. 
Malik, R. et al. (2016) ‘Low-frequency and common genetic variation in ischemic stroke’, 
Neurology, 86(13), pp. 1217–1226. 
Malik, R. et al. (2018) ‘Multiancestry genome-wide association study of 520,000 subjects 
identifies 32 loci associated with stroke and stroke subtypes’, Nature Genetics. Nature 
Publishing Group, 50(4), pp. 524–537. 
Mammadova-Bach, E. et al. (2015) ‘Platelet glycoprotein VI binds to polymerized fibrin and 
promotes thrombin generation.’, Blood, 126(5), pp. 683–691. 
Mangin, P. H. et al. (2018) ‘Immobilized fibrinogen activates human platelets through 
glycoprotein VI.’, Haematologica. Ferrata Storti Foundation, 103(5), pp. 898–907. 
Mant, J. et al. (2007) ‘Warfarin versus aspirin for stroke prevention in an elderly 
 246 
community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment 
of the Aged Study, BAFTA): a randomised controlled trial’, Lancet, 370(9586), pp. 493–503. 
Marcus, A. J. et al. (1997) ‘The endothelial cell ecto-ADPase responsible for inhibition of 
platelet function is CD39.’, Journal of Clinical Investigation, 99(6), pp. 1351–1360. 
Marcus, G. M. et al. (2008) ‘Interleukin-6 and atrial fibrillation in patients with coronary 
artery disease: Data from the Heart and Soul Study’, American Heart Journal, 155(2), pp. 
303–309. 
Marder, V. J. (2012) Hemostasis and thrombosis : basic principles and clinical practice. 
Sixth Edit. Edited by V. J. Marder. Wolters Kluwer/Lippincott Williams & Wilkins Health. 
Markus, H. S. (2008) ‘Genes, endothelial function and cerebral small vessel disease in 
man.’, Experimental Physiology, 93(1), pp. 121–7. 
Marquardt, L. et al. (2002) ‘Course of Platelet Activation Markers After Ischemic Stroke’, 
Stroke, 33(11), pp. 2570–2574. 
Martín-Molina, A., Rodríguez-Beas, C. and Faraudo, J. (2012) ‘Effect of Calcium and 
Magnesium on Phosphatidylserine Membranes: Experiments and All-Atomic Simulations’, 
Biophysical Journal, 102(9), pp. 2095–2103. 
Masawa, N. et al. (1993) ‘Diagnosis of cardiac thrombosis in patients with atrial fibrillation 
in the absence of macroscopically visible thrombi.’, Virchows Archiv. A, Pathological 
anatomy and histopathology, 422(1), pp. 67–71. 
Massberg, S. et al. (2003) ‘A crucial role of glycoprotein VI for platelet recruitment to the 
injured arterial wall in vivo.’, The Journal of experimental medicine, 197(1), pp. 41–9. 
Massberg, S. et al. (2004) ‘Soluble glycoprotein VI dimer inhibits platelet adhesion and 
aggregation to the injured vessel wall in vivo.’, The FASEB journal : official publication of 
the Federation of American Societies for Experimental Biology, 18(2), pp. 397–399. 
Matsumoto, Y. et al. (2007) ‘Highly potent anti-human GPVI monoclonal antibodies 
derived from GPVI knockout mouse immunization.’, Thrombosis research, 119(3), pp. 319–
29. 
Matus, V. et al. (2013) ‘An adenine insertion in exon 6 of human GP6 generates a truncated 
protein associated with a bleeding disorder in four Chilean families’, Journal of Thrombosis 
and Haemostasis. John Wiley & Sons, Ltd (10.1111), 11(9), pp. 1751–1759. 
Medved, L., Weisel, J. W. and Fibrinogen and Factor XIII Subcommittee of Scientific 
Standardization Committee of International Society on Thrombosis and Haemostasis 
(2009) ‘Recommendations for nomenclature on fibrinogen and fibrin.’, Journal of 
 247 
thrombosis and haemostasis : JTH. NIH Public Access, 7(2), pp. 355–9. 
Meek, I. L., Van de Laar, M. A. F. J. and E Vonkeman, H. (2010) ‘Non-Steroidal Anti-
Inflammatory Drugs: An Overview of Cardiovascular Risks.’, Pharmaceuticals. 
Multidisciplinary Digital Publishing Institute (MDPI), 3(7), pp. 2146–2162. 
Michelson, A. D. et al. (2019) Platelets. Fourth Edi. Edited by A. D. Michelson. Academic 
Press. 
Miller, V. T. et al. (1993) ‘Ischemic stroke in patients with atrial fibrillation: effect of aspirin 
according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators.’, 
Neurology, 43(1), pp. 32–6. 
Misra,  a and Dikshit, M. (2014) ‘Platelets and Arterial Thrombosis: Evolving Role of Platelet 
Gpvi as an Antithrombotic Drug Target’, Proceedings of the Indian National Science 
Academy, 80(2), p. 289. 
Miura, Y. et al. (2002) ‘Analysis of the interaction of platelet collagen receptor glycoprotein 
VI (GPVI) with collagen: A dimeric form of GPVI, but not the monomeric form, shows 
affinity to fibrous collagen’, Journal of Biological Chemistry, 277(48), pp. 46197–46204. 
Mojica Muñoz, A.-K. et al. (2017) ‘Recombinant GPVI-Fc added to single or dual 
antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation’, 
Thrombosis and Haemostasis, 117(08), pp. 1651–1659. 
Mok, V. and Kim, J. S. (2015) ‘Prevention and Management of Cerebral Small Vessel 
Disease.’, Journal of Stroke. Korean Stroke Society, 17(2), pp. 111–22. 
Monroe, D. M., Hoffman, M. and Roberts, H. R. (2002) ‘Platelets and thrombin 
generation.’, Arteriosclerosis, thrombosis, and vascular biology, 22(9), pp. 1381–9. 
Montague, S. J. et al. (2018) ‘Soluble GPVI is elevated in injured patients: shedding is 
mediated by fibrin activation of GPVI.’, Blood advances. American Society of Hematology, 
2(3), pp. 240–251. 
Moore, K. J., Sheedy, F. J. and Fisher, E. A. (2013) ‘Macrophages in atherosclerosis: a 
dynamic balance.’, Nature reviews Immunology. NIH Public Access, 13(10), pp. 709–21. 
Moroi, M et al. (1989) ‘A patient with platelets deficient in glycoprotein VI that lack both 
collagen-induced aggregation and adhesion.’, The Journal of clinical investigation, 84(5), 
pp. 1440–5. 
Moroi, M. et al. (1989) ‘A patient with platelets deficient in glycoprotein VI that lack both 
collagen-induced aggregation and adhesion’, Journal of Clinical Investigation, 84(5), pp. 
1440–1445. 
 248 
Moroi, M. and Jung, S. M. (2004) ‘Platelet glycoprotein VI: Its structure and function’, 
Thrombosis Research, 114(4), pp. 221–233. 
Morton, L. F. et al. (1995) ‘Integrin alpha 2 beta 1-independent activation of platelets by 
simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) 
structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity.’, The 
Biochemical journal, 306 ( Pt 2, pp. 337–44. 
Mosesson, M. W. (2005) ‘Fibrinogen and fibrin structure and functions.’, Journal of 
thrombosis and haemostasis : JTH, 3(8), pp. 1894–1904. 
Mukamal, K. J. et al. (2006) ‘Fibrinogen and Albumin Levels and Risk of Atrial Fibrillation in 
Men and Women (the Copenhagen City Heart Study)’, The American Journal of Cardiology, 
98(1), pp. 75–81. 
Muszbek, L. et al. (2011) ‘Factor XIII: A Coagulation Factor With Multiple Plasmatic and 
Cellular Functions’, Physiological Reviews, 91(3), pp. 931–972. 
Muzard, J. et al. (2009) ‘Design and humanization of a murine scFv that blocks human 
platelet glycoprotein VI in vitro’, FEBS Journal, 276(15), pp. 4207–4222. 
NICE CG180 May 2019 (no date) ‘NICE guidelines (CG180) Management of atrial 
fibrillation’. 
NICE NG128 (no date) Stroke and transient ischaemic attack in over 16s: diagnosis and 
initial management. Guideline (NG128). NICE. 
Nieswandt, B. et al. (2000) ‘Expression and function of the mouse collagen receptor 
glycoprotein VI is strictly dependent on its association with the FcRγ chain’, Journal of 
Biological Chemistry, 275(31), pp. 23998–24002. 
Nieswandt, B. B. et al. (2001) ‘Long-term Antithrombotic Protection by In Vivo Depletion 
of Platelet Glycoprotein VI in Mice’, Journal of Experimental Medicine, 193(4), pp. 459–
469. 
Nieswandt, B., Pleines, I. and Bender, M. (2011) ‘Platelet adhesion and activation 
mechanisms in arterial thrombosis and ischaemic stroke.’, Journal of Thrombosis and 
Haemostasis, 9 Suppl 1, pp. 92–104. 
Nieswandt, B. and Watson, S. P. (2003) ‘Platelet-collagen interaction: Is GPVI the central 
receptor?’, Blood, 102(2), pp. 449–461. 
Niiya, K. et al. (1987) ‘Increased surface expression of the membrane glycoprotein IIb/IIIa 
complex induced by platelet activation. Relationship to the binding of fibrinogen and 
platelet aggregation’, Blood, 70(2), pp. 475–83. 
 249 
Nomura, S., Kanazawa, S. and Fukuhara, S. (2002) ‘Effects of efonidipine on platelet and 
monocyte activation markers in hypertensive patients with and without type 2 diabetes 
mellitus’, Journal of Human Hypertension. Nature Publishing Group, 16(8), pp. 539–547. 
van Norden, A. G. et al. (2011) ‘Causes and consequences of cerebral small vessel disease. 
The RUN DMC study: a prospective cohort study. Study rationale and protocol’, BMC 
Neurology. BioMed Central, 11(1), p. 29. 
Nurden, A. (2014) ‘Platelet Membrane Glycoproteins: A Historical Review’, Seminars in 
Thrombosis and Hemostasis, 40(05), pp. 577–584. 
Nurden, A. T. (2006) ‘Glanzmann thrombasthenia.’, Orphanet journal of rare diseases. 
BioMed Central, 1, p. 10. 
O’Brien, E. C. et al. (2014) ‘Physician practices regarding contraindications to oral 
anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better 
Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry’, American Heart Journal. 
Mosby, Inc., 167(4), pp. 601-609.e1. 
O’Connor, C. M., Gurbel, P. A. and Serebruany, V. L. (1999) ‘Usefulness of soluble and 
surface-bound P-selectin in detecting heightened platelet activity in patients with 
congestive heart failure.’, The American journal of cardiology, 83(9), pp. 1345–9. 
O’Shea, J. C. et al. (2001) ‘Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide 
in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.’, JAMA, 
285(19), pp. 2468–73. 
Oberheiden, T. et al. (2010) ‘Activation of platelets and cellular coagulation in cerebral 
small-vessel disease’, Blood Coagulation & Fibrinolysis, 21(8), p. 1. 
Onselaer, M. et al. (2017) ‘Fibrin and D-dimer bind to monomeric GPVI’, Blood Advances, 
1(19), pp. 1495–1504. 
Pachel, C. et al. (2016) ‘Inhibition of Platelet GPVI Protects Against Myocardial Ischemia-
Reperfusion Injury’, Arteriosclerosis, Thrombosis, and Vascular Biology, 36(4), pp. 629–
635. 
Palta, S., Saroa, R. and Palta, A. (2014) ‘Overview of the coagulation system’, Indian Journal 
of Anaesthesia. Wolters Kluwer -- Medknow Publications, 58(5), p. 515. 
Pantoni, L. (2010) ‘Cerebral small vessel disease: from pathogenesis and clinical 
characteristics to therapeutic challenges.’, Lancet Neurology. Elsevier, 9(7), pp. 689–701. 
Park, Y., Schoene, N. and Harris, W. (2002) ‘Mean platelet volume as an indicator of 
platelet activation: methodological issues’, Platelets, 13(5–6), pp. 301–306. 
 250 
Patel, M. R. et al. (2011) ‘Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation’, 
New England Journal of Medicine. Massachusetts Medical Society, 365(10), pp. 883–891. 
Patel, P. et al. (2010) ‘Update on the Association of Inflammation and Atrial Fibrillation’, 
Journal of Cardiovascular Electrophysiology. Wiley/Blackwell (10.1111), 21(9), pp. 1064–
1070. 
Pierre, S. et al. (2017) ‘GPVI and Thromboxane Receptor on Platelets Promote 
Proinflammatory Macrophage Phenotypes during Cutaneous Inflammation’, Journal of 
Investigative Dermatology, 137(3), pp. 686–695. 
Pizzo, S. V. et al. (1973) ‘Subunit structure of fragment D from fibrinogen and cross linked 
fibrin’, Journal of Biological Chemistry, 248(13), pp. 4584–4590. 
Poulter, N. S. et al. (2017) ‘Clustering of glycoprotein VI (GPVI) dimers upon adhesion to 
collagen as a mechanism to regulate GPVI signaling in platelets’, Journal of Thrombosis and 
Haemostasis. Wiley/Blackwell (10.1111), 15(3), pp. 549–564. 
Pratt, K. P. et al. (1997) ‘The primary fibrin polymerization pocket: three-dimensional 
structure of a 30-kDa C-terminal gamma chain fragment complexed with the peptide Gly-
Pro-Arg-Pro.’, Proceedings of the National Academy of Sciences of the United States of 
America. National Academy of Sciences, 94(14), pp. 7176–81. 
Preston, R. A. et al. (2007) ‘Elevated platelet P-selectin expression and platelet activation 
in high risk patients with uncontrolled severe hypertension.’, Atherosclerosis. Elsevier, 
192(1), pp. 148–54. 
Previtali, E. et al. (2011) ‘Risk factors for venous and arterial thrombosis.’, Blood 
transfusion. SIMTI Servizi, 9(2), pp. 120–38. 
Pugh, D., Pugh, J. and Mead, G. E. (2011) ‘Attitudes of physicians regarding anticoagulation 
for atrial fibrillation: A systematic review’, Age and Ageing, 40(6), pp. 675–683. 
Rabie, T. et al. (2007) ‘Diverging signaling events control the pathway of GPVI down-
regulation in vivo.’, Blood. American Society of Hematology, 110(2), pp. 529–35. 
Rajendran, P. et al. (2013) ‘The vascular endothelium and human diseases.’, International 
Journal of Biological Sciences. Ivyspring International Publisher, 9(10), pp. 1057–69. 
Rajkumar, C. A., Floyd, C. N. and Ferro, A. (2015) ‘Antiplatelet therapy as a modulator of 
stroke aetiology: a meta-analysis’, British Journal of Clinical Pharmacology, 80(3), pp. 331–
341. 
Ramakrishnan, V. et al. (2001) ‘A thrombin receptor function for platelet glycoprotein Ib-
IX unmasked by cleavage of glycoprotein V’, Proceedings of the National Academy of 
 251 
Sciences, 98(4), pp. 1823–1828. 
Ramshaw, J. A. ., Shah, N. K. and Brodsky, B. (1998) ‘Gly-X-Y Tripeptide Frequencies in 
Collagen: A Context for Host–Guest Triple-Helical Peptides’, Journal of Structural Biology, 
122(1–2), pp. 86–91. 
Rayes, J. et al. (2018) ‘The contribution of platelet glycoprotein receptors to inflammatory 
bleeding prevention is stimulus and organ dependent’, Haematologica, 103(6), pp. e256–
e258. 
Raynal, N. et al. (2006) ‘Use of Synthetic Peptides to Locate Novel Integrin  2beta1-binding 
Motifs in Human Collagen III’, Journal of Biological Chemistry, 281(7), pp. 3821–3831. 
Reiffel, J. A. (2014) ‘Atrial Fibrillation and Stroke: Epidemiology’, The American Journal of 
Medicine, 127(4), pp. e15–e16. 
Reimann, A. et al. (2016) ‘Combined administration of the GPVI-Fc fusion protein Revacept 
with low-dose thrombolysis in the treatment of stroke.’, Heart. Wichtig Publishing, 11(1), 
pp. e10–e16. 
Reininger, A. J., Korndörfer, M. A. and Wurzinger, L. J. (1998) ‘Adhesion of ADP-activated 
platelets to intact endothelium under stagnation point flow in vitro is mediated by the 
integrin alphaIIbeta3.’, Thrombosis and haemostasis, 79(5), pp. 998–1003. 
Rincon, F. and Wright, C. B. (2014) ‘Current pathophysiological concepts in cerebral small 
vessel disease.’, Frontiers in Aging Neuroscience. Frontiers Media SA, 6, p. 24. 
van Rooy, M.-J. et al. (2015) ‘Platelet hyperactivity and fibrin clot structure in transient 
ischemic attack individuals in the presence of metabolic syndrome: a microscopy and 
thromboelastography study.’, Cardiovascular Diabetology. BioMed Central, 14, p. 86. 
Rosenblum, W. I. (1997) ‘Platelet Adhesion and Aggregation without Endothelial 
Denudation or Exposure of Basal Lamina and/or Collagen’, Journal of Vascular Research, 
34(6), pp. 409–417. 
Roth, G. A. et al. (2017) ‘Global, Regional, and National Burden of Cardiovascular Diseases 
for 10 Causes, 1990 to 2015’, Journal of the American College of Cardiology. Journal of the 
American College of Cardiology, 70(1), pp. 1–25. 
Rothlisberger, J. M. and Ovbiagele, B. (2015) ‘Antiplatelet therapies for secondary stroke 
prevention: an update on clinical and cost-effectiveness.’, Journal of Comparative 
Effectiveness Research. Future Science Group, 4(4), pp. 377–84. 
Rothwell, P. M. et al. (2016) ‘Effects of aspirin on risk and severity of early recurrent stroke 
after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised 
 252 
trials.’, Lancet. Elsevier, 388(10042), pp. 365–375. 
Rothwell, P. M. and Warlow, C. P. (2005) ‘Timing of TIAs preceding stroke’, Neurology, 
64(5), pp. 817–820. 
Ruf, A. and Patscheke, H. (1995) ‘Flow Cytometric Detection of Activated Platelets: 
Comparison of Determining Shape Change, Fibrinogen Binding, and P-Selectin Expression’, 
Seminars in Thrombosis and Hemostasis, 21(02), pp. 146–151. 
Ruggeri, Z. M. (2007) ‘The role of von Willebrand factor in thrombus formation.’, 
Thrombosis research. NIH Public Access, 120(Suppl 1), pp. S5-9. 
Sakariassen, K. S., Orning, L. and Turitto, V. T. (2015) ‘The impact of blood shear rate on 
arterial thrombus formation.’, Future science OA. Future Science Group, 1(4), p. FSO30. 
Sakata, Y. and Aoki, N. (1980) ‘Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-
stabilizing factor.’, Journal of Clinical Investigation, 65(2), pp. 290–297. 
Sandercock, P. et al. (2003) ‘Antiplatelet therapy for acute ischaemic stroke’, in 
Sandercock, Peter (ed.) Cochrane Database of Systematic Reviews. Chichester, UK: John 
Wiley & Sons, Ltd, p. CD000029. 
Santos, E. M. M. et al. (2016) ‘Permeable Thrombi Are Associated With Higher Intravenous 
Recombinant Tissue-Type Plasminogen Activator Treatment Success in Patients With 
Acute Ischemic Stroke’, Stroke. Lippincott Williams & WilkinsHagerstown, MD, 47(8), pp. 
2058–2065. 
Sato, T. et al. (1998) ‘Binding and regulation of thrombopoietin to human 
megakaryocytes.’, British Journal of Haematology, 100(4), pp. 704–11. 
Savage, B., Saldívar, E. and Ruggeri, Z. M. (1996) ‘Initiation of platelet adhesion by arrest 
onto fibrinogen or translocation on von Willebrand factor’, Cell, 84(2), pp. 289–297. 
Savi, P. et al. (1998) ‘Clopidogrel: a review of its mechanism of action’, Platelets, 9(3–4), 
pp. 251–255. 
Schenone, M., Furie, B. C. and Furie, B. (2004) ‘The blood coagulation cascade.’, Current 
Opinion in Hematology, 11(4), pp. 272–7. 
Schönberger, T. et al. (2012) ‘The dimeric platelet collagen receptor GPVI-Fc reduces 
platelet adhesion to activated endothelium and preserves myocardial function after 
transient ischemia in mice’, American Journal of Physiology. American Physiological 
Society Bethesda, MD, 303(7), pp. C757–C766. 
Schuhmann, M. K. et al. (2019) ‘Targeting Platelet GPVI Plus rt-PA Administration but Not 
 253 
α2β1-Mediated Collagen Binding Protects against Ischemic Brain Damage in Mice’, 
International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute  
(MDPI), 20(8). 
Seiffge, D. J. et al. (2019) ‘Timing of anticoagulation after recent ischaemic stroke in 
patients with atrial fibrillation.’, Lancet Neurology. Elsevier, 18(1), pp. 117–126. 
Sentinal Stroke National Audit Programme (SSNAP) (2017) SSNAP - Regional Results Apr 
2016 -Mar 2017. 
Shimizu, A., Nagel, G. M. and Doolittle, R. F. (1992) ‘Photoaffinity labeling of the primary 
fibrin polymerization site: isolation and characterization of a labeled cyanogen bromide 
fragment corresponding to gamma-chain residues 337-379.’, Proceedings of the National 
Academy of Sciences of the United States of America, 89(7), pp. 2888–92. 
Shin, J. W. et al. (2018) ‘High red blood cell composition in clots is associated with 
successful recanalization during intra-arterial thrombectomy’, PLoS ONE. Public Library of 
Science, 13(5), p. e0197492. 
Shinohara, H. et al. (1998) ‘Relationship between flow dynamics in the left atrium and 
hemostatic abnormalities in patients with nonvalvular atrial fibrillation.’, Japanese Heart 
Journal, 39(6), pp. 721–30. 
Shoulders, M. D. and Raines, R. T. (2009) ‘Collagen structure and stability.’, Annual Review 
of Biochemistry. NIH Public Access, 78, pp. 929–58. 
Silverstein, F. E. et al. (1995) ‘Misoprostol reduces serious gastrointestinal complications 
in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A 
randomized, double-blind, placebo-controlled trial.’, Annals of internal medicine, 123(4), 
pp. 241–9. 
Simon, T. et al. (2009) ‘Genetic Determinants of Response to Clopidogrel and 
Cardiovascular Events’, New England Journal of Medicine.  Massachusetts Medical Society 
, 360(4), pp. 363–375. 
Singh, H. S. et al. (2012) ‘Comparison of Abciximab Versus Eptifibatide During 
Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (from 
the HORIZONS-AMI Trial)’, The American Journal of Cardiology, 110(7), pp. 940–947. 
Siudut, J. et al. (2016) ‘Reduced plasma fibrin clot permeability and susceptibility to lysis 
are associated with increased risk of postthrombotic syndrome’, Journal of Thrombosis 
and Haemostasis. John Wiley & Sons, Ltd (10.1111), 14(4), pp. 784–793. 
Slater, A. et al. (2019) ‘Does fibrin(ogen) bind to monomeric or dimeric GPVI, or not at 
all?’, Platelets, 30(3), pp. 281–289. 
 254 
Smethurst, P. a. et al. (2004) ‘Identification of the primary collagen-binding surface on 
human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody’, 
Blood, 103(3), pp. 903–911. 
Smethurst, P. A. et al. (2007) ‘Structural basis for the platelet-collagen interaction: The 
smallest motif within collagen that recognizes and activates platelet Glycoprotein VI 
contains two glycine-proline-hydroxyproline triplets’, Journal of Biological Chemistry, 
282(2), pp. 1296–1304. 
Snoep, J. D. et al. (2010) ‘The minor allele of GP6 T13254C is associated with decreased 
platelet activation and a reduced risk of recurrent cardiovascular events and mortality: 
results from the SMILE-Platelets project’, Journal of Thrombosis and Haemostasis. John 
Wiley & Sons, Ltd (10.1111), 8(11), pp. 2377–2384. 
Sohara, H. et al. (1997) ‘Atrial fibrillation activates platelets and coagulation in a time-
dependent manner: A study in patients with paroxysmal atrial fibrillation’, Journal of the 
American College of Cardiology, 29(1), pp. 106–112. 
Spalton, J. C. et al. (2009) ‘The novel Syk inhibitor R406 reveals mechanistic differences in 
the initiation of GPVI and CLEC-2 signaling in platelets’, Journal of Thrombosis and 
Haemostasis, 7(7), pp. 1192–1199. 
Sporns, P. B. et al. (2017) ‘Ischemic Stroke. What Does the Histological Composition Tell 
Us About the Origin of the Thrombus?’, Stroke, 48(8), pp. 2206–2210. 
Spraggon, G., Everse, S. J. and Doolittle, R. F. (1997) ‘Crystal structures of fragment D from 
human fibrinogen and its crosslinked counterpart from fibrin.’, Nature, 389(6650), pp. 
455–462. 
Springer, T. A., Zhu, J. and Xiao, T. (2008) ‘Structural basis for distinctive recognition of 
fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3.’, Journal of Cell Biology. 
The Rockefeller University Press, 182(4), pp. 791–800. 
Stack, J. R. et al. (2017) ‘Soluble glycoprotein VI, a specific marker of platelet activation is 
increased in the plasma of subjects with seropositive rheumatoid arthritis.’, PLoS ONE. 
Public Library of Science, 12(11), p. e0188027. 
Stalker, T. J. et al. (2014) ‘A systems approach to hemostasis: 3. Thrombus consolidation 
regulates intrathrombus solute transport and local thrombin activity’, Blood. American 
Society of Hematology, 124(11), pp. 1824–1831. 
Stangl, P. A. and Lewis, S. (2010) ‘Review of Currently Available GP IIb/IIIa Inhibitors and 
Their Role in Peripheral Vascular Interventions.’, Seminars in interventional radiology. 
Thieme Medical Publishers, 27(4), pp. 412–21. 
Stone, P. C. and Nash, G. B. (1999) ‘Conditions under which immobilized platelets activate 
 255 
as well as capture flowing neutrophils.’, British Journal of Haematology, 105(2), pp. 514–
22. 
Sugiyama, T. et al. (1987) ‘A novel platelet aggregating factor found in a patient with 
defective collagen-induced platelet aggregation and autoimmune thrombocytopenia.’, 
Blood, 69(6), pp. 1712–20. 
SuzukiI-Inoue, K., Inoue, O. and Ozaki, Y. (2011) ‘Novel platelet activation receptor CLEC-
2: from discovery to prospects’, Journal of Thrombosis and Haemostasis, 9, pp. 44–55. 
Swieringa, F. et al. (2018) ‘Integrating platelet and coagulation activation in fibrin clot 
formation’, Research and Practice in Thrombosis and Haemostasis. Wiley-Blackwell, 2(3), 
pp. 450–460. 
Tangelder, G. J. et al. (1985) ‘Distribution of blood platelets flowing in arterioles’, American 
Journal of Physiology-Heart and Circulatory Physiology, 248(3), pp. H318–H323. 
Taylor, L. et al. (2014) ‘Discovery of Novel GPVI Receptor Antagonists by Structure-Based 
Repurposing’, PLoS ONE. Edited by I. Ahrens. Public Library of Science, 9(6), p. e101209. 
Tcheng, J. E. (1997) ‘Randomised placebo-controlled trial of effect of eptifibatide on 
complications of percutaneous coronary intervention: IMPACT-II’, Lancet, 349(9063), pp. 
1422–1428. 
Tekin, G. et al. (2013) ‘Mean platelet volume in patients with nonvalvular atrial fibrillation’, 
Blood Coagulation & Fibrinolysis, 24(5), pp. 537–539. 
Tong, F. C. et al. (2000) ‘Abciximab rescue in acute carotid stent thrombosis.’, American 
journal of neuroradiology. American Journal of Neuroradiology, 21(9), pp. 1750–2. 
Topakian, R. et al. (2010) ‘Blood-brain barrier permeability is increased in normal-
appearing white matter in patients with lacunar stroke and leucoaraiosis’, Journal of 
Neurology, Neurosurgery & Psychiatry, 81(2), pp. 192–197. 
Trifiro, E. et al. (2009) ‘The low-frequency isoform of platelet glycoprotein VIb attenuates 
ligand-mediated signal transduction but not receptor expression or ligand binding’, Blood, 
114(9), pp. 1893–1899. 
Tsuji, M. et al. (1997) ‘A novel association of Fc receptor gamma-chain with glycoprotein 
VI and their co-expression as a collagen receptor in human platelets.’, Journal of Biological 
Chemistry, 272(38), pp. 23528–31. 
Tu, H. T. H. et al. (2015) ‘Worse Stroke Outcome in Atrial Fibrillation is Explained by More 
Severe Hypoperfusion, Infarct Growth, and Hemorrhagic Transformation’, International 
Journal of Stroke, 10(4), pp. 534–540. 
 256 
Undas, A. et al. (2009) ‘Altered Fibrin Clot Structure/Function in Patients With Cryptogenic 
Ischemic Stroke’, Stroke, 40(4), pp. 1499–1501. 
Ungerer, M. et al. (2011) ‘Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) 
specifically and efficiently inhibited collagen-induced platelet aggregation without 
affecting general hemostasis in humans’, Circulation, 123(17), pp. 1891–1899. 
Varga-Szabo, D., Pleines, I. and Nieswandt, B. (2008) ‘Cell Adhesion Mechanisms in 
Platelets’, Arteriosclerosis, Thrombosis, and Vascular Biology, 28(3), pp. 403–412. 
Varon, D. et al. (1993) ‘Inhibition of integrin-mediated platelet aggregation, fibrinogen-
binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-
Asp.’, Thrombosis and haemostasis, 70(6), pp. 1030–6. 
Violi, F. et al. (2016) ‘Atrial Fibrillation and Myocardial Infarction: A Systematic Review and 
Appraisal of Pathophysiologic Mechanisms.’, Journal of the American Heart Association. 
American Heart Association, Inc., 5(5), p. e003347. 
Volz, J. et al. (2019) ‘Inhibition of platelet GPVI induces intratumor hemorrhage and 
increases efficacy of chemotherapy in mice.’, Blood. American Society of Hematology, 
133(25), pp. 2696–2706. 
Voors-Pette, C. et al. (2019) ‘Safety and Tolerability, Pharmacokinetics, and 
Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab’, 
Arteriosclerosis, Thrombosis, and Vascular Biology, 39(5), pp. 956–964. 
Wachter, R. et al. (2017) ‘Holter-electrocardiogram-monitoring in patients with acute 
ischaemic stroke (Find-AF RANDOMISED ): an open-label randomised controlled trial’, 
Lancet Neurology, 16(4), pp. 282–290. 
Wakefield, T. W., Myers, D. D. and Henke, P. K. (2008) ‘Mechanisms of venous thrombosis 
and resolution.’, Arteriosclerosis, thrombosis, and vascular biology. American Heart 
Association, Inc., 28(3), pp. 387–91. 
Walker, A. et al. (2009) ‘Single domain antibodies against the collagen signalling receptor 
glycoprotein VI are inhibitors of collagen induced thrombus formation’, Platelets, 20(4), 
pp. 268–276. 
Wang, Yongjun et al. (2013) ‘Clopidogrel with Aspirin in Acute Minor Stroke or Transient 
Ischemic Attack’, New England Journal of Medicine.  Massachusetts Medical Society , 
369(1), pp. 11–19. 
Wang, Z.-T., Wang, Z. and Hu, Y.-W. (2016) ‘Possible roles of platelet-derived 
microparticles in atherosclerosis’, Atherosclerosis, 248, pp. 10–16. 
 257 
Wardlaw, J. M. et al. (2013) ‘Neuroimaging standards for research into small vessel disease 
and its contribution to ageing and neurodegeneration’, Lancet Neurology, 12(8), pp. 822–
838. 
Wardlaw, J. M. et al. (2017) ‘Blood-brain barrier failure as a core mechanism in cerebral 
small vessel disease and dementia: evidence from a cohort study’, Alzheimer’s & 
Dementia. Elsevier, 13(6), pp. 634–643. 
Watson, S. P. et al. (2005) ‘GPVI and integrin alphaIIbbeta3 signaling in platelets’, Journal 
of Thrombosis and Haemostasis, 3(8), pp. 1752–1762. 
Weber, A.-A. and Schror, K. (1999) ‘The significance of platelet-derived growth factors for 
proliferation of vascular smooth muscle cells’, Platelets, 10(2), pp. 77–96. 
Weber, C. and Springer, T. A. (1997) ‘Neutrophil accumulation on activated, surface-
adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to 
alphaIIbbeta3 and stimulated by platelet-activating factor.’, The Journal of clinical 
investigation. American Society for Clinical Investigation, 100(8), pp. 2085–93. 
Weyrich, A. S. et al. (2009) ‘Protein Synthesis by Platelets: Historical and New 
Perspectives’, Journal of Thrombosis and Haemostasis. NIH Public Access, 7(2), p. 241. 
White, J. G. and Escolar, G. (1991) ‘The blood platelet open canalicular system: a two-way 
street.’, European journal of cell biology, 56(2), pp. 233–42. 
Wood, A. J. J. and Patrono, C. (1994) ‘Aspirin as an Antiplatelet Drug’, New England Journal 
of Medicine, 330(18), pp. 1287–1294. 
Woollard, K. J. et al. (2014) ‘Raised Soluble P-Selectin Moderately Accelerates 
Atherosclerotic Plaque Progression’, PLoS ONE. Edited by X.-L. Ma. Public Library of 
Science, 9(5), p. e97422. 
Wozakowska-Kapłon, B. et al. (2010) ‘B-type natriuretic peptide level after sinus rhythm 
restoration in patients with persistent atrial fibrillation - clinical significance.’, Kardiologia 
polska, 68(7), pp. 781–6. 
Wożakowska-Kapłon, B. (2004) ‘Effect of sinus rhythm restoration on plasma brain 
natriuretic peptide in patients with atrial fibrillation’, The American Journal of Cardiology, 
93(12), pp. 1555–1558. 
Wurster, T. et al. (2013) ‘Plasma levels of soluble glycoprotein VI (sGPVI) are associated 
with ischemic stroke’, Platelets, 24(7), pp. 560–565. 
Xu, H. et al. (2011) ‘Collagen binding specificity of the discoidin domain receptors: Binding 
sites on collagens II and III and molecular determinants for collagen IV recognition by 
 258 
DDR1’, Matrix Biology, 30(1), pp. 16–26. 
Xu, Y. et al. (2012) ‘The relationship between TLR2, HIF-1α, MMP-9 with the occurance 
and maintanence of atrial fibrillation’, Heart. BMJ Publishing Group Ltd and British 
Cardiovascular Society, 98(Suppl 2), p. E74.3-E75. 
Yamamoto, H. and Bogousslavsky, J. (1998) ‘Mechanisms of second and further strokes.’, 
Journal of neurology, neurosurgery, and psychiatry. BMJ Publishing Group Ltd, 64(6), pp. 
771–6. 
Yamashita, T. et al. (2010) ‘Recruitment of immune cells across atrial endocardium in 
human atrial fibrillation.’, Circulation journal : official journal of the Japanese Circulation 
Society, 74(2), pp. 262–70. 
Yo, C.-H. et al. (2014) ‘Value of high-sensitivity C-reactive protein assays in predicting atrial 
fibrillation recurrence: a systematic review and meta-analysis.’, BMJ open. British Medical 
Journal Publishing Group, 4(2), p. e004418. 
You, J. J. et al. (2012) ‘Antithrombotic Therapy for Atrial Fibrillation’, Chest, 141(2), pp. 
e531S-e575S. 
Yun, S.-H. et al. (2016) ‘Platelet Activation: The Mechanisms and Potential Biomarkers.’, 
BioMed Research International. Hindawi Limited, 2016, p. 9060143. 
Zahn, A. et al. (2006) ‘Hepatitis C virus interacts with human platelet glycoprotein VI’, 
Journal of General Virology. Microbiology Society, 87(8), pp. 2243–2251. 
Zhang, L. et al. (2017) ‘The influence of surface chemistry on adsorbed fibrinogen 
conformation, orientation, fiber formation and platelet adhesion’, Acta Biomaterialia. 
Acta Materialia Inc., 54, pp. 164–174. 
Zhang, Y. et al. (2018) ‘Platelet integrins exhibit anisotropic mechanosensing and harness 
piconewton forces to mediate platelet aggregation’, Proceedings of the National Academy 
of Sciences, 115(2), pp. 325–330. 
Zimmerman, G. A. and Weyrich, A. S. (2008) ‘Signal-dependent protein synthesis by 
activated platelets: new pathways to altered phenotype and function.’, Arteriosclerosis, 
Thrombosis, and Vascular Biology. NIH Public Access, 28(3), pp. s17-24. 
Zupan, M. (2016) ‘Pathogenesis of Leukoaraiosis: A Review’, in Microcirculation Revisited 




APPENDIX A. PRIZES, PUBLICAITONS 
AND PRESENTATIONS DURING PHD 
 
AWARDS AND PRIZES 
Young Investigator Award 2017 
International Society of Thrombosis and Haemostasis World Congress, Berlin 
 
Healthcare Pioneers Award 2018 
Implementation of a secondary care service for screening, optimisation and support for 
stroke prevention in atrial fibrillation (SOS-AF). AF Association and Arrhythmia Alliance, 
London  
 
British Association of Stroke Physicians Abdul Majid Basic Neuroscience and 
Translational Research Prize 2018 
Highest scored abstract in translational category, UK Stroke Forum, Telford 
 
British Association of Stroke Physicians - Warlow Prize 2018 
Best Oral Presentation, UK Stroke Forum, Telford 
 
Royal College of Physicians Edinburgh, Senior Fellows’ Club Prize 2019 
Highest scored paper by trainee, Edinburgh 
 
Finalists BMJ Awards April 2019 - Stroke and Cardiovascular Team of the Year 
Implementation of a secondary care service for screening, optimisation and support for 




1. Induruwa I, Jung S, Warburton EA 
Beyond antiplatelets: The role of glycoprotein VI in ischaemic stroke. Int J Stroke 
11 2016 (6), 618-625. 
 
2. Induruwa I, Evans NR, Aziz A, et al. 
Clinical frailty is independently associated with non-prescription of anticoagulation 
in older patients with atrial fibrillation. Geriatr Gerontol Int 2017; 17: 2178-2183. 
 
3. Induruwa I, Amis E, Hannon N, Khadjooi K. 
The increasing burden of atrial fibrillation in acute medical admissions, an 
opportunity to optimise stroke prevention. J R Coll Physicians Edinb. 2017; 47: 331-
5. 
 
4. Induruwa I, Moroi M, Bonna A, et al.  The platelet collagen receptor GPVI-dimer 
recognizes fibrinogen and fibrin through their D-domains, contributing to platelet 
adhesion and activation during thrombus formation. J Thromb Haemost. 
2018;16(2):389-404. 
 
5. Induruwa I, Liu W, Khadjooi K. 
Screening. Optimisation. Support: a call for stroke prevention in atrial fibrillation. 
Br J Hosp Med (Lond). 2018;79(8):424-425. 
 
6. Hinz C, Liggi S, Mocciaro G, Jung SM, Induruwa I, et al. 
A comprehensive UHPLC ion mobility QTOF method for profiling and quantification 
of eicosanoids, other oxylipins and fatty acids. Anal Chem. 2019; 91(13):8025-8035. 
 
7. Induruwa I, Holland N, Gregory R, Khadjooi K. The impact of misdiagnosing Bell’s 






CONFERENCE ORAL PRESENTATIONS 
1. The platelet collagen receptor GPVI-dimer binds to the D-domain of fibrinogen and 
D-dimer and may contribute to platelet adhesion and activation during thrombus 
formation. International Society on Thrombosis and Haemostasis World 
Congress, Berlin, Germany 2017 
 
2. Platelet receptor glycoprotein VI-dimer is overexpressed in ischaemic but not 
haemorrhagic stroke; a promising future anti-thrombotic target? UK Stroke 
Forum, Telford, 2018 
 
3. The increasing burden of atrial fibrillation in acute medical admissions, an 
opportunity to optimise stroke prevention (Invited). Royal College of Physicians 
Edinburgh, Medical Trainees Symposium: New Approaches to Old Problems, 
Edinburgh, 2019 
 
4. Patients with atrial fibrillation significantly overexpress fibrin-binding platelet 
surface receptor GPVI-dimer. A future anti-thrombotic target? International 
Society on Thrombosis and Haemostasis World Congress, Melbourne, Australia 
2019 
 
5. Platelet receptor glycoprotein VI-dimer in ischaemic stroke; a promising future 
anti-thrombotic target? (Invited as 2018 Warlow Prize winner). Stroke Society of 




APPENDIX B. RELEVANT PEPTIDE 





GPO  Glycine-Proline-Hydroxyproline 
GPP  Glycine-Proline-Proline 
GPR  Glycine-Proline-Arginine 
GPRP  Glycine-Proline-Arginine-Proline 
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APPENDIX C. ILLNESS ACUITY, AF AND 
STROKE SCORING SYSTEMS 
 
 
CHA2DS2-VASc score  
 
Modified Rankin Scale 
Level Description 
0 No symptoms 
1 No significant disability, despite symptoms; able to perform all 
usual duties and activities 
2 Slight disability; unable to perform all previous activities but able 
to look after own affairs without assistance 
3 Moderate disability; requires some help but able to walk without 
assistance 
4 Moderately severe disability; unable to walk without assistance 
and unable to attend to own bodily needs without assistance 




Risk factor + Point  Annual Stroke Risk (%) 
Congestive Cardiac Failure 1  1 = 1.3 
Hypertension 1  2 = 2.2 
Age > 75 years 2  3 = 3.2 





5 = 7.2 
Vascular disease 1  6 = 9.7 
Age 65-74 years 1  7 = 11.2 
Sex (Female) 1  8 = 10.8 
   9 = 12.2 
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+3 +2 +1 0 +1 +2 +3 
Respiration rate/min ≤ 8  9-11 12-20  21-24 ≥ 25 
Sp02 scale 1 (%) ≤ 91 92-93 94-95 ≥ 96    














Air or oxygen  Oxygen  Air    





   




Consciousness    Alert   CVPU 







≥ 39.1  
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Beyond antiplatelets: The role of
glycoprotein VI in ischemic stroke
Isuru Induruwa1, Stephanie M Jung2 and
Elizabeth A Warburton1
Abstract
Background: Platelets are essential to physiological hemostasis or pathological thrombus formation. Current antiplate-
let agents inhibit platelet aggregation but leave patients at risk of systemic side-effects such as hemorrhage. Newer
therapeutic strategies could involve targeting this cascade earlier during platelet adhesion or activation via inhibitory
effects on specific glycoproteins, the thrombogenic collagen receptors found on the platelet surface.
Aims: Glycoprotein VI (GPVI) is increasingly being recognized as the main platelet-collagen receptor involved in arterial
thrombosis. This review summarizes the crucial role GPVI plays in ischemic stroke as well as the current strategies used
to attempt to inhibit its activity.
Summary of review: In this review, we discuss the normal hemostatic process, and the role GPVI plays at sites of
atherosclerotic plaque rupture. We discuss how the unique structure of GPVI allows for its interaction with collagen and
creates downstream signaling that leads to thrombus formation. We summarize the current strategies used to inhibit
GPVI activity and how this could translate to a clinically viable entity that may compete with current antiplatelet therapy.
Conclusion: From animal models, it is clear that GPVI inhibition leads to an abolished platelet response to collagen and
reduced platelet aggregation, culminating in smaller arterial thrombi. There is now an increasing body of evidence that
these findings can be translated into the development of a bleeding free pharmacological entity specific to sites of plaque
rupture in humans.
Keywords
Stroke, platelets, glycoprotein VI, antiplatelets
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Introduction
Ischemic stroke is a worldwide leading cause of disabil-
ity and death.1 An important and distinct subtype of
ischemic stroke is due to the acute rupture of athero-
sclerotic plaques seen in large artery disease.2 The
mechanism of cerebral hypoperfusion involves platelets
binding to exposed sub-endothelial collagen (adhesion),
resulting in platelet activation, aggregation, and throm-
bus formation. Unstable thrombi can detach and travel
to cerebral vessels causing stroke. As a result, the cur-
rent management of acute stroke involves using anti-
platelet agents such as aspirin and clopidogrel that
inhibit platelet activation/aggregation, but often at
the risk of off-target adverse effects such as
hemorrhage.3,4
Novel therapeutic strategies could involve targeting
this cascade earlier during platelet adhesion or
activation via inhibitory effects on specific platelet
glycoproteins, the thrombogenic collagen receptors on
their surfaces. Glycoprotein VI (GPVI) is one such
crucial transmembrane collagen receptor and pharma-
cological inhibition of GPVI, in order to stop patho-
logical thrombus formation specific to the site of vessel
injury, is currently being explored.
Hemostasis – clotting and thrombus
formation
Platelets are anucleate cells derived from megakaryo-
cytes. They contain unique cytoplasmic structures,
a- and dense granules that can rapidly release their con-
tents upon activation, promoting thrombus formation.
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Under normal hemostasis numerous protective barriers
to thrombus formation exist to contain it to the injured
site. This includes the continuous lining of endothelium
that prevents platelets coming into contact with the
prothrombotic sub-endothelial matrix,5 expression of
ectonucleoside triphosphate diphosphohydrolase
(CD39/ENTPD1)6 and secretion of prostacyclin
(PGI2) and nitric oxide.
There are four main platelet glycoprotein receptors
that participate in the platelet–collagen interaction and
facilitate thrombus formation. The GPIb-IX-V com-
plex (GPlba, GPIbb, GPIX and GPV) binds to von
Willebrand factor (VWF) immobilized on collagen.
Both GP Ia/IIa (integrin a2b1) and GPVI bind directly
to exposed collagen. GPIIb/IIIa (integrin aIIbb3) are
converted to their high-affinity forms via inside-out sig-
naling in activated platelets, enabling them to bind free
fibrinogen and VWF.
Fibrous collagen is the ligand for both GPVI and
integrin a2b1. Each collagen monomer comprises
three 1000 amino acid polypeptides arranged in a
triple helix, and bundles of these monomers align to
form collagen fibers.7 With atherosclerotic plaque rup-
ture, the sub-endothelial fibrillar collagens (types I and
III) are exposed to the blood stream. Under high shear
(arterial flow), VWF becomes immobilized on the
exposed collagen fibers and binds with the GPIb-IX-V
complex8–10 (Figure 1). Platelets translocate on the col-
lagen surface until firmly arrested through almost sim-
ultaneous binding with integrin a2b1 and GPVI. GPVI
engagement with collagen (via GPVI dimers) initiates a
signaling cascade leading to platelet activation and
inside-out signaling (and intracellular calcium mobiliza-
tion) that converts low affinity forms of integrins aIIbb3
and a2b1 into their active forms, as well as further clus-
tering of GPVI receptors.8
Activated platelets rapidly synthesize thromboxane
A2 (TxA2) and secrete this, along with the contents
of their alpha (fibrinogen, P-selectin, and VWF
multimers) and dense granules (ADP).9 An increase in
intracellular calcium in response to ADP and TxA2
induces platelet shape change to an irregular shape
with multiple filipoidal surfaces. This facilitates the for-
mation of a close structure of folded platelets in the
platelet plug.
Now non-activated platelets are recruited into the
growing thrombus, also becoming activated by
ADP and TxA2. GPVI-activated platelets provide a
pro-coagulant surface for the generation of throm-
bin—separately through the coagulation cascade by
Figure 1. Collagen-binding receptors (GPIb, GPVI, and integrin a2b1) involved in platelet adhesion and activation. Sub-
endothelial collagen exposed upon vessel injury binds to von Willebrand factor (vWF) in the blood (step 1). Platelets become
tethered to collagen fibers by their vWF receptor GPIb—a weak interaction—so platelets transiently bind and detach, moving
along the collagen (step 2). Platelets become firmly attached when their collagen receptors GPVI dimer and integrin a2b1 binds to
collagen; signaling through either GPVI or GPIb converts integrin a2b1 to its high affinity form (step 3). GPVI engagement with
collagen initiates a signaling cascade that culminates in platelet activation, spreading, and granule contents release (step 4),
recruiting other platelets and forming a thrombus (steps 5 and 6). Integrin aIIbb3 (not shown) becomes activated through inside-
out-signaling, enabling it to bind fibrinogen, through which inter-platelet bridges can be formed, allowing thrombus propagation.
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releasing several substances like FV, FXIII, fibrinogen,
and Protein S. This further activates platelets and con-
verts fibrinogen to fibrin, resulting in a strong mesh
structure.
Glycoprotein VI and its structure
Glycoprotein VI, a 62-kDA transmembrane
glycoprotein exclusively expressed in platelets and
megakaryocytes, is associated with an immunoreceptor
tyrosine-based-activation motif (ITAM) containing sig-
naling subunit FcRg (Figure 2).10 Its gene is mapped to
19q13.4 of the human genome. GPVI contains two
IgG-like extracellular domains (D1 and D2) linked by
a peptide strand; D2 is connected to the transmem-
brane domain via a glycosylated stem; and its 51
amino acid cytoplasmic tail is required for signal
transmission.11,12
GPVI exists in both monomeric and back-to-back
dimeric forms on the platelet surface13 and forms a
non-covalently linked complex with the Fc receptor g-
chain (FcRg) via a salt bridge formed between their
transmembrane domains. FcRg itself is also a dimer,
held together by covalent links and is essential for
GPVI expression, as FcRg knockout mice do not
express GPVI.14 Dimerization or multimerization of
GPVI was first suggested by Berlanga et al.15 but
proof of the actual existence on platelets was first pro-
vided by Jung et al.16 Later, they found that constitu-
tive dimers of GPVI make up of about 20% of the total
GPVI13,17 in resting platelets of normal individuals and
platelet activation increases the number of dimers.17
Only GPVI dimer has high affinity for collagen, while
the monomer binds weakly if at all. Inhibition by dimer
specific antibody m-Fab-F markedly inhibited collagen-
induced platelet aggregation, highlighting its role as the
functional form of GPVI.
Interaction with collagen and signaling
So how does GPVI interact with the fibrous suben-
dothelial collagen exposed upon vessel injury to
induce platelet activation? Much of this data has been
gained by using snake venom-derived convulxin and
CRP (collagen-related peptide) in vitro, which activate
platelets in a similar way to collagen.7,18 CRP, a triple
Figure 2. Structures of GPVI monomer and dimer. The extracellular domain of each monomer comprises two IgG domains (D1
and D2) and a mucin-like Ser/Thr-rich domain connecting D1/D2 to the transmembrane domain. The binding site recognizing the
GPO triplets of collagen, resides in D1. Each monomer is non-covalently associated through a salt bridge with FcRg. FcRg is a
disulphide-linked dimer, each chain containing an ITAM sequence, which when phosphorylated binds to the tyrosine kinase Syk.
The phosphorylated Syk now initiates signaling. The short intracellular domain of GPVI contains a basic domain that binds to
calmodulin; a proline-rich domain that binds to Src kinases Fyn and Lyn, which participate in phosphorylation of ITAM; and a C-
terminal tail.
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helical peptide containing 10 glycine–proline–hydroxy-
proline (GPO) sequences, is an especially potent plate-
let agonist specific for GPVI. GPVI was suggested to
bind to the GPO sequences in collagen. Smethurst
et al.19 later found that the minimum recognition
motif for GPVI is one GPO.
Using the crystal structure of GPVI and a docking
model with CRP, Horii et al.20 found that GPVI
formed back-to-back dimers, each containing a shallow
groove on the D1 domain that is perpendicular to the
collagen triple helix, which fits precisely into this 5.5-
nm gap.
Loyau et al.21 proposed that at least two GPVI
dimer-FcRg complexes are required to create a working
signaling unit, as the FcRg chain is also essential for the
function of GPVI and each chain contains an ITAM.
Upon GPVI–collagen binding, the Tyr residues of the
ITAM sequence become phosphorylated, initiating
signal transduction. PCLg2 is subsequently activated,
leading to eventual activation of protein kinase C,
resulting in calcium mobilization, degranulation and
GPIIb/IIIa activation and the start of the next step in
the process—platelet aggregation.
GPVI shedding and receptor
downregulation
An important consequence of GPVI downstream
signaling, which serves to limit thrombus growth, is
antibody or metalloproteinase (MMP) induced shed-
ding of a 55 kDa GPVI ectodomain into the blood
stream, leaving a 10 kDa remnant that remains plate-
let-associated.22–24 This plasma soluble form of GPVI
(sGPVI) has been the marker for many quantitative
studies on platelet activation through GPVI. The trans-
membrane metalloproteinases with protease activity,
ADAM10 and ADAM17, have been identified as two
sheddases that cleave the extracellular portion of GPVI
independently of each other under various stimuli
including the binding of GPVI ligands.25 However,
when antibody-mediated GPVI downregulation
occurs, the catalyst for GPVI shedding appears to be
independent of these MMPs, as antibody induced
GPVI shedding occurred in mice depleted of
ADAM10 and ADAM17.25 Thus, it is likely that
more sheddases participate in GPVI shedding and
their role in stroke as a therapeutic target is yet to be
determined.26
GPVI and ischemic stroke
The importance of GPVI in hemostasis was first
reported in a Japanese patient deficient in GPVI who
had mild bleeding tendency and whose platelets failed
to aggregate in response to collagen.27 Since then it has
been found that platelets treated with GPVI-specific
inhibitory antibodies show no interaction with collagen
in vivo;28 In addition, GPVI-deficient individuals exhi-
bit a mild bleeding tendency28 and GPVI-deficient mice
show increased bleeding times.30 These observations
cement GPVI’s role as the main signal generator lead-
ing to platelet activation, rather than functioning pri-
marily as a platelet adhesion receptor,29 but suggest
that more work is needed to clarify the exact bleeding
profile once GPVI is inhibited.
The exact role of GPVI in the different phenotypes
of stroke is yet to be elucidated. We know that it plays a
role in large artery atherosclerotic infarcts, but its role
in lacunar and cardioembloic stroke is unclear. In large
artery disease, elevated GPVI expression was shown to
be associated with increased risk of stroke develop-
ment. Enhanced GPVI expression is also seen after
ischemic stroke and TIA, with these patients having a
poorer clinical outcome at follow-up.30 Elevated sGPVI
levels were found in patients specifically after large
artery infarcts and these levels decrease after 3–6
months, which may highlight a role for sGPVI meas-
urements in this stroke substrate, but the evidence in
cardioembolic and lacunar types were less convincing.31
The pathogenesis of lacunar infarcts is believed to be
due to progressive ischemic leukoaraiosis caused by a
genetic susceptibility to inflammation-mediated cere-
brovascular injury in combination with the classic ath-
erosclerotic risk factors.32 There is evidence that
chronic endothelial dysfunction and activation leading
to a prothrombotic environment may cause progression
of leukoaraiosis. This is evidenced by higher levels of
prothormbotic proteins such as ICAM1, thrombomo-
dulin, fibrinogen, tissue factor in patients with cerebral
leukoaraiosis compared to controls.33–35 Recently,
thrombogenic fibrin was shown to be an activator of
GPVI in mice.36 Therefore, we could postulate that
GPVI is involved in lacunar stroke and small vessel
disease. Nevertheless, further studies are needed look-
ing at GPVI in this subtype of stroke, where currently
aspirin and clopidogrel play an important role in sec-
ondary prevention.
Recently, functional GPVI has been implicated as a
possible receptor for polymerized fibrin, propagating
thrombin generation.37 Further studies may reveal the
role of GPVI in cardioembloic stroke as well as throm-
bus propagation, clot stabilization and infarct growth
after ischemic stroke.38
Increased GPVI dimerization/multimerization could
be one of the earliest measurable steps in platelet acti-
vation after plaque rupture. Studies are underway to
measure GPVI dimer levels after acute stroke in com-
parison to healthy controls, which may be a useful diag-
nostic tool in the future. Since the dimer is the
functional receptor form of GPVI, this may partially
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explain why the studies discussed above measuring
total GPVI (dimers plus monomers) did not find any
correlation between its levels and severity of stroke.30
Targeting GPVI in ischemic stroke:
Beyond antiplatelet therapy
Current antiplatelet therapy acts on this cascade of
platelet activation via different methods and is licenced
for both acute coronary syndrome (ACS) and ischemic
stroke. Aspirin irreversibly inhibits both COX 1 and 2,
thus stopping TxA2 formation after platelet activation.
Clopidogrel and ticagrelor both irreversibly block the
ADP receptor P2Y12.
39 Thus both these classes of anti-
platelet drugs work by inhibiting platelet aggregation.
In comparison with single antiplatelet therapy, dual
antiplatelets do convey a reduction in early stroke
recurrence, combined transient ischemic attack (TIA),
stroke and ACS, and all death40 but dual antiplatelet
therapy is reserved for high-risk individuals after TIA
or stroke due to the risk of hemorrhage.
Studies on whether other platelet glycoprotein
receptors could be targets for antithrombotic therapy
have yielded less promising results. Abciximab, the Fab
fragment of a chimeric mouse/human monoclonal anti-
body, is licenced in ACS for patients awaiting percu-
taneous coronary intervention. It antagonizes GPIIb/
IIIa, which is the final mediator in the pathway to plate-
let aggregation. Unfortunately it has shown no benefit
in functional outcome in acute stroke, coupled with
significant increases in fatal or symptomatic intracra-
nial hemorrhage.41
Due to the fact that GPlba (part of the GPIb-IX-V
complex) plays a crucial role in platelet adhesion to endo-
thelium in high shear conditions, it has become an attract-
ive target for potential pharmaceutical development.
GPlba andGPVI are closely linked on the platelet surface
and are thought to activate similar signaling processes.42
Much of the knowledge on platelet receptors and ische-
mic stroke has come from experimentation on animal
models, particularly rats and mice, by causing transient
middle cerebral artery occlusion (tMCAO). Blockade of
GP1ba using Fab fragments, although reducing infarct
volume after tMCAO, led to prolonged tail bleeding
times compared to those treated with the monoclonal
antibody (mAb) anti-GPVI JAQ1.43
From similar studies in mice, GPVI was shown to
have a huge role in the formation of arterial thrombi.
After tMCAO, GPVI-depleted mice (via JAQ1) dem-
onstrate significantly reduced brain infarct volumes, no
hemorrhagic transformation, normal platelet counts,
and only moderately increased tail bleeding times.28,43
As platelets are anucleate cells and cannot synthesis
protein de novo, injection of rat anti-GPVI antibodies
(JAQ 1, 2, and 3) into mice in other studies offered
long-term depletion of GPVI from murine platelet sur-
faces.28,44 Furthermore, the Fab fragments of antibo-
dies 5C4,45 OM2,46 OM4,47 9O12,48 and mFab-F16 are
also potent inhibitors of GPVI-mediated platelet acti-
vation (Table 1). The evidence for antibody-driven
Table 1. Antibodies that inhibit GPVI-mediated activation
Type Effects
JAQ 128 Rat anti-mouse GPVI Abolished platelet response to collagen or CRP
Significantly reduced infarct size in tMCAO mice
Thrombocytopaenia and moderate bleeding-time prolongation
9O12 (Fab)48 Mouse mAb against human GPVI Protects against arterial thrombus propagation and collagen-induced
aggregation in vitro and ex vivo
Mild bleeding-time prolongation
5C4 (Fab)45 Rat mAb against human GPVI Almost complete inhibition of platelet aggregation in vivo
OM2 (Fab)46 Mouse mAb against human GPVI Inhibits collagen-induced platelet aggregation
Mild bleeding-time prolongation
OM4 (Fab)47 Mouse mAb against human GPVI Inhibits collagen-induced platelet aggregation in vitro and ex vivo
Reduces in vivo thrombosis in rat carotid artery model
No bleeding-time prolongation
10B1258 Human scFv against human GPVI Inhibits CRP- and collagen-induced platelet aggregation in vitro
m-Fab-F16 Human Fab against human GPVI GPVI dimer specific
Inhibits aggregation and platelet adhesion on collagen
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GPVI blockade as a target for stroke therapy is increas-
ing, with further efforts being made to attempt clearer
translation into clinical medicine. Recently, Kraft et al.49
successfully showed that GPVI inhibition using JAQ 1 in
adult mice with diabetes and hypertension resulted in
smaller cerebral infarcts, better functional outcome,
and reduced intracerebral hemorrhage rates compared
to mice treated with anti-GPIIb/IIIa.49
Patients with autoantibodies to GPVI-FcRg chain,
causing its clearance from the platelet surface are seen
to have inefficiently formed thrombi on collagen-coated
surfaces.50 However, their clinical presentation of mild
thrombocytopenia, ecchymosis, epistaxis, and pro-
longed bleeding times highlights the difficulty in trans-
lating experimental findings into clinical practice.
Buildingon thework initiallydoneonanimalmodels,45
Revacept (PR-15, GPVI-Fc), a recombinant, soluble
fusion protein between the human extracellular col-
lagen-binding domain of GPVI and the C-terminal of
human Fc, has been developed to competitively inhibit
GPVI binding sites on exposed collagen. It was tested in
a phase I trial, after intravenous administration to 30
healthymales, in 201151 and showed clear dose-dependent
inhibition of collagen responsiveness and platelet aggre-
gation. This was done without any significant effect on
hemostasis and no significant thrombocytopenia.
Revacept appears to avoid bleeding tendencies by
blocking both the GPVI and VWF-mediated platelet
activation processes specifically at the site of collagen
exposure, thereby avoiding prolongation of bleeding
times as described with antibodies to GPVI.28,43
However, this has only been confirmed on trials in
mice after left MCA lesions.52 Revacept also seems to
exert an anti-atherosclerotic effect via vessel endothelial
remodelling and a role as a primary preventative medi-
cation in the absence of plaque rupture may emerge.53
It is currently undergoing phase II trials on patients
with symptomatic carotid artery stenosis.54
Losartan, the angiotensin II receptor blocker has
previously shown anti-atherosclerotic effects by block-
ing inflammogenic mediators and also anti-aggregatory
effects independent of its effects on hypertension.55
EXP3179, its active metabolite, selectively inhibits
GPVI function and therefore platelet adhesion and
aggregation both in vitro and in vivo.56 This occurs
when losartan binds to the IgG-like domain of
GPVI57 and this interaction, coupled with the fact
that losartan has no effect on bleeding profiles, may
be the basis of a therapeutic target in the future.
Conclusion
The platelet–collagen interaction, and subsequent
platelet activation and thrombus formation, can lead
to devastating neurological damage via ischemic
stroke. There is a growing body of evidence pointing
towards the importance of platelet glycoprotein recep-
tors in stroke due to their requisite role in initiating
downstream signaling mechanisms leading to platelet
activation and pathological thrombus generation.
Current understanding of thrombus formation suggests
that GPVI is one such crucial receptor and inhibition of
its collagen-induced signaling would be a specific
pharmacological target for ischemic stroke. However,
most of the research has been carried out in murine
experimental models and may not necessarily translate
to bleeding-free therapy in humans. The current clinical
trials that are underway on Revacept are promising and
could lead the way to a better understanding of GPVI
antagonism in humans. Smaller studies are being car-
ried out looking at novel small molecule inhibitors of
GPVI and if a successful entity is discovered, the next
decade should see the development of efficacious and
highly specific therapies in ischemic stroke that a have
large safety margin.
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Essentials
• Glycoprotein VI (GPVI) binds collagen, starting throm-
bogenesis, and fibrin, stabilizing thrombi.
• GPVI-dimers, not monomers, recognize immobilized
fibrinogen and fibrin through their D-domains.
• Collagen, D-fragment and D-dimer may share a com-
mon or proximate binding site(s) on GPVI-dimer.
• GPVI-dimer–fibrin interaction supports spreading, acti-
vation and adhesion involving aIIbb3.
Summary. Background: Platelet collagen receptor Glyco-
protein VI (GPVI) binds collagen, initiating thrombogen-
esis, and stabilizes thrombi by binding fibrin. Objectives:
To determine if GPVI-dimer, GPVI-monomer, or both
bind to fibrinogen substrates, and which region common
to these substrates contains the interaction site. Meth-
ods: Recombinant GPVI monomeric extracellular domain
(GPVIex) or dimeric Fc-fusion protein (GPVI-Fc2) bind-
ing to immobilized fibrinogen derivatives was measured
by ELISA, including competition assays involving col-
lagenous substrates and fibrinogen derivatives. Flow
adhesion was performed with normal or Glanzmann
thrombasthenic (GT) platelets over immobilized fibrino-
gen, with or without anti-GPVI-dimer or anti-aIIbb3. Re-
sults: Under static conditions, GPVIex did not bind to
any fibrinogen substrate. GPVI-Fc2 exhibited specific, sat-
urable binding to both D-fragment and D-dimer, which
was inhibited by mFab-F (anti-GPVI-dimer), but showed
low binding to fibrinogen and fibrin under our conditions.
GPVI-Fc2 binding to D-fragment or D-dimer was abro-
gated by collagen type III, Horm collagen or CRP-XL
(crosslinked collagen-related peptide), suggesting proxim-
ity between the D-domain and collagen binding sites on
GPVI-dimer. Under low shear, adhesion of normal plate-
lets to D-fragment, D-dimer, fibrinogen and fibrin was
inhibited by mFab-F (inhibitor of GPVI-dimer) and abol-
ished by Eptifibatide (inhibitor of aIIbb3), suggesting that
both receptors contribute to thrombus formation on these
substrates, but aIIbb3 makes a greater contribution.
Notably, thrombasthenic platelets showed limited adhe-
sion to fibrinogen substrates under flow, which was fur-
ther reduced by mFab-F, supporting some independent
GPVI-dimer involvement in this interaction. Conclusion:
Only dimeric GPVI interacts with fibrinogen D-domain,
at a site proximate to its collagen binding site, to support
platelet adhesion/activation/aggregate formation on
immobilized fibrinogen and polymerized fibrin.
Keywords: fibrin; fibrin fragment D-dimer; fibrinogen
fragment D; platelet membrane glycoprotein VI; platelet
membrane glycoproteins; receptors, collagen.
Introduction
Myocardial infarction and ischemic stroke, leading causes
of disability and death worldwide [1], usually result from
atherosclerotic plaque rupture, leading to arterial throm-
bus formation followed by distal tissue infarction; plate-
lets are crucial for the development of such thrombi.
Disruption of the thrombo-protective endothelial layer
within blood vessels during plaque rupture exposes colla-
gen and tissue factor (TF). Platelet GPIb-IX-V binds to
von Willebrand factor (VWF) deposited on exposed
subendothelial collagens, slowing them down so
Correspondence: Stephanie M. Jung, Department of Biochemistry,
University of Cambridge, Tennis Court Road (Downing Site),
Cambridge CB2 1QW, UK
Tel.: +44 12 2333 3681
E-mail: smj52@cam.ac.uk
Received: 22 May 2017
Manuscript handled by: T. Lisman
Final decision: P. H. Reitsma, 26 November 2017
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Journal of Thrombosis and Haemostasis, 16: 389–404 DOI: 10.1111/jth.13919
Glycoprotein VI (GPVI) can bind to the collagen, which
initiates a signaling cascade leading to thrombus forma-
tion [2,3]. A dimer consisting of two GPVI-monomers is
the functionally active form of this receptor, which is con-
stitutively present (about 20% of the total GPVI) on rest-
ing platelets [4]. GPVI-dimers recognize Gly-Pro-Hyp
(GPO) peptide repeats on collagen [5,6] and once platelets
adhere via GPVI, activation of integrin a2b1 supports
firm adhesion to collagen [7].
The subsequent growth and stability of a clot relies on
coordinated activation of both the collagen pathway and
TF (tissue factor) pathway [8], which can also form
thrombi independent of collagen exposure [9], relying on
thrombin (factor IIa) generation via the proteolytic
extrinsic coagulation cascade. Thrombin generates insol-
uble fibrin from soluble circulating fibrinogen, which
polymerizes and acts to stabilize the growing clot via pla-
telet receptor integrin aIIbb3 [10,11].
Human fibrinogen molecules are comprised of six disul-
fide-linked polypeptide chains (Aa, Bb, c)2 organized as
outer D-domains containing the C-termini of the three
chains, connected to a central E-domain. Thrombin cleaves
fibrinopeptides A and B from the N-termini of the a- and
b-chains within the E-domain, exposing new binding sites
that allow fibrin polymerization through linking to one or
two D-domains in an end-to-middle configuration [12]. D-
domain c-chains undergo reciprocal crosslinking mediated
by FXIIIa, leading to a strengthened fibrin mesh [13]. The
peptide Gly-Pro-Arg-Pro (GPRP), which binds to the fibrin
polymerization sites in the D-domain, inhibits its binding
to an adjacent E-domain, leading to formation of non-
crosslinked, or monomeric fibrin [14]. Plasmin can act on
fibrinogen to release D- or E-domains separately, or on
polymerized fibrin to release D-dimer, typically consisting
of two FXIIIa crosslinked D-domains from an original fib-
rinogen molecule [15].
Initially, aIIbb3 is converted to its high-affinity form,
enabling binding to fibrinogen and fibrin, leading to pla-
telet aggregation, thrombus growth and formation of a
hemostatic plug [16]. The complex role that aIIbb3 plays
in thrombus formation has already been extensively inves-
tigated, but translation of its inhibition to an antiplatelet
agent has not been successful in conditions such as
ischemic stroke [17].
It has been long suspected that GPVI plays a role in
thrombus growth independent of collagen exposure
through ligands such as thrombin [18,19], laminin [20],
fibronectin [21,22] and vitronectin [23]. Recently, it has
been reported that GPVI interacts with polymerized fibrin
to facilitate thrombus growth [24–26].
The present study provides evidence indicating that the
collagen-binding, dimeric form of GPVI, is also able to
recognize the D-domain, a region universal to fibrinogen,
D-fragment (resulting from proteolytic cleavage of fib-
rinogen), D-dimer, and monomeric and polymerized
fibrin. The binding site on GPVI-dimer for the D-domain
is proximate to its collagen-binding site and GPVI-dimer
assists aIIbb3 in thrombus growth and stabilization,
suggesting that GPVI-dimer could be the central platelet




Figure S1 summarizes the commercial preparations of
human fibrinogen and derivatives used; SDS-PAGE con-
firmed the manufacturer’s stated purity. Preliminary stud-
ies showed that all the listed fibrinogens gave similar
results. We used Fibrinogen 3 (Fbg-3) in this study
because it was plasminogen-, VWF- and fibronectin-
depleted, but not factor XIII– depleted.
Recombinant GPVI-dimer and -monomer
GPVIex is a recombinant protein comprising the extracel-
lular domain of GPVI, including the collagen binding
portions D1D2 and most of the highly glycosylated extra-
cellular stem portion. GPVI-Fc2 is a fusion protein of the
GPVI extracellular domain (same amino acid sequence as
GPVIex) and the Fc domain of IgG, which spontaneously
dimerizes ([GPVI-Fc]2, abbreviated as GPVI-Fc2). Both
proteins were designed and characterized by M. Moroi
and colleagues [4,27].
Collagen substrates (synthesized and crosslinked in-house)
CRP-XL (crosslinked collagen-related peptide; GCO-
(GPO)10-GCOG-NH2) is a GPVI-specific agonist [28] and
GPP10-XL is its inactive analogue (GCP-(GPP)10G-NH2) [5].
GPVI-dimer-specific antibodies
mFab-F is a GPVI-dimer-specific inhibitory Fab [3] that
recognizes the dimers on resting platelets. GPVI-dimer-
specific non-inhibitory 204-11 Fab [4] recognizes the
GPVI-dimers on resting and activated platelets. Both
antibodies were developed by M Moroi and colleagues.
Immobilization of fibrinogen substrates and collagens
For ELISA, static adhesion, confocal microscopy and flow
adhesion, respectively, 96-well black optical polymer-bot-
tom ELISA plates (Nunc A/S, Roskilde, Denmark), Max-
isorp ELISA plates (Nunc A/S), glass-bottomed dishes (10-
mm, No. 0; MatTek, Ashland, MA, USA) or glass slides
were incubated with fibrinogen or collagenous substrates in
phosphate-buffered saline (PBS; for all substrates except
Horm, which was diluted in supplied diluent), overnight at
4 °C; details are provided in the figure legends. The immo-
bilized surfaces were blocked by incubating with 1%
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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bovine serum albumin (BSA)/PBS for 1 h, washed twice
with PBS, and used for experiments.
Polymerized fibrin (pFibrin) was prepared by adding
thrombin (2 U mL!1; Sigma-Aldrich, Dorset, England)
to Fbg-3 (10 lg mL!1 unless otherwise stated), and
incubated for 30 min at RT, aliquoted to the surface
to be coated and left overnight at 4 °C. The coated
surface was blocked with 1% BSA, treated with hiru-
din or protease inhibitor cocktail for 10 min to inhibit
active thrombin, and washed with PBS. The presence
of fibrin strands was confirmed by staining with anti-
fibrin (UC45)/Alexa-Fluor-Plus 555 anti-mouse IgG
(ThermoFisher Scientific, Warrington, UK); Fig. 4(B)
shows a representative image.
Immobilized monomeric fibrin (mFibrin) was prepared
by adding GPRP (2 mM) to Fbg-3 (10 lg mL!1, unless
stated otherwise) and incubated for 30 min at RT before
adding thrombin as above; other procedures are the same
as for pFibrin.
ELISA analysis of GPVI-dimer and GPVI-monomer binding
to fibrinogen and its derivatives
GPVI binding to immobilized substrates was measured
by ELISA as described previously [4]. Bound GPVI
was measured by reacting the wells with 1G5 (mouse
anti-pan GPVI Mab; Biocytex, Marseille, France)
[20,29] followed by IRDye!800CW goat anti-mouse
IgG (Licor Biosciences, Cambridge, UK) or Alexa-
fluor 647-conjugated anti-human Fc (BioLegend, Lon-
don, UK).
Washed platelets
ACD-anticoagulated blood from healthy volunteers or the
Glanzmann thrombasthenic (GT) patient was obtained
with informed consent, in accordance with the Treaty of
Helsinki. Washed platelets were prepared as described pre-
viously [30] and resuspended in HEPES-Tyrode’s buffer
(HT: 134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl,
12 mM NaHCO3, 10 mM N-2-hydroxyethylpiperazine-N’-
2-ethanesulfonic acid, 5.5 mM glucose, pH 7.3).
Other platelet assays
Aggregometry was performed with a PAP-8E aggre-
gometer (Bio/Data Corporation, Alpha Laboratories
(UK distributor), Hampshire, UK); details are given in
the legend for Fig. 5. Flow cytometry was performed
with an Accuri C6 flow cytometer (BD, Oxford, UK) on
washed platelets; details are given in the legend for
Fig. 3. Static platelet adhesion (Fig. 3) experiments were
performed as described previously [4] to determine the
effects of mFab-F and Hip8 (anti-aIIbb3) on adhesion
of washed platelets to fibrinogen-substrate-coated or col-
lagen-coated ELISA plates.
Confocal imaging
Washed platelets (3 9 107 mL!1 in HT/2 mM MgCl2)
were allowed to adhere on fibrinogen-substrate-coated
MatTek dishes for 1 h at 37 °C and formalin fixed as
described previously [31]. Pre- and post-staining details
are provided in the figure legends. Stained samples were
imaged under an Olympus FV300 IX81 laser-scanning
confocal microscope (Olympus, Essex, UK), with a 60x
oil immersion objective).
Effect of anti-GPVI-dimer antibodies on platelets under flow
Flow adhesion experiments were performed with normal
or GT blood and image acquisition was carried out as
described [32]; details are given in the figure legends.
After 5 min, Z-stacks (DZ = 0.69-lm increments from the
coverslip plane) were collected and analyzed by Ima-
geJ1.35 (National Institutes of Health). The coverslip
plane was defined as the Z-plane with the largest fluores-
cent platelet area and used to calculate the surface area
coverage (SA; lm2). Thrombus volume (lm3) was calcu-
lated as the sum of the detected surface areas of all
images in the Z-stack, multiplied by DZ. Mean thrombus
height (MTH) was calculated as thrombus volume/field
area.
Data analyses
Non-linear regression (one-site model) to obtain dissocia-
tion constants (Kd) and statistical analyses was performed
with Prism version 7.2 (GraphPad Software, San Diego,
CA, USA).
Results
Dimeric, but not monomeric, GPVI binds to immobilized D-
fragment and D-dimer with high affinity
We measured GPVI-Fc2 binding to immobilized fibrinogen
derivatives and collagen III (col III) (Fig. 1A;
mean " SEM, 3 experiments, duplicate replicates). GPVI-
Fc2 showed high levels of binding to D-fragment and D-
dimer, but did not bind E-fragment. There was very low
but measurable binding to fibrinogen, pFibrin and mFib-
rin. GPVI-Fc2 binding to D-fragment or D-dimer was
specific and saturable, their Kd values being higher but sim-
ilar in magnitude to that for col III (Fig. 1E). At all coating
concentrations (10–200 lg mL!1, Fig. 1C), fibrinogen,
mFibrin or pFibrin binding was too low and scattered to
determine Kd. Bmax, which depends on the amount of
immobilized substrate, cannot be determined by ELISA.
Monomeric GPVI, GPVIex (0–50 lg mL
!1), did not
bind D-fragment, D-dimer or fibrinogen and exhibited
feeble col III binding compared with GPVI-Fc2, as previ-
ously reported [4] (Fig. 1B).
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Furthermore, mFab-F significantly reduces GPVI-Fc2
binding to D-fragment (P < 0.01), D-dimer (P < 0.01)
and collagen type III (P < 0.05), compared with a non-
specific human Fab (hFab; Jackson ImmunoResearch)
control (Fig. 5B). These results suggest that the binding
site for GPVI lies in the D-domain, universally present in
fibrinogen, D-dimer, mFibrin and pFibrin, for which only
GPVI-dimer has good affinity.
Human Fc and DDR2-Fc2 (recombinant Fc-fusion
protein of discoidin domain-containing receptor 2,
another collagen-binding protein [33]) and human IgG
did not bind to any of the fibrinogen substrates, whereas
DDR2-Fc2 bound to collagen as expected, confirming the
specificity of our assay to the GPVI portion of GPVI-Fc2
(Fig. 1D).
Collagenous substrates inhibit the binding of GPVI-dimer to
D-fragment and D-dimer, suggesting proximity of binding
sites
To determine if the binding site on GPVI-dimer for
D-fragment and D-dimer is close to that for collagen, we
incubated GPVI-Fc2 (20 lg mL
!1) with 0–20 lg mL!1 of
col III (non-fibrous), Horm collagen (fibrous), CRP-XL
and GPP10-XL and reacted it with immobilized D-frag-
ment and D-dimer. The converse experiment, where
immobilized collagenous substrates were reacted with
GPVI-Fc2 incubated with fibrinogen, fibrins or fibrinogen
subdomains, was also performed (described in next sec-
tion). Col III and Horm showed similar concentration-
dependent abilities to inhibit binding of GPVI-Fc2 to D-
fragment, with complete inhibition at ≥ 0.5 lg mL!1
(Fig. 2A-i). CRP-XL was effective at lower concentra-
tions, producing complete inhibition at ≥ 0.05 lg mL!1.
Higher col III and Horm concentrations were needed to
inhibit GPVI-Fc2 binding to D-dimer, whereas the inhibi-
tion curve of CRP-XL was similar to that against D-frag-
ment (Fig. 2A-ii). As expected, GPP10-XL had little
effect against GPVI-Fc2 binding.
Determining if GPVI-Fc2 and platelet GPVI can interact with
fibrinogen or its derivatives in solution
D-fragment, E-fragment, D-dimer, fibrinogen and pFibrin
(0–20 lg mL!1) could not inhibit binding of GPVI-Fc2
(20 lg mL!1) to immobilized col III, Horm or CRP-XL
(Fig. 2B i–iii), suggesting that GPVI-Fc2 cannot bind to
them in solution.
Flow cytometry (Fig. 5C) shows that the washed nor-
mal platelets bind to fibrinogen and D-dimer, at a low
level, but thrombasthenic platelets that lack aIIbb3 exhi-
bit no binding to either. This means that activation
through aIIbb3 is required for expression of D-dimer
and fibrinogen binding; in this case, the platelets may
have become slightly activated during the washing proce-
dures.
pFibrin (> 5 lg mL!1) was able to induce platelet
aggregation (Figure S2); mFab-F prolonged its lag-time
but did not reduce maximum aggregation, whereas 45-
lM Eptifibatide (anti-aIIbb3) abrogated it. This suggests
that platelet aggregation through pFibrin in suspension
doesn’t require GPVI-dimer. Fibrinogen, D-fragment
and D-dimer (5–20 lg mL!1) did not induce platelet
aggregation (Fig. 5A-i). However, D-dimer concentra-
tion-dependently inhibited Horm-induced aggregation of
washed platelets (Fig. 5A-ii). In platelets pre-incubated
with 100 lg mL!1 Horm, lower D-dimer concentrations
did not affect mFab-F inhibition of Horm-induced
aggregation, but high D-dimer concentration relieves the
inhibition, suggesting that D-dimer may bind at a
Fig. 1. Interaction of GPVI-Fc2 and GPVIex with immobilized fibrinogen derivatives. The following abbreviations were used in the graphs:
collagen type III (Col); D-fragment (D-frag); D-dimer (D-D); E-fragment (E-frag); fibrinogen-Sigma (Fbg-Sig), pFibrin-Sigma (pFn-Sig), mFib-
rin-Sigma (mFn-Sig); fibrinogen-1 (Fbg-1), pFibrin-1 (pFn-1), mFibrin-1 (mFn-1); fibrinogen-3 (Fbg-3), pFibrin-3 (pFn-3), mFibrin-3 (mFn-3);
fibrinogen peak 1 (Fbg Pk1); fibronectin (Fibro); vitronectin (Vitro); BSA (bovine serum albumin). Binding of GPVI-Fc2 (recombinant GPVI-
dimer), GPVIex (recombinant GPVI monomer), DDR2-Fc2, human Fc and human IgG to immobilized fibrinogen derivatives was measured by
ELISA (enzyme-linked immunosorbent assay) as detailed in the Methods. Collagen type III (Col) was used as a positive control. The numbers
in parentheses indicate the concentrations of substrate used to coat the ELISA plate wells in lg mL!1 in PBS. Non-specific binding was deter-
mined with BSA alone, which was subtracted from the total binding to obtain specific binding. (A) Fibrinogen-Sigma, fibrinogen-1, fibrinogen-
3 and fibrinogen peak 1 are the fibrinogens described in Figure S1 and the corresponding polymerized (pFibrin) and monomeric fibrins (mFib-
rin) produced from thrombin +/! GPRP addition, respectively. Fluorescence values shown are the mean " SEM, from five different experi-
ments, with duplicate repeats in each. GPVI-Fc2 (50 lg mL
!1 shown) shows high levels of binding to D-fragment, D-dimer and col III. In
contrast, there is only very low binding to fibrinogen, mFibrin and pFibrin and no binding to E-fragment, fibrinogen peak 1, fibronectin or vit-
ronectin. (B) GPVIex (50 lg mL
!1) showed no binding to immobilized fibrinogen-Sigma, fibrinogen-1, fibrinogen-3, D-fragment or D-dimer
with some binding to collagen III, suggesting that the GPVI monomer is unable to recognize the D-domain. (C) No increase in binding to
GPVI-Fc2 is seen with fibrinogen-3 (Fbg-3) or pFibrin-3 and mFibrin-3 produced from it, at higher concentrations (Fbg-3; 10–200 lg mL
!1),
whereas collagen III, D-fragment and D-dimer bind at 10 lg mL!1. (D) Human Fc shows no binding to the fibrinogen derivatives and no
binding to col III. Immobilized DDR2-Fc2 (20 lg/mL) binds collagen as expected, but neither DDR2-Fc2, human Fc (20 lg/mL) nor human
IgG (25 lg mL!1) bind to fibrinogen, whereas matched concentrations of GPVI-Fc2 bind well to D-fragment, D-dimer and collagen. (E)
Kinetic analyses of the binding of GPVI-Fc2 to D-fragment and D-dimer to determine Kd (dissociation constant) values. GPVI-Fc2 exhibits sat-
urable binding to both D-fragment and D-dimer (coated at two different concentrations), with Kd values (data fit to a non-linear regression,
one-site model) shown in the inset. The Kd values for D-fragment and D-dimer are similar and they are comparable to the Kd value for col III.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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separate but nearby site, perhaps producing a conforma-
tional change that may reduce the affinity of mFab
(Fig. 5A-iii).
Therefore, fibrinogen derivatives in solution are not
able to bind to platelet GPVI-dimer or GPVI-Fc2.
Although D-dimer appears to bind to GPVI-dimer in














































































































































© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
394 I. Induruwa et al
suspension, it does not cause aggregation, and indeed
inhibited it, an important physiological barrier to prevent
platelets from spontaneous aggregation through GPVI-
dimer.
Platelet adhesion to fibrinogen substrates under static
conditions and effect of inhibiting antibodies
Under static conditions, washed platelets adhere to fib-
rinogen, D-fragment, pFibrin, mFibrin and D-dimer (Fig.
3), but not to E-fragment (data not shown in Fig. 3).
mFab-F mildly but significantly inhibited platelet adhe-
sion to D-fragment, mFibrin, pFibrin and col III,
whereas hFab (human Fab) had no effect. Hip8 dramati-
cally decreased platelet adhesion on fibrinogen, D-frag-
ment, D-dimer, mFibrin and pFibrin. mFab-F + Hip8
further decreased platelet adhesion on D-fragment, D-
dimer, mFibrin and pFibrin. Thus, static adhesion to fib-
rinogen substrates is mainly aIIbb3-dependent, with a

















































Fig. 3. Platelet adhesion to immobilized fibrinogen substrates under static conditions and effect of antibodies against GPVI-dimer and integrin
aIIbb3. Adhesion of washed platelets pretreated with human Fab (control, 200 lg mL!1), mFab-F (200 lg mL!1), Hip8 (anti-GPIIba, inhibi-
tory, 10 lg mL!1), or a combination of mFab-F (200 lg mL!1) and Hip8 (10 lg mL!1), was determined as previously described; in this assay,
the adhered platelets are lysed and their content of alkaline phosphatase measured in an assay using the chromogenic substrate p-nitrophenyl
phosphate, which is hydrolyzed by this enzyme to p-nitrophenol, which is detectable at 405-nm absorbance. Data shown are the mean " SD of
three separate experiments, each data point run in duplicate, using platelets from three different healthy control individuals. Data were ana-
lyzed by the paired t-test, with significances shown on the figure: control (human Fab) vs. mFab-F, Hip8 or mFab8 + Hip8 (*P < 0.05,
**P < 0.01,***P < 0.001); mFab vs. Hip8 (**P < 0.01, ***P < 0.001); Hip8 vs. Hip8 + m-Fab-F (a*P < 0.05,**P < 0.01); ns = not significant.
Platelets adhere to fibrinogen, pFibrin (polymerized fibrin made from Fib-3), mFibrin (monomeric fibrin made from Fib-3), D-fragment,
D-dimer and collagen type III (col III), the positive control. Platelets do not adhere to E-fragment, so the following discussion of antibody
effects only refers to the substrates supporting platelet adhesion. mFab-F mildly but significantly decreased platelet binding to D-fragment,
m-fibrin, p-fibrin and collagen. Hip8 markedly decreases platelet adhesion to all fibrinogen substrates, but has no effect on platelet adhesion to
collagen, which is mainly supported by integrin a2b1. Adding mFab-F and Hip8 together further diminishes platelet adhesion to all immobi-
lized fibrinogen substrates, suggesting that integrin aIIbb3 plays the predominant role but GPVI-dimer makes a significant contribution.
Fig. 2. Collagenous substrates compete with GPVI-dimer binding to immobilized D-fragment and D-dimer, but fibrinogen substrates in solu-
tion do not displace binding of GPVI-dimer to immobilized collagen substrates. (A) Collagenous substrates inhibit the binding of GPVI-Fc2 to
D-fragment and D-dimer. D-fragment or D-dimer (10 lg mL!1) was immobilized to ELISA wells and left overnight at 4 °C. GPVI-Fc2
(20 lg mL!1) was incubated with increasing concentrations of collagenous substrate (0–20 lg mL!1) and ELISA performed as described in the
Methods. The following collagenous substrates were tested: collagen type III (col III, non-fibrous), Horm collagen (fibrous), CRP-XL and
GPP10-XL. (A i) CRP-XL inhibited GPVI-Fc2 binding to D-fragment, abrogating it at ≥ 0.05 lg mL
!1 and col III and Horm, at ≥ 0.5
lg mL!1. GPP10-XL, which does not bind to GPVI-Fc2, did not affect the binding. (A ii) GPVI-Fc2 binding to D-dimer was similarly inhib-
ited by col III, Horm and CRP-XL, although slightly higher concentrations of col III and Horm were needed to obtain the same degree of
inhibition. (B) Col III, Horm and CRP-XL (10 lg mL!1) were immobilized to ELISA wells and left overnight at 4 °C. D-fragment, D-dimer,
E-fragment, fibrinogen (Fib-3) and its respective pFibrin (0–20 lg mL!1) incubated with GPVI-Fc2 (20 lg mL
!1) cannot inhibit GPVI-Fc2
binding to col III (B i), HORM (B ii), or CRP-XL (B iii), suggesting that D-domain in solution does not have sufficient affinity for GPVI-Fc2.
Data are presented as the mean " SEM obtained from three separate experiments with each data point as a duplicate.
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Fig. 4. Confocal images of washed platelets adhered to fibrinogen derivatives and Horm collagen and the effect of inhibitors. Washed platelets
suspended in HT buffer were pretreated with human Fab (control, 200 lg mL!1), inhibitory anti-GPVI-dimer mFab-F (200 lg mL!1) or the
Src inhibitor Dasatinib (50 nM) for 10 min and then were allowed to adhere to fibrinogen, fibrinogen derivative or Horm collagen immobilized
on MatTek glass dishes, followed by fixation and staining with fluorescently labelled antibody (as described in the Methods). (A) Images show
platelets stained with Alexa-fluor 488–1G5 (green; pan GPVI) and Alexa-fluor 647–anti-P-selectin (red) to measure platelet activation. Images
were obtained with a 60x oil immersion objective on an Olympus confocal microscope. As shown in (A) (left-most column of images), platelets
spread well on fibrinogen, D-fragment, mFibrin and Horm collagen, with evident surface expression of P-selectin. Platelet aggregate formation
was seen on pFibrin, whereas platelets spread but did not appear aggregated on mFibrin. Horm collagen supported aggregate formation, with
the characteristic binding of GPVI along the Horm fibers [31]. In contrast, platelets did not spread well on D-dimer, with only some platelets
showing P-selectin expression. Treatment with mFab-F (A, middle column of images) prevented platelet spreading on fibrinogen, D-fragment
and Horm collagen, and decreased the extent of spreading, with evident filopodia observed, on mFibrin and pFibrin, whereas there was little
change in the less-spread platelets on D-dimer. mFab-F prevented aggregate formation on both pFibrin and Horm collagen, consistent with
inhibition of activation through GPVI. Dasatinib (A, right-most column of images) shows effects similar to those of mFab-F. (B) In these
experiments, the immobilized pFibrin or mFibrin (data not shown) was stained with anti-fibrin/Alexa-fluor 547–anti-mouse IgG (blue) after the
surface was blocked with 1% bovine serum albumin; the dishes were then thoroughly washed and used for the platelet adhesion experiments,
which were performed as shown in (A). pFibrin (blue) is clearly evident, whereas there was no staining of the immobilized mFibrin (data not
shown). P-selectin (red) expression and aggregate formation is evident on the surface of the adhered platelets. [Color figure can be viewed at
wileyonlinelibrary.com]
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adhesion on collagen mainly depends on a2b1, with a les-
ser contribution by GPVI-dimers, under the present non-
cation-depleted conditions [4].
Platelet spreading on immobilized fibrinogen substrates
requires GPVI-dimer
Confocal images (Fig. 4A) of platelets labeled for pan-
GPVI (Alexa-fluor 488–1G5, green) and P-selectin
(Alexa-fluor 647–anti-CD 62p, red) indicate that platelets
spread well, with P-selectin expression, on fibrinogen,
D-fragment, mFibrin and pFibrin, which shows clear
aggregate formation. Little spreading occurred on
D-dimer. mFab-F and Dasatinib (Src-kinase inhibitor)
cause similar inhibition of platelet spreading on fibrino-
gen and D-fragment, and although platelets still spread
on pFibrin, aggregate formation is obviously reduced.
As expected, platelets bind through GPVI on Horm
fibers, with surface P-selectin expression, as reported
before [31]. Figure 4(B) shows a representative image of
immobilized pFibrin fibers, pre-stained as described in
the Methods, before platelets were added, with adhered







2. mFab-F (100) + D-dimer (20)
3. mFab-F (100) + D-dimer (5)
















































































































Fig. 5. Binding of GPVI-dimer to D-fragment, D-dimer, fibrinogen and fibrin in solution and effect of mFab-F on static adhesion to
D-domain. (A) Aggregometry was performed with washed platelets (2.5 9 108) either untreated or incubated for 5 min with mFab-F
(100 lg mL!1)). At 3 min, D-fragment, D-dimer or fibrinogen (parentheses indicate concentrations in lg mL!1) was added to the platelets
(A i–iii). D-fragment, D-dimer or fibrinogen do not cause aggregation up to the maximum concentration (20 lg mL!1). If no aggregation
occurred by 8 min, Horm was added to induce platelet aggregation, verifying that the platelets were active. D-dimer inhibits Horm-induced
aggregation (A i) in a concentration-dependent manner (A ii). (A iii) Washed platelets were pre-incubated with 100 lg mL!1 of mFab-F for
5 min. D-dimer (5–20 lg mL!1) was added at 3 min and Horm (3 lg mL!1) at 8 min. Horm-induced aggregation is inhibited when mFab-F is
present, although at higher concentrations of D-dimer (20 lg mL!1) some aggregation occurs. The images are representative of results from
three experiments. (B) ELISA plates were coated with col III, D-fragment or D-dimer (25 lg mL!1) and left overnight at 4 °C. GPVI-Fc2
(25 lg mL!1) was incubated with either 100 lg mL!1 human Fab (hFab), as a control, or 100 lg mL!1 mFab-F for 1 h at room temperature
and reacted with the coated substrates. Bound GPVI-Fc2 was detected as detailed in the Methods. Results, presented as the mean " SEM, con-
firm that mFab-F significantly reduces GPVI-Fc2 binding to D-fragment, D-dimer (P < 0.01) and collagen (P < 0.05). (C) Flow cytometry
assessment of fibrinogen and D-dimer binding in normal and GT platelets, with isotype control (IgG1). Washed platelets from the GT patient
and a normal donor were incubated with 20 lg mL!1 of fibrinogen or D-dimer for 30 min; samples were diluted 10-fold with CBS, pelleted by
centrifugation and resuspended in HT; then each sample was incubated with anti-human fibrinogen for 10 min, followed by addition of an
excess of Alexa fluor-488–anti-mouse Fab. Samples were measured in an Accuri C6 flow cytometer. The normal platelets show low levels of fib-
rinogen and D-dimer binding, but the GT platelets show neither, suggesting that integrin aIIbb3 is mainly responsible for binding to fibrinogen
and D-dimer.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
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Fig. 6. Adhesion of platelets in whole blood to fibrinogen substrates and collagen under flow conditions. The following abbreviations were used
in the graphs (B–E): D-fragment (D-frag), D-dimer (D-D), fibrinogen (Fbg), pFibrin (pFn), mFibrin (mFn) and collagen type III (col). Glass
coverslips were coated with fibrinogen (Fbg-3), pFibrin and mFibrin (produced from Fbg-3), D-fragment, D-dimer and collagen type III at
10 lg mL!1 in PBS and left overnight at 4 °C. Blood was anticoagulated with 36 lL D-phenylalanyl-prolyl-arginyl chloromethyl ketone
(PPACK) and topped up at 1 : 1000 ratio every hour. Platelets in whole blood were fluorescently labelled with 1:4500 DiOC6 (3,30-dihexyloxa-
carbocyanine iodide). After 1-min perfusion of flow buffer (136 mM NaCl, 2.7 mM KCl, 5 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic
acid, 10 mM glucose, 2 mM MgCl2, 2 mM CaCl2, pH 7.4), whole blood was perfused over the coverslips at a shear rate of 350 s
!1. Z-stack
images were used to calculate surface coverage (SA) of adhered platelets and mean thrombus height (MTH) in panels B–E. (A) Fluorescently
labelled whole blood was left untreated (control) or treated with one of the following: human Fab (hFab, 100 lg mL!1), mFab-F (GPVI-dimer
specific, inhibitory; 100 lg mL!1), Eptifibatide (aIIbb3 inhibitor, 45 lM; Tocris Bioscience, UK), Gi9 (anti-a2b1, inhibitory; GeneTex, USA).
The images in Panel A are representative of six flow experiments performed with blood from different donors. Statistical significance between
control and antibody inhibition (B + C) or human Fab and mFab-F inhibition (D + E) was calculated using paired t-tests (*P < 0.05,
**P < 0.01 ***P < 0.001). (B + C) Inhibition of aIIbb3 abrogated SA and MTH to all surfaces. mFab-F reduced platelet adhesion (SA) to all
five fibrinogen derivatives (D-fragment, **P < 0.01; all others, *P < 0.05) and col III (*P < 0.05). mFab-F also significantly suppressed MTH
on D-fragment, mFibrin and col type III (**P < 0.01) and reduced it on D-dimer, fibrinogen and pFibrin compared with the control. This sug-
gests that GPVI-dimer is able to facilitate platelet adhesion and thrombus growth on fibrinogen derivatives, through the D-domain. (C + D)
The inhibition of GPVI-dimer with mFab-F compared with the effect of human Fab and anti-a2b1 Gi9 under the same conditions. a2b1 had
little to no effect on adhesion to fibrinogen derivatives, and as expected caused some reduction of aggregate formation (MTH) on collagen.
mFab-F significantly reduced SA and MTH compared with human Fab on all tested substrates, except SA on D-fragment and D-dimer, which
nevertheless tended towards significance (P = 0.07 and P = 0.08, respectively). [Color figure can be viewed at wileyonlinelibrary.com]
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platelets showing pan-GPVI and surface P-selectin
expression.
Both GPVI-dimer and integrin aIIbb3 contribute to platelet
adhesion and thrombus formation on fibrinogen derivatives
under flow conditions
Human blood from a healthy donor was perfused over
immobilized fibrinogen derivatives or col III (control) at
350 s!1 (Fig. 6) and 1000-s!1 (Figure S3). Thrombus
formation is apparent on all control images (left column,
Fig. 6A). Addition of mFab-F (middle column of images,
Fig. 6A) decreases both platelet adhesion (SA) (Fig. 6B)
and mean thrombus height (MTH) (Fig. 6C) on all tested
surfaces. Eptifibatide abrogated platelet adhesion on all
four fibrinogen derivatives (right column, Fig. 6A).
Inhibition of a2b1 by mAb Gi9 (10 lg mL!1) only
mildly inhibited adhesion on collagen, but not the fibrino-
gen substrates. Compared with hFab (100 lg mL!1),







































































Fig. 7. Static adhesion of platelets from an individual with Glanzmann thrombasthenia (GT) on immobilized fibrinogen substrates. (A) Flow
cytometry analysis verified that the GT platelets contain no integrin aIIbb3, but had normal levels of GPVI. (B) In these experiments, the
ELISA wells were coated by adding a 100-lg mL!1 solution of each substrate. The GT platelets did not adhere to fibrinogen or D-fragment,
but retained the ability to adhere to pFibrin and D-dimer, although this was markedly reduced. mFab-F markedly reduced the adhesion on
pFibrin, suggesting that GPVI-dimer may be involved in this interaction. (C) Confocal images of normal platelet and GT platelets adhered to
immobilized pFibrin. Both normal and GT platelets were prelabelled with Alexa fluor 488-conjugated 204-11 Fab and allowed to adhere on
pFibrin-coated MatTek dishes, for 30 min at 37 °C. The platelets were then fixed and stained with Alexa fluor 647-conjugated antibody specific
for integrin aIIbb3 (normal platelets) or GPIb (GT platelets), as described in the text, before imaging. The GT platelets retain the ability to
adhere to pFibrin, although they do not spread; close inspection of the transmitted light images shows that the GT platelets adhere on or close
to the fibers of pFibrin. [Color figure can be viewed at wileyonlinelibrary.com]
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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on all fibrinogen derivatives (Fig. 6D and E). All differ-
ences were statistically significant apart from mean SA on
D-fragment and D-dimer, which was close to reaching sig-
nificance (P = 0.07 and P = 0.08, respectively). This con-
firms that GPVI-dimer contributes to platelet adhesion and
thrombus formation on immobilized fibrinogen and fibrin
surfaces, although the effect of aIIbb3 is greater.
Assessing the role of GPVI-dimer in platelets from a patient
with Glanzmann’s thrombasthenia (GT)
Because platelets contain far fewer GPVI-dimers than
integrin aIIbb3, which may mask the subtler effects of
GPVI-dimer, we examined static adhesion and flow adhe-
sion using blood from a GT patient, whose platelets were
confirmed to have no aIIbb3 but a normal GPVI level
(Fig. 7A).
Static adhesion of GT platelets: Washed GT platelets
showed essentially no adhesion on fibrinogen or D-frag-
ment, but retained a low level of adhesion on pFibrin
and D-dimer (Fig. 7B). mFab-F (100 lg mL!1) further
diminished the adhesion to pFibrin, suggesting that this
low level of interaction involved GPVI-dimer.
Confocal imaging showed that some GT platelets pre-
labelled with Alexa-fluor 488-conjugated 204-11-Fab
(green) and post-labelled with Alexa-fluor 647-conjugated
anti-GPIb (red) (Fig. 7C) adhered to pFibrin fibers
(Fig. 7C, transmitted light image), but did not spread/ag-




































































































Fig. 8. Analysis of Glanzmann thrombasthenia (GT) platelets under flow conditions. Blood was obtained from an individual with GT, whose
platelets lack integrin aIIbb3. (A) Labelled whole blood was then perfused over surfaces of D-fragment, D-dimer, fibrinogen and pFibrin (slides
were coated with 100 lg mL!1 of substrate in PBS, overnight at 4 °C). Whole blood was obtained from a healthy volunteer for control mea-
surements. Thrombasthenic blood was perfused with or without the addition of mFab-F (100 lg mL!1) at 350 s!1. GT platelets retain some
ability to adhere on all four surfaces, albeit at dramatically reduced levels compared with normal platelets and there is no aggregate formation.
mFab-F further reduced the level of adherent GT platelets. Z-stack images were used to calculate SA (B) and MTH (C). For the GT platelets,
inhibition of GPVI-dimers by mFab-F causes a further reduction of platelet adherence and activation on D-fragment and D-dimer. [Color fig-
ure can be viewed at wileyonlinelibrary.com]
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Under flow conditions, adhesion of GT platelets to
D-fragment, D-dimer, fibrinogen and pFibrin was dra-
matically reduced, but platelet adhesion was still evident
(Fig. 8A). Quantitation of SA (Fig. 8B) showed that GT
platelets retain some ability to adhere to fibrinogen, pFib-
rin, D-fragment and D-dimer. Their SA on D-fragment
and D-dimer was reduced by mFab-F, suggesting GPVI-
dimer involvement in this adhesion. MTH for the GT
platelets (Fig. 8C) was very low, indicating little platelet
activation had occurred. This suggests that the absence of
aIIbb3 does not abolish the interaction between GPVI
and fibrinogen substrates, although it appears that its
absence impairs the ability of platelets to activate on fib-
rinogen and fibrin.
Discussion
GPVI-dimer, constitutively present in resting platelets [4],
by virtue of its high affinity for collagen, is the functional
form of this receptor that initiates signaling leading to
thrombogenesis [27]. Recent work has identified GPVI as
a fibrin receptor. Mammadova-Bach et al. [24] first
showed that GPVI promoted thrombin generation
through fibrinogen and fibrin-dependent mechanisms and
that Fab 9O12 (inhibitory antibody against pan GPVI)
[34] reduced platelet adhesion to fibrin and platelet
recruitment to formed fibrin-rich thrombi [24]. Subse-
quently, Alshehri et al. concluded that fibrin stimulates
tyrosine kinase phosphorylation and platelet spreading
through GPVI, independent of aIIbb3 [25], and Onselaer
et al. recently reported that GPVI-monomer binds to fib-
rin [26].
The present study presents the novel finding that
GPVI-dimer, not the monomer, binds to immobilized fib-
rinogen and fibrin through their D-domains. GPVI-dimer
binds to the D-domain with high affinity, exhibiting Kd
values similar to that for collagen (Fig. 1A, E). We found
that GPVI-monomer bound to none of the fibrinogen
derivatives (Fig. 1B), confirming a specific interaction
between GPVI-dimer and the D-domain. Neither recom-
binant nor platelet GPVI-dimer binds E-fragment. Inter-
estingly, the ability of collagenous substrates to inhibit
GPVI-dimer binding to D-fragment and D-dimer
(Fig 2A), as well as the ability of soluble D-dimer to inhi-
bit collagen-induced platelet aggregation (Fig 5A-ii), sug-
gests that the collagen and D-domain binding sites on
GPVI-dimer are proximate.
The collagen-binding properties of the GPVI-ectodomain
used by the Watson group (Alsheri et al. [25]) initially have
not been characterized, so we are unable to compare it with
our GPVIex. Subsequently, they (Onselaer et al. [26]) used
recombinant GPVI proteins and concluded that GPVI-
monomer selectively binds to fibrin. We found the opposite
to be true: only GPVI-dimer binds to the D-domain com-
mon to fibrinogen and its derivatives, consistent with the
specific binding of the recombinant GPVI-Fc to fibrin
reported by Mammadova-Bach et al. [24]. These discrepan-
cies would come from the difference between our GPVI
recombinant proteins and those used by the Watson group:
their recombinant proteins do not include the highly glyco-
sylated, sialic-acid-rich stem portion of GPVI and the lack
of such strong anionic charges would influence the binding
of their recombinant GPVI to fibrin. To obviate the poten-
tial problem caused by the lack of carbohydrate in their
constructs, they showed that Revacept, a dimeric GPVI-Fc-
fusion protein, also did not bind fibrin. However, Revacept
has a different structure from platelet GPVI-dimer and our
recombinant dimer because a flexible linker sequence has
been inserted between the GPVI-extracellular domain and
the Fc portion [35]. This may make its conformation differ-
ent from that of physiological GPVI-dimer and thereby
change its ability to bind to fibrin. It must be highlighted
that our antibodies 204-11 Fab and mFab-F, designed
against our GPVI-Fc2, are able to recognize both the con-
stitutive dimers present on resting platelets and those on
activated platelets and mFab-F inhibits Horm-induced
aggregation, supporting that our GPVI-Fc2 is similar to
physiological platelet GPVI-dimers.
A key finding from our work is that the immobilized
nature of the fibrinogen substrates is important for plate-
let activation through GPVI-dimer. Fibrinogen subdo-
mains in solution with GPVI-dimer cannot inhibit its
binding to collagen (Fig. 2B) and GT platelets lacking
aIIbb3 fail to bind fibrinogen and D-dimer in solution
(Fig. 5C). Aggregometry confirms that D-fragment, D-
dimer and fibrinogen in solution do not cause platelet
aggregation (Fig. 5A-i), and pFibrin suspension induces
platelet aggregation independent of GPVI-dimer, presum-
ably via aIIbb3, as mFab-F increased the lag-time, but
did not affect the level of maximum aggregation (Fig-
ure S2). Together, these results suggest that GPVI-dimer
cannot bind to fibrinogen or its subdomains to cause acti-
vation unless they are immobilized. This is crucial as pla-
telet aggregation through binding to soluble fibrinogen
does not occur in the circulation under normal condi-
tions, unless initial platelet activation has occurred, con-
verting resting aIIbb3 to a high-affinity state [36].
Although the fibrinogen and its subdomains in solution
cannot activate platelets, D-dimer, which is found in plasma
at high concentrations under pathological conditions as a
fibrinolytic product, is inhibitory towards platelet activation
through GPVI. Lee et al. [37] reported the ability of
soluble, crosslinked fibrin, which contains the D-dimer moi-
ety, to inhibit platelet activation through GPVI-signaling
and we and Onselaer et al. [26] both found that D-dimer
inhibits collagen-induced platelet aggregation.
GPVI-dimer contributes significantly to static platelet
adhesion, independently of aIIbb3, on immobilized D-
fragment, pFibrin and mFibrin (Fig. 3). Furthermore,
mFab-F inhibition of GPVI-Fc2 leads to a significant
reduction in its binding to D-fragment, D-dimer and col
III in ELISA (Fig. 5B). GPVI-dimer not only contributes
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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to adhesion but also to spreading on fibrinogen, D-frag-
ment, mFibrin, and pFibrin, and aggregate formation on
pFibrin (Fig. 4).
Platelet adhesion to fibrinogen substrates under flow is
more complex than measuring direct binding using ELISA,
because it involves a dominant role for aIIbb3 at lower
(350 s!1) and higher (1000 s!1) shear, as demonstrated by
the abrogation of thrombus formation in the presence of
Eptifibatide (Fig. 6, Figure S3). GPVI-dimer, however,
appears to play its most significant role at low shear,
because mFab-F significantly decreases SA on all tested
substrates and MTH is significantly reduced on D-frag-
ment, mFibrin and collagen (Fig. 6, Table S1). At
1000 s!1, GPVI inhibition appears to produce more vari-
able results, which suggests that GPVI-dimer is less able to
recognize immobilized D-domain at higher shear. This
indicates that aIIbb3 does play a significant role in platelet
interactions with fibrinogen and fibrin in both static
(Fig. 3) and shear (Fig. 6) conditions, whereas GPVI-
dimer has a secondary but requisite role for inducing plate-
let adhesion and thrombus formation.
This could be through convergent tyrosine kinase signal-
ing downstream from GPVI and aIIbb3. For example, the
crosslinking of GPVI induces Src-dependent tyrosine phos-
phorylation of FcRc [2] and, similarly, signaling mediated
by aIIbb3 also includes tyrosine kinases such as Syk and
Src [38,39], with specific blockade reducing the tyrosine
phosphorylation of signaling proteins downstream from
Syk in both the GPVI and aIIbb3 signaling pathways [40].
Dasatinib and mFab-F each exert a similar inhibitory effect
on platelet adhesion, indicating platelet-adhesion-induced
signaling through GPVI-dimer is an important step in pla-
telet spreading and activation on fibrinogen and fibrin
(Fig. 4). This is consistent with Onselaer et al., who show
that fibrin is unable to activate GPVI-deficient human pla-
telets, which is further evidence of shared signaling path-
ways between GPVI and aIIbb3 [26].
Under static conditions, aIIbb3-deficient GT platelets
can adhere to pFibrin, but are not activated (Fig. 7).
Under flow, the GT platelets show drastically reduced
adhesion to D-fragment, D-dimer, fibrinogen and pFibrin,
but residual adherent but non-spread platelets remain
(Fig. 8). mFab-F reduces GT platelet adhesion on all sub-
strates tested, suggesting that GT platelets can bind inde-
pendently through GPVI-dimer, even without functional
aIIbb3, but these adhered GT platelets appear neither
spread nor activated, suggesting that signaling may not
occur without the assistance of aIIbb3. This means that
platelet surface GPVI-dimers may support a weak interac-
tion with immobilized fibrinogen or fibrin, but it is not suf-
ficient to initiate platelet activation. It is more likely that
aIIbb3 and GPVI-dimer have collaborative roles in platelet
activation on fibrinogen and fibrin, especially as platelets
treated with both mFab-F and Hip8 show a further
decrease in adhesion compared with Hip8 alone (Fig. 3).
GPVI antagonism could provide highly specific phar-
macological drugs that prevent thrombus formation in
acute coronary syndrome [41] and ischemic stroke [42].
This study is the first to describe an interaction between
GPVI-dimer and fibrinogen and fibrin. GPVI-dimer binds
to the D-domain and is involved in signaling, leading to
platelet spreading and activation on fibrinogen substrates,
in conjunction with aIIbb3 and independent of collagen
exposure. GPVI-dimer clearly plays a key part in both ini-
tiation and propagation of thrombosis at sites of
atherosclerotic plaque rupture through collagen and
fibrin. However, our findings also intimate a role for
GPVI-dimer in conditions where blood clots form with-
out collagen exposure, including atrial fibrillation and
deep vein thrombosis, making it an even more tantalizing
pharmacological target.
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and fibrinogen derivatives that were examined in our pre-
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Table S1. Comparing thrombus formation at low
(350 s!1) and high shear (1000 s!1).
References
1 Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ,
Cushman M, Das SR, de Ferranti S, Despr!es J-P, Fullerton HJ,
Howard VJ, Huffman MD, Isasi CR, Jim!enez MC, Judd SE,
Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH,
et al. Heart disease and stroke statistics—2016 update. Circula-
tion 2015; 138: e38–60.
2 Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP.
Glycoprotein VI is the collagen receptor in platelets which under-
lies tyrosine phosphorylation of the Fc receptor c-chain. FEBS
Lett 1997; 413: 255–9.
3 Jung SM, Tsuji K, Moroi M. Glycoprotein (GP) VI dimer as a
major collagen-binding site of native platelets: direct evidence
obtained with dimeric GPVI-specific Fabs. J Thromb Haemost
2009; 7: 1347–55.
4 Jung SM, Moroi M, Soejima K, Nakagaki T, Miura Y, Berndt
MC, Gardiner EE, Howes JM, Pugh N, Bihan D, Watson SP,
Farndale RW. Constitutive dimerization of glycoprotein VI
(GPVI) in resting platelets is essential for binding to collagen
and activation in flowing blood. J Biol Chem 2012; 287: 30000–
13.
5 Smethurst PA, Onley DJ, Jarvis GE, O’Connor MN, Graham
Knight C, Herr AB, Ouwehand WH, Farndale RW. Structural
basis for the platelet-collagen interaction: the smallest motif
within collagen that recognizes and activates platelet Glycopro-
tein VI contains two glycine-proline-hydroxyproline triplets.
J Biol Chem 2007; 282: 1296–304.
6 Knight CG, Morton LF, Onley DJ, Peachey AR, Ichinohe T,
Okuma M, Farndale RW, Barnes MJ. Collagen-platelet interac-
tion: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and
mediates platelet activation by collagen. Cardiovasc Res 1999; 41:
450–7.
7 Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington
RC. Structural basis of collagen recognition by integrin a2b1.
Cell 2000; 101: 47–56.
8 Furie B, Furie BC. Mechanisms of thrombus formation. N Engl
J Med 2008; 359: 938–49.
9 Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie
BC. Glycoprotein VI–dependent and –independent pathways of
thrombus formation in vivo. Blood 2006; 107: 3902–6.
10 Law DA, Nannizzi-Alaimo L, Phillips DR. Outside-in integrin
signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine
phosphorylation induced by platelet aggregation. J Biol Chem
1996; 271: 10811–5.
11 Brass LF. Thrombin and platelet activation. Chest 2003; 124:
18S–25S.
12 Mosesson MW. Fibrinogen and fibrin structure and functions.
J Thromb Haemost 2005; 3: 1894–904.
13 Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr
Opin Cell Biol 2005; 17: 509–16.
14 Achyuthan KE, Dobson JV, Greenberg CS. Gly-Pro-Arg-Pro
modifies the glutamine residues in the alpha- and gamma-chains
of fibrinogen: inhibition of transglutaminase cross-linking. Bio-
chim Biophys Acta 1986; 872: 261–8.
15 Spraggon G, Everse SJ, Doolittle RF. Crystal structures of frag-
ment D from human fibrinogen and its crosslinked counterpart
from fibrin. Nature 1997; 389: 455–62.
16 Fullard JF. The role of the platelet glycoprotein IIb/IIIa in
thrombosis and haemostasis. Curr Pharm Des 2004; 10: 1567–76.
17 Adams HP, Effron MB, Torner J, D!avalos A, Frayne J, Teal P,
Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W. Emer-
gency administration of abciximab for treatment of patients with
acute ischemic stroke: results of an international phase III trial:
abciximab in Emergency Treatment of Stroke Trial (AbESTT-
II). Stroke 2008; 39: 87–99.
18 Mangin P, Yap CL, Nonne C, Sturgeon SA, Goncalves I, Yuan
Y, Schoenwaelder SM, Wright CE, Lanza F, Jackson SP.
Thrombin overcomes the thrombosis defect associated with pla-
telet GPVI/FcRgamma deficiency. Blood 2006; 107: 4346–53.
19 Hughan SC, Hughes CE, McCarty OJT, Schweighoffer E, Soul-
tanova I, Ware J, Tybulewicz VLJ, Watson SP. GPVI potentia-
tion of platelet activation by thrombin and adhesion molecules
independent of Src kinases and Syk. Arterioscler Thromb Vasc
Biol 2007; 27: 422–9.
20 Inoue O, Suzuki-Inoue K, McCarty OJT, Moroi M, Ruggeri
ZM, Kunicki TJ, Ozaki Y, Watson SP. Laminin stimulates
spreading of platelets through integrin alpha6beta1-dependent
activation of GPVI. Blood 2006; 107: 1405–12.
21 Maurer E, Schaff M, Receveur N, Bourdon C, Mercier L, Nies-
wandt B, Dubois C, Jandrot-Perrus M, Goetz JG, Lanza F,
Gachet C, Mangin PH. Fibrillar cellular fibronectin supports
efficient platelet aggregation and procoagulant activity. Thromb
Haemost 2015; 114: 1175–88.
22 B€ultmann A, Li Z, Wagner S, Peluso M, Sch€onberger T, Weis
C, Konrad I, Stellos K, Massberg S, Nieswandt B, Gawaz M,
Ungerer M, M€unch G. Impact of glycoprotein VI and platelet
adhesion on atherosclerosis–a possible role of fibronectin. J Mol
Cell Cardiol 2010; 49: 532–42.
23 Schonberger T, Ziegler M, Borst O, Konrad I, Nieswandt B,
Massberg S, Ochmann C, Jurgens T, Seizer P, Langer H, Munch
G, Ungerer M, Preissner KT, Elvers M, Gawaz M. The dimeric
platelet collagen receptor GPVI-Fc reduces platelet adhesion to
activated endothelium and preserves myocardial function after
transient ischemia in mice. AJP Cell Physiol 2012; 303: C757–66.
24 Mammadova-Bach E, Ollivier V, Loyau S, Schaff M, Dumont
B, Favier R, Freyburger G, Latger-Cannard V, Nieswandt B,
Gachet C, Mangin PH, Jandrot-Perrus M. Platelet glycoprotein
VI binds to polymerized fibrin and promotes thrombin genera-
tion. Blood 2015; 126: 683–92.
25 Alshehri OM, Hughes CE, Montague S, Watson SK, Frampton
J, Bender M, Watson SP. Fibrin activates GPVI in human and
mouse platelets. Blood 2015; 126: 1601–8.
26 Onselaer M, Hardy AT, Wilson C, Sanchez X, Babar AK, Miller
JLC, Watson CN, Watson SK, Bonna A, Philippou H, Herr AB,
Mezzano D, As R. Fibrin and D-dimer bind to monomeric
GPVI. Blood Adv 2017; 1: 1495–504.
27 Miura Y, Takahashi T, Jung SM, Moroi M. Analysis of the
interaction of platelet collagen receptor glycoprotein VI (GPVI)
with collagen: a dimeric form of GPVI, but not the monomeric
form, shows affinity to fibrous collagen. J Biol Chem 2002; 277:
46197–204.
28 Morton LF, Hargreaves PG, Farndale RW, Young RD, Barnes
MJ. Integrin alpha 2 beta 1-independent activation of platelets
by simple collagen-like peptides: collagen tertiary (triple-helical)
and quaternary (polymeric) structures are sufficient alone for
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
GPVI-dimer recognizes the fibrin(ogen) D-domain 403
alpha 2 beta 1-independent platelet reactivity. Biochem J 1995;
306: 337–44.
29 Al-Tamimi M, Mu F-T, Arthur JF, Shen Y, Moroi M, Berndt
MC, Andrews RK, Gardiner EE. Anti-glycoprotein VI mono-
clonal antibodies directly aggregate platelets independently of
FcgammaRIIa and induce GPVI ectodomain shedding. Platelets
2009; 20: 75–82.
30 Jung SM, Moroi M. Platelets interact with soluble and insoluble
collagens through characteristically different reactions. J Biol
Chem 1998; 273: 14827–37.
31 Poulter NS, Pollitt AY, Owen DM, Gardiner EE, Andrews
RK, Shimizu H, Ishikawa D, Bihan D, Farndale RW, Moroi
M, Watson SP, Jung SM. Clustering of glycoprotein VI (GPVI)
dimers upon adhesion to collagen as a mechanism to regulate
GPVI signaling in platelets. J Thromb Haemost 2017; 15: 549–
64.
32 Pugh N, Simpson AMC, Smethurst PA, De Groot PG, Raynal
N, Farndale RW. Synergism between platelet collagen receptors
defined using receptor-specific collagen-mimetic peptide substrata
in flowing blood. Blood 2010; 115: 5069–79.
33 Xu H, Raynal N, Stathopoulos S, Myllyharju J, Farndale RW,
Leitinger B. Collagen binding specificity of the discoidin domain
receptors: binding sites on collagens II and III and molecular
determinants for collagen IV recognition by DDR1. Matrix Biol
2011; 30: 16–26.
34 Loyau S, Dumont B, Ollivier V, Boulaftali Y, Feldman L,
Ajzenberg N, Jandrot-Perrus M. Platelet glycoprotein VI dimer-
ization, an active process inducing receptor competence, is an
indicator of platelet reactivity. Arterioscler Thromb Vasc Biol
2012; 32: 778–85.
35 Ungerer M, Rosport K, B€ultmann A, Piechatzek R, Uhland K,
Schlieper P, Gawaz M, M€unch G. Novel antiplatelet drug reva-
cept (dimeric glycoprotein VI-Fc) specifically and efficiently
inhibited collagen-induced platelet aggregation without affecting
general hemostasis in humans. Circulation 2011; 123: 1891–9.
36 Li Z, Delaney MK, O’Brien KA, Du X. Signaling during platelet
adhesion and activation. Arterioscler Thromb Vasc Biol NIH
Public Access 2010; 30: 2341–9.
37 Lee MY, Verni CC, Herbig BA, Diamond SL. Soluble fibrin
causes an acquired platelet glycoprotein VI signaling defect:
implications for coagulopathy. J Thromb Haemost 2017; 15:
2393–5.
38 Gao J, Zoller KE, Ginsberg MH, Brugge JS, Shattil SJ. Regula-
tion of the pp72syk protein tyrosine kinase by platelet integrin
alpha IIbbeta 3. EMBO J 1997; 16: 6414–25.
39 Clark EA, Shattil SJ, Ginsberg MH, Bolen J, Brugge JS. Regula-
tion of the protein tyrosine kinase pp72syk by platelet agonists
and the integrin alpha IIb beta 3. J Biol Chem 1994; 269: 28859–
64.
40 Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble J, Watson SP.
The novel Syk inhibitor R406 reveals mechanistic differences
in the initiation of GPVI and CLEC-2 signaling in platelets.
J Thromb Haemost 2009; 7: 1192–9.
41 Bigalke B, Haap M, Stellos K, Geisler T, Seizer P, Kremmer E,
Overkamp D, Gawaz M. Platelet glycoprotein VI (GPVI) for
early identification of acute coronary syndrome in patients with
chest pain. Thromb Res 2010; 125: e184–9.
42 Induruwa I, Jung SM, Warburton EA. Beyond antiplatelets: the
role of glycoprotein VI in ischemic stroke. Int J Stroke 2016; 11:
618–25.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
404 I. Induruwa et al
 
